<SEC-DOCUMENT>0001493152-24-005873.txt : 20240212
<SEC-HEADER>0001493152-24-005873.hdr.sgml : 20240212
<ACCEPTANCE-DATETIME>20240212150452
ACCESSION NUMBER:		0001493152-24-005873
CONFORMED SUBMISSION TYPE:	424B1
PUBLIC DOCUMENT COUNT:		28
FILED AS OF DATE:		20240212
DATE AS OF CHANGE:		20240212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Telomir Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001971532
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				872606031
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275534
		FILM NUMBER:		24619372

	BUSINESS ADDRESS:	
		STREET 1:		900 WEST PLATT STREET, SUITE 200
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33606
		BUSINESS PHONE:		(813) 864-2562

	MAIL ADDRESS:	
		STREET 1:		900 WEST PLATT STREET, SUITE 200
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33606
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B1
<SEQUENCE>1
<FILENAME>form424b1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"> <B>Filed Pursuant to Rule 424(b)(1)</B> </P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right"> <B>Registration No. 333-275534</B> </P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1,000,000
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_001.jpg" ALT="A blue and black logo&#10;&#10;Description automatically generated" STYLE="height: 84px; width: 288px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is the initial public offering of 1,000,000 shares of common stock, no par value, of Telomir Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for shares of our common stock. The assumed initial public offering price is $7.00
per share. Our common stock has been approved for listing on the Nasdaq Capital Market under the symbol &ldquo;TELO.&rdquo;
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise
noted, the share and per share information in this prospectus reflects a 1-for-2.05 reverse stock split of our common stock that became
effective as of December 11, 2023.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as defined in the federal securities laws, and, as such, are subject to reduced public company
reporting requirements. See &ldquo;<I>Prospectus Summary&thinsp;&mdash;&thinsp;Implications of Being an Emerging Growth Company</I>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in shares of our common stock involves risks. See &ldquo;Risk Factors&rdquo; beginning on page 11 to read about factors you should consider
before buying shares of our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left">Initial public offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">7.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">7,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">0.49</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">490,000</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">6.51</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">6,510,000</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &ldquo;Underwriting&rdquo; for a description of
    the compensation payable to the underwriters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters have the option for a period of 45 days from the date of this prospectus to purchase up to 150,000 additional shares
of our common stock from us at the initial public offering price, less underwriting discounts and commissions. If the underwriters exercise
the option in full, the total underwriting discounts and commissions payable by us will be $563,500, and the total proceeds, before
expenses, to us will be $7,486,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the shares to investors on or about February 13, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Kingswood
Investments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">division
of Kingswood Capital Partners, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is February 8, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#rs_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDUSTRY AND MARKET DATA</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#rs_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRADEMARKS AND COPYRIGHTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#rs_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#rs_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLOSSARY OF CERTAIN SCIENTIFIC TERMS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#rs_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#rs_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_001">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_002">DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_003">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_004">DILUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_005">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_006">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_007">MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_008">EXECUTIVE COMPENSATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_009">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#da_010">PRINCIPAL SHAREHOLDERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_001">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_002">SHARES ELIGIBLE FOR FUTURE SALE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_003">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_004">UNDERWRITING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_005">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_006">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_007">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_008">INDEX TO FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
read this prospectus carefully. It describes our business, financial condition, results of operations and prospects, among other things.
We are responsible for the information contained in this prospectus and in any free-writing prospectus we have authorized. Neither we
nor the underwriters have authorized anyone to provide you with different information, and neither we nor the underwriters take responsibility
for any other information others may give you. Neither we nor the underwriters are making an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date on the front of
this prospectus, regardless of the time of delivery of this prospectus or any sale of securities. You should not assume that the information
contained in this prospectus is accurate as of any date other than its date.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="rs_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDUSTRY
AND MARKET DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are responsible for the disclosure in this prospectus. However, this prospectus includes industry data that we obtained from internal
surveys, market research, publicly available information, and industry publications. We did not fund and are not otherwise affiliated
with any of the sources cited in this prospectus. The market research, publicly available information, and industry publications that
we use generally state that the information contained therein has been obtained from sources believed to be reliable. The information
therein represents the most recently available data from the relevant sources and publications, and we believe remains reliable. However,
this data involves a number of assumptions and limitations regarding our industry which are necessarily subject to a high degree of uncertainty
and risk due to a variety of factors, including those described in the section titled &ldquo;<I>Risk Factors</I>.&rdquo; Forward-looking
information obtained from these sources is also subject to the same qualifications and additional uncertainties regarding the other forward-looking
statements in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="rs_002"></A><B>TRADEMARKS
AND COPYRIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our
business. This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of
their respective owners. Our use or display of third parties&rsquo; trademarks, service marks and trade names or products in this
prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience,
the trademarks, service marks and trade names referred to in this prospectus may appear without the &reg;, trademark (&trade;) or
servicemark (<SUP>SM</SUP>) symbols, but the omission of such references is not intended to indicate, in any way, that we will not
assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service
marks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="rs_003"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo;
&ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
&ldquo;potential&rdquo;, or &ldquo;continue&rdquo; or the negative of these terms or other similar expressions. In particular, statements
about the markets in which we operate, including growth of our various markets, and our expectations, beliefs, plans, strategies, objectives,
prospects, assumptions, or future events or performance contained in this prospectus under the headings &ldquo;Prospectus Summary,&rdquo;
&ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and &ldquo;Business&rdquo; are forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these
expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed
in this prospectus under the headings &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Business,&rdquo; may cause our actual results, performance,
or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking
statements, or could affect our share price. Important factors that could cause actual results or events to differ materially from those
expressed in forward-looking statements include, but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our use of the net proceeds
    from this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain regulatory approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    commercialize and market our product candidates, if approved by the FDA; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to contract
    with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential market size,
    opportunity, and growth potential for our product candidates, if approved by the FDA;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain additional
    funding for our operations and development activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accuracy of our estimates
    regarding expenses, capital requirements and needs for additional financing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation, timing,
    progress and results of our pre-clinical studies and clinical trials, and our research and development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of anticipated
    regulatory filings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of availability
    of data from our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our future expenses, capital
    requirements, need for additional financing, and the period over which we believe that the net proceeds from this offering, together
    with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to retain the
    continued service of our key professionals and to identify, hire and retain additional qualified professionals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance
    product candidates into, and successfully complete, clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit
    and enroll suitable patients in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing or likelihood
    of the accomplishment of various scientific, clinical, regulatory, and other product development objectives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pricing and reimbursement
    of our product candidates, if approved by the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rate and degree of
    market acceptance of our product candidates, if approved by the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the implementation of our
    business model and strategic plans for our business, product candidates, and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of protection
    we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments relating to
    our competitors and our industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development of major
    public health concerns, including the novel coronavirus outbreak or other pandemics arising globally, and the future impact of it
    and COVID-19 on our clinical trials, business operations and funding requirements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other risks and factors
    listed under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the risks and uncertainties set forth in this prospectus, you are cautioned not to place undue reliance on such forward-looking statements.
The forward-looking statements contained in this prospectus are not guarantees of future performance and our actual results of operations,
financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking
statements contained in this prospectus. In addition, even if our results of operations, financial condition and liquidity, and events
in the industry in which we operate, are consistent with the forward-looking statements contained in this prospectus, they may not be
predictive of results or developments in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement that we make in this prospectus speaks only as of the date of such statement. Except as required by federal
securities laws, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the
forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="rs_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GLOSSARY
OF CERTAIN SCIENTIFIC TERMS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following medical and scientific terms used in this prospectus have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Antineoplastic
drugs&rdquo; are medications used to treat cancer, also known as chemotherapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;API&rdquo;
stands for Active Pharmaceutical Ingredient, which is the main ingredient in a medicine that causes the desired effect of the medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;AMES
test&rdquo; is a biological assay to assess the mutagenic potential of chemical compounds. It utilizes bacteria to test whether a given
chemical can cause mutations in the DNA of the test organism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;C282Y&rdquo;
is a gene mutation associated with hereditary hemochromatosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CDMO&rdquo;
stands for Contract Development and Manufacturing Organization, a specialized type of supplier of development and production services
to the pharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;cGMP&rdquo;
is the current Good Manufacturing Practices under the US Food and Drug Administration&rsquo;s standards. cGMP contains the minimum requirements
for the methods, facilities, and controls used in the manufacturing, processing, and packing of a drug product. The regulations make
sure that a product is manufactured under conditions and tested to ensure that it meets standards of identity, strength, quality, and
purity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CMC&rdquo;
stands for chemistry, manufacturing, and controls and covers the various procedures used to assess the physical and chemical characteristics
of drug products, and to ensure their quality and consistency during manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CYP&rdquo;
stands for cytochrome P450 enzymes, which are a complex and important component of drug metabolism. It is the root of many drug interactions
due to inhibition, induction, and competition for common enzymatic pathways by different drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Cytokines&rdquo;
are a broad category of small proteins that are important in cell signaling. The release of pro-inflammatory cytokines leads to activation
of immune cells and production of and release of additional cytokines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;DNA&rdquo;
is the molecule that carries genetic information for the development and functioning of an organism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;FDA&rdquo;
is the U.S. Food and Drug Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;GMP&rdquo;
is good manufacturing practice &ndash; a standard that is observed in regulated pharmaceutical-manufacturing facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;H63D&rdquo;
is a gene mutation associated with hereditary hemochromatosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HFE
gene&rdquo; is a gene that provides instructions for producing a protein that is located on the surface of cells, primarily liver and
intestinal cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Hereditary
Hemochromatosis&rdquo; a genetic disorder that can cause severe liver disease and other health problems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;IL-17&rdquo;
or Interleukin-17 is a pro-inflammatory cytokine that modulates protective innate immunity to pathogens or contributes to the pathogenesis
of inflammatory conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;In
situ&rdquo; means in the original or normal place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Iron
Overload&rdquo; is a condition in which your body stores too much iron.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Maximum
tolerated dose&rdquo; is the highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated
dose is determined in clinical trials by testing increasing doses on different subjects until the highest dose with acceptable side effects
is found.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Metabolite&rdquo;
is a substance made or used when the body breaks down food, drugs or chemicals, or its own tissue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;mTOR&rdquo;
stands for mammalian target of rapamycin which regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling
pathways in the body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Pluripotent
stem cells&rdquo; are stem cells that are able to self-renew by dividing and developing into primary groups of cells that make up the
human body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;qPCR&rdquo;
stands for quantitative polymerase chain reaction (qPCR). qPCR is the accumulation of amplification product is measured as the reaction
progresses, in real time, with product quantification after each cycle.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="rs_005"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary highlights selected information about our company and this offering that is included elsewhere in this prospectus in
greater detail. It does not contain all of the information that you should consider before investing in our common stock. Before investing
in our common stock, you should read this entire prospectus carefully, including the information presented under the heading &ldquo;Risk
Factors&rdquo; and in our financial statements and notes thereto.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Unless
otherwise noted, the share and per share information in this prospectus reflects a 1-for-2.05 reverse stock split of our common stock
that became effective as of December 11, 2023.</I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
this prospectus, unless we indicate otherwise or the context requires, &ldquo;Telomir,&rdquo; &ldquo;the company,&rdquo; &ldquo;our company,&rdquo;
&ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;ours&rdquo; and &ldquo;us&rdquo; refer to Telomir Pharmaceuticals, Inc.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Overview</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule
being developed to function as an oral in situ therapeutic treatment for human stem cells. Based on our pre-clinical studies and if approved
by the FDA and comparable foreign regulators, we believe that TELOMIR-1 may potentially serve as a metal enzyme inhibitor of essential
metals such as zinc and copper. These essential metals play an important role in the production and function of many enzymatic reactions
and the modulation of key cellular pathways. In particular, zinc is essential to the function of pro-inflammatory cytokines such as Interleukin-17,
or IL-17, that play a role in a host of age-related inflammatory conditions such as hemochromatosis and osteoarthritis as well as in
post-chemotherapy health problems. IL-17 is a type of pro-inflammatory cytokine, and while the pro-inflammatory properties of IL-17 are
key to its host-protective capacity, unrestrained IL-17 signaling is associated with immunopathology, inflammatory disease and cancer
progression. Our initial focus will be on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral
administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. To the best of our knowledge, there is no approved oral
IL-17 inhibitor. Our goal is to advance the clinical development of TELOMIR-1 in the United States for the treatment of age-related inflammatory
conditions such as hemochromatosis and osteoarthritis, as well as in post-chemotherapy recovery, with our initial targeted indications
being hemochromatosis and post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pluripotent
stem cells are a type of stem cells that have the ability to undergo self-renewal and to give rise to various cell types of the tissues
of the body. Based on pre-clinical studies, we believe that TELOMIR-1 may have the potential to protect stem cells <I>in situ</I> by
reducing the overload of metals such as zinc and copper that accompany age-related inflammatory conditions and certain cancers by modulating
pro-inflammatory cytokines such as IL-17. If demonstrated by future clinical trials and approved by the FDA and comparable foreign
regulators, we believe TELOMIR-1 may protect the stem cells by elongating and stimulating the telomeres to sustain self-renewal
of stem cells. Telomeres are repetitive DNA sequences at the end of chromosomes that protect the chromosomes from becoming frayed or
tangled. Each time a cell divides, the telomeres become slightly shorter, and eventually they become so short that the cell can no longer
divide, with the result being that the cell dies. Effectively, telomeres protect the ends of our chromosomes by forming a cap, much like
the plastic tip on shoelaces, thereby allowing the chromosome to be replaced properly during cell division.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
is currently under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as
hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that
create the systemic imbalance of cellular metals. Our pre-clinical studies suggest that TELOMIR-1 may inhibit the concentration and accumulation
of metals such as zinc and copper in the serum that drive the hyperactivity of pro-inflammatory cytokines such as IL-17. Our studies
suggest that TELOMIR-1 may achieve this outcome by selectively binding to metal ions in a dose dependent manner, slowing enzyme reactivity,
and protecting and lengthening telomeres in the human chromosome. If demonstrated in clinical trials and approved by the FDA and
comparable foreign regulators, we believe that TELOMIR-1 has potential as a non-toxic oral enzyme inhibitor that may regulate the overactivity
of the enzymes caused by excessive metal reactivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were organized as a Florida corporation in August 2021 for the purpose of pursuing the development and commercialization of TELOMIR-1
in the United States in human applications. We were originally incorporated under the name &ldquo;Metallo Therapies Inc.&rdquo; and changed
our name to &ldquo;Telomir Pharmaceuticals, Inc.&rdquo; in October 2022. We are an early-stage company that had net losses of $0.14 million
and $0.85 million for the years ended December 31, 2021 and 2022, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
Situ Therapeutic Treatment of Stem Cells</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem
cells have the potential to renew themselves. They can develop into many different cell types in the body during early and adult life.
Pluripotent stem cells have the ability to differentiate into all of the cells of the adult body. Since pluripotent stem cells are undifferentiated,
they do not have any tissue-specific characteristics that allow them to perform specialized functions. Given their unique regenerative
abilities and limited quantities in the adult human body, <I>in situ</I> treatment and protection of stem cells may provide an important
therapeutic mechanism for treatment of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Metal
Overload and Telomere Length</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
studies have demonstrated that metal overload in stem cells could severely impair the proliferation of pluripotent stem cells through
excessive DNA damage. Furthermore, many pro-inflammatory cytokine-induced conditions create an imbalance of cellular metals such as zinc
and copper. This metal imbalance may impact the length of telomeres in stem cells and impact their ability to sustain self-renewal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Hemochromatosis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the CDC, hemochromatosis is a disorder in which the body builds up too much iron in the skin, heart, liver, pancreas, pituitary glands,
and joints. This overload of iron is toxic to the body, and over time, the high levels of iron can damage tissues and organs and lead
to conditions such as liver damage, liver cancer, heart problems, arthritis, and diabetes. Other conditions associated with high iron
levels include inflammatory conditions, chronic kidney disease, and autoimmune disorders. Hemochromatosis is a life-long condition requiring
regular treatment to avoid long-term serious effects with poor pharmacologic options. The most used treatment for hemochromatosis is
phlebotomy, a procedure to remove some of the patient&rsquo;s blood. Phlebotomy is relatively inexpensive, well accepted, and well tolerated,
but it requires regular visits to health care professionals and blood draws and may not be appropriate for all patients. Additionally,
iron chelators, <FONT STYLE="background-color: white">which are molecules that bind to iron to help the body excrete it,</FONT> are sometimes
used, but they have limited use due to gastrointestinal and kidney toxicity issues. Iron chelators can be natural or synthetic and are
used to treat iron overload, which can occur after regular blood transfusions. Despite the presence of these potential treatment options,
we believe significant unmet need remains such that an innovative therapy achieving reduction in iron overload with a new profile could
be subject to widespread use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are pursuing TELOMIR-1 as a metal enzyme inhibitor that, if approved by the FDA and comparable foreign regulators, may selectively bind
metal ions to inhibit pro-inflammatory cytokines such as IL-17 and protect telomeres and that aims to increase the average telomere length,
or ATL, by selectively binding iron and reducing blood iron levels, therefore supporting the ability to treat hemochromatosis. On average,
about 750,000 US patients express one or more iron overload symptoms. There are 2 types of hemochromatosis, with the following patient
mix: 150,000 primary hemochromatosis and 65,000 secondary hemochromatosis confirmed diagnoses in the United States. Over 150,000 patients
have sought treatment since 2018, with most receiving phlebotomy, which is the withdrawal of blood to bring iron to normal levels. At
present, 99% of hemochromatosis patients receive phlebotomy, with a portion of patients also receiving iron chelators as a co-treatment.
Note that in the last 12 months, there have been 76,000 confirmed diagnoses of hereditary hemochromatosis and approximately 1% of hemochromatosis
patients received deferasirox or deferoxamine off-label for 12 weeks (1 year for primary).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
sub-groups of hemochromatosis patients may benefit from TELOMIR-1, in addition to phlebotomy, which is the current standard of care for
the treatment of hemochromatosis, if contraindicated for this treatment method. Lastly, iron chelation is used off-label, poorly tolerated
and has toxic long-term effects. In pre-clinical stage testing, TELOMIR-1 may have more effective metal complexing than Doxycycline,
an FDA-approved metalloproteinases (&ldquo;MMP&rdquo;) inhibitor. However, pre-clinical data may prove inaccurate and is not necessarily
indicative of future results. MMP inhibitors act as &ldquo;brakes&rdquo; for enzymes in our body. MMP enzymes sometimes become too active
and break down compounds and structures they should not, such as the body&rsquo;s tissues. MMP inhibitors are compounds that typically
slow down or stop these overactive enzymes, preventing them from causing damage to our tissues. They act as a control switch to keep
the body in balance and protect it from harm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Post-Chemotherapy
Recovery</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-chemotherapy
recovery from adverse effects of antineoplastic treatments is often important for cancer therapy success. While chemotherapy treatment
can be highly effective for cancer, it can also come with many side effects, as chemotherapy drugs destroy both cancerous and healthy
cells. We are investigating the use of TELOMIR-1 as a potential complementary treatment for patients receiving chemotherapy in the form
of a twice daily, oral regimen to inhibit pro-inflammatory cytokines and to reduce blood iron levels, enabling potentially more effective
adherence and improved outcomes. In exploratory early discovery studies, proof of concept was demonstrated, and the animal studies are
pending. Post-chemotherapy recovery space contains several treatments that are used symptomatically based on the nature or severity of
side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that post-chemotherapy recovery presents several potential unmet commercial needs for TELOMIR-1. There is potential to enable
a more rapid recovery of patients receiving chemotherapy, improving adherence with chemotherapy regimens. Additionally, as current recovery
management is based on severity and treated as needed, we believe that TELOMIR-1 could potentially be used as a preventative measure.
As a complementary treatment, side effect reduction in post-chemotherapy is important to minimize patient burden while improving treatment
outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
Strategy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to develop and commercialize new treatment options for treatment of age-related inflammatory conditions, with hemochromatosis
as our initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader
range of other age-related inflammatory diseases and conditions such as osteoarthritis. The key elements of our strategy to achieve this
goal include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advancing TELOMIR-1 through
    clinical development and approval for hemochromatosis. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing pre-clinical
    development of TELOMIR-1 for post-chemotherapy recovery and across a range of inflammatory diseases associated with cellular aging.
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploring strategic collaborations
    to maximize the value of TELOMIR-1.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pre-Clinical
Studies</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have completed several pre-clinical proof-of-concept studies with respect to TELOMIR-1 that were designed to demonstrate that
TELOMIR-1 is not mutagenic and has good biological and metal binding capabilities. These studies included an Ames test for the TELOMIR-1
compound and several Eurofins BioMap studies. Eurofins BioMAP studies are scientific experiments that help with understanding how different
chemicals or drugs impact the human body. These <I>in vitro</I> studies use cells and tissues to see how they react when exposed to various
substances. BioMAP studies may demonstrate the safety and efficacy of drugs and chemicals in treatment of diseases. They assist researchers
in assessing whether a substance, at microscopic level, has a positive or negative impact on health of the subject by studying how it
interacts within the cells or with other cells. The Ames test assesses whether a chemical or substance causes DNA mutations. Scientists
use this test to figure out if a chemical might be harmful and could potentially cause cancer because DNA mutations are often linked
to cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Eurofins <I>in vitro</I> studies showed that TELOMIR-1 was more active against malignant cells, colorectal cancer cells, and lung cancer
cells than rapamycin. Rapamycin is a compound that has anti-tumor and immunosuppressive properties, and it was selected to compare
against TELOMIR-1 because rapamycin and TELOMIR-1 both inhibit similar cytokines involved in immune responses. Several pro-inflammatory
cytokines are common proteins that are affected by TELOMIR-1 and rapamycin. Rapamycin is also known by the brand names Rapamune and
Sirolimus. It is a mammalian target of rapamycin (mTOR) inhibitor which works by slowing down cellular multiplication. mTOR inhibitors
have been associated with anemia (a condition characterized by a low red blood cell count or low hemoglobin levels) due to a change in
iron metabolism. Rapamycin is used to prevent organ transplant rejection and to treat certain types of cancer. mTORs regulates cell proliferation,
autophagy, and apoptosis by participating in multiple signaling pathways in the body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doxycycline
possesses anti-inflammatory properties that are in part attributed to its ability to chelate metal ions such as zinc, which are involved
in the enzymatic processes related to inflammation. In particular, doxycycline has been shown to inhibit the TNF-&alpha; Converting Enzyme
(TACE) as this enzyme requires zinc to function. Inhibition of TACE in turn leads to decreased systemic levels of the active TNF-&alpha;,
which is implicated in inflammation and autoimmune diseases. This action contributes to the anti-inflammatory properties of doxycycline,
which are beneficial in diseases such as rheumatoid arthritis and inflammatory skin conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to doxycycline, TELOMIR-1 is also a metal ion chelating drug, which underlies its ability to inhibit TACE by competing for the zinc that
is required for its enzymatic activity. Both Doxycycline and TELOMIR-1inhibit the enzymatic activity of TACE which plays a key role in
both acute and chronic inflammation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thus,
doxycycline is a reasonable choice for comparison with TELOMIR-1 since, similar to doxycycline TELOMIR-1 is believed to exert its anti-inflammatory
effects by inhibiting TACE in the same manner as doxycycline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
studies showed that, in comparison to Doxycycline, TELOMIR-1 was more active at metal complexing. Extensive analysis is being
conducted on the potential of TELOMIR-1 to protect and treat stem cells and lower blood ferritin. We have also completed a variety
of toxicology studies, and several others are ongoing or planned. Upon completion of the toxicology studies, we plan to submit to
the FDA an Investigational New Drug application, IND for TELOMIR-1, focused on investigating TELOMIR-1 for the treatment of
hemochromatosis. We may consider a second IND for post-chemotherapy recovery. All pre-clinical studies described in this prospectus
were conducted with the assistance of third parties. For a summary of completed, ongoing, and planned pre-clinical studies and
development activities, see the section entitled &ldquo;Business&mdash;Pre-Clinical Studies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
Clinical Development Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
completion of our pre-clinical development program, we plan to submit to the FDA an IND, focused on investigating TELOMIR-1 for the treatment
of hemochromatosis. We may consider a second IND for post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first IND application submission investigating TELOMIR-1 for the treatment of hemochromatosis is currently planned for the third
quarter of 2024. If allowed to proceed by the FDA, a Phase I double-blind, randomized, placebo-controlled trial to evaluate the safety,
tolerability, and pharmacokinetics of TELOMIR-1 in 40-60 healthy male and female adult subjects will be initiated approximately 30 days
post-IND submission. We have contracted with Frontage Laboratories Phase I clinic in New Jersey consisting of 160 beds across three units
for normal volunteers. After the Phase I trial is complete, a Phase II trial in the hemochromatosis population is planned to commence
after results and guidance from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second IND application will likely focus on investigating TELOMIR-1 for the treatment of post-chemotherapy recovery and is planned for
submission with guidance from the FDA. Additionally, osteoarthritis may be considered as a future contender with additional guidance
from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical development plans will depend on FDA acceptance of our IND applications. As appropriate and pursuant to discussions with the
FDA, we may periodically adjust the timeline for certain filings and associated clinical trials. It is important to note that the process
for conducting clinical trials is uncertain and there is no assurance that our clinical development activities will meet the planned
timelines set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intellectual
Property</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
license the U.S. patent rights for the use of TELOMIR-1 in human applications from MIRALOGX, LLC (&ldquo;MIRALOGX&rdquo;), an intellectual
property development and holding company established by Jonnie R. Williams, Sr., the founder of our company and the sole inventor of
TELOMIR-1. MIRALOGX has filed a Patent Cooperation Treaty (PCT) application, PCT/US2023/073106 on August 29, 2023. The application designated
the U.S. and will enter U.S. national phase. The application, if granted and subject to payment of patent maintenance fees, would offer
protection extending through at least August 29, 2043 in the U.S. The patent rights for TELOMIR-1 outside of the United States are
not included in our current patent rights. Mr. Williams, our founder, does not hold any formal degrees in chemistry or certifications
related to the development of pharmaceuticals; however, he developed extensive knowledge of tobacco alkaloid chemistry in the 1990&rsquo;s
through collaboration with industry experts during his development of techniques for preventing the formation of carcinogenic tobacco-specific
nitrosamines (TSNAs) during the tobacco curing process. To better understand the mechanism by which TSNAs are formed, Mr. Williams
collaborated closely with a leading expert in tobacco chemistry at the University of Kentucky, where he developed a working knowledge
of tobacco alkaloid chemistry, which led to his development of patented curing technologies which would become the industry standard.
This work led to him focusing on the therapeutic properties of tobacco alkaloids, and later to his design of novel small molecule therapeutics.
He is a named inventor on 31 issued US patents and approximately 30 pending or published US patent applications, all of which are in
the life sciences, a field that embraces the study of living organisms, including biology, botany, zoology, and biochemistry. Approximately
20 of his issued patents and 27 of his applications involve therapeutic treatment methods, and 4 issued patents and approximately 18
applications are directed to novel small molecules, principally involving alkaloid and cannabinoid chemistries. His work on TELOMIR-1
began in late 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
license from MIRALOGX is set forth in an Amended and Restated Exclusive License Agreement, dated August 11, 2023, between the Company
and MIRALOGX, pursuant to which we obtained the exclusive perpetual right and license under the above-described patent rights to make,
have made, use, and sell &ldquo;Licensed Products&rdquo; in the U.S. for human uses and pre-clinical studies and activities of any kind
conducted in furtherance of obtaining regulatory approval or commercialization for human uses (the &ldquo;Initial MIRALOGX License Agreement&rdquo;).
On November 10, 2023, we and MIRALOGX entered into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant to which
the field of use relating to the license was amended to include therapeutic treatments and other medical or health uses in animals, in
addition to humans, and related preclinical studies and activities conducted in furtherance of obtaining regulatory approval for and
commercialization of veterinary, in addition to human, therapeutic treatments and uses (together with the &ldquo;Initial MIRALOGX License
Agreement, the &ldquo;MIRALOGX License Agreement&rdquo;). &ldquo;Licensed Product&rdquo; is defined in the agreement as a drug product
containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl)pyridine or a pharmaceutically acceptable salt, ester, or solvate
thereof. We also have the right to grant corresponding sublicenses under the licensed patent rights. The MIRALOGX License Agreement provides
for the payment to MIRALOGX of an 8% royalty (payable quarterly) on our net sales of Licensed Products by us or our sublicensees and
on non-royalty bearing milestone revenue. There are no up-front, execution, or milestone payments in the license agreement. Further,
no payments have been made to date under the agreement. For a more detailed description of the MIRALOGX License Agreement, see the section
entitled &ldquo;Business&mdash;Intellectual Property.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of risks that you should understand before making an investment decision regarding this offering. These risks are discussed
more fully in the section entitled &ldquo;Risk Factors&rdquo; following this prospectus summary. If any of these risks actually occur,
our business, financial condition, or results of operations would likely be materially and adversely affected. In such a case, the trading
price of our common stock would likely decline, and you may lose all or part of your investment. These risks include, but are not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are an early development-stage
    company with no revenues.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included
    an explanatory paragraph relating to our ability to continue as a going concern in their audit report for the year ended December
    31, 2022.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because we have a limited
    operating history, you may not be able to accurately evaluate our operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are dependent on additional
    financing for the continuation of our operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operating results may
    fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues and succeed
    overall.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have yet to achieve
    a profit and may not achieve a profit in the near future, if at all.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    of our executive officers, including our Chief Executive Officer and Chairman of our board of directors, Dr. Christopher Chapman,
    will not be employed by us on a full-time basis and will working for us on a part-time and as-needed basis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of our directors
    and officers may have actual or potential conflicts of interest because of their positions with other companies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflicts of interest may
    arise between us and MIRALOGX.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future success will
    largely depend on the success of TELOMIR-1 and any future product candidates, which development will require significant capital
    resources and years of clinical development effort.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are dependent on the
    success of our current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business may be materially
    and adversely affected in the future by the evolving effects of the COVID-19 pandemic as a result of the current and potential future
    impacts on our commercialization efforts, supply chain, regulatory and clinical development activities, and other business operations,
    in addition to the impact of a global economic slowdown.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results of pre-clinical
    studies and earlier clinical trials are not necessarily predictive indicators of future results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should we later determine
    it is in our best interest to develop a sales force we may be unable to effectively train and equip our sales force, therefore our
    ability to successfully commercialize our products may be harmed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates,
    if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate revenue from
    new products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the price for any future
    approved products decreases or if government and other third-party payers do not provide coverage and adequate reimbursement levels,
    our revenue and prospects for profitability will suffer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect to face intense
    competition, often from companies with greater resources and experience than we have.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business interruptions
    could delay us in the process of developing our product candidates and could disrupt our product sales.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have significant and
    increasing liquidity needs and may require additional funding.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results may vary
    significantly in future periods.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If product liability lawsuits
    are successfully brought against us, we will incur substantial liabilities and may be required to limit the commercialization of
    TELOMIR-1 and our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend upon our key
    personnel and our ability to attract and retain employees.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure of our information
    technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt the operation of
    our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security breaches, loss
    of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing critical
    information or expose us to liability, which could adversely affect our business and our reputation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative or regulatory
    reform of the health care system in the U.S. may affect our ability to profitably sell our products, if approved.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect additional federal
    and state legislative proposals for health care reform, which could limit the prices that can be charged for the products we develop
    and may limit our commercial opportunity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may acquire other companies
    which could divert our management&rsquo;s attention, result in additional dilution to our shareholders and otherwise disrupt our
    operations and harm our operating results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trials for our
    product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results of clinical
    trials are open to differing interpretations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any failure by us to comply
    with existing regulations could harm our reputation and operating results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The regulatory approval
    processes with the FDA are lengthy and inherently unpredictable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is a high rate of
    failure for drug candidates proceeding through clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our existing collaboration
    arrangements and any that we may enter into in the future may not be successful, which could adversely affect our ability to develop
    and commercialize our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain our cash at
    financial institutions, at times in balances that exceed federally insured limits. The failure of financial institutions could adversely
    affect our ability to pay operational expenses or make other payments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to adequately
    protect our product candidates or our proprietary technology in the marketplace.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If third parties claim
    that the Company&rsquo;s intellectual property, products, processes, or anything else used by us infringes upon their intellectual
    property, our operating profits could be adversely affected.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of the speculative
    nature of investment risk, you may lose your entire investment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $1.235 billion in annual gross revenue during our last fiscal year, we qualify as an &ldquo;emerging growth
company&rdquo; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). An emerging growth
company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies.
These provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are required to present
    only two years of audited financial statements and related management&rsquo;s discussion and analysis of financial condition and
    results of operations in the registration statement of which this prospectus is a part;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are exempt from compliance
    with the requirement that our independent registered public accounting firm provide an attestation report on the effectiveness of
    our internal control over financial reporting;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are exempt from compliance
    with any requirement that the Public Company Accounting Oversight Board (the &ldquo;PCAOB&rdquo;) has adopted regarding communication
    of critical accounting matters and may adopt regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report
    providing additional information about the audit and the financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are exempt from the
    &ldquo;say on pay,&rdquo; &ldquo;say when on pay,&rdquo; and &ldquo;say on golden parachute&rdquo; non-binding advisory vote requirements;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we can provide reduced
    disclosures about our executive compensation arrangements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to take advantage of each of the exemptions described above. It is possible, therefore, that some investors will find
our common stock less attractive, which may result in a less active trading market for our common stock and higher volatility in our
stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this
offering or such an earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon
the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues are $1.235 billion or more; (ii) the date
on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt securities; or (iii) the
date on which we are deemed to be a &ldquo;large accelerated filer,&rdquo; which will occur as of the end of any fiscal year in which
we (x) have an aggregate market value of our common stock held by non-affiliates of $700 million or more as of the last business day
of our most recently completed second fiscal quarter, (y) have been required to file annual and quarterly reports under the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), for a period of at least 12 months and (z) have filed at least one
annual report pursuant to the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, emerging growth companies may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of
this extended transition period. For risks related to our status as an emerging growth company, see &ldquo;Risk Factors&thinsp;&mdash;&thinsp;Risks
Related to Ownership of Our Common Stock&thinsp;&mdash;&thinsp;Taking advantage of the reduced disclosure requirements applicable to
&ldquo;emerging growth companies&rdquo; may make our common stock less attractive to investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &ldquo;smaller reporting company&rdquo; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of any fiscal year for so long as either: (i) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30<SUP>th</SUP>; or (ii) our annual
revenues did not equal or exceed $100 million during such completed fiscal year. To the extent we take advantage of such reduced disclosure
obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
December 11, 2023, we completed a reverse stock split of our outstanding common stock upon the filing of our Second Amended and Restated
Articles of Incorporation with the Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse
stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number.
Unless otherwise noted, the shares issuable upon the exercise of our outstanding warrants, and the exercise prices of such warrants,
have been adjusted to reflect the reverse stock split. Unless otherwise noted, the share and per share information in this prospectus
reflects the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland 21205. Our telephone number is (737) 289-0835.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is www.telomirpharma.com. The information contained on, or that can be accessed through, our website is deemed not to
be incorporated in this prospectus or to be part of this prospectus. You should not consider information contained on our website to
be part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial public offering price</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    assumed initial public offering price is $7.00 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
    share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares of common stock outstanding before this offering
    (1)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,609,814 shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares of common stock to be outstanding immediately
    after this offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,609,814
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (or 29,759,814 shares if the underwriters
    exercise the option to purchase additional shares from us in full. See &ldquo;Over-allotment Option&rdquo; below).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment Option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriters an option exercisable for a period of 45 days from the date of this prospectus to purchase from us
    in whole or in part and at any time or from time to time up to 150,000 additional shares of common stock, solely to cover
    overallotments, if any, at a purchase price equal to the initial public offering price less underwriting discounts and commissions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that we will receive net proceeds from the sale of shares of our common stock in this offering of approximately $5.9 million,
    assuming an initial public offering price of $7.00 per share, and after deducting underwriting discounts and commissions and estimated
    offering expenses payable by us. We intend to use the net proceeds from this offering to advance the clinical development of our
    programs, to fund our research and development activities, and for working capital and general corporate purposes. In order to advance
    our clinical development programs, we plan to use an estimated $3.0 million. Our management will have broad discretion in
    the application of the net proceeds from this offering and investors will be relying on the judgment of our management regarding
    the application of the proceeds. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock up</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    directors and officers, our initial stockholders holding an aggregate of 26,332,026 shares of our common stock (the &ldquo;Initial
    Stockholders&rdquo;), and other shareholders who beneficially own 3% or more of the outstanding shares of our common stock
    have agreed not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or
    securities convertible into common stock for a period of 180 days (or 365 days for the Initial Stockholders), commencing on the date
    of this prospectus, except with the prior written consent of the underwriters.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
    warrants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to issue to the representative of the underwriters or its designees at the closing of this offering, warrants to purchase
    the number of shares of our common stock equal to 5.0% of the aggregate number of shares sold in this offering (the &ldquo;Representative&rsquo;s
    Warrants&rdquo;). The Representative&rsquo;s Warrants will be exercisable at any time and from time to time, in whole or in part,
    during the four-and-a-half-year period commencing six months after the commencement of sales in this offering. The exercise price
    of the Representative&rsquo;s Warrants will equal 100% of the initial public offering price per share, subject to adjustments. The
    Representative&rsquo;s Warrants provide for registration rights (including a one-time demand registration right and piggyback registration
    rights that expire 5 years from the commencement of sales of the offering) and customary anti-dilution provisions as permitted under
    FINRA Rule 5110(g)(8). The registration statement of which this prospectus is a part also covers the Representative&rsquo;s Warrants
    and the shares of common stock issuable upon the exercise thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq Capital
    Market Symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock has been approved for listing on the Nasdaq Capital Market under the symbol &ldquo;TELO.&rdquo;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our common
    stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 11 of this prospectus for a discussion of
    factors you should carefully consider before investing in our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of shares of our common stock to be outstanding immediately after this is based on an aggregate of 28,609,814 shares of our
    common stock outstanding as of December 31, 2023, which excludes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,500,000
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock reserved for
    future issuance under the Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan, as well as any automatic increases in the number
    of shares of common stock reserved for future issuance under such plan:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">268,025 shares of our common stock to be issued
    upon the exercise of outstanding warrants at an exercise price of $15.42 per share; and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,506,035
    shares of</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> our common stock to be issued upon
    the exercise of outstanding warrants at an exercise price of $3.73 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless the context otherwise
    requires, the information presented in this prospectus assumes the following:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    the shares of our common stock to be sold in this offering are sold at the assumed initial public offering price of $7.00 per
    share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise by the underwriters
    of their over-allotment option; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise by the Representative
    of the Representative&rsquo;s Warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial data as of the dates and for the periods presented. We have derived the summary statements of
operations data for the years ended December 31, 2022 and 2021, and the balance sheet data as of December 31, 2022 and 2021, from our
audited financial statements included elsewhere in this prospectus. We have derived the summary statement of operations data for the
three months ended September 30, 2023 and 2022, and the balance sheet data as of September 30, 2023 and 2022, from our unaudited financial
statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary financial and other data should be read in conjunction with the section titled &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements and related notes included elsewhere
in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Statement
of Operations data:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating costs:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 36%; text-align: left">General and administrative expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">102,191</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">3,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">20,941</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">11,639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Related party travel costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">589,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">262,562</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">229,747</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">833,206</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">126,492</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">954,153</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">233,497</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">854,147</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">138,131</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(757,173</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,711,326</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(233,497</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(854,147</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(138,131</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Balance
Sheet data:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; padding-left: 10pt">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,452</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,419</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Due from related parties</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">130,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,730</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 10pt">Deferred Financing Costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,082,292</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,318,601</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">48,730</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Trade accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">496,027</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">404,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,735</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,517</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Due to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,293,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">581,787</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Related party line of credit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,337,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,140,528</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">986,008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,131</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,140,528</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">986,008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,131</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Preferred Stock, no par value, 100,000,000 shares authorized and none issued
    or outstanding.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common Stock, no par value; 300,000,000 shares authorized, 27,097,294 and 26,829,269 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,915,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,736,927</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(992,278</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(138,131</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Stock subscription receivable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(55,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,178,073</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(937,278</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total liabilities and stockholders&rsquo;
    deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,318,601</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">48,730</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="rs_006"></A><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below,
the section of this prospectus entitled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and our financial statements and related notes included elsewhere in this prospectus before investing in shares of our common stock.
The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of,
or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur,
our business, operating results and prospects could be materially harmed. In that event, the price of our common stock could decline,
and you could lose part or all of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Operations and Financial Condition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an early development-stage company with no revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an early development-stage enterprise that is focused on the development of a pre-clinical pharmaceutical product, we have generated
no revenue and have an accumulated deficit of $4.7 million through September 30, 2023, and $1.0 million through December 31, 2022. There
can be no assurance that sufficient funds required to pursue our development program will be generated from operations or that funds
will be available from external sources, such as debt or equity financings or other potential sources. The lack of additional capital
resulting from the inability to generate cash flow from operations, or to raise capital from external sources would force us to substantially
curtail or cease operations and would, therefore, have a material adverse effect on business. Furthermore, there can be no assurance
that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect
on our existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to overcome the circumstances that impact our ability to remain a going concern in the future through the growth of revenues with
interim cash flow deficiencies being addressed through additional equity and debt financing. We anticipate raising additional funds through
public or private financing, strategic relationships, or other arrangements in the near future to support our business operations; however,
we may not have commitments from third parties for a sufficient amount of additional capital. We cannot be certain that any such financing
will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue operations.
Our ability to obtain additional funding will determine our ability to continue as a going concern. Failure to secure additional financing
in a timely manner and on favorable terms would have a material adverse effect on our financial performance, results of operations and
stock price and require us to curtail or cease operations, sell off our assets, seek protection from our creditors through bankruptcy
proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of our common stock, and debt financing,
if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require
that we relinquish valuable rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Management
has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory
paragraph relating to our ability to continue as a going concern in their audit report for the year ended December 31, 2022.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will continue to report losses and negative cash flow for the foreseeable future. We have concluded that our historical
recurring losses from operations and negative cash flows from operations as well as our dependence on debt and other financings raise
substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to
our ability to continue as a going concern in its audit report for the year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company do not include any adjustments that might result from the outcome of this
uncertainty. These adjustments would likely include substantial impairment of the carrying amount of our assets and potential
contingent liabilities that may arise if we are unable to fulfill various operational commitments. In addition, the value of our
securities would be greatly impaired. Our ability to continue
as a going concern is dependent upon generating sufficient cash flow from operations and obtaining additional capital and financing.
If our ability to generate cash flow from operations is delayed or reduced and we are unable to raise additional funding from other
sources, we may be unable to continue in business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
we have a limited operating history, you may not be able to accurately evaluate our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have had limited operations to date. Therefore, we have a limited operating history upon which to evaluate the merits of investing in
our company. Potential investors should be aware of the difficulties normally encountered by new companies and the high rate of failure
of such enterprises. The likelihood of success must be considered in light of the problems, expenses, difficulties, complications, and
delays encountered in connection with the operations that we plan to undertake. These potential problems include, but are not limited
to, unanticipated problems relating to the ability to generate sufficient cash flow to operate our business, and additional costs and
expenses that may exceed current estimates. We expect to continue to incur significant losses into the foreseeable future. We recognize
that if the effectiveness of our business plan is not forthcoming, we will not be able to continue business operations. There is no history
upon which to base any assumption as to the likelihood that we will prove successful, and it is doubtful that we will generate any operating
revenues or ever achieve profitable operations. If we are unsuccessful in addressing these risks, our business will most likely fail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are dependent on additional financing for the continuation of our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have generated no revenues and currently operate at a loss, we are completely dependent on the continued availability of financing
in order to continue our business operations. There can be no assurance that financing sufficient to enable us to continue our operations
will be available to us in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need additional funds to complete further development of our business plan to achieve a sustainable level where ongoing operations
can be funded out of revenues. We expect that the proceeds from this Offering will provide adequate resources to fund our operations
and initial clinical development programs through January 2025. We will require further funding to fully implement our business
plan to its fullest potential and achieve our growth plans. There is no assurance that any additional financing will be available or
if available, on terms that will be acceptable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to obtain future financing or to produce levels of revenue to meet our financial needs could result in our inability to continue
as a going concern in the future and, as a result, our investors could lose their entire investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues
and succeed overall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations may fluctuate as a result of a number of factors, some of which are beyond our control including but not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic conditions
    in the geographies and industries where we sell our services and conduct operations; legislative policies where we sell our services
    and conduct operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the budgetary constraints
    of our customers; seasonality;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">success of our strategic
    growth initiatives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with the
    launching or integration of new or acquired businesses; timing of new product introductions by us, our suppliers and our competitors;
    product and service mix, availability, utilization and pricing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the mix, by state and country,
    of our revenues, personnel, and assets; movements in interest rates or tax rates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in, and application
    of, accounting rules; changes in the regulations applicable to us; and litigation matters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, we may not succeed in our business, and we could go out of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have yet to achieve a profit and may not achieve a profit in the near future, if at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet produced any revenues or profit and may not in the near future, if at all. We cannot be certain that we will be able to
realize sufficient revenue to achieve profitability. Further, many of our competitors have a significantly larger industry presence and
revenue stream but have yet to achieve profitability. Our ability to continue as a going concern in the future is dependent upon raising
capital from financing transactions, increasing revenue and keeping operating expenses below our revenue levels in order to achieve positive
cash flows, none of which can be assured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
of our executive officers, including our Chief Executive Officer and Chairman of our board of directors, Dr. Christopher Chapman,
will not be employed by us on a full-time basis and will working for us on a part-time and as-needed basis.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Christopher Chapman, our Chief Executive Officer and Chairman of our board of directors, will not be employed by our company on
a full-time basis. As intended to be provided in his employment agreement with our company, he is expected to work on a part-time and
as-needed basis. Because he will not work full time for our company, instances may occur where he may not be immediately available to
provide solutions to problems or address concerns that arise in the course of us conducting our business and thus adversely affect our
business. In addition, he can become subject to conflicts of interest because he devotes part of his working time to other business endeavors
and may have responsibilities to other entities. Although Dr. Chapman is aware of his duties and accountability to our company and to
applicable laws and policies relating to corporate opportunity and conflicts of interest, such conflicts of interest may include deciding
how much time to devote to our affairs, as well as what business opportunities should be presented to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
of our directors and officers may have actual or potential conflicts of interest because of their positions with other companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
this offering, Dr. Christopher Chapman, our Chief Executive Officer and Chairman of our board of directors, will continue to serve
as the Executive Chairman of MIRA Pharmaceuticals, Inc. (&ldquo;MIRA&rdquo;) and as a director, President, and Chief Medical Officer
of MyMD Pharmaceuticals, Inc. (&ldquo;MyMD&rdquo;). Further, each of Christos Nicholoudis, Brad Kroenig, Talhia Tuck, and Hugh McColl
serve as members of the board of directors of MIRA and will continue to serve on our board of directors following this offering,
and Mr. Nicholoudis also serves as our General Counsel and the General Counsel of MIRA. Although these persons are not full-time employees
of MyMD or MIRA, it is possible that the amount of time that they expend on their work for other companies may adversely impact the amount
of time that they can spend on their work for our company. These persons may also own or acquire shares of MyMD or MIRA common stock
and options to purchase such common stock. Their respective positions at MyMD or MIRA, as applicable, and the ownership of any equity
or equity awards of MyMD or MIRA, as applicable, creates, or may create the appearance of, conflicts of interest when these individuals
are faced with decisions that could have different implications for MyMD or MIRA than the decisions have for us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conflicts
of interest may arise between us and MIRALOGX.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MIRALOGX
holds the patent rights to TELOMIR-1. MIRALOGX is a separate intellectual property development company owned by the Bay Shore Trust,
which is an irrevocable trust established by the Company&rsquo;s founder, Jonnie R. Williams, Sr., and in which Brian McNulty is the
trustee. The Bay Shore Trust is also our largest stockholder. Additionally, our General Counsel and one of our directors, Christos
Nicholoudis, performs certain consulting work for MIRALOGX through his law firm, The Law Firm of Christos Nicholoudis PLLC, on an as-needed
basis. We have an exclusive license from MIRALOGX to develop and commercialize TELOMIR-1 in the U.S. for human and non-human applications.
Although the interests of MIRALOGX are 100% owned by the Bay Shore Trust, and neither Mr. Williams nor Mr. Nicholoudis is an officer
or director of MIRALOGX and Mr. Williams does not have voting or dispositive power over the shares of the Company held by Bay Shore Trust,
our relationship with the Bay Shore Trust, Mr. Williams, or Mr. Nicholoudis may create, or may create the appearance of, conflicts of
interest when we are faced with decisions that could have different implications for MIRALOGX than the decisions have for us. Furthermore,
in light of the license agreement that we have with MIRALOGX, if a dispute were to arise between MIRALOGX and us relating to our past
or future relationship with MIRALOGX or with respect to intellectual property matters, these potential conflicts of interest may make
it more difficult for us to favorably resolve such disputes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business and Our Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future success will largely depend on the success of TELOMIR-1 and any future product candidates, which development will require significant
capital resources and years of clinical development effort.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no drug products on the market, and all of our drug development projects are in a pre-clinical stage of development. Our
business depends almost entirely on the successful pre-clinical and clinical development, FDA regulatory approval, and commercialization
of our product candidates, principally TELOMIR-1. Investors need to be aware that substantial additional investments including pre-clinical
and clinical development and FDA regulatory submission and approval efforts will be required before we are permitted to undertake clinical
studies and market and commercialize our product candidates, if ever. It may be several years before we can commence clinical trials,
if ever. Any clinical trial will be subject to extensive and rigorous review and regulation by numerous government authorities in the
United States and other jurisdictions where we intend, if approved, to market our product candidates. Before obtaining regulatory approvals
for any of our product candidates, we must demonstrate through pre-clinical testing and clinical trials that the product candidate is
safe and effective for its specific application. This process can take many years and may include post- marketing studies and surveillance,
which would require the expenditure of substantial resources. Of the large number of drugs in development for approval in the United
States (and the rest of the world), only a small percentage will successfully complete the FDA regulatory approval financing to fund
our planned research, development, and clinical programs, we cannot assure you that any of our product candidates will be successfully
developed or commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to formulate or scale up any or all of our product candidates. There is no guarantee that any of the product candidates
will be or are able to be manufactured or produced in a manner to meet the FDA&rsquo;s criteria for product stability, content uniformity
and all other criteria necessary for product approval in the United States and other markets. Any of our product candidates may fail
to achieve their specified endpoints in clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
product candidates may not be approved even if they achieve their specified endpoints in clinical trials. The FDA may disagree with our
trial design and our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed
and commented on the design for our clinical trials. The FDA may also approve a drug for fewer or more limited indications than we request
or may grant approval contingent on the performance of costly post-approval clinical trials (i.e., Phase IV trials). In addition, the
FDA may not approve the labeling claims that we believe are necessary or desirable for the successful commercialization of our product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to expand our pipeline and obtain regulatory approval for our product candidates within the timelines we anticipate, we
will not be able to execute our business strategy effectively and our ability to substantially grow our revenues will be limited, which
would have a material adverse impact on our long-term business, results of operations, financial condition, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are dependent on the success of our current and future product candidates, some of which may not receive regulatory approval or be successfully
commercialized.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend on our ability to successfully commercialize our product candidates. Our ability to successfully commercialize our
product candidates will depend on, among other things, our ability to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully complete pre-clinical
    and other nonclinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receive regulatory approvals
    from the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">produce, through a validated
    process, in manufacturing facilities inspected and approved by regulatory authorities, including the FDA, sufficiently large quantities
    of product candidates to permit successful commercialization;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain reimbursement from
    payers such as government health care programs and insurance companies and achieve commercially attractive levels of pricing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">secure acceptance of our
    product candidates from physicians, health care payers, patients, and the medical community;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create positive publicity
    surrounding our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our spending as
    costs and expenses increase due to clinical trials and commercialization; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and enforce sufficient
    intellectual property for our product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure or delay with respect to any of the factors above could have a material adverse effect on our business, results of operations
and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business may be materially and adversely affected in the future by the evolving effects of the COVID-19 pandemic as a result of the current
and potential future impacts on our commercialization efforts, supply chain, regulatory and clinical development activities, and other
business operations, in addition to the impact of a global economic slowdown.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be materially and adversely affected in the future by the evolving effects of the COVID-19 pandemic. If we are unable
to obtain adequate supplies of personal protective equipment due to shortages or encounter other challenges related to the evolving COVID-19
pandemic, we may have to place or may experience additional limitations on our in-person activities. In addition, our increased reliance
on personnel working from home may negatively impact productivity or disrupt, delay or otherwise adversely impact our business. This
could also increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions,
any of which could adversely impact our business operations. Impacts related to the COVID-19 pandemic could materially and adversely
affect our business, our ability to generate sales of and revenues from our approved products, and our ability to advance the development
of our products and product candidates, as described elsewhere in this &ldquo;Risk Factors&rdquo; section. The magnitude of such impacts
will depend, in large part, on the ultimate duration and severity of the evolving effects of the COVID-19 pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effects of the COVID-19 pandemic continue to rapidly evolve. These effects have increased market volatility and could result in a significant
long-term disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect
our liquidity. In addition, market corrections resulting from the effects of the COVID-19 pandemic could materially affect our business
and the value of our common stock. The extent to which the evolving effects of the COVID-19 pandemic impact our business, our ability
to generate sales of and revenues from our approved products, and our clinical development and regulatory efforts will depend on future
developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate duration and severity of the pandemic,
government actions, such as travel restrictions, quarantines and social distancing requirements in the U.S. and in other countries, business
closures or business disruptions and the effectiveness of actions taken in the U.S. and in other countries to contain and treat the disease.
Accordingly, we do not yet know the full extent of potential delays or impacts on our business, sales of our products, our clinical and
regulatory activities, our research programs, healthcare systems or the global economy as a whole. However, these effects could materially
and adversely affect our business, financial condition, results of operations and growth prospects. In addition, to the extent the evolving
effects of the COVID-19 pandemic adversely affect our business, financial condition, results of operations and growth prospects, they
may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &ldquo;Risk Factors&rdquo;
section. It is also possible that future global pandemics could also occur and materially and adversely affect our business, financial
condition, results of operations and growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 2.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
positive results from future pre-clinical testing of our product candidates and potential future clinical trials may not necessarily
be predictive of the results from Phase I, Phase II or Phase III clinical trials. In addition, our interpretation of results derived
from clinical data or our conclusions based on our pre-clinical data may prove inaccurate. Frequently, pharmaceutical and biotechnology
companies have suffered significant setbacks in clinical trials after achieving positive results in pre-clinical testing and early phase
clinical trials, and we cannot be certain that we will not face similar setbacks. These setbacks may be caused by the fact that pre-clinical
and clinical data can be susceptible to varying interpretations and analyses. Furthermore, certain product candidates may perform satisfactorily
in pre-clinical studies and clinical trials, but nonetheless fail to obtain FDA approval or appropriate approvals by the appropriate
regulatory authorities in other countries. If we fail to produce positive results in our clinical trials for our product candidates,
the development timeline and regulatory approval and commercialization prospects for them and as a result our business and financial
prospects, would be materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have limited marketing experience, and we do not anticipate at this time establishing a sales force or distribution and reimbursement
capabilities, and we may not be able to successfully commercialize any of our product candidates if they are approved in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenues ultimately depends on our ability to sell our approved products and secure adequate third-party reimbursement.
We currently have limited experience in marketing and selling our products. We currently do not have any products approved for sale in
the United States or in any other country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our product candidates will depend on a number of factors beyond our control, including the willingness of physicians
to prescribe our products to patients, payers&rsquo; willingness and ability to pay for the drugs, the level of pricing achieved, patients&rsquo;
response to our drugs and the ability of our marketing partners to generate sales. There can be no guarantee that we will be able to
establish or maintain the personnel, systems, arrangements and capabilities necessary to successfully commercialize TELOMIR-1 or any
product candidate approved by the FDA in the future. If we fail to establish or maintain successful marketing, sales and reimbursement
capabilities or fail to enter into successful marketing arrangements with third parties, our product revenues may suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Should
we later determine it is in our best interest to develop a sales force we may be unable to effectively train and equip our sales force,
therefore our ability to successfully commercialize our products may be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to expend significant time and resources to train our sales force to be credible, persuasive, and compliant with applicable
laws in marketing TELOMIR-1 or our other product candidates to physicians for their approved uses. In addition, we must continue to train
our sales force to ensure that a consistent and appropriate message about TELOMIR-1 or our other product candidates is being delivered
to our potential customers. If we are unable to effectively train our sales force and equip them with effective materials, including
medical and sales literature to help them inform and educate potential customers about the benefits of TELOMIR-1 and our product candidates
and its proper administration, our efforts to successfully commercialize TELOMIR-1 and our product candidates could be jeopardized, which
would negatively impact our ability to generate product revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing
our growth and executing our growth strategy.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management and personnel, systems, and facilities currently in place may not be adequate to support our business plan and future growth.
As a result, we may need to further expand certain areas of our organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
need to effectively manage our operations, growth and various projects requires that we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to improve our
    operational, financial, management and regulatory compliance controls and reporting systems and procedures;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract and retain enough
    talented employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our clinical trials
    effectively;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our external manufacturing
    operations with contract research organizations effectively and in a cost-effective manner;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our development
    efforts effectively while carrying out our contractual obligations to contractors and other third parties; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may utilize the services of part-time outside consultants and contractors to perform several tasks for us, including tasks
related to compliance programs, clinical trial management, regulatory affairs, formulation development and other drug development functions.
Our growth strategy may entail expanding our use of consultants and contractors to implement these and other tasks going forward. If
we are not able to effectively expand our organization by hiring new employees and expanding our use of consultants and contractors,
we may be unable to successfully implement the tasks necessary to effectively execute on our planned research, development, manufacturing,
and commercialization activities and, accordingly, may not achieve our research, development and commercialization goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates, if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate
revenue from new products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
when product development is successful and regulatory approval has been obtained, our ability to generate sufficient revenue depends
on the acceptance of our products by physicians and patients. We cannot assure you that our product candidates will achieve the expected
level of market acceptance and revenue if and when they obtain the requisite regulatory approvals. The market acceptance of any product
depends on a number of factors, including the indication statement and warnings required by regulatory authorities in the product label.
Market acceptance can also be influenced by continued demonstration of efficacy and safety in commercial use, physicians&rsquo; willingness
to prescribe the product, reimbursement from third-party payers such as government health care programs and private third-party payers,
the price of the product, the nature of any post-approval risk, management activities mandated by regulatory authorities, competition,
and marketing and distribution support. Further, an ineffective or inefficient distribution model at launch may lead to the inability
to fulfill demand, and consequently a loss of revenue. Any factors preventing or limiting the market acceptance of our products could
have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the price for any future approved products decreases or if government and other third-party payers do not provide coverage and adequate
reimbursement levels, our revenue and prospects for profitability will suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
who are prescribed medicine for the treatment of their conditions generally rely on third-party payers to reimburse all or part of the
costs associated with their prescription drugs. Reimbursement systems in international markets vary significantly by country and by region,
and reimbursement approvals generally must be obtained on a country-by-country basis. Coverage and adequate reimbursement from governmental
healthcare programs, such as Medicare and Medicaid, and commercial payers is critical to new product acceptance. Coverage decisions may
depend upon clinical and economic standards that disfavor new drug products when more established or lower-cost therapeutic alternatives
are already available or subsequently become available. Even if we obtain coverage for products we may market, the resulting reimbursement
payment rates may require co-payments that patients find unacceptably high. Patients may not use our products if coverage is not provided,
or reimbursement is inadequate to cover a significant portion of its cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the market for our products will depend significantly on access to third-party payers&rsquo; drug formularies or lists of medications
for which third-party payers provide coverage and reimbursement. The industry competition to be included in such formularies often leads
to downward pricing pressures on pharmaceutical companies. Also, third-party payers may refuse to include a particular branded drug in
their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is
available, even if not approved for the indications for which our products are approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payers or governmental or commercial entities are developing increasingly sophisticated methods of controlling healthcare costs. The
current environment is putting pressure on companies to price products below what they may feel is appropriate. Selling our products
at less than an optimized price could impact our revenues and overall success as a company. It will be difficult to determine the optimized
price for our products. In addition, in the U.S., no uniform policy of coverage and reimbursement for drug products exists among third-party
payers. Therefore, coverage and reimbursement for our products may differ significantly from payer to payer. As a result, the coverage
determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for
the use of our products to each payer separately, with no assurance that coverage will be obtained. If we are unable to obtain coverage
of, and adequate payment levels for, products we may market to third-party payers, physicians may limit how much or under what circumstances
they will prescribe or administer them, and patients may decline to purchase them. This in turn could affect our ability to successfully
commercialize products we may market, and thereby adversely impact our profitability, results of operations, financial condition, and
future success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, where we have chosen to collaborate with a third party on product candidate development and commercialization, our partner
may elect to reduce the price of our products in order to increase the likelihood of obtaining reimbursement approvals. In many countries,
products cannot be commercially launched until reimbursement is approved and the negotiation process in some countries can exceed 12
months. In addition, pricing and reimbursement decisions in certain countries can be affected by decisions taken in other countries,
which can lead to mandatory price reductions and/or additional reimbursement restrictions across a number of other countries, which may
thereby adversely affect our sales and profitability. If countries impose prices that are not sufficient to allow us or our partners
to generate a profit, our partners may refuse to launch the product in such countries or withdraw the product from the market, which
would adversely affect sales and profitability. Events, such as price decreases, government mandated rebates or unfavorable reimbursement
decisions, could affect the pricing and reimbursement of TELOMIR-1 and our other product candidates and could have a material adverse
effect on our business, reputation, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to face intense competition, often from companies with greater resources and experience than we have.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs and medicines is highly competitive. We compete with a variety of multinational pharmaceutical
companies and specialized biotechnology companies, as well as products and processes being developed by universities and other research
institutions. Many of our competitors have developed, are developing, or will develop drugs and processes which may be competitive with
our drug candidates. Competitive products include those that have already been approved by medicines regulators and accepted by the medical
community and any new products that may enter the market. For some of our drug development programs / areas of interest, other treatment
options or products are currently available, under development, and may become commercially available in the future. If any of our product
candidates are approved for the diseases and conditions we are currently pursuing, they may compete with a range of medicines or therapeutic
treatments that are either in development, will be developed in the future or currently marketed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
companies may have a competitive advantage over us due to their size and experiences, financial resources, and institutional networks.
Many of our competitors may have significantly greater financial, technical, and human resources than we do. Due to these factors, our
competitors may have an advantage in marketing their approved drugs and may obtain regulatory approval of their drug candidates before
we are able to, which may limit our ability to develop or commercialize our drug candidates. Our competitors may also develop drugs or
medicines that are safer, more effective, more widely used and less expensive than ours. These advantages could materially impact our
ability to develop and, if approved, commercialize our product candidates successfully. Furthermore, some of these competitors may make
acquisitions or establish collaborative relationships among themselves or with third parties to increase their ability to rapidly gain
market share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
as generic versions of drug products enter the market, the price for such medicines may be expected to decline rapidly and substantially.
Even if we are the first to obtain FDA approval of one of our product candidates, the future potential approval of generics could adversely
affect the price we are able to charge, and the profitability of our product(s) will likely decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mergers
and acquisitions in the pharmaceutical and biotechnology industries may result in more resources being concentrated among a smaller number
of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
companies may compete with us in recruiting and retaining qualified scientific, management and commercial personnel, utilizing contract
manufacturing facilities or contract research organizations (CROs), or establishing clinical trial sites and subject registration for
clinical trials, as well as in acquiring technologies complementary to our research projects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Problems
in our manufacturing process, failure to comply with manufacturing regulations or unexpected increases in our manufacturing costs could
harm our business, results of operations and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing of our product candidates necessitates compliance with cGMP and other regulatory requirements in jurisdictions internationally.
We must ensure chemical consistency among our batches of products, including clinical batches and, if approved, marketing batches. Demonstrating
such consistency may require typical manufacturing controls as well as clinical data. We must also ensure that our batches conform to
complex release specifications. If we are unable to manufacture our product candidates in accordance with regulatory specifications,
including cGMP, or if there are disruptions in our manufacturing process due to damage, loss or otherwise, or failure to pass regulatory
inspections of our manufacturing facilities, we may not be able to meet current demand or supply sufficient product for use in clinical
trials, and this may also harm our ability to commercialize our product candidates on a timely or cost-competitive basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may fail to expand our manufacturing capability in time to meet market demand for our products and product candidates, and the FDA may
refuse to accept our facilities or those of our contract manufacturers as being suitable for the production of our products and product
candidates. Any problems in our manufacturing process could have a material adverse effect on our business, results of operations and
financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, before we can begin commercial manufacture of any product candidates for sale in the U.S., we must obtain FDA regulatory approval
for the product, which requires a successful FDA inspection of our manufacturing facilities and those of our contract manufacturers,
processes, and quality systems in addition to other product-related approvals. Although we may successfully navigate this pre-approval
inspection process as it relates in the U.S., pharmaceutical manufacturing facilities are continuously subject to post-approval inspection
by the FDA and foreign regulatory authorities. Due to the complexity of the processes used to manufacture our product candidates, we
may be unable to initially or continue to pass federal, state or international regulatory inspections in a cost-effective manner. If
we are unable to comply with manufacturing regulations, we may be subject to fines, unanticipated compliance expenses, recall or seizure
of any approved products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or
civil prosecution. These possible sanctions would adversely affect our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Business
interruptions could delay us in the process of developing our product candidates and could disrupt our product sales.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development activities are conducted through outside contractors and manufacturers. Loss of our contracted manufacturing
facilities, stored inventory or laboratory facilities through fire, theft or other causes, or loss of our raw material, could have an
adverse effect on our ability to continue product development activities and to conduct our business. Failure to supply our partners
with commercial product may lead to adverse consequences, including the right of partners to take over responsibility for product supply.
We currently do not have insurance coverage to compensate us for such business interruptions. Our contract manufacturers and suppliers
provide that in their separate operations; however, such coverage may prove insufficient to fully compensate us for the damage to our
business resulting from any significant property or casualty loss to those facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have significant and increasing liquidity needs and may require additional funding.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations have consumed substantial amounts of cash since inception. For the nine months ended September 30, 2023, we reported a net
operating cash outflow of $2.8 million and a net cash inflow from financing activities of $2.8 million. For the year ended December 31,
2022, we reported a net operating cash outflow of $0.5 million and a net cash inflow from investing activities of $0.5 million. For the
year ended December 31, 2021, we reported a net operating cash outflow of $0.1 million and a net cash inflow from investing activities
of $0.1 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development, and general and administrative expenses, and cash used for operations will continue to be significant and may increase
substantially in the future in connection with new research and development initiatives and continued product commercialization efforts.
We may need to raise additional capital to fund our operations, continue to conduct clinical trials to support potential regulatory approval
of marketing applications and to fund commercialization of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of FDA approval,
    if any, and approvals in international markets of our product candidates, if at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and amount of
    revenue from sales of our products, or revenue from grants or other sources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rate of progress and
    cost of our clinical trials and other product development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of establishing or
    outsourcing sales, marketing, and distribution capabilities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs and timing of completion
    of expanded in-house manufacturing facilities as well as any outsourced commercial manufacturing supply arrangements for our product
    candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of filing, prosecuting,
    defending, and enforcing any patent claims and other intellectual property rights associated with our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of competing
    technological and market developments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel, facilities,
    and equipment requirements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and timing of
    any additional collaborative, licensing, co-promotion, or other arrangements that we may establish.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we expect to fund our future capital requirements from several sources including existing cash balances, future cash flows from operations
and the proceeds from equity offerings, we cannot assure you that any of these funding sources will be available to us on favorable terms,
or at all. Further, even if we can raise funds from all of the above sources, the amounts raised may not be sufficient to meet our future
capital requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
results may vary significantly in future periods.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expenses and operating results have fluctuated in the past and our revenues, expenses, and operating results are likely to fluctuate
significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial sales of our
    products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our achievement of product
    development objectives and milestones;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trial enrollment
    and expenses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">research and development
    expenses; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and nature of
    contract manufacturing and contract research payments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus,
small declines in revenue could disproportionately affect financial results in a quarter. Because of these factors, our financial results
in one or more future quarters may fail to meet the expectations of securities analysts or investors, which could cause our share price
to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
product liability lawsuits are successfully brought against us, we will incur substantial liabilities and may be required to limit the
commercialization of TELOMIR-1 and our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have never had any product liability claims or lawsuits brought against us, we face potential product liability exposure related to
the testing of our product candidates in human clinical trials. We may face exposure to claims by an even greater number of persons when
we begin to market and distribute our products commercially in the U.S., Europe and elsewhere. Now, and in the future, an individual
may bring a liability claim against us alleging that TELOMIR-1 or one of our product candidates caused an injury. While we continue to
take what we believe are appropriate precautions, we may be unable to avoid significant liability if any product liability lawsuit is
brought against us. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side
effects. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities. Regardless
of merit or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for TELOMIR-1 and our product candidates if such product candidates are approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of related litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients and others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    cost of liability insurance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenue; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to successfully commercialize our products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Counterfeit
versions of our products could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterfeiting
activities and the presence of counterfeit products in a number of markets and over the Internet continue to be a challenge for maintaining
a safe drug supply for the pharmaceutical industry. Counterfeit products are frequently unsafe or ineffective and can be life-threatening.
To distributors and users, counterfeit products may be visually indistinguishable from the authentic version. Reports of adverse reactions
to counterfeit drugs along with increased levels of counterfeiting could be mistakenly attributed to the authentic product, affect patient
confidence in the authentic product and harm the business of companies such as ours. If our products were to be the subject of counterfeits,
we could incur reputational and financial harm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend upon our key personnel and our ability to attract and retain employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future growth and success depend on our ability to recruit, retain, manage, and motivate our employees. The inability to hire or retain
experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results. Due
to the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific,
technical, and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense
competition, we may be unable to continue to attract and retain the qualified personnel necessary for the development of our business
or to recruit suitable replacement personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
FDA or foreign regulations, provide accurate information to FDA or other regulatory authorities, comply with applicable manufacturing
standards, comply with other foreign, federal, and state laws and regulations, report information or data accurately or disclose unauthorized
activities to us. Employee misconduct could also involve the improper use of information, including information obtained during clinical
trials, or illegal appropriation of drug products, which could result in government investigations and serious harm to our reputation.
The precautions we take to detect and prevent these prohibited activities may not be effective in controlling unknown or unmanaged risks
or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such
laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions
laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties,
other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;FCPA&rdquo;),
and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and
our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons
to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions
that pose a high risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions
could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope,
or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws
might be administered or interpreted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to other laws and regulations governing our international operations, including regulations administered by the government
of the U.S. and other countries in which we operate or plan to operate, including applicable export control regulations, economic sanctions
on countries and persons, customs requirements, and currency exchange regulations, (collectively referred to as the &ldquo;Trade Control
laws&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including
the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anti-corruption
laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures,
and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity, as
well as our reputation. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control
laws by the U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
proprietary information, or that of our customers, suppliers, and business partners, may be lost or we may suffer security breaches.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we will collect and store sensitive data, including valuable and commercially sensitive intellectual
property, clinical trial data, our proprietary business information and that of our customers, suppliers and business partners, and personally
identifiable information of our customers, clinical trial subjects and employees, and patients, on our networks, and with our third-party
cloud service providers. The secure processing, maintenance and transmission of this information is critical to our operations. Despite
our security measures, our information technology and infrastructure, and that of our third parties, may be vulnerable to attacks by
hackers or breached due to employee error, malfeasance, or other disruptions. Any breach could compromise our networks and the information
stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure or other loss of information could result
in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, disrupt
our operations, damage our reputation, and cause a loss of confidence in our products and our ability to conduct clinical trials, which
could adversely affect our business and reputation and lead to delays in gaining regulatory approvals for TELOMIR-1 or other product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt
the operation of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is increasingly dependent on critical, complex, and interdependent information technology (&ldquo;IT&rdquo;) systems, including
internet-based systems, some of which are managed or hosted by third parties, to support business processes as well as internal and external
communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion,
and computer viruses, which may result in the impairment of our ability to operate our business effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are continuously evaluating and, where appropriate, enhancing our IT systems to address our planned growth, including to support our
planned manufacturing operations. There are inherent costs and risks associated with implementing the enhancements to our IT systems,
including potential delays in access to, or errors in, critical business and financial information, substantial capital expenditures,
additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced
systems, demands on management time, and costs of delays or difficulties in transitioning to the enhanced systems, any of which could
harm our business and results of operations. In addition, the implementation of enhancements to our IT systems may not result in productivity
improvements at a level that outweighs the costs of implementation, or at all. In addition, our systems and the systems of our third-party
providers and collaborators are potentially vulnerable to data security breaches which may expose sensitive data to unauthorized persons
or to the public. Such data security breaches could lead to the loss of confidential information, trade secrets or other intellectual
property, could lead to the public exposure of personal information (including personally identifiable information or individually identifiable
health information) of our employees, clinical trial patients, customers, business partners, and others, could lead to potential identity
theft, or could lead to reputational harm. Data security breaches could also result in loss of clinical trial data or damage to the integrity
of that data. In addition, the increased use of social media by our employees and contractors could result in inadvertent disclosure
of sensitive data or personal information, including but not limited to, confidential information, trade secrets and other intellectual
property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such disruption or security breach, as well as any action by us or our employees or contractors that might be inconsistent with the rapidly
evolving data privacy and security laws and regulations applicable within the United States and elsewhere where we conduct business,
could result in enforcement actions by U.S. states, the U.S. federal government or foreign governments, liability or sanctions under
data privacy laws, including healthcare laws such as HIPAA, that protect certain types of sensitive information, regulatory penalties,
other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to
our development programs, business operations and collaborations, diversion of management efforts and damage to our reputation, which
could harm our business and operations. Because of the rapidly moving nature of technology and the increasing sophistication of cybersecurity
threats, our measures to prevent, respond to and minimize such risks may be unsuccessful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Security
breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing
critical information or expose us to liability, which could adversely affect our business and our reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we, our vendors, and our third-party cloud service providers may collect and store sensitive data,
including legally protected patient health information, credit card information, personally identifiable information about our employees
and patients, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing
cloud-based and on-site systems. These applications and data encompass a wide variety of business-critical information including research
and development information, commercial information and business and financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy,
and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized
access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches, or
interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any
such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties,
publicly disclosed, lost or stolen. We have measures in place that are designed to prevent, and if necessary to detect and respond to
such security incidents, breaches of privacy, and security mandates. However, in the future, any such access, disclosure or other loss
of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such
as HIPAA in the United States and the General Data Protection Regulation in the European Union, or GDPR, government enforcement actions
and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process
samples, provide test results, share and monitor safety data, bill payers or patients, provide customer support services, conduct research
and development activities, process and prepare company financial information, manage various general and administrative aspects of our
business and may damage our reputation, any of which could adversely affect our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Legislative
or regulatory reform of the health care system in the U.S. may affect our ability to profitably sell our products, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize our future products successfully, alone or with collaborators, will depend in part on the extent to which coverage
and reimbursement for the products will be available from government and health administration authorities, private health insurers and
other third-party payers. The continuing efforts of the U.S., European, and foreign governments, insurance companies, managed care organizations
and other payers for health care services to contain or reduce health care costs may adversely affect our ability to set prices for our
products which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
in both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health
care system in ways that could affect our ability to sell our products profitably.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect additional federal and state legislative proposals for health care reform, which could limit the prices that can be charged for
the products we develop and may limit our commercial opportunity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuing efforts of government and other third-party payers to contain or reduce the costs of health care through various means may
limit our commercial opportunity. It will be time-consuming and expensive for us to go through the process of seeking coverage and reimbursement
from Medicare, Medicaid, and other governmental health programs and from private payers. Our products may not be considered cost-effective,
and government and third-party private health insurance coverage and reimbursement may not be available to patients for any of our future
products or sufficient to allow us to sell our products on a competitive and profitable basis. Our results of operations could be adversely
affected by the Patient Protection and Affordable Care Act (the &ldquo;ACA&rdquo;), changes to the ACA, and by other health care reforms
that may be enacted or adopted in the future. In addition, increasing emphasis on managed care in the U.S. will continue to put downward
pressure on the pricing of pharmaceutical products. Cost-control initiatives could decrease the price that we or any potential collaborators
could receive for any of our future products and could adversely affect our ability to generate revenue in the U.S. market and maintain
profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may acquire other companies which could divert our management&rsquo;s attention, result in additional dilution to our shareholders and
otherwise disrupt our operations and harm our operating results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future seek to acquire businesses, products, or technologies that we believe could complement or expand our product offerings,
enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention
of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not
they are consummated. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and technologies
successfully, effectively manage the combined business following the acquisition or realize anticipated cost savings or synergies. We
also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurrence
    of acquisition-related costs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management&rsquo;s attention from other business concerns;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    costs or liabilities associated with the acquisition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">harm
    to our existing business relationships with collaboration partners as a result of the acquisition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">harm
    to our brand and reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential loss of key employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
    of resources that are needed in other parts of our business; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
    of substantial portions of our available cash to consummate the acquisition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results arising from
the impairment assessment process. Acquisitions may also result in dilutive issuances of equity securities or the incurrence of debt,
which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our business,
results of operations and financial condition may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Development and Regulatory Approval of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results
of clinical trials are open to differing interpretations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are expensive, time consuming and difficult to design and implement. Regulatory agencies may analyze or interpret the results
differently than us. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates
are expected to continue for several years and may take significantly longer to complete. In addition, we, the FDA, or other regulatory
authorities, including state and local authorities, or an Institutional Review Board, or IRB, with respect to a trial at its institution,
may suspend, delay or terminate our clinical trials at any time, require us to conduct additional clinical trials, require a particular
clinical trial to continue for a longer duration than originally planned, require a change to our development plans such that we conduct
clinical trials for a product candidate in a different order, e.g., in a step-wise fashion rather than running two trials of the same
product candidate in parallel, or the DEA could suspend or terminate the registrations and quota allotments we require in order to procure
and handle controlled substances, for various reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of effectiveness of any product candidate during clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions,
    including those which cause confounding changes to the levels of other concomitant medications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates in clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects who have initiated a clinical trial but may withdraw at any time due to adverse side effects from the therapy,
    insufficient efficacy, fatigue with the clinical trial process or for any other reason;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    evolving effects of the COVID-19 pandemic;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing
    constraints;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in our manufacturing process or product formulation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining regulatory authorization to commence a trial, including &ldquo;clinical holds&rdquo; or delays requiring suspension
    or termination of a trial by a regulatory agency, such as the FDA, before or after a trial is commenced;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature, or timing of studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper dosing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply product for use in clinical trials which conforms to regulatory specification;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    results from ongoing pre-clinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our contract research organizations, or CROs, or other third-party contractors to comply with all contractual requirements or
    to perform their services in a timely or acceptable manner;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees to comply with all applicable FDA or other regulatory requirements relating to
    the conduct of clinical trials or the handling, storage, security, and recordkeeping;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    data to support regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical protocols; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with patients during or after treatment, which may result in incomplete data.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the foregoing could have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
failure by us to comply with existing regulations could harm our reputation and operating results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive regulation by U.S. federal and state governments in each of the markets where we have product candidates progressing
through the approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must also adhere to all regulatory requirements including FDA&rsquo;s Good Laboratory Practice, Good Clinical Practice, and current Good
Manufacturing Practices requirements (&ldquo;cGMP&rdquo;) pharmacovigilance requirements, advertising, and promotion restrictions, reporting
and recordkeeping requirements. If we or our suppliers fail to comply with applicable regulations, including FDA pre-or post-approval
cGMP requirements, then FDA could sanction us. Even if a drug is FDA-approved, regulatory authorities may impose significant restrictions
on a product&rsquo;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing trials. TELOMIR-1,
and any of our product candidates that may be approved in the U.S. in the future, will be subject to ongoing regulatory requirements
for manufacturing, labeling, packaging, storage, distribution, import, export, advertising, promotion, sampling, recordkeeping and submission
of safety and other post-market information, including both federal and state requirements in the U.S. In addition, manufacturers and
manufacturers&rsquo; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing
procedures conform to GMP. As such, we, and our contract manufacturers (in the event contract manufacturers are appointed in the future)
are subject to continual review and periodic inspections to assess compliance with GMP. Accordingly, we and others with whom we work
must continue to spend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, quality control
and quality assurance. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and
to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription
drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&rsquo;s
approved label.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of the product,
it may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply
with applicable regulatory requirements, a regulatory agency or enforcement authority may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    untitled or warning letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to enjoin our activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    civil or criminal penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any of our ongoing clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to approved applications submitted by us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    restrictions on our operations, including by requiring us to enter into a Corporate Integrity Agreement or closing our contract manufacturers&rsquo;
    facilities, if any; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products or require a product recall.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any government investigation of alleged violations of law could require us to expend significant time and resources in response
and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect
our ability to commercialize and generate revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval
is withdrawn, the value of our business and our operating results may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses,
divert our management&rsquo;s attention from the operation of our business and damage our reputation. We expend significant resources
on compliance efforts and such expenses are unpredictable and might adversely affect our results. Changing laws, regulations and standards
might also create uncertainty, higher expenses and increase insurance costs. As a result, we intend to invest all reasonably necessary
resources to comply with evolving standards, and this investment might result in increased management and administrative expenses and
a diversion of management time and attention from revenue-generating activities to compliance activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to federal and state healthcare laws and regulations and implementation of or changes to such healthcare laws and regulations
could adversely affect our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could
impact our ability to sell our product candidates. If we are found to be in violation of any of these laws or any other federal or state
regulations, we may be subject to administrative, civil and/or criminal penalties, damages, fines, individual imprisonment, exclusion
from federal health care programs and the restructuring of our operations. Any of these could have a material adverse effect on our business
and financial results. Since many of these laws have not been fully interpreted by the courts, there is an increased risk that we may
be found in violation of one or more of their provisions. Any action against us for violation of these laws, even if we ultimately are
successful in our defense, will cause us to incur significant legal expenses and divert our management&rsquo;s attention away from the
operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we may receive for any approved product. There have been judicial challenges
to certain aspects of the ACA and numerous legislative attempts to repeal and/or replace the ACA in whole or in part, and we expect there
will be additional challenges and amendments to the ACA in the future. At this time, the full effect that the ACA will have on our business
in the future remains unclear. An expansion in the government&rsquo;s role in the U.S. healthcare industry may cause general downward
pressure on the prices of prescription drug products, lower reimbursements, or any other product for which we obtain regulatory approval,
reduce product utilization, and adversely affect our business and results of operations. Any reduction in reimbursement from Medicare
or other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize products
for which we may receive regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval processes with the FDA are lengthy and inherently unpredictable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to market our drug candidates as medicines in the United States or other countries until we receive approval of a New
Drug Application (&ldquo;NDA&rdquo;) from the FDA or in any foreign countries until we receive the approval from the regulatory authorities
of such countries. Prior to submitting an NDA to the FDA for approval of our drug candidates we will need to have completed our pre-clinical
studies and clinical trials and demonstrate that our products meet all applicable standards of identity, strength, quality, and purity
throughout their expiration date. Successfully completing any clinical program and obtaining approval of an NDA is a complex, lengthy,
expensive, and uncertain process, and the FDA (or other country medicines regulatory body) may delay, limit, or deny approval of product
candidates for many reasons, including, among others, because:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to demonstrate that our product candidates are safe and effective in treating patients to the satisfaction of the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of clinical trials that may not meet the level of statistical or clinical significance required by the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
    with the FDA with respect to the number, design, size, conduct or implementation of clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    by the FDA to conduct additional clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disapproval
    by the FDA of certain formulations, labeling or specifications of product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">findings
    by the FDA that the data from pre-clinical studies and clinical trials are insufficient;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">findings
    by the FDA that our API or finished products do not meet all applicable standards of identity, strength, quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the interpretation of data from pre-clinical studies and clinical trials; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may change their approval policies or adopt new regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors, many of which are beyond our control, could increase development time and / or costs or jeopardize our ability to obtain
regulatory approval for our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is a high rate of failure for drug candidates proceeding through clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
there is a high rate of failure for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical
trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving
promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, FDA may disagree with our
interpretation of the data. In the event that we obtain negative results from clinical trials for product candidates or other problems
related to potential chemistry, manufacturing and control issues or other hurdles occur and our product candidates are not approved,
we may not be able to generate sufficient revenue or obtain financing to continue our operations, our ability to execute on our current
business plan may be materially impaired, our reputation in the industry and in the investment community might be significantly damaged
and the price of our common stock could decrease significantly. In addition, our inability to properly design, commence and complete
clinical trials may negatively impact the timing and results of our clinical trials and ability to seek approvals for our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are found in violation of federal or state &ldquo;fraud and abuse&rdquo; laws, we may be required to pay a penalty and/or be suspended
from participation in federal or state health care programs, which may adversely affect our business, financial condition, and results
of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we are subject to various federal and state health care &ldquo;fraud and abuse&rdquo; laws, including anti-kickback
laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect
us particularly upon successful commercialization of our products in the U.S. The Medicare and Medicaid Patient Protection Act of 1987,
or federal Anti-Kickback Statute, makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its
behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business,
including the purchase, order or prescription of a particular drug for which payment may be made under a federal health care program,
such as Medicare or Medicaid. Under federal law, some arrangements, known as safe harbors, are deemed not to violate the federal Anti-Kickback
Statute. Although we seek to structure our business arrangements in compliance with all applicable requirements, it is often difficult
to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged
under the federal Anti-Kickback Statute and Federal False Claims Act. Violations of fraud and abuse laws may be punishable by criminal
and/or civil sanctions, including fines and/or exclusion or suspension from federal and state health care programs such as Medicare and
Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions
on behalf of the government under the federal False Claims Act as well as under the false claims laws of several states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have adopted laws similar to the federal anti-kickback statute, some of which apply to the referral of patients for health care
services reimbursed by any source, not just governmental payers. There are ambiguities as to what is required to comply with these state
requirements and if we fail to comply with an applicable state law requirement, we could be subject to penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the government nor the courts have provided definitive guidance on the application of fraud and abuse laws to our business. Law enforcement
authorities are increasingly focused on enforcing these laws, and it is possible that some of our practices may be challenged under these
laws. While we believe we have structured our business arrangements to comply with these laws, it is possible that the government could
allege violations of, or convict us of violating, these laws. If we are found in violation of one of these laws, we could be required
to pay a penalty and could be suspended or excluded from participation in federal or state health care programs, and our business, results
of operations and financial condition may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Serious
adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our product candidates,
limit the scope of any approved label or market acceptance, or cause the recall or loss of marketing approval of products that are already
marketed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates prior to or after any approval for commercial sale, cause serious or unexpected side effects, or are associated
with other safety risks such as misuse, abuse or diversion, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may interrupt, delay or halt clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may deny regulatory approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for
    use, and/or impose restrictions on distribution in the form of a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) in
    connection with approval or post-approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval, require more onerous labeling statements, impose a more restrictive REMS, or require us
    to recall any product that is approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered or conduct additional clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    relationships with our collaboration partners may suffer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer. The reputational risk is heightened with respect to those of our product candidates that are being developed
    for pediatric indications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants
or if preliminary data demonstrate that our product candidates are unlikely to receive regulatory approval or unlikely to be successfully
commercialized. Following receipt of approval for commercial sale of a product we may voluntarily withdraw or recall that product from
the market if at any time we believe that its use, or a person&rsquo;s exposure to it, may cause adverse health consequences or death.
To date we have not withdrawn, recalled, or taken any other action, voluntary or mandatory, to remove an approved product from the market.
In addition, regulatory agencies, IRBs, or data safety monitoring boards may at any time recommend the temporary or permanent discontinuation
of our clinical trials or request that we cease using investigators in the clinical trials if they believe that the clinical trials are
not being conducted in accordance with applicable regulatory requirements, or that they present an unacceptable safety risk to participants.
Although we have never been asked by a regulatory agency, IRB, or data safety monitoring board to discontinue a clinical trial temporarily
or permanently, if we elect or are forced to suspend or terminate a clinical trial of any of our product candidates, the commercial prospects
for that product will be harmed and our ability to generate product revenue from that product may be delayed or eliminated. Furthermore,
any of these events may result in labeling statements such as warnings or contraindications. In addition, such events or labeling could
prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the
costs of commercializing our product candidates and impair our ability to generate revenue from the commercialization of these products
either by us or by our collaboration partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Reliance Upon Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect
our ability to develop and commercialize our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization
of our product candidates. We may, with respect to our product candidates, enter into new arrangements on a selective basis depending
on the merits of retaining commercialization rights for ourselves as compared to entering into selective collaboration arrangements with
leading pharmaceutical or biotechnology companies for each product candidate, both in the U.S. and internationally. To the extent that
we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators and the terms
of any collaboration or other arrangements that we may establish may not be favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
existing or future collaboration that we enter may not be successful. The success of our collaboration arrangements will depend heavily
on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and
resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding development,
intellectual property, regulatory or commercialization matters can lead to delays in the development process or commercialization of
the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult
to resolve if neither of the parties has final decision-making authority. Any such termination or expiration could harm our business
reputation and may adversely affect us financially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend on a limited number of suppliers for materials and components required to manufacture our product candidates. The loss of these
suppliers, or their failure to supply us on a timely basis, could cause delays in our current and future capacity and adversely affect
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on a limited number of suppliers for the materials and components required to manufacture our product candidates. As a result,
we may not be able to obtain sufficient quantities of critical materials and components in the future. A delay or interruption by our
suppliers may also harm our business, results of operations and financial condition. In addition, the lead time needed to establish a
relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new
supplier. The time and effort to qualify for and, in some cases, obtain regulatory approval for a new supplier could result in additional
costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Our dependence
on single-source suppliers exposes us to numerous risks, including the following: our suppliers may cease or reduce production or deliveries,
raise prices or renegotiate terms; our suppliers may become insolvent or cease trading; we may be unable to locate a suitable replacement
supplier on acceptable terms or on a timely basis, or at all; and delays caused by supply issues may harm our reputation, frustrate our
customers and cause them to turn to our competitors for future needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
maintain our cash at financial institutions, at times in balances that exceed federally insured limits. The failure of financial institutions
could adversely affect our ability to pay operational expenses or make other payments.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash held in non-interest-bearing and interest-bearing accounts can at times exceed the Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;)
insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance
limitations. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&rsquo;
access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in
the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability
to pay our operational expenses or make other payments, which could adversely affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend on rights to TELOMIR-1 that are or will be licensed to us. We do not own the intellectual property rights to TELOMIR-1 and any
loss of our rights to it could prevent us from selling our product.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 42.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
our present and future pipeline of treatments, TELOMIR-1 is in-licensed from another company. We do not currently own any intellectual
property rights, including the patent application that underlies this license. Our rights to use TELOMIR-1 is subject to the negotiation
of, continuation of and compliance with the terms of this license. Thus, the non-provisional patent application is not written by us
or our attorneys, and we did not have control over the drafting and prosecution. The patent owner and our licensor might not have given
the same attention to the drafting and prosecution of these patents and applications as we would have if we had been the owner of the
patent application and had control over the drafting. We cannot be certain that drafting of the licensed patent application, or patent
prosecution, by the licensor have been or will be conducted in compliance with applicable laws and regulations or will result in
valid and enforceable patents and other intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
additional research and development activity, pre-clinical testing, and/or clinical testing TELOMIR-1 is required before we will have
a chance to achieve a viable product for licensing or commercialization. Our business currently depends entirely on the successful development,
regulatory approval, and licensing or commercialization of our product candidate, which may never occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcement
of our licensed patent application or defense of any claims asserting invalidity of these patents is often subject to the control or
cooperation of our licensor. Legal action could be initiated against the owners of the intellectual property that we license and an adverse
outcome in such legal action could harm our business because it might prevent such companies or institutions from continuing to license
intellectual property that we may need to operate our business. In addition, such licensor may resolve such litigation in a way that
benefits it but adversely affects our ability to have freedom to operate to develop and commercialize TELOMIR-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and operate without infringing on the proprietary
rights of others. We may rely upon a combination of patents, trade secret protection (i.e., know-how), trademarks, licenses, and confidentiality
agreements to protect the intellectual property of our product candidates. The strengths of patents in the pharmaceutical field involve
complex legal and scientific questions and can be uncertain. Where appropriate, we seek patent protection for certain aspects of our
products and technology. However, patent protection for naturally occurring compounds is exceedingly difficult to obtain, defend and
enforce. Filing, prosecuting and defending patents throughout the world would be prohibitively expensive, so our policy is to look to
patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However, patent protection
may not be available for some of the products or technology we are developing. If we must spend significant time and money protecting,
defending, or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other
proprietary rights held by others, our business, results of operations and financial condition may be harmed. We may not develop additional
proprietary products that are patentable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical products are complex and uncertain. Although we have sought and expect to continue to seek patent
protection for our product candidates, their methods of use, and methods of manufacture, any, or all of them may not be subject to effective
patent protection. If any of our products are approved and marketed for an indication for which we do not have an issued patent, our
ability to use our patents to prevent a competitor from commercializing a non-branded version of our commercial products for that non-patented
indication could be significantly impaired or even eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of information related to our product candidates by us, or others may prevent us from obtaining or enforcing patents relating to these
products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or may design
around our patent rights. In addition, any of our issued patents may be opposed and/or declared invalid or unenforceable. If we fail
to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product to compete
with our product candidates. We may also face competition from companies who develop a substantially similar product to one of our product
candidates that is not covered by any of our patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting, defending and enforcing intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we do not own the rights to the intellectual property and technology that will be used to commercially develop our initial product candidate,
TELOMIR-1. MIRALOGX, which is a separate intellectual property development company owned by a trust established by the Company&rsquo;s
founder, holds the patent rights to TELOMIR-1, which are currently comprised of a pending non-provisional patent application. We have
an exclusive, license from MIRALOGX to develop and commercialize TELOMIR-1 in the U.S. for human and non-human applications. The term
of the license will continue through the date of the expiration of the last-to-expire licensed patent or, if later, the date of the expiration
of the last strategic partnership/sublicensing agreement covering the licensed products. The licensed patent rights are expected to extend
through 2043. We expect additional patent terms may be awarded, including additional patent terms based on the time for regulatory review
of drug products. There are no up-front, execution, or milestone payments required under the license agreement. Further, no payments
have been made to date under the agreement. We are also required to pay an 8% royalty on net sales or revenue in exchange for an exclusive,
worldwide license to patent rights, and we may bring suit in our own name to enforce our patent rights under the license agreement. In
the event we are unable to enforce our rights under the agreement or are unable to detect unauthorized use of our intellectual property,
we may lose the benefit of the licensed rights used to commercially develop TELOMIR-1. MIRALOGX will control the prosecution of the patent
applications for TELOMIR-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
third parties claim that the Company&rsquo;s intellectual property, products, processes, or anything else used by us infringes upon their
intellectual property, our operating profits could be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the
pharmaceutical industry. We may, from time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights,
or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the
future, pursue such infringement claims against us, our commercial partners or any third-party proprietary technologies we have licensed.
If we were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a
patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found
to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including
damages of up to three times the damages found or assessed, if the infringement is found to be willful, suspend the manufacture of certain
products or reengineer or rebrand our products, if feasible, or we may be unable to enter certain new product markets. Any such claims
could also be expensive and time consuming to defend and divert management&rsquo;s attention and resources. Our competitive position
could suffer as a result. In addition, if we have declined or failed to enter into a valid non-disclosure or assignment agreement for
any reason, we may not own the invention or our intellectual property, and our products may not be adequately protected. Thus, we cannot
guarantee that our product candidates, or our commercialization thereof, does not and will not infringe any third party&rsquo;s intellectual
property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have been granted a license to the right to develop TELOMIR-1 in the United States in human and non-human application, but we have not
been granted a license to the rights to patents covering TELOMIR-1 in foreign jurisdictions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been granted a license to the right to develop TELOMIR-1 in the United States but not in countries outside the United States, as
MIRALOGX has retained all rights outside the United States and may license such rights to other parties. Accordingly, MIRALOGX potentially
could develop a competing product for such jurisdictions outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
of the speculative nature of investment risk, you may lose your entire investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our securities carries a high degree of risk and should be considered as a speculative investment. We have a limited operating
history, no revenues, have not paid dividends, and are unlikely to pay dividends in the immediate or near future. The likelihood of our
success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection
with the establishment of any business. An investment in our securities may result in the loss of an investor&rsquo;s entire investment.
Only potential investors who are experienced in high-risk investments and who can afford to lose their entire investment should consider
an investment in our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
requirements of being a public company may strain our resources, divert management&rsquo;s attention and affect our ability to attract
and retain executive management and qualified board members.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a reporting issuer, we will be subject to the reporting requirements of applicable securities legislation of the jurisdiction in which
it is a reporting issuer, the listing requirements of Nasdaq and other applicable securities rules and regulations. Compliance with these
rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or
costly and increase demand on its systems and resources. Applicable securities laws will require us to, among other things, file certain
annual and quarterly reports with respect to its business and results of operations. In addition, applicable securities laws require
us to, among other things, maintain effective disclosure controls and procedures and internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to maintain and, if required, improve its disclosure controls and procedures and internal control over financial reporting to meet
this standard, significant resources and management oversight are required. Specifically, due to the increasing complexity of its transactions,
it is anticipated that we will improve our disclosure controls and procedures and internal control over financial reporting primarily
through the continued development and implementation of formal policies, improved processes and documentation procedures, as well as
the continued sourcing of additional finance resources. As a result, management&rsquo;s attention may be diverted from other business
concerns, which could harm our business and results of operations. To comply with these requirements, we may need to hire more employees
in the future or engage outside consultants, which will increase its costs and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations
and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application
in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty
regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to
continue to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general
and administrative expenses and a diversion of management&rsquo;s time and attention from revenue-generating activities to compliance
activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing
bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us,
which could adversely affect our business and financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company subject to these rules and regulations, we may find it more expensive for it to obtain director and officer liability
insurance, and it may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could
also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on
its Audit Committee and Compensation Committee, and qualified executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of disclosure of information in filings required of a public company, our business and financial condition will become more
visible, which may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful,
our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in its favor,
these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm its business
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an &ldquo;emerging growth company&rdquo; and any decision on our part to comply only with certain reduced reporting and disclosure
requirements applicable to emerging growth companies could make shares of our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act. For as long as we continue to be an emerging
growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies
that are not emerging growth companies, including, but not limited to, not being required to have our independent registered public accounting
firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in our periodic reports and exemptions from the requirements of holding a nonbinding advisory vote on
executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth
company until the fifth anniversary of the fiscal year end date following the completion of this offering, however, our status would
change more quickly if we have more than US$1.235 billion in annual revenue, if the market value of our shares of common stock held by
non-affiliates equals or exceeds US$700 million as of June 30 of any year, or we issue more than US$1.0 billion of non-convertible debt
over a three-year period before the end of that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
could find our shares less attractive if we choose to rely on these exemptions. If some investors find shares less attractive as a result
of any choice to reduce future disclosure, there may be a less active trading market for our shares and our share price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
as long as we are an &ldquo;emerging growth company&rdquo;, our independent registered public accounting firm will not be required to
attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We could be an &ldquo;emerging
growth company&rdquo; until the fifth anniversary of the fiscal year end date following the completion of this offering. An independent
assessment of the effectiveness of our internal controls could detect problems that our management&rsquo;s assessment might not. Undetected
material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we identify material weaknesses in our internal control over financial reporting, or if we are unable to comply with the requirements
of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered
public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting when
required, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our securities
could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed,
the SEC, or other regulatory authorities, which could require additional financial and management resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a &ldquo;smaller reporting company&rdquo; and, even if we no longer qualify as an emerging growth company, we may still be subject
to reduced reporting requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are a &ldquo;smaller reporting company&rdquo; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until the last day of any fiscal year for so long as either: (i) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30<SUP>th</SUP>; or (ii) our annual
revenues did not equal or exceed $100 million during such completed fiscal year. To the extent we take advantage of such reduced disclosure
obligations, it may also make the comparison of our financial statements with other public companies difficult or impossible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways
that increase the value of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion over the use of our net proceeds from this offering and you will be relying on the judgment of
our management regarding the application of these proceeds. Our management might not use our net proceeds in ways that ultimately increase
the value of your investment. We expect to use the net proceeds from this offering to advance the clinical development of our programs,
to fund our research and development activities and to fund working capital and for general corporate purposes. Our management might
not be able to yield a significant return, if any, on any investment or use of these net proceeds. You will not have the opportunity
to influence the decision on how to use the net proceeds from this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to maintain compliance with Nasdaq Listing Rules, our shares may be delisted from Nasdaq, which would result in a limited trading
market for our shares and make obtaining future debt or equity financing more difficult for the Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock has been approved for listing
on the Nasdaq Capital Market under the symbol &ldquo;TELO.&rdquo; However, there is no assurance that we will be able to
continue to maintain our compliance with the Nasdaq continued listing requirements. If we fail to do so, our securities may be de-listed
and cease trading on Nasdaq. As a result, selling our securities could be more difficult because smaller quantities of shares or warrants
would likely be bought and sold, transactions could be delayed, and security analysts&rsquo; coverage of us may be reduced. In addition,
in the event our securities are delisted, broker-dealers would face certain regulatory requirements which may discourage them from effecting
transactions in the securities and further limit the liquidity of the securities. These factors could result in lower prices and larger
spreads in the bid and ask prices for the securities. Such delisting from Nasdaq and continued or further declines in the share price
of the securities could also greatly impair our ability to raise additional necessary capital through equity or debt financing and could
significantly increase the ownership dilution to shareholders caused by our issuing equity in financing or other transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our shares were to be delisted from Nasdaq, they may become subject to the SEC&rsquo;s &ldquo;penny stock&rdquo; rules.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delisting
from Nasdaq may cause the securities of the Company to become subject to the SEC&rsquo;s &ldquo;penny stock&rdquo; rules. The SEC generally
defines a penny stock as an equity security that has a market price of less than $5.00 per share or an exercise price of less than $5.00
per share, and that is not listed on a national securities exchange, such as Nasdaq subject to certain exemptions. Therefore, if shares
of our common stock were to be delisted from Nasdaq, the securities of the Company could become subject to the SEC&rsquo;s &ldquo;penny
stock&rdquo; rules. These rules require, among other things, that any broker engaging in a purchase or sale of our securities provide
its customers with: (i) a risk disclosure document, (ii) disclosure of market quotations, if any, (iii) disclosure of the compensation
of the broker and its salespersons in the transaction, and (iv) monthly account statements showing the market values of our securities
held in the customer&rsquo;s accounts. A broker would be required to provide the bid and offer quotations and compensation information
before effecting the transaction. This information must be contained in the customer&rsquo;s confirmation. Generally, brokers are less
willing to effect transactions in penny stocks due to these additional delivery requirements. These requirements may make it more difficult
for shareholders to purchase or sell the shares of our common stock. Since the broker, not us, prepares this information, we would not
be able to assure that such information is accurate, complete or current.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase shares in this offering, the value of your shares based on our actual book value will immediately be less than the price
you paid. This reduction in the value of your equity is known as dilution. This dilution occurs in large part because our existing stockholders
paid less than the assumed public offering price when they acquired their shares of common stock. Based upon the issuance and sale of
1,000,000 shares of common stock by us in this offering at an assumed public offering price of $7.00 per share, you will
incur immediate dilution of in the net tangible book value per share. If the underwriters exercise their over-allotment option, or if
outstanding warrants to purchase shares of our common stock are exercised, investors will experience additional dilution. For
more information, see &ldquo;Dilution&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no existing market for our securities and we do not know if one will develop to provide you with adequate liquidity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has not been a public market for our securities. We cannot assure you that an active trading market for shares
of our common stock will develop following this offering, or if it does develop, it may not be maintained. You may not be able to sell
your shares of our common stock quickly or at the market price if trading in our securities is not active. The initial public offering
price for the shares of common stock offered hereby will be determined by negotiations between us and the underwriter and may not be
indicative of prices that will prevail in the trading market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Some
provisions of Florida law and our amended and restated articles of incorporation and amended and restated bylaws that will be in effect
immediately prior to the completion of this offering may have anti-takeover effects that could discourage an acquisition of us by others,
even if an acquisition would be beneficial to our shareholders, and may prevent attempts by our shareholders to replace or remove our
current management.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, our status as a Florida corporation and the anti-takeover provisions of the Florida Business Corporation
Act, which we sometimes refer to as the FBCA, may discourage, delay or prevent a change in control even if a change in control would
be beneficial to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
control share acquisition statute, Section 607.0902 of the FBCA, generally provides that in the event a person acquires voting shares
of the company in excess of 20% of the voting power of all of our issued and outstanding shares, such acquired shares will not have any
voting rights unless such rights are restored by the holders of a majority of the votes of each class or series entitled to vote separately,
excluding shares held by the person acquiring the control shares or any of our officers or employees who are also directors of the company.
Certain acquisitions of shares are exempt from these rules, such as shares acquired pursuant to the laws of intestate succession or pursuant
to a gift or testamentary transfer, pursuant to a merger or share exchange effected in compliance with the FBCA if we are a party to
the agreement, or pursuant to an acquisition of our shares if the acquisition has been approved by our board of directors before the
acquisition. The control share acquisition statute generally applies to any &ldquo;issuing public corporation,&rdquo; which means a Florida
corporation which has:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    hundred or more shareholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its
    principal place of business, its principal office, or substantial assets within Florida; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    (i) more than 10% of its shareholders are resident in Florida; (ii) more than 10% of its shares are owned by residents of Florida;
    or (iii) one thousand shareholders are resident in Florida.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affiliated transaction (or so-called &ldquo;business combination&rdquo;) statute, Section 607.0901 of the FBCA, provides that we may
not engage in certain mergers, consolidations, sales of assets, issuances of stock, reclassifications, recapitalizations, and other affiliated
transactions with any &ldquo;interested shareholder&rdquo; for a period of three years following the time that such shareholder became
an interested shareholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to the time that such shareholder became an interested shareholder, our board of directors approved either the affiliated transaction
    or the transaction which resulted in the shareholder becoming an interested shareholder; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned
    at least 85% of our voting shares outstanding at the time the transaction commenced; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    or subsequent to the time that such shareholder became an interested shareholder, the affiliated transaction is approved by our board
    of directors and authorized at an annual or special meeting of shareholders, and not by written consent, by the affirmative vote
    of at least two-thirds of the outstanding voting shares which are not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;interested shareholder&rdquo; is generally defined as any person who is the beneficial owner of more than 15% of our outstanding
voting shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
voting requirements set forth above do not apply to a particular affiliated transaction if one or more conditions are met, including,
but not limited to, the following: if the affiliated transaction has been approved by a majority of our disinterested directors; if we
have not had more than 300 shareholders of record at any time during the three years preceding the date the affiliated transaction is
announced; if the interested shareholder has been the beneficial owner of at least 80% of our outstanding voting shares for at least
three years preceding the date the affiliated transaction is announced; or if the consideration to be paid to the holders of each class
or series of voting shares in the affiliated transaction meets certain requirements of the statute with respect to form and amount, among
other things.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the control share acquisition statute and the affiliated transactions statute may have the effect of discouraging or preventing certain
change of control or takeover transactions involving us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our amended and restated articles of incorporation and amended and restated bylaws that will be in effect immediately prior
to the completion of this offering contain provisions that may make it more difficult for a third party to acquire us or increase the
cost of acquiring us, even if doing so would benefit our shareholders, including transactions in which shareholders might otherwise receive
a premium for their shares. These provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nothing
    in our amended and restated articles of incorporation precludes future issuances without shareholder approval of the authorized but
    unissued shares of our common stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    notice procedures apply for shareholders to nominate candidates for election as directors or to bring matters before an annual meeting
    of shareholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    special meeting of shareholders can only be called by our chairman of the board of directors, our chief executive officer, our president
    (in the absence of a chief executive officer), a majority of our board of directors or the holders of 10% or more of all of our votes
    entitled to be cast on any issue proposed to be considered at the special meeting of shareholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    provision in our amended and restated articles of incorporation or amended and restated bylaws provides for cumulative voting, which
    limits the ability of minority shareholders to elect director candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">directors
    will only be able to be removed for cause;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    amended and restated articles of incorporation authorizes undesignated preferred stock, the terms of which may be established and
    shares of which may be issued, without the approval of the holders of our capital stock; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    litigation against us can only be brought in Florida.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions could discourage, delay or prevent a transaction involving a change in control of our company. These provisions could also
discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and cause us
to take corporate actions other than those you desire. See &ldquo;Description of Capital Stock.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
amended and restated bylaws that will be in effect immediately prior to the completion of this offering designates the state courts located
within the state of Florida as the exclusive forum for substantially all disputes between us and our shareholders and the federal district
courts as the exclusive forum for Securities Act claims, which could limit our shareholders&rsquo; ability to obtain a favorable judicial
forum for disputes with us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws that will be in effect immediately prior to the completion of this offering provide that, unless we consent
in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought
on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers
or other employees to us or our shareholders, (iii) any action arising pursuant to any provision of the FBCA, our amended and restated
articles of incorporation or our amended and restated bylaws, or (iv) any other action asserting a claim that is governed by the internal
affairs doctrine shall be a state court located within the state of Florida (or, if a state court located within the state of Florida
does not have jurisdiction, the federal district court for the Middle District of Florida); provided that, the exclusive forum provision
will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or to any claim for which the federal courts
have exclusive jurisdiction. Our amended and restated bylaws that will be in effect immediately prior to the completion of this offering
also provide that, unless we consent in writing to the selection of an alternative forum, the U.S. federal district courts shall be the
exclusive forum for the resolution of any claims arising under the Securities Act. Under the Securities Act, federal and state courts
have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot
waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether
a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
becoming a shareholder in our company, you will be deemed to have notice of and have consented to the provisions of our amended and restated
bylaws related to choice of forum. The choice of forum provisions in our amended and restated bylaws may limit our shareholders&rsquo;
ability to obtain a favorable judicial forum for disputes with us. Additionally, the enforceability of choice of forum provisions in
other companies&rsquo; governing documents has been challenged in legal proceedings, and it is possible that, in connection with any
applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated bylaws
to be inapplicable or unenforceable in such action. If so, we may incur additional costs associated with resolving such action in other
jurisdictions, which could harm our business, results of operations, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Securities
or industry analysts may not regularly publish reports on us, which could cause the price of our securities or trading volumes to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our securities could be influenced by research and reports that industry and/or securities analysts may publish us,
our business, the market or our competitors. We do not have any control over these analysts and cannot be assured that such analysts
will cover us or provide favorable coverage. If any of the analysts who may cover our business change their recommendation regarding
our securities adversely, or provide more favorable relative recommendations about our competitors, the price of our securities would
likely decline. If any analysts who may cover our business were to cease coverage or fail to regularly publish reports on us, we could
lose visibility in the financial markets, which in turn could cause the price of our securities or trading volumes to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will likely conduct further offerings of our equity securities in the future, in which case your proportionate interest may become diluted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will likely be required to conduct equity offerings in the future to finance our current projects or to finance subsequent projects that
we decide to undertake. If our common stock shares are issued in return for additional funds, the price per share could be lower than
that paid by our current shareholders. We anticipate continuing to rely on equity sales of our common stock shares in order to fund our
business operations. If we issue additional common stock shares or securities convertible into shares of our common stock, your percentage
interest in us could become diluted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise
adversely affect holders of our common stock, which could depress the price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes us to issue one or more series of preferred stock. Our board of directors will have the authority
to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting
any series and the designation of such series, without any further vote or action by our shareholders. Our preferred stock could be issued
with voting, liquidation, dividend and other rights superior to the rights of our common stock. The potential issuance of preferred stock
may delay or prevent a change in control of us, discouraging bids for our common stock at a premium to the market price, and materially
adversely affect the market price and the voting and other rights of the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have never declared or paid any cash dividends or distributions on our capital stock. We do not anticipate paying any cash dividends
on our common stock in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends or distributions on our capital stock. We currently intend to retain our future earnings,
if any, to support operations and to finance expansion and therefore we do not anticipate paying any cash dividends on our common stock
in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
declaration, payment and amount of any future dividends will be made at the discretion of the board of directors, and will depend upon,
among other things, the results of our operations, cash flows and financial condition, operating and capital requirements, and other
factors as the board of directors considers relevant. There is no assurance that future dividends will be paid, and, if dividends are
paid, there is no assurance with respect to the amount of any such dividend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_001"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to us from the sale of shares of common stock by us in this offering will be approximately $5.9 million, assuming
an initial public offering price of $7.00 per share, and
after deducting underwriting discounts and commissions and estimated offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $3.0 million to advance our clinical development programs, including:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $2.0 million to fund our pre-clinical animal toxicology studies and CMC activities,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $0.3 million for expenses associated with our initial IND application, and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $0.7 million for expenses relating to our Phase I clinical trials for TELOMIR-1; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    remaining amounts to fund working capital and general corporate purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current operating plan, we believe that the net proceeds of this offering, together with our existing cash and cash
equivalents, will be sufficient to fund our operations and our planned development and research activities through at
least January 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot specify with certainty the particular uses of the net proceeds that we will receive from this offering or the amounts we actually
spend on the uses set forth above. Pending the use of proceeds from this offering as described above, we plan to invest the net proceeds
that we receive in this offering in short-term and intermediate-term interest-bearing obligations, investment-grade investments, certificates
of deposit or direct or guaranteed obligations of the U.S. government. Our management will have broad discretion in the application of
the net proceeds from this offering and investors will be relying on the judgment of our management regarding the application of the
proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_002"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid dividends on our capital stock. We currently intend to retain all available funds and future earnings, if
any, for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future.
Investors should not purchase our common stock with the expectation of receiving dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_003"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and cash equivalents, as well as our total capitalization, as of September 30, 2023 (after giving
effect to the 1-for-2.05 reverse stock split that occurred on December 11, 2023):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma basis giving effect to the following: (i) the incurrence of, in the aggregate, an additional $0.5 million in debt from
    September 30, 2023 through November 30, 2023, and (ii) the conversion of an aggregate of $3.1 million of outstanding debt into 1,512,478
    shares of common stock, as described below, on November 30, 2023; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma as adjusted basis to give effect to our issuance and sale of 1,000,000 shares of our common stock in this offering (assuming
    no exercise of the underwriters&rsquo; overallotment option) at an assumed initial public offering price of $7.00 per share, and
    after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this table together with our financial statements and related notes and the section titled &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; that are included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
    Forma<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
                                            Forma</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
                                            Adjusted <SUP>(2)</SUP></B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-weight: bold; padding-bottom: 1.5pt">Cash</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">2,452</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">2,452</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">5,875,666</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Related party line of credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,337,914</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Due to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,293,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">525</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">525</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; deficit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding, actual,
    pro forma, and pro forma as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common Stock, no par value; 300,000,000 shares authorized, 27,097,294 issued and outstanding, actual;
    28,609,814 issued and outstanding, pro forma; and 29,609,814 shares issued and outstanding
    pro forma as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,915,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,015,579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,888,793</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,736,927</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,736,927</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,736,927</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,178,073</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,278,652</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,151,866</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,809,057</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,279,177</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">11,152,391</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    the conversion on November 30, 2023 of approximately (i) $1.7 million of outstanding debt due to MIRALOGX LLC into 837,841
    shares of common stock, and (ii) $1.4 million of outstanding debt due to the Bay Shore Trust into 674,637 shares of common stock,
    each such conversion made at a conversion price of $2.05 per share (after giving effect to the 1-for-2.05 reverse stock split that
    occurred on December 11, 2023). See &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&mdash;Liquidity
    and Capital Resources.&rdquo; Share amounts are approximate and actual amounts may differ due to rounding of fractional shares
    in connection with the reverse stock split.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    $1.00 increase or decrease in the assumed initial public offering price per share of our common stock would increase or decrease
    each of cash, additional paid-in-capital and total capitalization on a pro forma as adjusted basis by approximately $0.92 million,
    assuming the number of shares of our common stock offered by us remains the same and after deducting the estimated underwriting discounts
    and commissions and offering expenses payable by us.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_004"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the public offering price per share of our common stock and the pro forma net tangible book value per share of our common stock
immediately after this offering. Dilution in pro forma net tangible book value per share to new investors represents the difference between
the amount per share paid by purchasers of shares of our common stock in this offering and the pro forma net tangible book value per
share of our common stock immediately after completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
tangible book value per share is determined by dividing our total tangible assets less our total liabilities and common stock in stockholders&rsquo;
equity (deficit) by the number of shares of our common stock outstanding. Our historical net tangible book value (deficit) as of September
30, 2023, was approximately $2.1 million, or $0.08 per share. Our pro forma net tangible book value as of September 30, 2023 was
approximately $2.0 million, or $0.06 per share, adjusted to give effect to the following: (i) the incurrence of, in the aggregate,
an additional $0.5 million in debt from September 30, 2023 through November 30, 2023, and (ii) the conversion of an aggregate of $3.1
million of outstanding debt into 1,512,478 shares of common stock on November 30, 2023. After giving effect to the sale by us of shares
of our common stock in this offering at the assumed public offering price of $7.00 per share, and after deducting underwriting discounts
and commissions, and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September 30,
2023, would have been approximately $7.5 million, or $0.25 per share. This represents an immediate increase in pro forma
net tangible book value of $0.19 per share to our existing stockholders and an immediate dilution in pro forma net tangible book
value of $6.75 per share to investors purchasing shares of our common stock in this offering. The following table illustrates
this dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%">Public offering price per share of common stock</TD><TD STYLE="width: 2%; font-size: 12pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 12pt; text-align: right"></TD><TD STYLE="width: 1%; font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">7.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Historical net tangible book value per share as of September 30, 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Decrease in historical net tangible book value per share attributable to pro forma events</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 12pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 12pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Pro forma net tangible book value per share as of September 30, 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Increase in pro forma net tangible book value per share attributable to new investors purchasing
    shares of common stock in this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Pro forma as adjusted net tangible book value per share immediately after this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.25</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">Dilution in pro forma as adjusted net tangible book value per share to new common stock investors in this offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.75</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents, on a pro forma as adjusted basis as of September 30, 2023, after giving effect to (i) the incurrence of, in
the aggregate, an additional $0.5 million in debt from September 30, 2023 through November 30, 2023, (ii) the conversion of an aggregate
of $3.1 million of outstanding debt into 1,512,478 shares of common stock on November 30, 2023, and (iii) the sale by us of 1,000,000
shares of our common stock in this offering at the assumed offering price of $7.00 per share, the difference between the existing
shareholders and the new investors purchasing shares of our common stock in this offering with respect to the number of shares of
our common stock purchased from us, the total consideration paid or to be paid to us, and the average price per share paid or to be paid
to us by such shareholders during the last five years and new investors, before deducting underwriting discounts and commissions
and estimated offering expenses payable by us:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    Purchased</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Consideration</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average
    Price</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    Share</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="19" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">($
    in millions)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
    shareholders</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,609,814</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,155,579</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    investors</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,000,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,609,814</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.0</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,155,579</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.0</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the underwriters exercise in full their option to purchase 150,000 additional shares of our common stock from us in this offering, the
pro forma as adjusted net tangible book value (deficit) per share after this offering would be $0.28 per share and the dilution
to new investors in this offering would be $6.72 per share. If the underwriters exercise such option in full, the number of shares
held by new investors will increase to approximately 1,150,000 shares of our common stock, or approximately 3.74% of the total number
of shares of our common stock outstanding after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
$1.00 increase (decrease) in the assumed public offering price of $7.00 per share would increase (decrease) the pro forma
as-adjusted net tangible book value per share by $0.03, and the dilution per share to new investors in this offering by $0.97,
assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have
sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity,
as common stock, or other securities that are convertible into our common stock, such as convertible debt securities, the issuance of
these securities could result in further dilution to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_005"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of
our results of operations and financial condition. You should read the following discussion and analysis of our results of operations
and financial condition together with our financial statements and related notes and other information included elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations
that involve risks and uncertainties. Our actual results could differ materially from such forward-looking statements as a result of
various factors, including those set forth under &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo;
included elsewhere in this prospectus. Additionally, our historical results are not necessarily indicative of the results that may be
expected for any period in the future.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule
being developed to function as an oral in situ therapeutic treatment for human stem cells. Our initial focus will be on treatments to
inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for
stem cells in situ. Our goal is to advance the clinical development of TELOMIR-1 in the United States for the treatment of age-related
inflammatory conditions such as hemochromatosis and osteoarthritis, as well as in post-chemotherapy recovery, with our initial targeted
indications being hemochromatosis and post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had net losses of $3.7 million and $0.4 million for the nine months ended September 30, 2023 and 2022, respectively. We had net losses
of $0.9 million and $0.1 million for the years ended December 31, 2022 and December 31, 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
December 11, 2023, we completed a reverse stock split of our outstanding common stock upon the filing of our Second Amended and
Restated Articles of Incorporation with the Florida Secretary of State. No fractional shares were or will be issued in connection with
the reverse stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded up to the nearest
whole number. The shares issuable upon the exercise of our outstanding warrants, and the exercise prices of such warrants, have been
adjusted to reflect the reverse stock split. Unless otherwise noted, the share and per share information in this prospectus reflects
the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supply
Chain Disruption / COVID-19 Business Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the residual impact of the global COVID-19 pandemic, we have taken measures to secure our research and development activities, while
work in laboratories and facilities has been organized to reduce the risk of COVID-19 transmission. The extent of the impact of the COVID-19
pandemic on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments,
including the duration and spread of the outbreak and its impact on our clinical trials, CROs, manufacturing process, supply chain, and
other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel.
While we are experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global
supply chains and the other risks and uncertainties associated with the pandemic, our business, financial condition, and results of operations
ultimately could be materially adversely affected. Some of our suppliers have experienced delays in securing critical raw materials;
while this has not materially impacted their services, we have observed delays in certain activities. Therefore, we continue to closely
monitor the COVID-19 pandemic as we evolve our business continuity plans, clinical development plans and response strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of our Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research
and development costs as they are incurred. Research and development expenses consist primarily of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contracted
    research and manufacturing;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    arrangements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    expenses incurred to advance the Company&rsquo;s research and development activities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.25in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses have historically been the costs associated with our initial investment in pre-clinical research and development activities.
We expect research and development expenses will increase in the future as we advance TELOMIR-1 into and through clinical trials and
pursue regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory support, and contract
manufacturing. In addition, we will evaluate opportunities to acquire or in-license additional product candidates and technologies, which
may result in higher research and development expenses due to license fee and/or milestone payments, as well as added clinical development
costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely
development and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be
affected by numerous factors, including clinical data, competition, manufacturing capability and commercial viability. As a result, we
are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue
from the commercialization and sale of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of administrative functions, as well as fees paid for legal, consulting fees and facilities costs
not otherwise included in research and development expense. Legal costs include general corporate legal fees and patent costs. We expect
to incur additional expenses as a result of becoming a public company, including expenses related to compliance with the rules and regulations
of the SEC and Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of Operations for nine months ended September 30, 2023 and 2022</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating costs:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">204,902</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">11,150</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Related Party Travel costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,288,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,370,522</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">355,901</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Total operating costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">2,863,424</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">367,051</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Interest Expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(881,225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(3,744,649</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(367,051</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses.</I></B> We incurred general and administrative expenses of $0.2 million and $0.01 million during the nine
months September 30, 2023 and September 30, 2022, respectively. General and administrative expenses consisted of consulting fees, office
and rent expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Related
Party Travel Costs.</I></B> We incurred $1.3 million in related party travel costs during the nine months ended September 30, 2023. There
was no such expense incurred during the same period ended September 30, 2022. Related party travel costs consisted of a shared lease
and use of an airplane with an entity under common control. The increase in related party travel costs is due to CRO and vendor site
visits, plus IPO related efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses. </I></B>We incurred research and development expenses of $1.4 million and $0.4 million during the nine months
ended September 30, 2023 and September 2022, respectively. The increase in research and development expenses during 2023 compared to
2022 is due to the expansion of pre-clinical programs during 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
components of research and development expenses during 2023 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">R&amp;D Category</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Expense</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 76%">Toxicology</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">0.5 million</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Pre-clinical research</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5 million</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">R&amp;D consultants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4 million</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interest
expense.</I></B> We recognized $0.9 million in interest expense during the nine months ended September 30, 2023. There was no such expense
during the same period ended September 30, 2022. Interest expense during 2023 was composed of debt issuance costs related to a line of
credit financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of Operations for years ended December 31, 2022 and 2021</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating costs:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">20,941</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">11,639</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">833,206</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">126,492</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Total operating costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">854,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(854,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses.</I></B> We incurred general and administrative expenses of $0.02 million and $0.01 million during the year
ended December 31, 2022 and December 31, 2021, respectively. General and administrative expenses consisted of consulting fees, office
and rent expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses. </I></B>We incurred research and development expenses of $0.8 million and $0.1 million during the year ended
December 31, 2022 and December 31, 2021, respectively. The increase in research and development expenses during 2022 compared to 2021
is due to the expansion of pre-clinical programs during 2022 as our contract research organizations (&ldquo;CROs&rdquo;) began substantive
pre-clinical efforts on TELOMIR-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
components of research and development expenses during 2022 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">R&amp;D Category</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Expense</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 76%">Toxicology</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">0.2 million</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Pre-clinical research</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4 million</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">R&amp;D consultants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2 million</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sources
of Liquidity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the Company&rsquo;s inception in August 2021, we have financed our operations primarily through an unsecured line of credit with a major
shareholder and an affiliated company and through a private placement of shares of our common stock that occurred during the first quarter
2023. We intend to finance our clinical development programs and working capital needs from existing cash, potential new sources of debt
and equity financing, including the proceeds from our anticipated initial public offering. We may enter into new licensing and commercial
partnership agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, we entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by our founder, Jonnie
R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan Agreement (the
&ldquo;Bay Shore Note&rdquo;), we have the right to borrow up to an aggregate of $5 million from the Bay Shore Trust at any time up to
the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of our initial public offering (&ldquo;IPO&rdquo;).
Our right to borrow funds under the Bay Shore Note is subject to the absence of a material adverse change in its assets, operations,
or prospects. The Bay Share Note, together with accrued interest, will become due and payable on the second anniversary of the issuance
of the note, provided that it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at a rate equal to
7% per annum, simple interest, during the first year that the note is outstanding and 10% per annum, simple interest, thereafter.
The Bay Shore Note is unsecured. As of November 30, 2023, the total amount outstanding under the Bay Shore Note was $1.4 million.
The total amount outstanding was converted into 674,637 shares of our common stock on November 30, 2023 at a conversion rate of $2.05
per share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023) pursuant to a conversion agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
January 1, 2023, MIRALOGX, an intellectual property development and holding company owned by Bay Shore Trust, and The Starwood Trust,
a separate trust established by our founder, have advanced funds on behalf of Bayshore Trust to our company in order to fund operating
activities. The total amount advanced and outstanding as of November 30, 2023, was $1.7 million. These advances were converted
into 837,841 shares of our common stock on November 30, 2023 at a conversion rate of $2.05 per share (after giving effect to our 1-for-2.05
reverse stock split that occurred on December 11, 2023) pursuant to a conversion agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, we issued to the Bay Shore Trust a common stock purchase warrant
on June 15, 2023 giving the Bay Shore Trust the right to purchase up to 2,439,024 shares of common stock at an exercise price
of $3.73 per share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023), which
warrant will expire five years after the date of grant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023 and December 31, 2022, we had cash of $0.002 million and $0.001 million, respectively. In total, we have
raised $1.0 million in 2023 through the issuance of equity. Substantially all our equity capital has been raised at $3.73 per
share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023). We used $0.5 million in
operating activities during the year ended December 31, 2022, compared to $0.1 million in operating activities during the year ended
December 31, 2021. We expect that our existing cash and available line of credit, before our anticipated initial public offering, will
be sufficient to finance our planned level of operations through April 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commercializing or monetizing our product candidates, we anticipate that additional capital will be required to support ongoing activities
and further phases of development. Should that be required, our available capital may be consumed more rapidly than currently anticipated,
resulting in the need for additional funding. In addition, there can be no assurance that additional funding, when and if required, will
be available at commercially favorable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we may need to raise additional capital, which may be available to us through a variety of sources, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    equity markets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">private
    equity financings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercialization
    agreements and collaborative arrangements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of product royalty;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">grants
    and new license revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bank
    loans; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    or private debt.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funding, capital, or loans (including, without limitation, milestone, or other payments from potential commercialization agreements)
may be unavailable on favorable terms, if at all. If adequate funds are not available, we may be required to significantly reduce or
refocus our operations or to obtain funds through arrangements that may require us to relinquish rights to certain technologies and drug
formulations or potential markets, any of which could have a material adverse effect on us, our financial condition, and our results
of operations. To the extent that additional capital is raised through the sale of equity or convertible debt securities or exercise
of warrants and options, the issuance of such securities would result in ownership dilution to existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to attract additional funds on commercially acceptable terms, it may adversely affect our ability to achieve our development
and commercialization goals, which could have a material and adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash
Flows</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding our cash flows for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended <BR> September 30, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Year Ended<BR> December 31, 2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Period from August 2021 (Inception) to December 31, 2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash provided by (used in):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt">Operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(2,772,581</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(468,661</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(119,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">2,773,614</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">470,080</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">119,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,033</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Cash Used in Operating Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cash used in operating activities resulted primarily from our net losses and changes in components of accounts payable and accrued liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
August 2021 (inception) to December 31, 2021, operating activities used $0.12 million of cash, primarily due to a net loss of $0.14 million,
offset by a $0.02 million in accounts payable and accrued liabilities. Accounts payable and accrued liabilities was composed of research
and development payables and accrued rent expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
year ended December 31, 2022, operating activities used $0.47 million of cash, primarily due to a net loss of $0.85 million, offset by
a $0.38 million change in accounts payable. Accounts payable was composed of research and development payables and rent expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2023, operating activities used $2.8 million of cash, primarily due to a net loss of $3.7
million, offset by a $0.1 million change in accounts payable and $0.9 million in amortization of debt issuance costs. Accounts payable
was composed of research and development payables, rent and legal expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Cash Provided by Financing Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
August 2021 (inception) to December 31, 2021, financing activities provided $0.12 million of cash, resulting from $0.12 million in amounts
due to a related party. Related party advances were used to pay research and development payables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
year ended December 31, 2022, financing activities provided $0.47 million of cash, resulting from $0.46 million in amounts due to a related
party, $0.06 million in collection of stock subscription receivable, offset by a $0.05 million in deferred offering costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2023, financing activities provided $2.8 million of cash, resulting from $0.9 million from the
sale of common stock, net of deferred offering costs, and from $1.9 million in advances from affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
Funding Requirements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue from product sales. We do not expect to generate revenue from product sales unless and until
we successfully complete pre-clinical and clinical development of, receive regulatory approval for, and commercialize a program and we
do not know when, or if at all, that will occur. We expect our expenses to increase substantially in connection with our ongoing activities,
particularly as we advance the pre-clinical activities and studies and initiate clinical trials. In addition, if we obtain regulatory
approval for any programs, we expect to incur significant expenses related to product sales, marketing, and distribution to the extent
that such sales, marketing and distribution are not the responsibility of potential collaborators. Further, upon the completion of this
offering, we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating expenditure
will depend largely on the factors set out above. For more information, see the section titled &ldquo;Risk Factors-Risks Related to Our
Operations and Financial Condition.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
funding requirements and timing and amount of our operating expenditures will depend on many factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the rate of progress in the development of our TELOMIR-1 program and other development programs&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the scope, progress, results and costs of pre-clinical studies and clinical trials for any other current and future programs&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the number and characteristics of programs and technologies that we develop or may in-license&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our
programs for which we receive marketing approval&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and
the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights
and defending any intellectual property-related claims&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the costs we incur in maintaining business operations&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the costs of hiring additional clinical, quality control, manufacturing and other scientific personnel&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the costs adding operational, financial and management information systems and personnel&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the costs associated with being a public company&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the revenue, if any, received from commercial sales of our programs for which we receive marketing approval&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the effect of competing technological and market developments&#894; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration
arrangements for programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential programs, product candidates, conducting pre-clinical studies and clinical trials is a time consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our programs, if approved, may not achieve commercial success. Our commercial revenues, if any, will
be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need
to obtain substantial additional funds to achieve our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued and Adopted Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2022, we adopted Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 842 ASC Topic 842, which is intended to improve
financial reporting about leasing transactions. Under the standard, organizations that lease assets, referred to as &ldquo;Lessees&rdquo;
shall recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. In addition,
the standard requires disclosures including financial statements to assess the amount, timing and uncertainty of cash flows arising from
leases. We do not expect that the adoption of Topic 842 will materially impact our Company&rsquo;s operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under Generally Accepted
Accounting Principles (GAAP) and SEC rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quantitative
and Qualitative Disclosures about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate risks and inflation risks.
Periodically, we maintain deposits in accredited financial institutions in excess of the FDIC federally insured limits. We deposit our
cash in financial institutions that we believe have high credit quality and have not experienced any losses on such accounts and do not
believe we are exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest
Rate Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash consists of cash in readily available checking accounts. We may also invest in short-term money market fund investments. Such interest-earning
instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inflation
Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had
a material effect on our results of operations during the periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_006"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule
being developed to function as an oral <I>in situ</I> therapeutic treatment for human stem cells. Based on our pre-clinical studies and
if approved by the FDA and comparable foreign regulators, we believe that TELOMIR-1 may effectively serve as a metal enzyme inhibitor
of essential metals such as zinc and copper. These essential metals play an important role in the production and function of many enzymatic
reactions and the modulation of key cellular pathways. In particular, zinc is essential to the function of pro-inflammatory cytokines
such as Interleukin-17, or IL-17, that play a role in a host of age-related inflammatory conditions such as hemochromatosis and osteoarthritis
as well as in post-chemotherapy health problems. IL-17 is a type of pro-inflammatory cytokine, and while the pro-inflammatory properties
of IL-17 are key to its host-protective capacity, unrestrained IL-17 signaling is associated with immunopathology, inflammatory disease
and cancer progression. Our initial focus will be on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17,
by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells <I>in situ</I>. To the best of our knowledge, there is
no approved oral IL-17 inhibitor. Our goal is to advance the clinical development of TELOMIR-1 in the United States for the treatment
of age-related inflammatory conditions such as hemochromatosis and osteoarthritis, as well as in post-chemotherapy recovery, with our
initial targeted indications being hemochromatosis and post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pluripotent
stem cells are a type of stem cells that have the ability to undergo self-renewal and to give rise to various cell types of the tissues
of the body. Based on pre-clinical studies, we believe that TELOMIR-1 may have the potential to protect stem cells <I>in situ</I> by
reducing the overload of metals such as zinc and copper that accompany age-related inflammatory conditions and certain cancers by modulating
pro-inflammatory cytokines such as IL-17. If demonstrated in clinical trials and approved by the FDA and comparable foreign regulators,
we believe that TELOMIR-1 may protect the stem cells by elongating and stimulating the telomeres to sustain self-renewal of stem
cells. Telomeres are repetitive DNA sequences at the end of chromosomes that protect the chromosomes from becoming frayed or tangled.
Each time a cell divides, the telomeres become slightly shorter, and eventually they become so short that the cell can no longer divide,
with the result being that the cell dies. Effectively, telomeres protect the ends of our chromosomes by forming a cap, much like the
plastic tip on shoelaces, thereby allowing the chromosome to be replaced properly during cell division.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
is currently under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as
hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that
create the systemic imbalance of cellular metals. Our pre-clinical studies suggest that TELOMIR-1 may inhibit the concentration and accumulation
of metals such as zinc and copper in the serum that drive the hyperactivity of pro-inflammatory cytokines such as IL-17. Our studies
suggest that TELOMIR-1 may achieve this outcome by selectively binding to metal ions in a dose dependent manner, slowing enzyme reactivity,
and protecting and lengthening telomeres in the human chromosome. We believe that TELOMIR-1 has potential as a non-toxic oral enzyme
inhibitor that may regulate the overactivity of the enzymes caused by excessive metal reactivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have completed several pre-clinical proof-of-concept studies with respect to TELOMIR-1 that were designed to demonstrate that
TELOMIR-1 is not mutagenic and has good biological and metal binding capabilities. These studies included an Ames test for the TELOMIR-1
compound and several Eurofins BioMap studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were organized as a Florida corporation in August 2021 for the purpose of pursuing the development and commercialization of TELOMIR-1
in the United States in human applications. We were originally incorporated under the name &ldquo;Metallo Therapies Inc.&rdquo; and changed
our name to &ldquo;Telomir Pharmaceuticals, Inc.&rdquo; in October 2022. Our rights to develop and commercialize TELOMIR-1 are licensed
to us under a license agreement with MIRALOGX under which we have the exclusive right to develop and commercialize TELOMIR-1 for human
and non-human applications in the United States. See &ldquo;&mdash;Intellectual Property.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage company that had net losses of $3.7 million for the nine months ended September 30, 2023, $0.85 million for
the year ended December 31, 2022, and $0.14 million for the year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>In
Situ Therapeutic Treatment of Stem Cells</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem
cells have the potential to renew themselves. They can develop into many different cell types in the body during early and adult life.
Pluripotent stem cells have the ability to differentiate into all of the cells of the adult body. Since pluripotent stem cells are undifferentiated,
they do not have any tissue-specific characteristics that allow them to perform specialized functions. Given their unique regenerative
abilities and limited quantities in the adult human body, in situ treatment and protection of stem cells may provide an important therapeutic
mechanism for treatment of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Metal
Overload and Telomere Length</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
studies have demonstrated that metal overload in stem cells could severely impair the proliferation of pluripotent stem cells through
excessive DNA damage. Furthermore, many pro-inflammatory cytokine-induced conditions create an imbalance of cellular metals such as zinc
and copper. This metal imbalance may impact the length of telomeres in stem cells and impact their viability and survival.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hemochromatosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Centers for Disease Control (&ldquo;CDC&rdquo;), hemochromatosis is a disorder in which the body builds up too much iron in the
skin, heart, liver, pancreas, pituitary glands, and joints. This overload of iron is toxic to the body, and over time, the high levels
of iron can damage tissues and organs and lead to conditions such as liver damage, liver cancer, heart problems, arthritis, and diabetes.
Hemochromatosis is most commonly hereditary and caused by certain variants in the HFE gene. In the U.S., about 1 in 300 non-Hispanic
white persons have hereditary hemochromatosis, with lower rates among other races and ethnicities. Hemochromatosis can also result in
persons who need multiple blood transfusions, which can lead to excess iron build up in a condition also referred to as &ldquo;iron overload.&rdquo;
Other conditions associated with high iron levels include inflammatory conditions, chronic kidney disease, and autoimmune disorders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hemochromatosis
is a life-long condition requiring regular treatment to avoid long-term serious effects with poor pharmacologic options. The most used
treatment for hemochromatosis is phlebotomy, a procedure to remove some of the patient&rsquo;s blood. Phlebotomy is relatively inexpensive,
well accepted, and well tolerated, but it requires regular visits to health care professionals and blood draws and may not be appropriate
for all patients. Additionally, iron chelators are sometimes used, but they have limited use due to gastrointestinal and kidney toxicity
issues. Despite the presence of these potential treatment options, we believe significant unmet need remains such that an innovative
therapy achieving reduction in iron overload with a new profile could be subject to widespread use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved by the FDA and comparable foreign regulators, we are pursuing TELOMIR-1 as a metal enzyme inhibitor that may selectively bind
metal ions to inhibit pro-inflammatory cytokines such as IL-17 and protect telomeres and that aims to increase the average telomere length,
or ATL, by selectively binding iron and reducing blood iron levels, therefore supporting the ability to treat hemochromatosis. On average,
about 750,000 US patients express one or more iron overload symptoms. There are 2 types of hemochromatosis, with the following patient
mix: 150,000 primary hemochromatosis and 65,000 secondary hemochromatosis confirmed diagnoses in the United States. Over 150,000 patients
have sought treatment since 2018, with most receiving phlebotomy, which is the withdrawal of blood to bring iron to normal levels. At
present, 99% of hemochromatosis patients receive phlebotomy, with a portion of patients also receiving iron chelators as a co-treatment.
Note that in the last 12 months, there have been 76,000 confirmed diagnoses of hereditary hemochromatosis and approximately 1% of hemochromatosis
patients received deferasirox or deferoxamine off-label for 12 weeks (1 year for primary). Certain sub-groups of hemochromatosis patient
may benefit from TELOMIR-1 in addition to phlebotomy, which is the current standard of care for the treatment of hemochromatosis if contraindicated
for this treatment method. Lastly, iron chelation is used off-label, poorly tolerated and has toxic long-term effects. In pre-clinical
stage testing, TELOMIR-1 is potentially has more effective metal complexing than Doxycycline, an FDA-approved MMP inhibitor. However,
pre-clinical data may prove inaccurate and is not necessarily indicative of future results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Post-Chemotherapy
Recovery</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-chemotherapy
recovery from adverse effects of antineoplastic treatments is often important for cancer therapy success. While chemotherapy treatment
can be highly effective for cancer, it can also come with many side effects, as chemotherapy drugs destroy both cancerous and healthy
cells. According to a study published in the British Journal of Clinical Pharmacology<SUP>1</SUP>, of approximately 650,000 patients
who use chemotherapy each year, only a fraction use drugs for side effects. Side effects and toxicity of chemotherapy lead to reduced
compliance, and therefore treating chemotherapy side effects can increase compliance. Common barriers center around the complexity of
post-chemotherapy side effects, obtaining reimbursement without significant outcomes, avoiding pauses, and/or delays in treatment due
to side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are investigating the use of TELOMIR-1 as a potential complementary treatment for patients receiving chemotherapy in the form of a twice
daily, oral regimen to inhibit pro-inflammatory cytokines and to reduce blood iron levels, potentially enabling more effective adherence
and improved outcomes. In exploratory early discovery studies, proof of concept was demonstrated, and the animal studies are pending.
Post-chemotherapy recovery space contains several treatments that are used symptomatically based on the nature or severity of side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-chemotherapy
recovery may present several potential unmet commercial needs for TELOMIR-1. There is potential to enable a more rapid recovery of patients
receiving chemotherapy, improving adherence with chemotherapy regimens. Additionally, as current recovery management is based on severity
and treated as needed, we believe that TELOMIR-1 could potentially be used as a preventative measure. As a complementary treatment, side
effect reduction in post-chemotherapy is important to minimize patient burden while improving treatment outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to develop and commercialize new treatment options for treatment of age-related inflammatory conditions such as hemochromatosis
as our initial clinical focus and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as broader
range of other age-related inflammatory diseases and conditions such as osteoarthritis. The key elements of our strategy to achieve this
goal include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advancing
    TELOMIR-1 through clinical development and approval for hemochromatosis. </I></B>Our product candidate, TELOMIR-1, is in pre-clinical
    studies. Existing treatment options for hemochromatosis have significant limitations, and, if approved, we believe TELOMIR-1 may
    represent a major therapeutic advancement for patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Explore
    the potential of TELOMIR-1 for Post-Chemotherapy Recovery.</I></B> TELOMIR-1 may represent a major therapeutic advancement for post-chemotherapy
    patients. Our product candidate, TELOMIR-1, may have the potential in post-chemotherapy recovery.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Continuing
    pre-clinical development of TELOMIR-1 across a range of inflammatory diseases associated with cellular aging. </I></B>Given the impact
    of telomere cap regrowth on a variety of age-related inflammatory diseases, we intend to explore TELOMIR-1&rsquo;s broader potential,
    as we believe TELOMIR-1 may have potential in several inflammatory diseases, such as osteoarthritis, associated with a range of metabolic
    and geriatric related conditions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exploring
    strategic collaborations to maximize the value of TELOMIR-1.</I></B> We plan to explore collaborations opportunistically to maximize
    the value of TELOMIR-1. We intend to retain significant economic and commercial rights to our programs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Completed
Proof-of-Concept and Pre-Clinical Studies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Ames Test - Computational Mutagenicity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of <I>in silico</I> (computational) tools to predict toxicity has increased significantly and has become well-established not only
in the pharmaceutical industry, but also in the chemical and cosmetic industries. This is specifically reflected in the area of potential
genotoxic impurities and finalization in 2015 of the ICH M7 guidance, which was the first regulatory document that supports use of <I>in
silico</I> tools as an initial surrogate for conducting <I>in vitro</I> or <I>in vivo</I> testing (ICH M7_Sept 5, 2015). The purpose
of the M7 guidance is to aid in the identification and characterization of impurities with mutagenic risk and to outline the control
strategy for the various classes (Class 1-5) of compounds in order to limit potential carcinogenic risk to humans. According to ICH M7,
&ldquo;the absence of structural alerts from two complementary quantitative structure activity relationship (&ldquo;(Q)SAR&rdquo;) methodologies
(expert rule-based and statistical) is sufficient to conclude that the impurity is of no mutagenic concern, and no further testing is
recommended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoint of concern in the ICH M7 guidance is DNA reactive mutagenicity, with the Ames bacterial mutagenicity assay being the
preferred assay for this endpoint. The structure based <I>in silico</I> evaluations demonstrate reasonable ability to differentiate mutagens
from non-mutagens with generally high concordance when compared with Ames assay results (Sutter et al, 2013).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of this study was to evaluate the bacterial mutagenicity of three potential drug candidates by testing the structures
in at least two complementary <I>in silico</I> software programs, followed by expert review of the <I>in silico</I> data. The emphasis
of the overall computational assessment of toxicity was placed on the potential for DNA reactive mutagenicity, in accordance with the
ICH M7 guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rule-based systems, TELOMIR-1 was predicted non-reactive (no mutagenic concern. Therefore, according to ICH M7 criteria with negative
predictions in two complementary <I>in silico</I> systems, it is considered non-mutagenic (Class 5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ames Test - Computational Mutagenicity study was not powered for statistical significance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMap
Studies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1_002.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BioMAP&reg; Platform provides an unbiased, target-agnostic and data-driven approach to understanding the effect of mono- or combination
therapies on human disease models and translational biomarkers. Validated with clinically approved drugs and known test agents, the BioMAP
Platform is powered by human primary cultures or co-cultures stimulated to recapitulate specific disease states and qualified with clinically
approved and investigative test agents, a Reference Database of over 4,500+ molecules, data analytics, and expert interpretation to provide
clients with actionable insights.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>System
    Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Icon</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Human
    Cell Types</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stimulation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disease/Tissue
    Relevance</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biomarker
    Readouts</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>System
    Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3C</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_020.jpg" ALT="Red blood cells in a blue circle&#10;&#10;Description automatically generated" STYLE="height: 54px; width: 54px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Venular
    endothelial cells</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNF&alpha;,
    IL-1&beta;, IFN&gamma;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cardiovascular
    Disease, Chronic Inflammation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL2/MCP-1,
    CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD54/ICAM-1, CD62E/E-Selectin, CD87/uPAR, CXCL8/IL-8, CXCL9/MIG, HLA-DR,
    Proliferation, SRB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    3C system models Th1 type vascular inflammation and is an anti-angiogenic environment that promotes monocyte and T cell adhesion
    and recruitment. The 3C system is relevant for chronic inflammatory diseases, vascular inflammation and restenosis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4H</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_021.jpg" ALT="A red cell in a circle&#10;&#10;Description automatically generated" STYLE="height: 54px; width: 52px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Venular
    endothelial cells</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL-4,
    Histamine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Autoimmunity,
    Allergy, Asthma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL26/Eotaxin-3,
    CCL2/MCP-1, CD106/VCAM-1, CD62P/P-Selectin, CD87/uPAR, SRB, VEGFR2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    4H system models Th2 type vascular inflammation and is a pro-angiogenic environment that promotes mast cell, basophil, eosinophil,
    T and B cell recruitment. The 4H system is relevant for diseases where Th2-type inflammatory conditions play a role such as allergy,
    asthma, and ulcerative colitis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LPS</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_022.jpg" ALT="A red and blue cell&#10;&#10;Description automatically generated" STYLE="height: 53px; width: 55px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Venular
    endothelial cells, Peripheral blood mononuclear cells</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TLR4
    ligand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
    Inflammation, Cardiovascular Disease</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL2/MCP-1,
    CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, IL-1 alpha, M-CSF, sPGE2, SRB,
    sTNF-alpha</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    LPS system models Th1 type chronic inflammation and monocyte activation responses. The LPS system is relevant to chronic inflammatory
    conditions where monocytes play a key role including atherosclerosis, restenosis, rheumatoid arthritis, and metabolic diseases.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SAg</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_023.jpg" ALT="A yellow circle with red and blue circles&#10;&#10;Description automatically generated" STYLE="height: 59px; width: 55px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Venular
    endothelial cells, Peripheral blood mononuclear cells</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCR
    ligands (1X)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
    Inflammation, Autoimmune Disease</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL2/MCP-1,
    CD38, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, CXCL9/MIG, PBMC Cytotoxicity, Proliferation, SRB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    SAg system models Th1 type chronic inflammation and T cell effector responses related to T cell proliferation and activation in the
    context of the vascular endothelium. Modeling chronic inflammation of the Th1 type and T cell effector responses, the SAg systemis
    relevant for T-cell driven inflammatory conditions including organ transplantation, rheumatoid arthritis, psoriasis, Crohn&rsquo;s
    disease and hematological oncology.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BT</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_024.jpg" ALT="A red circle with blue and purple circles&#10;&#10;Description automatically generated" STYLE="height: 56px; width: 54px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peripheral
    blood mononuclear cells, B cells</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&alpha;-lgM,
    TCR ligands (0.001X, sub-mitogenic levels)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asthma,
    Oncology, Autoimmunity, Allergy</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B
    cell Proliferation, PBMC Cytotoxicity, Secreted lgG, sIL-17A, sIL-17F, sIL-2, sIL-6, sTNF-alpha</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BT system models the T cell dependent B cell proliferation, activation and class switching that occurs in the germinal centers of
    secondary lympnoid organs. The BT system is relevant for indications in which B cell activation and antibody production have been
    implicated including systemic lupus erythematosus (SLE), hematological oncology, autoimmune indications, asthma and allergy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BF4T</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_025.jpg" ALT="A logo of a cartoon character&#10;&#10;Description automatically generated with medium confidence" STYLE="height: 55px; width: 54px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bronchial
    epithelial cells, Dermal fibroblasts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL-4,
    TNF&alpha;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fibrosis,
    Lung Inflammation, Asthma, Allergy</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL26/Eotaxin-3,
    CCL2/MCP-1, CD106/VCAM-1, CD54/ICAM-1, CD90, CXCL8/IL-8, IL-1 alpha, Keratin 8/18, MMP-1, MMP-3, MMP-9, PAI-I, SRB, tPA, uPA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BF4T system models Th1 type lung inflammation and is an environment that promotes the recruitment of eosinophils, mast cells and
    basophils as well as effector memory T cells. The BF4T system is relevant for allergy and asthma, pulmonary fibrosis, as well as
    COPD exacerbations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BE3C</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_026.jpg" ALT="A group of green and red objects in a blue circle&#10;&#10;Description automatically generated" STYLE="height: 55px; width: 53px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bronchial
    epithelial cells</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL-1&beta;,
    IFN&gamma;, TNF&alpha;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COPD,
    Lung Inflammation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD54/ICAM-1,
    CD87/uPAR, CXCL10/IP-10, CXCL11/I-TAC, CXCL8/IL-8, CXCL9/MIG, EGFR, HLA-DR, IL-1 alpha, Keratin 8/18, MMP-1, MMP-9, PAI-I, SRB, tPA,
    uPA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BE3C system models Th1 type lung inflammation and is an environment that promotes monocyte and T cell adhesion and recruitment. The
    BE3C system is relevant for sarcoidosis and pulmonary responses to respiratory infections.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CASM3C</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_027.jpg" ALT="A blue circle with red and white objects in it&#10;&#10;Description automatically generated" STYLE="height: 57px; width: 53px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coronary
    artery smooth muscle cells</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL-1&beta;,
    IFN&gamma;, TNF&alpha;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cardiovascular
    Inflammation, Restenosis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL2/MCP-1,
    CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD87/uPAR, CXCL8/IL-8, CXCL9/MIG, HLA-DR, IL-6, LDLR, M-CSF, PAI-I, Proliferation,
    Serum Amyloid A, SRB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    CASM3C system models Th1 type vascular inflammation and is an environment that promotes monocyte and T cell recruitment. The CASm3C
    system is relevant for chronic inflammatory diseases, vascular inflammation and restenosis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HDF3CGF</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_028.jpg" ALT="A blue circle with orange and red shapes&#10;&#10;Description automatically generated" STYLE="height: 54px; width: 53px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dermal
    fibroblasts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN&gamma;,
    TNF&alpha;, IL-1&beta;, EGF, bFGF, PDGF-BB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fibrosis,
    Chronic Inflammation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL2/MCP-1,
    CD106/VCAM-1, CD54/ICAM-1, Collagen I, Collagen III, CXCL 10/IP-10, CXCL11/1-TAC, CXCL8/IL-8, CXCL9/MIG, EGFR, M-CSF, MMP-1, PAI-I,
    Proliferation_72hr, SRB, TIMP-1, TIMP-2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    HDF3CGF system models wound healing and matrix/tissue remodeling in the context of Th1-type inflammation. The HDF3CGF system is relevant
    for various diseases including fibrosis, rheumatoid arthritis, psoriasis as well as stromal biology in tumors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KF3CT</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_029.jpg" ALT="A green circle with yellow and orange shapes&#10;&#10;Description automatically generated" STYLE="height: 55px; width: 54px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keratinocytes,
    Dermal fibroblasts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL-1&beta;,
    IFN&gamma;, TGF&beta;, TNF&alpha;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dermatitis,
    Psoriasis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL2/MCP-1,
    CD54/ICAM-1, CXCL 10/IP-10, CXCL8/IL-8, CXCL9/MIG, IL-1 alpha, MMP-9, PAI-I, SRB, TIMP-2, uPA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    KF3CT system models model Th1 type cutaneous inflammation and is an environment that promotes monocyte and T cell adhesion and recruitment.
    The KF3CT system is relevant for cutaneous responses to tissue damage caused by mechanical, chemical, or infectious agents as well
    as certain states of psoriasis and dermatitis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MyoF</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_030.jpg" ALT="A group of orange and red stripes&#10;&#10;Description automatically generated with medium confidence" STYLE="height: 56px; width: 54px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lung
    fibroblasts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TGF&beta;,
    TNF&alpha;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wound
    Healing, Matrix Remodeling, Fibrosis, Chronic Inflammation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha-SM
    Actin, bFGF, CD106/VCAM-1, Collagen I, Collagen III, Collagen IV, CXCL8/IL-8, Decorin, MMP-1, PAI-I, SRB, TIMP-1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    MyoF system models general myofibroblast differentiation and tissue remodeling relevant for multiple fibrotic diseases. Biomarker
    readouts capture impacts on translationally relevant matrix remodeling, tissue repair and inflammation related responses in fibrotic
    tissue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mphg</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_031.jpg" ALT="A logo of a heart&#10;&#10;Description automatically generated" STYLE="height: 56px; width: 54px"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Macrophages,
    Venular endothelial cells</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TLR2
    ligand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
    Inflammation, Restenosis, Cardiovascular Disease</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCL2/MCP-1,
    CCL3/MIP-1 alpha, CD106/VCAM-1, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, IL-1 alpha, M-CSF, sIL-10, SRB, SRB, SRB-Mphg</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    /Mphg system models Th1 type chronic inflammation and macrophage activation responses. The /Mphg system is relevant to inflammatory
    conditions where monocytes play a key role including atherosclerosis, restenosis, rheumatoid arthritis, and other chronic inflammatory
    conditions.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>https://www.eurofinsdiscovery.com/solution/biomap-platform</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study was conducted with the assistance of Eurofins, a third-party vendor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eurofins
BioMap<SUP>&reg;</SUP> Diversity PLUS</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMap<I><SUP>&reg;
</SUP></I>Diversity PLUS panel of human primary cell-based systems designed to model complex human tissue and diseases. The studies below
with BioMap were conducted to investigate the anti-cancer activities versus Rapamycin. The BT system models the T cell proliferation
activation and is relevant for indications in which B cell activation and antibody production have been implicated including autoimmune
disorders. Rapamycin is selected to compare against TELOMIR-1 because rapamycin and TELOMIR-1 both inhibit similar cytokines involved
in the immune responses. The common proteins affected between TELOMIR-1 and rapamycin are several pro-inflammatory cytokines.</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
studies were not powered for statistical significance. They had no relationship to hemochromatosis. This study was conducted with
the assistance of Eurofins, a third-party vendor.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BT</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_032.jpg" ALT="A red circle with blue and purple circles&#10;&#10;Description automatically generated" STYLE="height: 56px; width: 54px"></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peripheral
    blood mononuclear cells, B cells</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&alpha;-lgM,
    TCR ligands (0.001X, sub-mitogenic levels)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asthma,
    Oncology, Autoimmunity, Allergy</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B
    cell Proliferation, PBMC Cytotoxicity, Secreted lgG, sIL-17A, sIL-17F, sIL-2, sIL-6, sTNF-alpha</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BT system models the T cell dependent B cell proliferation, activation and class switching that occurs in the germinal centers of
    secondary lympnoid organs. The BT system is relevant for indications in which B cell activation and antibody production have been
    implicated including systemic lupus erythematosus (SLE), hematological oncology, autoimmune indications, asthma and allergy.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>BioMAP<SUP>&reg;
</SUP>Diversity PLUS<SUP>&reg;</SUP> Data Analysis Report: TELOMIR-1 versus Rapamycin</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="graph_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="graph_002.jpg" ALT="" STYLE="height: 44px; width: 150px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biological
    and Disease Relevance Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Decreased
    Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Increase
    Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modulated
    Activity</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflammation-related
    activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VCAM-1,
    ITAC, Psel, SAA, MCP-1, IL6, MIG, Eot3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sPGE2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sTNFa,
    IL8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immunomodulatory
    activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HLA-DR,
    sIgG, sIL-2, CD38, sIL-6, CD40, sIL-17A, sIL17F, sIL-10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD69</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tissue
    Remodeling Activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIMP1,
    PAI-I, CoI-III, CoI-IV</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hemostasis-related
    activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TM</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LDLR</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study showed that TELOMIR-1 is an antiproliferative (suppress malignant cells) to human primary endothelial cells and fibroblasts vs
<I>Rapamycin.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">This
study was conducted with the assistance of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eurofins, a third-party
vendor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMAP<I><SUP>&reg;
</SUP></I>panels consist of human primary cell-based systems designed to model different aspects of the human body in an in vitro format.
Rapamycin was approved in 1999 to prevent rejection of transplanted organs. There are approximately 1,073 clinical trials including rapamycin
located on clinicaltrials.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>BioMAP<SUP>&reg;
</SUP>Colorectal Cancer (CRC) Data Report: TELOMIR-1 vs. Rapamycin</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><IMG SRC="graph_003.jpg" ALT="">&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="graph_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; ">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 26%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biological
    and Disease Relevance Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 36%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Decreased
    Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 16%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Increase
    Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 16%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modulated
    Activity</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inflammation-related
    activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sTNFa,
    VCAM-1, IP-10, MCP-1, MIG</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Matrix
    remodeling activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIMP2,
    CoI-I, COL-IV, MMP9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CoI-III</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Angiogenesis-related
    activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAI-I,
    tPA, uPA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sVegF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tumor-related
    activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEACAM5,
    Keratin 20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immune-related
    activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sIFNg,
    sGranB, sIL-10, sIL-2, sIL-6, CD40, CD69, sIL17-A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Colorectal Cancer study, TELOMIR-1 was not cytotoxic at the concentrations tested in this study and was broadly active in the BioMAP
Colorectal Cancer Panel with 32 activities versus <I>Rapamycin.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
impacted inflammation-related, matrix remodeling, angiogenesis-related, tumor-related, and immune-related activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">This study was conducted with
the assistance of Eurofins, a third-party vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><BR>
BioMAP<SUP>&reg; </SUP>Non-small Cell Lung Carcinoma (NSCLC) Data Report: TELOMIR-1 vs. Rapamycin&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="graph_004.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="graph_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top;">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 26%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biological
    and Disease Relevance Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 36%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Decreased
    Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 16%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Increase
    Activity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 16%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modulated
    Activity</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inflammation-related
    activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sTNFa,
    VCAM-1, sMDC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IP-10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Matrix
    remodeling activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EGFR,
    CoI-III, HGF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Angiogenesis-related
    activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">uPA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tPA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sVegF</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immune-related
    activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sIL-4,
    sIFNg, sGranB, sIL-10, sIL-2, sIL17-A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sIL-13</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the NSCLC study, TELOMIR-1 was active with 24 annotated readouts, 17 of which were in the StroNSCLC system, impacting inflammation-related,
matrix remodelling, angiogenesis-related, and immune-related activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Eurofins <I>in vitro</I> studies showed that TELOMIR-1 was more active against malignant cells, colorectal cancer cells, and lung cancer
cells than rapamycin. Other studies showed that versus Doxycycline TELOMIR-1 was more active at metal complexing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">This study was conducted
with the assistance of Eurofins, a third-party vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>TELOMIR-1
complexing ability compared to doxycycline study</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metal
Complexing of TELOMIR-1 vs Doxycycline</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Drug</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Metal</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Metal</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">LogK1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">K1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%">TELOMIR-1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 22%">Pb (II)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%">Lead</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">4.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">15,849</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">TELOMIR-1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cd (II)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Calcium</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.62</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41,687</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">TELOMIR-1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Zn (II)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Zinc</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">91,201</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">TELOMIR-1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Co (II)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Cobalt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">398,107</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">TELOMIR-1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Ni (II)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Nickel</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,981,072</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Doxycycline</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Zn (II)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Zinc</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,119</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K1
= stability constant (also called formation constant or binding constant) that represents the strength of association of compound with
metal ion. The K1 measures the strength of the interaction between the TELOMIR and each metal when they come together to form the complex.
TELOMIR-1 complexing ability compared to doxycycline and Zinc complexing ability. TELOMIR-1 is a good overall metal chelator. Results
indicate TELOMIR-1 is potentially more effective than Doxycycline in Zinc complexing or binding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study was not powered for statistical significance. This study started in Q1 2023 and was completed in Q2 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study was conducted with the assistance of the University of North Carolina - Wilmington, a third party vendor.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive
analysis is being conducted on the potential of TELOMIR-1 to protect and treat stem cells and lower blood ferritin. We have also completed
a variety of toxicology studies, and several others are ongoing or planned. Upon completion of the toxicology studies, we plan to submit
to the FDA an IND for TELOMIR-1, focused on investigating TELOMIR-1 for the treatment of hemochromatosis. We may consider a second IND
for post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1_010.jpg" ALT="" STYLE="height: 349px; width: 625px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<U>Source</U>:
Rini, D. John Hopkins School of Medical Arts)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
silico Affinity Studies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> by the FDA and comparable foreign regulators,
our pre-clinical studies demonstrate that TELOMIR-1 may uniquely and selectively bind critical metals to interrupt enzyme function,
and may return cellular metals like zinc, copper and, iron to homeostasis. TELOMIR-1 may selectively affect the key cytokine-driven inflammatory processes that drive the concentration and accumulation
of zinc, copper and iron in the serum that affects diseases like hemochromatosis and cancer. However, pre-clinical data may prove inaccurate
and is not necessarily indicative of future results and drug safety and efficacy is within the sole authority of the FDA and comparable
foreign regulators. If approved by the FDA or applicable foreign regulatory bodies, we believe that TELOMIR-1 may have
the potential to be a therapeutic intervention against hemochromatosis and cancer by interrupting and preventing the enzymatic actions
that create the systemic imbalance of cellular metals that allows elevated reactive oxygen species to oxidize and erode the protective
DNA telomere caps.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
graphic on the left below represents the structure of TELOMIR-1. Fe2+ (iron) is embedded in the structure (orange) and is attracted by
the nitrogen (blue) in each of the 5-member rings and 1 six-member ring.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
graphic on the right below represents is Fe2+ (iron) and the other molecules binding to the nitrogen (blue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1_011.jpg" ALT="" STYLE="height: 346px; width: 625px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
InSilicoTrials; Insilico Affinity Computations Between TELOMIR-1 and DIEN to Fe<SUP>2+ </SUP>ions in Water Solution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<I>in silico</I> study, conducted in the third quarter of 2023, aimed to investigate the affinity of TELOMIR-1 for Fe2+.The results of
the affinity tests show that TELOMIR-1 has a higher affinity to Fe2+ in comparison to Diethylenetriamine (&ldquo;DIEN&rdquo;), but for
1 micromolar Fe2+ more than 10 micro molar of TELOMIR-1 is needed to form an effective complex. Additionally, Fe2+ is the bound form
of iron in the human body; the majority of biological iron in the free state occurs in the Fe3+ (Ferric) state, and in the context of
Hemochromatosis the excess iron is in the ferric form, hence the chelating agents currently used primarily target Fe3+. This was a computerized
computation; therefore, serum was not used. Water is a complex substance that can mix with various substances, especially certain charged
molecules including iron complexes, in many different ways. Currently, scientists have ways to study and understand these interactions,
ranging from basic calculations to very detailed ones that look at tiny molecular details. To make sure these methods are accurate, scientists
need a standard test to compare it with. Accordingly, we decided to use a database called NIST SRD 46 (A Critically Selected Stability
Constants of Metal Complexes database) to get information about how well iron sticks to various molecules and find one that has similar
binding properties to our drug, TELOMIR-1. We narrowed our search down to diethylenetriamine (DIEN). We picked DIEN with a pH of 6.33,
or energy value of 36.11 kJ/mol, as our benchmark. This study was conducted with the assistance of InSilicoTrials, a third-party vendor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Completed
Pre-Clinical Toxicology Studies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the type, species, purpose and results of our completed pre-clinical toxicology studies. Each of these studies began
during the first quarter of 2023 and were completed during the third quarter of 2023. This study was conducted with the assistance
of Frontage Laboratories, Inc., a third-party vendor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
    of Study </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Species</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(<I>in
    vitro</I> studies)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metabolite
    Identification</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD-1
    mouse, SD-rat, Beagle dog, Cynomolgus monkey and human</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    determine the metabolic pathways of TELOMIR-1 across species </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
    showed little/no metabolism by CYP enzymes. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
    Reaction Phenotyping Using Liver S9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mouse,
    rat, monkey and human liver</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    of the Enzymes Involved in the Metabolism of TELOMIR-1 Using Hepatic S9 Fraction</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    compound does not appear to be a substrate of cytochrome P450 enzymes. There was little/no metabolism of TELOMIR-1 in dog S9, consistent
    with the fact that the dog lacks aldehyde oxidase activity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytochrome
    P450 (CYP) reaction phenotyping</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate the potential of TELOMIR-1 to be a victim of drug-drug interactions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
    was extensively metabolized in mouse, rat, monkey, dog, and human hepatocytes. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytochrome
    P450 (CYP) inhibition</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate the potential of TELOMIR-1 to cause drug-drug interactions as a perpetrator</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
    (up to 100 &micro;M) did not inhibit any of the tested CYP enzymes.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plasma
    protein binding</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD-1
    mouse, SD rat, Beagle dog, Cynomolgus monkey and human</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    know the unbound fraction of TELOMIR-1 in plasma </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
    highly Protein Bound</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
    Tolerated Dose and 7 Day Repeat-Dose Toxicity/Toxicokinetic Study in Rats</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rats</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate and characterize the toxicokinetic and toxicity of TELOMIR-1 and to estimate the MTD of TELOMIR-1 following </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    MTD following 7 days of repeated administration of TELOMIR-1 at dose levels of 50, 200, and 750 mg/kg/day in rats was determined
    to be &ge; 750 mg/kg/day </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
    Tolerated Dose and 7 Day Repeat-Dose Toxicity/Toxicokinetic Study in Dogs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beagle
    Dogs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate and characterize the toxicokinetic and toxicity of TELOMIR-1 and to estimate the MTD of TELOMIR- </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    were no treatment-related clinical observations, body weights, clinical pathology and anatomic gross pathology findings up to 7.5
    mg/kg/day.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SafetyScreen44
    <SUP>TM</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate, in Enzyme, and Radioligand Binding assays, the activity of TELOMIR-1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    significant results noted</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ongoing
and Planned Pre-Clinical Proof-of Concept Studies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the ongoing and planned pre-clinical proof-of-concept studies that we are conducting or anticipate conducting
with respect to TELOMIR-1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Efficacy
of TELOMIR-1 in reducing ferritin in aged mice:</U> A third-party vendor conducted a tolerability assessment, ferritin assay optimization,
whole blood Methylation assay optimization, efficacy assessment with ferritin assay, and whole blood DNA methylation assay in 24-month-old
mice, which have been shown to bioaccumulate hepatic ferritin compared with young mice. This was not powered for statistical significance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study began on August 22, 2023 and progressed over nine weeks as shown below. This study was conducted with the assistance of
Frontage Laboratories, Inc., a third-party vendor, and the results are expected to be ready in the first quarter of 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><IMG SRC="forms-1_012.jpg" ALT="" STYLE="height: 167px; width: 600px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Assay
development to detect plasma concentration of rat and dog ferritin</U>: The sample analysis for rat to measure concentrations of rat
ferritin from rat plasma samples will be done by using ELISA assay (LS Bio commercial kit cat# LS-F36491). The sample analysis for dog
to measure concentrations of dog ferritin from dog plasma samples will be done by using ELISA assay (LS Bio commercial kit cat# LS-F11494).
This was not powered for statistical significance. This study started in June 2023; results are anticipated in the first quarter of
2024. This study is being conducted with the assistance of Evotec, a third-party vendor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>In
Vitro</U></I><U> stem cell therapy study</U>: This study began in December 2023; Results are anticipated Q2 of 2024, which will
consist of cell line selection, telomere length determination, cell proliferation/renewal determination, cell death determination, R&amp;D
cell bank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Cell line selection: Based on the literature highlighting their appropriateness for telomere and aging research, a third-party collaborator
will acquire three vials for each cell line: Primary human umbilical vein endothelial cell, non-immortalized human fibroblast, and the
human BM-derived mesenchymal stem cell line.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Telomere length determination: A quantitative polymerase chain reaction (qPCR) kit will be employed to treat and assess the absolute
telomere length of the cells. As part of the R&amp;D analytical method development, assay performance will be determined to ensure the
assay meets the linearity, selectivity, and precision attributes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">qPCR
is the accumulation of amplification product is measured as the reaction progresses, in real time, with product quantification after
each cycle.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Cell Proliferation/renewal determination: The cells will be exposed to different concentrations of TELOMIR-1 at varying time intervals.
Multiple analytical attributes, including repeatability and linearity, will be evaluated to assess the experimental outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Cell death determination: Cellular apoptosis and necrosis are recognized as distinctive indicators of telomere shortening in stem cells
and other cell types. The assay&rsquo;s performance will be evaluated to ascertain repeatability and linearity criteria compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
R&amp;D cell bank: It is of utmost importance to preserve the original cell vial to ensure consistent cell line behavior throughout the
development of analytical assays and subsequent Good Manufacturing Practice (GMP) analytical testing. This approach aims to maintain
the integrity and stability of the cell strain throughout the experimental procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study will not be powered for statistical significance. This study is being conducted with the assistance of Frontage Laboratories,
Inc., a third-party vendor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Planned
Pre-Clinical Toxicology Studies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the type, species, and purpose, of additional planned pre-clinical toxicology designed to demonstrate that TELOMIR-1
will be not toxic before starting human clinical trials. Each of these studies are expected to begin during the first quarter
of 2024 and be completed during the second or third quarter of 2024. These studies will be conducted with the assistance
of third-party vendors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
    of Study </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Species</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    Vivo Micronucleus Study in Rats Using Bone Marrow</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rat</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    assess the potential of TELOMIR-1 and/or its metabolites to induce micronuclei (MN) in bone marrow reticulocytes (RETs) of male and
    female Sprague Dawley </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hERG
    (Manual Patch-Clamp)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    detect the risk of the protein product of the human-Ether-a-go-go -Related Gene (hERG) is an ion channel which plays an integral
    role in the repolarization and relaxation of the myocardium. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cardiovascular
    Study Dog (Telemetry)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beagle
    Dog</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cardiovascular
    analysis: ECG and Blood Pressure will be monitored continuously in conscious animals in their home cage for a minimum 1 hour of baseline
    (prior to dosing) and a minimum 24 hours after dosing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respiratory
    Study Rat</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rat</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plethysmography:
    Animals will be place in a whole-body plethysmograph and allowed to stabilize for a minimum of 1 hour prior to administration of
    the control or test article.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neurobehavioral
    Evaluation Rats</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rat</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
                                            observational battery will occur pre-dose and 1 time point (txmax) post-dose.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    activity conducted following functional observational battery using opto-varimax boxes.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Day
    Dog Study</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beagle
    Dog</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    evaluate the toxicity and toxicokinetic profile following oral gavage administration of TELOMIR-1 to male and female Beagle dogs
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Day
    Rat Study</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rat</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    objectives of this study are to evaluate the toxicity and toxicokinetic profile following oral gavage administration of TELOMIR-1
    to male and female Sprague Dawley rats. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
are IND enabling studies with the purpose of demonstrating there are no animal toxicity issues before dosing in humans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>CMC
Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below identifies our ongoing chemistry, manufacturing, and controls activities relating to TELOMIR-1. We started the analytical
development and manufacturing of TELOMIR-1 in the first quarter of 2023. By the first quarter of 2024, we anticipate our suppliers
will be developing TELOMIR-1 at scale and manufactured under cGMP conditions, expanding on earlier non-GMP volumes of TELOMIR-1 for use
in our advanced testing programs. We plan to work closely with our suppliers to generate sufficient volumes of cGMP-grade TELOMIR-1 materials
for the planned pre-clinical toxicity programs, expanded animal testing in human clinical trials expected to be performed in 2024, if
the FDA approves our clinical trial design. This study is being conducted with the assistance of Frontage Laboratories, Inc., a third-party
vendor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chemistry,
    Manufacturing, and Controls</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Planned/In
    process Activity</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
    Substance Preparation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
                                            Analytical Development</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 20pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;
    Method Development</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;Assay/impurity</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;
    Dissolution</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 20pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;
    Method Validation (cleaning method)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 20pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Drug Excipient Compatibility</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Formulation Development and Prototypes</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Lead Formulation Stability</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Scale-up Demo Batch Manufacturing</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    R&amp;D Demo Batch Stability</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Method Validation</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;Assay/impurity</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;Dissolution</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    GMP Manufacturing</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Release Testing</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    GMP Stability Study</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Clinical Development Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Regulatory
Submissions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of pre-clinical development program as described above, we plan to submit to the FDA an IND, focused on investigating
TELOMIR-1 for the treatment of hemochromatosis. We may consider a second IND for post-chemotherapy recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first IND application submission investigating TELOMIR-1 for the treatment of hemochromatosis is currently planned for the third
quarter of 2024. If allowed to proceed by the FDA, a Phase I double-blind, randomized, placebo-controlled trial to evaluate the safety,
tolerability, and pharmacokinetics of TELOMIR-1 in 40-60 healthy male and female adult subjects will be initiated approximately 30 days
post-IND submission. We have contracted with Frontage Laboratories Phase I clinic in New Jersey consisting of 160 beds across three units
for normal volunteers. After the Phase I trial is complete, a Phase II trial in the hemochromatosis population is planned to commence
after results and guidance from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second IND application will likely focus on investigating TELOMIR-1 for the treatment of post-chemotherapy recovery and is planned for
submission with guidance from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical development plans will depend on FDA acceptance of our IND applications. As appropriate and pursuant to discussions with the
FDA, we may periodically adjust the timeline for certain filings and associated clinical trials. It is important to note that the process
for conducting clinical trials is uncertain and there is no assurance that our clinical development activities will meet the planned
timelines set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Manufacture
of Product for Clinical Development Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthem,
a leading CDMO, has been developing a large-scale synthesis protocol for us and will be supplying quantities of TELOMIR-1 needed for
our pre-clinical and clinical development activities. We are currently in discussions with Frontage to have TELOMIR-1 formulated into
solid oral dosage forms for clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1,
if approved, is expected to initially compete in the hemochromatosis market. TELOMIR-1, if approved, may have the potential to
secondarily compete in the post-chemotherapy recovery market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disease
Epidemiology &ndash; Patient Targets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
target patient pool for TELOMIR-1 will vary depending on which indication is under review. The initial target patient pool relates to
hemochromatosis. Hemochromatosis is largely an inherited condition. The secondary category, post-treatment recovery, is a derivative
of broader oncology epidemiology and treatment seeking behaviors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Potential
Market in Hemochromatosis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
with two mutated copies of the <I>HFE</I> gene (C282Y and H63D) are at the greatest risk for developing hemochromatosis, alongside patients
with a family history of hemochromatosis. As a result, approximately 13 million U.S. patients carry mutations for hemochromatosis but
only a fraction of them has symptoms, and not every symptomatic patient develops hemochromatosis. On average, about 750,000 US patients
express one or more iron overload symptoms. There are 2 types of hemochromatosis, with the following patient mix: 150,000 primary hemochromatosis,
and 65,000 secondary hemochromatosis confirmed diagnoses in the United States. Today, we estimate that over 150,000 patients have sought
treatment since 2018, with most receiving phlebotomy, which is the withdrawal of blood to bring iron to normal levels. At present, 99%
of hemochromatosis patients receive phlebotomy, with a portion of patients also receiving iron chelators as a co-treatment. Note that
in the last 12 months, there have been 76,000 confirmed diagnoses of hereditary hemochromatosis and approximately 1% of hemochromatosis
patients received deferasirox or deferoxamine off-label for 12 weeks (1 year for primary). The chart below outlines the epidemiological
flow for hemochromatosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_013.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SOURCES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management
of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328-343.
doi:10.1002/hep.24330</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Gurrin, Lyle C., et al. &ldquo;The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis.&rdquo;
Gastroenterology 135.6 (2008): 1945-1952.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
P360 Scripts and Claims Database, retrieved on October 3, 2022.</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Potential
Market in Post-Chemotherapy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
undergoing chemotherapy irrespective of type of cancer are at risk. That said, older patients aged 65+ and above, have a higher risk
of developing post-chemotherapy side effects such as digestive issues, sleep and memory issues, fatigue, and body aches. Other risk factors
include the presence of metabolic conditions, dose levels of chemotherapy medication, blood count, and BMI.US CDC health data estimates
that 650,000 patients receive chemotherapy annually in the US, with 45% experiencing severe side effects and 40% having more moderate
side effects. Thus, ~158,000 patients were diagnosed with the adverse effects of chemotherapy (antineoplastic and immunosuppressive drugs.
Today, Neulasta is given to patients undergoing chemotherapy as a &ldquo;catch-all&rdquo; therapeutic to help manage side effects. Neulasta
is typically given to patients after chemotherapy for recovery. 95,000 patients with chemotherapy side effects got Neulasta over the
last 12 months while 5,500 patients with immunosuppressive therapy side effects got Jakafi, also used for myelofibrosis and polycythemia
vera. Given existing compliance levels around the use of Neulasta (~70%), we believe that adding TELOMIR-1 may boost overall compliance
levels higher especially if levels of side effects are reduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1_014.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SOURCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Bacon BR, Adams PC, Kowdley KV, Powell
LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline
by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328-343. doi:10.1002/hep.24330</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Gurrin, Lyle C., et al. &ldquo;The natural
history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis.&rdquo; Gastroenterology 135.6 (2008):
1945-1952.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. P360 Scripts and Claims Database, retrieved
on October 3, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to competition from pharmaceutical and biotechnology companies and academic and research institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TELOMIR-1
will face competition in its initial target indication, hemochromatosis, as well as in its potential second target indication, post-chemotherapy
recovery. Below we discuss the known competitors by target indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hemochromatosi</U>s:
    The current standard of care is phlebotomy, which typically costs $80 - $300/visit in community health facilities or offered for
    free at blood banks. Based on historical treatment data, phlebotomy serves more than 95% of hemochromatosis patients, as there are
    no FDA-approved indications. Each year, about 70,000 patients receive phlebotomy in healthcare facilities, excluding the blood banks
    (that provide the service for free). Patients who use it continue to embrace it given the lack of clinical options, its broad accessibility
    and low treatment cost. However, this option is not available to patients with hemophilia and other blood disorders. About 5% of
    patients are treated with iron chelators such as Exjade and Jadenu (and associated generics). This option is more expensive with
    pricing for Exjade at $532/day and Jadenu at $517/day. The last treatment option, deferasirox / deferoxamine was used with only 7,000
    patients (2018-2022) based on IQVIA claims and scripts data. Future clinical options for treating hemochromatosis exist and remain
    limited. For example, 2 molecules are pre-clinical, 2 in Phase I, 1 in Phase II, and 1 is in Phase III.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1_015.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SOURCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. Citeline, Pharma Projects, and Trial Trove Database Results
for &ldquo;hemochromatosis&rdquo;, retrieved on September 23, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Post-Chemo
    Recovery</U>: The current standard of care involves prescribing a small set of compounds designed to reduce patient discomfort from
    side effects. Filgrastim, pegfilgrastim, sargramostim are some examples of prescribed medication. These medications stimulate the
    growth of healthy white blood cells and granulocytes by subcutaneous injection. However, prices are high and can cost around $4,000-6,400
    per dose of injection. Jakafi, a tyrosine kinase inhibitor is used in polycythemia vera and graft-versus-host disease. Pricing for
    Jakafi is $16,200 per bottle, with a $270 wholesale acquisition cost (WAC) unit price. Thus, given cost, only a portion of the high-risk
    patients are given the script; these are usually patients who are older than 65, and with a weakened immune system and low white
    blood cell count. Patients who use the class of medication do so to reduce post-treatment infection risk, even if they suffer from
    fevers and aches because of usage. The development pipeline of competing assets is robust but targeted at specific side effects such
    as iron deficiency or thrombotic constraints.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1_016.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SOURCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. Citeline, Pharma Projects, and Trial Trove Database Results
for &ldquo;hemochromatosis&rdquo;, retrieved on September 23, 2022.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
license the U.S. patent rights for the use of TELOMIR-1 in human applications from MIRALOGX, an intellectual property development and
holding company established by Jonnie R. Williams, Sr., the founder of our company and the sole inventor of TELOMIR-1. MIRALOGX is owned
by the Bay Shore Trust, an irrevocable trust established by Mr. Williams. MIRALOGX filed a Patent Cooperation Treaty (PCT) application,
PCT/US2023/073106 on August 29, 2023 for TELOMIR-1. The PCT application, which is titled, &ldquo;ANTI-INFLAMMATORY COMPOUNDS, PHARMACEUTICAL
COMPOSITIONS, AND METHODS OF TREATING HEMOCHROMATOSIS, AND OTHER DISORDERS,&rdquo; covers, among other things, the TELOMIR-1 compound
and methods of treating hemochromatosis, hyperammonemia, or a disorder associated with chronic inflammation or a cancer, by administering
the compound to humans. The PCT application designated the U.S. and will enter U.S. national phase. The application, if granted and subject
to payment of patent maintenance fees, would offer protection extending through at least August 29, 2043, in the U.S. The patent rights
for TELOMIR-1 outside of the United States are not included in our current patent rights. Mr. Williams, our founder, does not hold any formal degrees in chemistry or certifications related to the development of pharmaceuticals;
however, he developed
extensive knowledge of tobacco alkaloid chemistry in the 1990&rsquo;s through collaboration with industry experts during his development
of techniques for preventing the formation of carcinogenic tobacco-specific nitrosamines (TSNAs) during the tobacco curing process. To
better understand the mechanism by which TSNAs are formed, Mr. Williams collaborated closely with a leading expert in tobacco chemistry
at the University of Kentucky, where he developed a working knowledge of tobacco alkaloid chemistry, which led to his development of
patented curing technologies which would become the industry standard. This work led to him focusing on the therapeutic properties of
tobacco alkaloids, and later to his design of novel small molecule therapeutics. He is a named inventor on 31 issued US patents and approximately
30 pending or published US patent applications, all of which are in the life sciences, a field that embraces the study of living organisms,
including biology, botany, zoology, and biochemistry. Approximately 20 of his issued patents and 27 of his applications involve therapeutic
treatment methods, and 4 issued patents and approximately 18 applications are directed to novel small molecules, principally involving
alkaloid and cannabinoid chemistries. His work on TELOMIR-1 began in late 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
license from MIRALOGX is set forth in the Initial MIRALOGX License Agreement, as amended on November 10, 2023, by the Amendment No. 1
to the Amended and Restated License Agreement, pursuant to which the field of use relating to the license was amended to include therapeutic
treatments and other medical or health uses in animals, in addition to humans, and related preclinical studies and activities conducted
in furtherance of obtaining regulatory approval for and commercialization of veterinary, in addition to human, therapeutic treatments
and uses (together with the &ldquo;Initial MIRALOGX License Agreement, the &ldquo;MIRALOGX License Agreement&rdquo;). &ldquo;Licensed
Product&rdquo; is defined as a drug product containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl)pyridine or a pharmaceutically
acceptable salt, ester, or solvate thereof. We also have the right to grant corresponding sublicenses under the licensed patent rights.
The MIRALOGX License Agreement provides for the payment to MIRALOGX of an 8% royalty (payable quarterly) on our net sales of Licensed
Products by us or our sublicensees and on non-royalty bearing milestone revenue, with the royalty obligation ceasing upon the later of
the expiration of the last-to-expire licensed patent or the expiration of the last strategic partnership/sublicensing agreement entered
into by us. There are no up-front, execution, or milestone payments required under the license agreement. Further, no payments have been
made to date under the agreement. The agreement provides for a perpetual license and does not contain a provision that permits MIRALOGX
to terminate the agreement. The MIRALOGX License Agreement provides that MIRALOGX will have sole control over the filing, prosecution,
maintenance, and management of the licensed patent rights, provided that we will be responsible for the cost of prosecuting, maintaining,
and managing the licensed patents. The agreement grants to us the primary right, but not the obligation, to enforce the licensed patent
rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Besides
relying on patents, we will also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive
position, especially when we do not believe that patent protection is appropriate or can be obtained. We will seek protection of these
trade secrets, proprietary know-how and any continuing innovation, in part, through confidentiality and proprietary information agreements.
However, these agreements may not provide meaningful protection for, or adequate remedies to protect, our technology in the event of
unauthorized use or disclosure of information. Furthermore, our trade secrets may otherwise become known to, or be independently developed
by, our competitors. We may in the future seek appropriate patent protection for technology in our research and development programs
to the extent not licensed from MIRALOGX or another third party, where applicable, and their uses by filing patent applications in the
appropriate jurisdiction. We intend for these patent applications to cover, where possible, claims for compositions of matter, medical
uses, processes for preparation and formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently use TELOMIR and TELOMIR-1 as unregistered trademarks, and we intend to rely on such trademarks and trade names and service
marks, as well as our domain names and logos, as appropriate, to distinguish, build, and market our brand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration (FDA) and comparable regulatory authorities in state and local jurisdictions impose substantial and
burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs. These
agencies and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture,
quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval
monitoring and reporting, sampling and export and import of our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Government Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes
and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA&rsquo;s refusal to approve pending New Drug Applications (NDAs), withdrawal of an approval, imposition
of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&rsquo;s good laboratory practice
    (&ldquo;GLP&rdquo;) regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an Investigational New Drug (&ldquo;IND&rdquo;) application, which must become effective before human clinical trials
    may begin;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent Institutional Review Board (&ldquo;IRB&rdquo;), at each clinical site before each trial may be initiated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with good clinical practices (&ldquo;GCP&rdquo;) requirements
    to establish the safety and efficacy of the proposed drug product for each indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    that the API and finished product are manufactured under cGMP conditions and meet all applicable standards of identity, strength,
    quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
    with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug&rsquo;s identity,
    strength, quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to commercial marketing
    or sale of the drug in the United States; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;)
    or to conduct a post-approval study.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pre-clinical
studies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
testing any drug or biological product candidate in humans, the product candidate must undergo rigorous pre-clinical testing. The pre-clinical
developmental stage generally involves laboratory evaluations of drug chemistry, formulation, and stability, as well as studies to evaluate
toxicity in animals, to assess the potential for adverse events (&ldquo;AEs&rdquo;) and, in some cases, to establish a rationale for
therapeutic use. The conduct of pre-clinical studies is subject to federal regulations and requirements, including GLP regulations for
safety/toxicology studies. An IND sponsor must submit the results of the pre-clinical studies, together with manufacturing information,
analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND is a request for authorization from the FDA to ship an investigation product and then administer it to humans and must be allowed
to proceed by the FDA before human clinical trials may begin. Some long-term pre-clinical testing, such as animal tests of reproductive
AEs and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the
FDA, unless the FDA raises concerns or questions before that time related to one or more proposed clinical trials and places the trial
on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.
As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
trials</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by, or under control of, the trial sponsor, in accordance with
GCPs, which include the requirement that all research patients provide their informed consent for their participation in any clinical
trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures,
subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol,
and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must
be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the
informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical
trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results
to public registries. Information about most clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov
website. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects
of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results
of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years
after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress
of development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to
    a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism,
    pharmacologic action, side effect tolerability and safety of the drug.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At
    the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety
    risks are identified, and a preliminary evaluation of efficacy is conducted.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III clinical trials generally involve a larger number of patients at multiple sites and are designed to provide the data necessary
    to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk
    relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo
    and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow
up. In certain instances, the FDA may mandate the performance of Phase IV clinical trials as a condition of approval of an NDA or a Biologics
License Application (&ldquo;BLA&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if significant
adverse events (&ldquo;SAEs&rdquo;) occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may
impose other sanctions on various grounds, including a finding that the research patients are being exposed to an unacceptable health
risk. Similarly, an IRB can refuse, suspend, or terminate approval of a clinical trial at its institution if the clinical trial is not
being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated with unexpected serious harm to patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with clinical trials, companies usually complete additional pre-clinical studies and must also develop additional information about the
physical characteristics of the drug or biological product as well as finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches
of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency,
and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must
be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Marketing
Approval</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical testing, the results of the pre-clinical studies and clinical trials, together with detailed
information relating to the product&rsquo;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted
to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of
an NDA is subject to a substantial application user fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
review process typically takes twelve months from the date the NDA is submitted to the FDA. The FDA conducts a preliminary review of
all NDAs within the first 60 days after submission to determine whether they are sufficiently complete to permit substantive review before
accepting them for &ldquo;filing.&rdquo; The FDA may request additional information rather than accept an NDA for filing. In this event,
the application must be resubmitted with the additional information and may be subject to an additional application user fee. The resubmitted
application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins
an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether
the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product&rsquo;s continued
safety, quality and purity. Under the current guidelines in effect in the Prescription Drug User Fee Act (PDUFA), the FDA has a goal
to review and act on the submission within ten months from the completion of the preliminary review of a standard NDA for a new molecular
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include
medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution
methods, patient registries, or other risk minimization tools.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect
one or more clinical trial sites to assure compliance with GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding
the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter.
A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of
the NDA and may require additional clinical trials or pre-clinical studies in order for FDA to reconsider the application. Even with
submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. If and when those conditions have been met to the FDA&rsquo;s satisfaction, the FDA will typically issue an approval letter.
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-approval
requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims are subject to prior FDA review and approval. There also are continuing annual user fee requirements for any
marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications
with clinical data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
administrative and accounting office is located in Tampa, Florida. We currently share space with MIRA Pharmaceuticals, Inc., another
pharmaceutical development company, under a lease of approximately 2,279 square feet of office space under a lease that is due to expire
on March 31, 2024. We share the office and costs in Tampa with two other companies. Our corporate headquarters and executive offices
are in Baltimore, Maryland. Our Baltimore location, which comprises approximately 150 square feet, is under a lease that is due to expire
on November 30, 2023. We believe that this facility will be sufficient for our current and planned operations, although we may require
additional office and laboratory space in Baltimore for our planned operations as we progress our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees
and Human Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had 2 full-time employees and 4 part-time employees, of which one of our part-time employees is engaged
in research and development. None of our employees is represented by a labor union or are covered by a collective bargaining agreement.
We consider our relationship with our employees to be satisfactory. In addition, we utilize the services of contractors and part-time
outside consultants to support our organization&rsquo;s needs. We expect to continue to build our team to ensure we can effectively execute
our development plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no material proceedings </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
which any director or officer, or any associate of any such director or officer, is a party that is adverse to our Company or any of
our subsidiaries or has a material interest adverse to our Company or any of our subsidiaries. No director or executive officer has been
a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against it during
the past ten years. No current director or executive officer has been convicted of a criminal offense or is the subject of a pending
criminal proceeding during the past ten years. No current director or executive officer has been the subject of any order, judgment or
decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business,
securities or banking activities during the past ten years. No current director or officer has been found by a court to have violated
a federal or state securities or commodities law during the past ten years. From time to time, we may be named in claims arising in the
ordinary course of business.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the
future if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial
resources to defend against claims that our products and services infringe upon the intellectual property rights of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporation
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland 21205. Our telephone number is (737) 289-0835.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is www.telomirpharma.com. The information contained on, or that can be accessed through, our website is deemed not to
be incorporated in this prospectus or to be part of this prospectus. You should not consider information contained on our website to
be part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_007"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers, Directors, and Key Advisors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information about our current executive officers and directors, including their ages as of December 31,
2023. With respect to our directors, each biography includes information regarding the experience, qualifications, attributes, or
skills that caused our board of directors to determine that such person should serve as a director of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 56%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Chapman, Jr., MD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nathen
    Fuentes, CPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Treasurer, and Secretary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christos
    Nicholoudis, Esq.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">General Counsel and <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Jerman, CPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brad
    Kroenig</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
    Eagle, MD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Talhia
    Tuck</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hugh
    McColl III</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Dr. Michael Roizen</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">77</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Key Advisor</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief biography of each of our current executive officers and directors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Christopher
Chapman, Jr., MD</I></B> was appointed to serve as our Chief Executive Officer and Chairman effective November 2022. He also currently
serves as the Executive Chairman of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), a publicly traded pre-clinical pharmaceutical development
company (&ldquo;MIRA&rdquo;), a position he has held since April 2023. As Executive Chairman of MIRA, Dr. Chapman&rsquo;s duties include
those that are customarily associated with the position of Chairman of our board of directors, as well as oversight of the regulatory
affairs and drug development activities of the company. Dr. Chapman has also served as one of MIRA&rsquo;s directors since November 1,
2021 and served as a consultant with respect to regulatory affairs and drug development from November 1, 2021 until he began serving
as MIRA&rsquo;s Executive Chairman in April 2023. Dr. Chapman also serves as the President, Chief Medical Officer, and a director of
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a publicly traded clinical-stage pharmaceutical development company (&ldquo;MyMD&rdquo;).
Dr. Chapman previously served as President and Chief Medical Officer of MyMD Pharmaceuticals (Florida), Inc. (&ldquo;MyMD Florida&rdquo;)
effective as of November 1, 2020. MyMD Florida is the predecessor by merger of MYMD. Prior to joining MyMD Florida and since 1999, Dr.
Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides
support to pharmaceutical and biotechnology companies in North America, Europe, Japan, India and Africa on issues such as product safety,
pharmacovigilance, medical devices, clinical trials and regulatory issues. Dr. Chapman served as Director, Medical Affairs, Drug Safety
and Medical Writing Departments at Quintiles (currently known as IQVIA), from 1995 to 2003, where he grew the division from no employees
to forty employees, including eight board certified physicians, four RNs, two pharmacists, eight medical writers and supporting staff.
Dr. Chapman has also served on the board of directors of Rock Creek Pharmaceuticals, Inc. (formerly, Star Scientific, Inc.) from 2007
to 2016, including as a member of the Audit Committee from 2007 to 2014, chairperson of the Compensation Committee from 2007 to 2014,
and chairperson of the Executive Search Committee from 2007 to 2014. Dr. Chapman is an experienced executive and global medical expert
and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult and pediatric subjects.
Dr. Chapman is also the founder of the Chapman Pharmaceutical Health Foundation, an IRS Section 501(c)(3) nonprofit organization established
to solicit public funds and to support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria and
tuberculosis, which was organized in 2006. Dr. Chapman earned an Executive Certificate in Nonprofit Financial Stewardship from the Harvard
Kennedy School in 2020. Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987, and completed his
internship in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular and Obstetric Anesthesiology at Georgetown.
We believe Dr. Chapman is qualified to serve as one of our directors due to his executive experience in the pharmaceutical and biotechnology
industries, as well as his medical expertise. Dr. Chapman&rsquo;s recent publications include two poster presentations: 1)British Society
of Immunology, Liverpool, UK, December 5-8, 2022 <I>Pharmacology and clinical profile of MYMD-1<SUP>&reg;</SUP> (isomyosamine), an oral,
selective, next-generation, TNF-alpha inhibitor that crosses the blood brain barrier </I>and 2) Society of Toxicology, Nashville, TN,
March 19-22, 2023, <I>A Naturally Occurring Novel Therapeutic </I>and Oral Selective Inhibitor of TNF-&alpha;, <I>MYMD-1</I><SUP>&reg;
</SUP><I>(Isomyosamine), </I>Significantly Reduced the Inflammation and Disease Severity in Murine Model of Collagen Antibody Induced
Arthritis. Additionally, Dr. Chapman published a manuscript in Drug Research, &ldquo;A Double-blind, Placebo-controlled, Randomized,
Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine
Capsules in Healthy Adult Subjects&rdquo; (Brager, J., Chapman, C., Dunn, L., &amp; Kaplin, A. (2023). A Double-blind, Placebo-controlled,
Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose
Isomyosamine Capsules in Healthy Adult Subjects. <I>Drug research</I>, <I>73</I>(2), 95&ndash;104. <U>https://doi.org/10.1055/a-1962-6834</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nathen
Fuentes, CPA, </I></B>joined our company as our Chief Financial Officer, Treasurer, and Secretary on September 21, 2023. Prior to serving
as our Chief Financial Officer, Treasurer, and Secretary, Mr. Fuentes has worked for mid-market private equity sponsored companies within
the specialty healthcare industry, including with Emergence Health Holdings as the Chief Financial Officer from May 2023 to September
2023; as the Chief Financial Officer of Divergent Dental Group from July 2022 to May 2023; the Chief Financial Officer of Family First
Homecare from 2019 to July 2022; and as the Chief Financial Officer and Partner of Dermatology Medical Partners from 2017 to 2019. He
also served as the Controller of Glytec from 2013 to 2017, as an Experienced Associate at PricewaterhouseCoopers from 2012 to 2013 and
held various managerial positions with homebuilding companies prior to his experience with PricewaterhouseCoopers. Mr. Fuentes has experience
leading acquisition and organic growth initiatives within highly levered environments while managing investor relations, human resources,
finance, accounting, and revenue cycle functions. Mr. Fuentes earned his Bachelor of Science in marketing from the University of Florida
and his Masters of Science in accounting from Fairfield University. Mr. Fuentes is a Certified Public Accountant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Christos
Nicholoudis </I></B>joined our company as a director and as our General Counsel on August 11, 2023. He was initially appointed under an agreement between
our company and our largest stockholder, the Bay Shore Trust, to serve as the designated representative of the Bay Shore Trust on our
board of directors. He has also served as a director of MIRA Pharmaceuticals, Inc., (Nasdaq: MIRA) since April 2023. Mr. Nicholoudis
was also named General Counsel of MIRA in April 2023, although he is not deemed to be an executive officer of that company. Mr. Nicholoudis
is an attorney who has practiced with his own firm, The Law Firm of Christos Nicholoudis PLLC, since February 2022, where he handles
a wide range of legal matters including contract work, personal injury, real estate, wills trusts and estates and criminal law. Prior
to that, from July of 2019 to February of 2022, Mr. Nicholoudis was employed by the State of Florida as a Public Defender for the 12<SUP>th
</SUP>Judicial Circuit and from July 2012 to February of 2020, Mr. Nicholoudis owned and operated a restaurant franchise under Cortez
Roadhouse, LLC. Mr. Nicholoudis is a 2012 graduate of Cornell University&rsquo;s School of Hotel Administration where he received a B.S.
in hospitality and a 2017 graduate of Stetson College of Law where he received his J.D. degree. He is admitted to the bar in New York,
Florida, Texas, and Washington D.C. We believe that Mr. Nicholoudis is qualified to serve as one of our directors based on his legal
experience and training and his diverse business management experience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Michael
Jerman, CPA</I></B> joined our company as a director in November 2023. He also serves as a member of the board of directors of
Inhibitor Therapeutics, Inc. (OTC:INTI). Mr. Jerman has served as the managing partner at Hollywell Partners, a professional accounting
and finance consulting firm, since May 2019, and has provided chief financial officer and other services to multiple private equity-backed
companies in the energy, SaaS, and manufacturing industries. Prior to his role with Hollywell Partners, he was a Director with PwC in
the US and UK from January 2007 to August of 2019 and was a Captain with the United States Air Force from July 2003 to June 2015. He
has led global public and private client engagements in the industries of retail and consumer, energy, utilities and mining, and transportation
and logistics. Mr. Jerman has significant experience in client equity and debt offerings, business combinations inclusive of public listing
and reporting requirements, initial valuations and ongoing goodwill impairment analyses, share-based awards, restructuring, and global
taxes, as well as stakeholder management, specifically with board and management presentation experience to include annual and quarterly
requirements, fee negotiations, technical accounting and finance discussions, and fraud and non-compliance investigations. Mr. Jerman
has specialized in rapid project mobilization and deployment of skilled resources for emergency issues, design, and implementation of
small to large scale assurance requirements and advisory projects. Mr. Jerman&rsquo;s additional experience includes leading PwC&rsquo;s
data acquisition methods and tools, client acquisitions and systems implementations to include new SOX-compliant control plan implementations
across multiple systems, leading co-sourced internal audit projects, and time spent driving PwC&rsquo;s lean efficiency initiatives.
Mr. Jerman was a member of the PwC national office within the SEC PCAOB quality group supporting Europe and the EMEA regions with complex
accounting and audit consultations. He earned a B.S. in accounting from the University of South Florida, an M.S. in accounting from the
University of Tampa, and an M.B.A. from the University of Oxford.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Brad
Kroenig</I></B> joined our company as director in November 2022. Since November 2021, he has also served as a member of the Board of
Directors of MIRA Pharmaceuticals, Inc., (Nasdaq: MIRA) a publicly traded early pre-clinical-stage pharmaceutical company focused on
the development and commercialization of a new molecular synthetic THC analog. Since 2000, Mr. Kroenig&rsquo;s principal occupation has
been serving as one of the world&rsquo;s leading fashion models. Mr. Kroenig was the face of Ralph Lauren, The Gap, Tommy Hilfiger, Chanel,
Fendi, Peter Millar, and many other top brands. Models.com ranked him the #1 male model in the world from 2004 to 2006, and Vogue magazine
ranked him the #3 male model of all time. Mr. Kroenig also serves as a business and strategy consultant for many private firms and early-stage
companies, where as a part of his consulting business he advises companies regarding building management teams and managing relationships
with investors. Mr. Kroenig is an experienced investor and business executive with significant experience in collaborating with executive-level
and cross-functional teams, analyzing business situations, and developing and implementing practical investor strategies. Mr. Kroenig
attended Florida International University on a NCAA Division I soccer scholarship. We believe that Mr. Kroenig&rsquo;s business experience
in the modeling industry as a business executive qualifies him to serve as one of our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Craig
Eagle, MD </I></B>joined our company as a director in November 2022. He has also served as a director of MyMD since April 16, 2021. Dr.
Eagle is currently the Chief Medical Officer of Guardant Health, Inc. since 2021. Previously, Dr. Eagle was Vice President of Oncology
for Genentech, where he oversaw the medical programs across Genentech&rsquo;s oncology portfolio. Prior to his current role, Dr. Eagle
worked in several positions at Pfizer from 2009 to 2019, including as the oncology business lead in the United Kingdom and Canada, the
global lead for Oncology Strategic Alliances and Partnerships based in New York, and as the head of the Oncology Therapeutic Area Global
Medical and Outcomes Group, including the U.S. oncology medical business. Through his multiple roles at Pfizer, Dr. Eagle delivered significant
business growth and was involved in multiple strategic acquisitions and divestitures. In addition, while at Pfizer, Dr. Eagle oversaw
extensive oncology clinical trial programs, multiple regulatory and payer approvals across Pfizer&rsquo;s oncology portfolio, health
outcomes assessments and scientific collaborations with key global research organizations like the National Cancer Institute (NCI), and
the European Organization for Research and Treatment of Cancer (EORTC), and led worldwide development of several compounds including
celecoxib, aromasin, irinotecan, dalteparin and ozagomicin. Dr. Eagle currently serves as a member of the board of directors and chair
of the Science and Policy Committee of Pierian Biosciences, a privately held life sciences company. Dr. Eagle attended Medical School
at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in
Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney and was granted
Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his
training, Dr. Eagle performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets
before moving into the pharmaceutical industry. Dr. Eagle&rsquo;s qualifications to sit on our board of directors include his
long and successful career in the international pharmaceutical industry, his senior executive experience in areas such as business growth,
strategic alliances and mergers and acquisition transactions, his experience as a member of both public and private company boards in
the healthcare and life science industries, and his wealth of oncology experience, including leading and participating in scientific
research, regulatory, pricing and re-imbursement negotiations for compounds in therapeutic areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Talhia
Tuck</I></B> joined our company as a director in November 2022. She has also served as a director of MIRA since November 1, 2021. She
has worked in the higher education field for over a decade, including her most recent position as an Admissions and Recruitment Counselor
for Georgetown Law School in 2023. From 2019 to 2023, Ms. Tuck was a Project Director with Georgetown Law School&rsquo;s Center for
Innovations in Community Safety, formerly the Innovative Policing Program, which identifies new approaches to long-standing issues in
policing. Ms. Tuck served as an Associate Director of Admissions at Georgetown University from 2016-2019, where she evaluated applications
for the undergraduate schools and chaired several admissions committees. Prior to 2016, Ms. Tuck worked in the investment relations and
communications field as Vice President for Communications and Investor Relations at Star Scientific, Inc. (OTC: STSC) where she was responsible
for coordinating communications with shareholders, the financial community, and the media. She also has experience in the legal industry,
as she participated in the Ropes &amp; Gray New Alternatives Program as a Fellow at the Office of the State&rsquo;s Attorney for Montgomery
County, Maryland, and subsequently worked in the Corporate Department at Ropes &amp; Gray LLP in Washington, D.C. Prior to attending
law school, Ms. Tuck was a journalist with MSNBC, NBC News, ABC News, and the CBS affiliate, WINK-TV, and worked as an admissions officer
for Harvard College at Harvard University. She also served as a financial analyst at Goldman Sachs in the Investment Management Division
from July 2000 until April 2001. We believe that Ms. Tuck&rsquo;s experience in public policy and investment relations qualifies her
to serve as one of our directors. She received her A.B. degree from Harvard College, <I>cum laude</I>, and received her J.D. degree from
Harvard Law School. We believe that Ms. Tuck&rsquo;s experience in public policy and investment relations qualifies her to serve as one
of our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hugh
McColl III</I></B> joined our company as a director in November 2022. He has served as a director of MIRA Pharmaceuticals, Inc., (Nasdaq:
MIRA) since November 1, 2021. Mr. McColl has served as Co-Managing Member of Collwick Capital LLC, a fund of funds, since 2010 and Managing
Member of McColl Brothers Lockwood LLC, a family investment office, since 2006. Since June 2015, he has served as a Senior Advisor at
Brown Brothers Harriman Capital Partners where he assists in sourcing, investment evaluation, transaction execution, and providing post-investment,
value-added oversight to portfolio companies. Before co-founding Collwick Capital LLC, Mr. McColl spent 14 years in the hedge fund industry,
where he was a private investments portfolio manager for Round Table Investment Management and McColl Brothers Lockwood LLC, served as
the Chief Operating Officer for M&amp;M Partners LLC and was the Chief Executive Officer for McColl Partners LLC. Mr. McColl has served
on the boards of directors of Heritage Brands Inc. since 2019 and Fintag Holdings Inc. since 2022. Mr. McColl received a B.S. degree
in Business Administration from the University of North Carolina at Chapel Hill in 1982 and an MBA degree from the University of Virginia
Darden School of Business in 1987. We believe that Mr. McColl&rsquo;s investment management and executive experience qualifies him to
serve as a member of our board of directors. We believe that Mr. McColl&rsquo;s investment management and executive experience qualifies
him to serve as a member of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Advisor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; text-indent: 0.5in"><B><I>Dr. Michael Roizen</I></B> has served as an advisor to the
Company since November 30, 2023. Since 2007, Dr. Roizen has served as the Chief Wellness Officer of the Cleveland Clinic, including as
the Chief Wellness Officer Emeritus since February 2019 and the Wellness Institute Chair since June 2007. He is also a professor of medicine
at the Cleveland Clinic Lerner College of Medicine. Dr. Roizen developed the &ldquo;RealAge&rdquo; concept and has authored or coauthored
five number one New York Times best sellers. He has over 165 peer-reviewed publications and 100 medical chapters, 14 U.S. patents, has
founded several of his own companies, served on FDA advisory committees for 16 years, and chaired an FDA advisory committee. He received
a B.A. degree from Williams College in 1967 in chemistry and economics, and he attended the University of California, San Francisco School
of Medicine and performed his residency at Harvard&rsquo;s Beth Israel Deconess Medical Center. He spent 9 years on the faculty at the
University of California, San Francisco, served as the chair of the Department of Anesthesia and Critical Care and Pain Management at
the University of Chicago for 16 years, and served as the Dean of the School of Medicine and Vice President for Biomedical Sciences at
SUNY Upstate.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Composition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs are managed under the direction of our board of directors, which currently consists of seven members. The number
of directors is determined by our board of directors, subject to the terms of our amended and restated articles of incorporation and
bylaws that will become effective upon the completion of this offering. Upon the completion of this offering, our board of directors
will continue to consist of seven members, and our directors will be elected for one-year terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors and executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
his or her background, employment, and affiliations, our board of directors has determined that Michael Jerman, Talhia Tuck, Dr. Craig
Eagle, and Hugh McColl III do not have any relationship that would interfere with the exercise of independent judgment in carrying out
the responsibilities of a director and are independent directors under the Nasdaq Listing Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making these determinations, our board of directors considered the current and prior relationships that each non-employee director has
with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including
the transactions described in the section of this prospectus titled &ldquo;Certain Relationships and Related Party Transactions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish an audit committee, a compensation committee, and a nominating and corporate governance committee prior
to the completion of this offering. The functions of these committees are described below. Members will serve on these committees until
their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it
deems necessary or appropriate from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish an audit committee, and we anticipate that Michael Jerman, Hugh McColl III, and Bradley Kroenig
will be the members of the committee, with Michael Jerman serving as the chair of the audit committee. Each member of the
committee will meet the requirements for independence under the listing standards of Nasdaq and SEC rules and regulations, including
Rule 10A-3(b)(1) under the Exchange Act. Each member of our audit committee will also meet the financial literacy requirements of the
listing standards of Nasdaq. In addition, our board of directors has determined that Mr. Jerman is an audit committee financial
expert within the meaning of Item 407(d) of Regulation S-K under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee&rsquo;s main purpose is to oversee our corporate accounting and financial reporting process. Our audit committee will
be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">helping
    to ensure the independence and performance of the independent registered public accounting firm;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
    the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the
    independent registered public accounting firm, our interim and year-end results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our policies on risk assessment and risk management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    related party transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and pre-approving, as required, all audit and all permissible non-audit services to be performed by the independent registered public
    accounting firm; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting
    our board of directors in monitoring the performance of our internal audit function.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee will operate under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards
of Nasdaq, a copy of which will be available on our website at www.telomirpharma.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish a compensation committee and we anticipate that Talhia Tuck, Michael Jerman, and Craig Eagle
will be the members of this committee, with Talhia Tuck serving as the chair of the compensation committee. Each member of the
committee will meet the requirements for independence under the listing standards of Nasdaq and SEC rules and regulations. Each member
of our compensation committee will also be a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange
Act, or Rule 16b-3. In arriving at these determinations, our board of directors will examine all factors relevant to determining whether
any compensation committee member has a relationship to us that is material to that member&rsquo;s ability to be independent from management
in connection with carrying out such member&rsquo;s duties as a compensation committee member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee&rsquo;s main purpose is to review and recommend policies relating to compensation and benefits of our officers
and employees. Our compensation committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    approving, and determining, or making recommendations to our board of directors regarding, the compensation and compensation arrangements
    of our executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our equity compensation plans;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving, or making recommendations to our board of directors regarding, incentive compensation and equity compensation plans;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and reviewing general policies relating to compensation and benefits of our employees.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will operate under a written charter that satisfies the applicable rules and regulations of the SEC and the listing
standards of Nasdaq, a copy of which will be available on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Corporate Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish a nominating and corporate governance committee, and we anticipate that Talhia Tuck, Bradley Kroenig,
and Craig Eagle will be the members of this committee, with Talhia Tuck serving as the chair of the nominating and corporate
governance committee. Each member of the committee will meet the requirements for independence under the listing standards of Nasdaq
and SEC rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    evaluating, and selecting, or making recommendations to our board of directors regarding, nominees for election to our board of directors
    and its committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and overseeing the annual evaluation of our board of directors and of its committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering
    and making recommendations to our board of directors regarding the composition of our board of directors and its committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our corporate governance practices; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    recommendations to our board of directors regarding corporate governance guidelines.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will operate under a written charter that satisfies the applicable listing standards of
Nasdaq, a copy of which will be available on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Committee Interlocks and Insider Participation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the members of our compensation committee is a current or former executive officer or employee of our company. None of our executive
officers serves as a member of the compensation committee of any entity that has one or more executive officers serving on our compensation
committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors administers
this oversight function directly through our board of directors as a whole, and through various standing committees of our board of directors
that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring
and assessing strategic risk exposure, including risks associated with cybersecurity and data protection, and our audit committee has
the responsibility to consider our major financial risk exposures and the steps our management has taken to monitor and control these
exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee
will review legal, regulatory, and compliance matters that could have a significant impact on our financial statements. Our nominating
and corporate governance committee will monitor the effectiveness of our corporate governance practices, including whether they are successful
in preventing illegal or improper liability-creating conduct. Our compensation committee will assess and monitor whether any of our compensation
policies and programs has the potential to encourage excessive risk taking. While each committee is responsible for evaluating certain
risks and overseeing the management of such risks, our entire board of directors will be regularly informed through committee reports
about such risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Diversity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the
appropriate characteristics, skills, and experience required for the board of directors as a whole and its individual members. Although
our board of directors does not have a formal written diversity policy with respect to the evaluation of director candidates, in its
evaluation of director candidates, our nominating and corporate governance committee will consider factors including, without limitation,
issues of character, integrity, judgment, potential conflicts of interest, other commitments, and diversity, and with respect to diversity,
such factors as gender, race, ethnicity, experience, and area of expertise, as well as other individual qualities and attributes that
contribute to the total diversity of viewpoints and experience represented on the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee will ensure compliance with the new rule by Nasdaq for board diversity (the &ldquo;Nasdaq
Diversity Rule&rdquo;), on or before the date required under the Nasdaq Diversity Rule. The Nasdaq Diversity Rule requires, assuming
our shares of common stock are listed on the Nasdaq Capital Market and that we are a smaller reporting company, that we will have at
least two directors serving on our board of directors, at least one of which identifies as female and the second of which identifies
as female, underrepresented minority or LGBTQ+, by December 31, 2026, unless our board of directors is comprised of five or less directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, our board of directors will adopt a code of business conduct and ethics applicable to all of our
directors, officers (including our principal executive officer, principal financial officer, and principal accounting officer) and all
global employees in accordance with applicable federal securities laws and corporate governance rules of the Nasdaq Capital Market. Our
code of business conduct and ethics will be available on our website. Any amendments to the code of business conduct and ethics, or waivers
of its requirements, will, if required, be disclosed on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Governance Guidelines</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, our board of directors will adopt corporate governance guidelines, a copy of which will be available
on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not provide any cash or equity compensation to any of our directors during the year ended December 31, 2023, in their capacity
as directors, and we have not yet adopted a compensation program for our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_008"></A>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section discusses the material components of the executive compensation program for the following persons: (i) all persons serving as
our principal executive officers during 2023 and (ii) the most highly compensated of our other executive officers who received
compensation during 2023 of at least $100,000 and who were executive officers on December 31, 2023. We refer to these persons
as our &ldquo;named executive officers&rdquo; elsewhere in this prospectus. Our &ldquo;named executive officers&rdquo; and their positions
are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Chapman, Jr., MD, Chief Executive Officer and Chairman; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nathen
    Fuentes,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Chief Financial Officer, Treasurer,
    and Secretary.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the compensation paid by us during the 2022 and 2021 fiscal years to our named executive officers. As indicated
below, there was no compensation paid to any named executive officer of our company during 2021 or 2022. For a description of the compensation
program for our named executive officers following 2022, see &ldquo;&mdash;Executive Compensation Arrangements&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Name and principal position</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Salary</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Bonus</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">All Other Compensation</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Christopher Chapman, Jr., MD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center">2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Executive Officer and Chairman</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Nathen Fuentes (1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,192</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,192</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Financial Officer, Treasurer, and Secretary</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Fuentes was appointed Chief Financial Officer, Treasurer, and Secretary</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    effective September 21, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Compensation Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a more detailed summary of the elements of our current executive compensation program as it relates to our named executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Christopher
Chapman, Jr., MD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Dr. Chapman, effective as of the date of the closing of this initial public offering,
pursuant to which Dr. Chapman will serve as our Chief Executive Officer and Chairman of our board of directors. Under his
employment agreement, Dr. Chapman will agree to work part-time and on an as-needed basis with respect to the affairs of our company.
Dr. Chapman&rsquo;s employment agreement provides that his employment will be on an at-will basis and can be terminated by either Dr.
Chapman or us at any time for cause. Under the agreement, Dr. Chapman will receive an initial base salary of $275,000 per year beginning
on the closing of this offering. In the event that Dr. Chapman&rsquo;s employment is terminated by our company without &ldquo;Cause&rdquo;
or is terminated by Dr. Chapman for &ldquo;Good Reason&rdquo;, Dr. Chapman will be entitled to severance compensation in the form of
salary continuation for a period of three months (subject to Dr. Chapman executing and delivering a customary general release in favor
of the company). &ldquo;Cause&rdquo; is defined in the agreement to include dishonesty, misappropriation, willful misconduct, breach
of the agreement, and other customary matters. &ldquo;Good Reason&rdquo; is defined to include a material adverse change in Dr. Chapman&rsquo;s
compensation or duties and level of responsibility. The employment agreement also contains customary confidentiality and invention-assignment
covenants to which Dr. Chapman is subject. Beginning in 2023, in lieu of health insurance coverage and 401k benefits, we have agreed
to pay Dr. Chapman&rsquo;s life insurance policy premium in an amount up to $2,215 per quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nathen
Fuentes, CPA</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an amended and restated employment agreement on December 11, 2023, with Mr. Fuentes which amended and restated
his original employment agreement, which was effective September 21, 2023, pursuant to which Mr. Fuentes serves as our Chief
Financial Officer, Treasurer, and Secretary. Under his employment agreement, Mr. Fuentes has agreed to devote his full business time
and effort to the business affairs of the Company. Mr. Fuentes&rsquo;s employment agreement provides that his employment will be on an
at-will basis and can be terminated by either Mr. Fuentes or our company at any time for cause. Under the agreement, Mr. Fuentes will
receive an initial base salary of $165,000 per year, however, should the Company complete the initial public offering prior to September
21, 2024, such salary shall be retroactively adjusted to equal $250,000 for his first full year of employment only. Additional bonuses
and adjustments to Mr. Fuentes&rsquo;s salary may be made by our board of directors in its sole discretion. In the event that
his employment is terminated by our company without &ldquo;Cause&rdquo; or is terminated by Mr. Fuentes for &ldquo;Good Reason&rdquo;,
Mr. Fuentes will be entitled to severance compensation in the form of salary continuation for a period of three months (subject to Mr.
Fuentes executing and delivering a customary general release in favor of the company). &ldquo;Cause&rdquo; is defined in the agreement
to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. &ldquo;Good Reason&rdquo;
is defined to include a material adverse change in Mr. Fuentes&rsquo;s compensation or duties and level of responsibility. The employment
agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Fuentes is subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Base
Salaries</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
base salaries of our employed executive officers are specified in their respective employment agreements, as summarized above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bonuses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not pay any bonuses to any of our named executive officers during 2022 or 2023. Our employment agreements with our executive
officers provide that bonuses may be granted to our executive officers in the discretion of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Equity
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
the date of this prospectus, none of our officers, directors, or employees have received any equity compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Retirement
Plans</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently maintain any retirement plans for our employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year-End</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options granted and outstanding as of December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023
Omnibus Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted, and our stockholders have approved,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
the Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan (the &ldquo;2023 Omnibus Plan&rdquo;) which will be effective upon the completion of
this offering. The 2023 Omnibus Plan will authorize the grant of incentive stock options, within the meaning of Section 422 of the Internal
Revenue Code, to our employees and any of our parent and subsidiary corporations&rsquo; employees, and the grant of non-statutory stock
options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to our employees,
directors, and consultants and any of our future subsidiary corporations&rsquo; employees and consultants. The following is a summary
of certain terms and conditions of the 2023 Omnibus Plan. This summary is qualified in its entirety by reference
to the 2023 Omnibus Plan attached as an exhibit to the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Administration</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan is administered by our board of directors or our compensation committee, or any other committee or subcommittee or
one or more of our officers to whom authority has been delegated (collectively, the &ldquo;Administrator&rdquo;). The Administrator has
the authority to interpret the 2023 Omnibus Plan and award agreements entered into with respect to the 2023 Omnibus Plan; to make, change
and rescind rules and regulations relating to the 2023 Omnibus Plan; to make changes to, or reconcile any inconsistency in, the 2023
Omnibus Plan or any award agreement covering an award; and to take any other actions needed to administer the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eligibility</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may designate any of the following as a participant under the 2023 Omnibus Plan: any officer or employee, or individuals
engaged to become an officer or employee, of our company or our affiliates; and consultants of our company or our affiliates, and our
directors, including our non-employee directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Types
of Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan permits the Administrator to grant stock options, stock appreciation rights (&ldquo;SARs&rdquo;), performance shares,
performance units, shares of common stock, restricted stock, restricted stock units (&ldquo;RSUs&rdquo;), cash incentive awards, dividend
equivalent units, or any other type of award permitted under the 2023 Omnibus Plan. The Administrator may grant any type of award to
any participant it selects, but only our employees or our subsidiaries&rsquo; employees may receive grants of incentive stock options
within the meaning of Section 422 of the Internal Revenue Code. Awards may be granted alone or in addition to, in tandem with, or (subject
to the repricing prohibition described below) in substitution for any other award (or any other award granted under another plan of our
company or any affiliate, including the plan of an acquired entity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shares
Reserved Under the 2023 Omnibus Incentive Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan will provide that 6,500,000 shares of our common stock are reserved for issuance under the 2023 Omnibus Plan,
all of which may be issued pursuant to the exercise of incentive stock options. The number of shares available for issuance under our
2023 Omnibus Plan will also include an annual increase on the first day of each fiscal year after the completion of this offering equal
to 1.0% of the outstanding shares of all class of our common stock as of the last day of the immediately preceding
fiscal year or such other amount as our board of directors may determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares reserved for issuance under the 2023 Omnibus Plan will be reduced on the date of the grant of any award by the maximum
number of shares, if any, with respect to which such award is granted. However, an award that may be settled solely in cash will not
deplete the 2023 Omnibus Plan&rsquo;s share reserve at the time the award is granted. If (a) an award expires, is canceled, or terminates
without issuance of shares or is settled in cash, (b) the Administrator determines that the shares granted under an award will not be
issuable because the conditions for issuance will not be satisfied, (c) shares are forfeited under an award, (d) shares are issued under
any award and we reacquire them pursuant to our reserved rights upon the issuance of the shares, (e) shares are tendered or withheld
in payment of the exercise price of an option or as a result of the net settlement of outstanding stock appreciation rights or (f) shares
are tendered or withheld to satisfy federal, state or local tax withholding obligations, then those shares are added back to the reserve
and may again be used for new awards under the 2023 Omnibus Plan. However, shares added back to the reserve pursuant to clauses (d),
(e) or (f) in the preceding sentence may not be issued pursuant to incentive stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant stock options and determine all terms and conditions of each stock option, which include the number of stock
options granted, whether a stock option is to be an incentive stock option or non-qualified stock option, and the grant date for the
stock option. However, the exercise price per share of common stock may never be less than the fair market value of a share of common
stock on the date of grant and the expiration date may not be later than 10 years after the date of grant. Stock options will be exercisable
and vest at such times and be subject to such restrictions and conditions as are determined by the Administrator, including with respect
to the manner of payment of the exercise price of such stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Appreciation Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant SARs, which represent the right of a participant to receive cash in an amount, or common stock with a fair market
value, equal to the appreciation of the fair market value of a share of common stock during a specified period of time. The 2023 Omnibus
Plan provides that the Administrator will determine all terms and conditions of each SAR, including, among other things: (a) whether
the SAR is granted independently of a stock option or relates to a stock option, (b) the grant price, which may never be less than the
fair market value of our common stock as determined on the date of grant, (c) a term that must be no later than 10 years after the date
of grant, and (d) whether the SAR will settle in cash, common stock or a combination of the two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Performance
and Stock Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant awards of shares of common stock, restricted stock, RSUs, performance shares or performance units. Restricted
stock means shares of common stock that are subject to a risk of forfeiture or restrictions on transfer, which may lapse upon the achievement
or partial achievement of performance goals (as described below) or upon the completion of a period of service. An RSU grants the participant
the right to receive cash or shares of common stock the value of which is equal to the fair market value of one share of common stock,
to the extent performance goals are achieved or upon the completion of a period of service. Performance shares give the participant the
right to receive shares of common stock to the extent performance goals are achieved. Performance units give the participant the right
to receive cash or shares of common stock valued in relation to a unit that has a designated dollar value or the value of which is equal
to the fair market value of one or more shares of common stock, to the extent performance goals are achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator will determine all terms and conditions of the awards including (a) whether performance goals must be achieved for the
participant to realize any portion of the benefit provided under the award, (b) the length of the vesting or performance period and,
if different, the date that payment of the benefit will be made, (c) with respect to performance units, whether to measure the value
of each unit in relation to a designated dollar value or the fair market value of one or more shares of common stock, and (d) with respect
to performance shares, performance units, and RSUs, whether the awards will settle in cash, in shares of common stock (including restricted
stock), or in a combination of the two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Incentive Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant cash incentive awards. An incentive award is the right to receive a cash payment to the extent one or more performance
goals are achieved. The Administrator will determine all terms and conditions of a cash incentive award, including, but not limited to,
the performance goals (described below), the performance period, the potential amount payable, and the timing of payment. While the 2023
Omnibus Plan permits cash incentive awards to be granted under the 2023 Omnibus Plan, we may also make cash incentive awards outside
of the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Performance
Goals</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the 2023 Omnibus Plan, the Administrator may establish objective or subjective performance goals which may apply to any performance
award. Such performance goals may include, but are not limited to, one or more of the following measures with respect to our company
or any one or more of our subsidiaries, affiliates, or other business units: net sales; cost of sales; gross income; gross revenue; revenue;
operating income; earnings before taxes; earnings before interest and taxes; earnings before interest, taxes, depreciation and amortization;
earnings before interest, taxes, depreciation, amortization and exception items; income from continuing operations; net income; earnings
per share; diluted earnings per share; total stockholder return; fair market value of a share of common stock; cash flow; net cash provided
by operating activities; net cash provided by operating activities less net cash used in investing activities; ratio of debt to debt
plus equity; return on stockholder equity; return on invested capital; return on average total capital employed; return on net capital
employed; return on assets; return on net assets employed before interest and taxes; operating working capital; average accounts receivable
(calculated by taking the average of accounts receivable at the end of each month); average inventories (calculated by taking the average
of inventories at the end of each month); economic value added; succession planning; manufacturing return on assets; manufacturing margin;
and customer satisfaction. Performance goals may also relate to a participant&rsquo;s individual performance. The Administrator reserves
the right to adjust any performance goals or modify the manner of measuring or evaluating a performance goal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Equivalent Units</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant dividend equivalent units. A dividend equivalent unit gives the participant the right to receive a payment, in
cash or shares of common stock, equal to the cash dividends or other distributions that we pay with respect to a share of common stock.
We determine all terms and conditions of a dividend equivalent unit award, except that dividend equivalent units may not be granted in
connection with a stock option or SAR, and dividend equivalent unit awards granted in connection with another award cannot provide for
payment until the date such award vests or is earned, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Stock-Based Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant to any participant shares of unrestricted stock as a replacement for other compensation to which such participant
is entitled, such as in payment of director fees, in lieu of cash compensation, in exchange for cancellation of a compensation right
or as a bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transferability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
are not transferable, including to any financial institution, other than by will or the laws of descent and distribution, unless the
Administrator allows a participant to (a) designate in writing a beneficiary to exercise the award or receive payment under the award
after the participant&rsquo;s death, (b) transfer an award to a former spouse as required by a domestic relations order incident to a
divorce, or (c) transfer an award without receiving any consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adjustments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
(a) we are involved in a merger or other transaction in which our shares of common stock are changed or exchanged; (b) we subdivide or
combine shares of common stock or declare a dividend payable in shares of common stock, other securities, or other property (other than
stock purchase rights issued pursuant to a stockholder rights agreement); (c) we effect a cash dividend that exceeds 10% of the fair
market value of a share of common stock or any other dividend or distribution in the form of cash or a repurchase of shares of common
stock that our board of directors determines is special or extraordinary, or that is in connection with a recapitalization or reorganization;
or (d) any other event occurs that in the Administrator&rsquo;s judgment requires an adjustment to prevent dilution or enlargement of
the benefits intended to be made available under the 2023 Omnibus Plan, then the Administrator will, in a manner it deems equitable,
adjust any or all of (1) the number and type of shares subject to the 2023 Omnibus Plan and which may, after the event, be made the subject
of awards; (2) the number and type of shares of common stock subject to outstanding awards; (3) the grant, purchase, or exercise price
with respect to any award; and (4) the performance goals of an award. In any such case, the Administrator may also provide for a cash
payment to the holder of an outstanding award in exchange for the cancellation of all or a portion of the award, subject to the terms
of the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may, in connection with any merger, consolidation, acquisition of property or stock, or reorganization, authorize the issuance
or assumption of awards upon terms and conditions we deem appropriate without affecting the number of shares of common stock otherwise
reserved or available under the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Change
of Control</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a change of control (as defined in the 2023 Omnibus Plan), the successor or surviving corporation may agree to assume some or all outstanding
awards or replace them with the same type of award with similar terms and conditions, without the consent of any participant, subject
to the following requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    award that is assumed must be appropriately adjusted, immediately after such change of control, to apply to the number and class
    of securities that would have been issuable to a participant upon the consummation of such change of control had the award been exercised,
    vested, or earned immediately prior to such change of control, and other appropriate adjustment to the terms and conditions of the
    award may be made.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the securities to which the awards relate after the change of control are not listed and traded on a national securities exchange,
    then (a) each participant must be provided the option to elect to receive, in lieu of the issuance of such securities, cash in an
    amount equal to the fair value of the securities that would have otherwise been issued, and (b) no reduction may be taken to reflect
    a discount for lack of marketability, minority, or any similar consideration, for purposes of determining the fair value of such
    securities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a participant is terminated from employment without cause, or due to death or disability, or the participant resigns employment for
    good reason (as defined in any award or other agreement between the participant and our company or an affiliate) within two years
    following the change of control, then upon such termination, all of the participant&rsquo;s awards in effect on the date of such
    termination will vest in full or be deemed earned in full.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54.7pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the purchaser, successor, or surviving entity does not assume the awards or issue replacement awards, then immediately prior to the change
of control date, unless the Administrator otherwise determines:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    stock option or SAR then held by a participant will become immediately and fully vested, and all stock options and SARs will be cancelled
    on the change of control date in exchange for a cash payment equal to the excess of the change of control price of the shares of
    common stock over the purchase or grant price of such shares under the award.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
    restricted stock and RSUs (that are not performance awards) will vest in full.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    performance shares, performance units and cash incentive awards for which the performance period has expired will be paid based on
    actual performance, and all such awards for which the performance period has not expired will be cancelled in exchange for a cash
    payment equal to the amount that would have been due under such awards, valued assuming achievement of target performance goals at
    the time of the change of control, prorated based on the number of full months elapsed in the performance period.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    unvested dividend equivalent units will vest (to the same extent as the award granted in tandem with such units) and be paid.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other unvested awards will vest and any amounts payable will be paid in cash.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54.7pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Term
of Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
earlier terminated by our board of directors, the 2023 Omnibus Plan will terminate on, and no further awards may be granted, after the
tenth (10<SUP>th</SUP>) anniversary of its effective date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Termination
and Amendment of Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors or the Administrator may amend, alter, suspend, discontinue, or terminate the 2023 Omnibus Plan at any time, subject
to the following limitations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    board of directors must approve any amendment to the 2023 Omnibus Plan if we determine such approval is required by prior action
    of our board of directors, applicable corporate law, or any other applicable law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
    must approve any amendment to the 2023 Omnibus Plan, which may include an amendment to materially increase the number of shares reserved
    under the 2023 Omnibus Plan, if we determine that such approval is required by Section 16 of the Exchange Act, the Code, the listing
    requirements of any principal securities exchange or market on which the shares are then traded, or any other applicable law; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
    must approve any amendment to the 2023 Omnibus Plan that would diminish the protections afforded by the participant award limits
    or repricing and backdating prohibitions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54.7pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment,
Modification, Cancellation and Disgorgement of Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.45pt; text-align: justify; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the requirements of the 2023 Omnibus Plan, the Administrator may modify or amend any award or waive any restrictions or conditions
applicable to any award or the exercise of the award, or amend, modify, or cancel any terms and conditions applicable to any award, in
each case, by mutual agreement of the Administrator and the participant or any other person that may have an interest in the award, so
long as any such action does not increase the number of shares of common stock issuable under the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not need to obtain participant (or other interested party) consent for any such action (a) that is permitted pursuant to the adjustment
provisions of the 2023 Omnibus Plan; (b) to the extent we deem the action necessary to comply with any applicable law or the listing
requirements of any principal securities exchange or market on which our common stock is then traded; (c) to the extent we deem the action
is necessary to preserve favorable accounting or tax treatment of any award for us; or (d) to the extent we determine that such action
does not materially and adversely affect the value of an award or that such action is in the best interest of the affected participant
or any other person as may then have an interest in the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator can cause a participant to forfeit any award, and require the participant to disgorge any gains attributable to the award,
if the participant engages in any action constituting, as determined by the Administrator in its discretion, cause for termination, or
a breach of a material company policy, any award agreement or any other agreement between the participant and us or one of our affiliates
concerning noncompetition, nonsolicitation, confidentiality, trade secrets, intellectual property, nondisparagement or similar obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
awards granted under the 2023 Omnibus Plan, and any shares of common stock issued or cash paid under an award, will be subject to any
recoupment or clawback policy that we adopt, or any recoupment or similar requirement otherwise made applicable by law, regulation or
listing standards to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_009"></A>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of transactions within the last three years to which we have been a party, in which the amount involved exceeded
or will exceed $120,000, and in which any of our executive officers, directors or holders of more than 5% of our voting securities, or
an immediate family member thereof, had or will have a direct or indirect material interest. We believe the terms obtained or consideration
that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or amounts
that would be paid or received, as applicable, in arm&rsquo;s-length transactions with unrelated third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Line
of Credit and Promissory Note with the Bay Shore Trust</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, we entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by our founder, Jonnie
R. Williams, Sr., and under which various of his family members are beneficiaries (the &ldquo;Bay Shore Trust&rdquo;). Under this Promissory
Note and Loan Agreement (the &ldquo;Bay Shore Note&rdquo;), we have the right to borrow up to an aggregate of $5,000,000 from the Bay
Shore Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of our
initial public offering. Our right to borrow funds under the Bay Shore Note is subject to the absence of a material adverse change in
our assets, operations, or prospects. The Bay Share Note, together with accrued interest, will become due and payable on the second anniversary
of the issuance of the note, provided that it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at
a rate equal to 7% per annum, simple interest, during the first year that the note is outstanding and 10% per annum, simple interest,
thereafter. The Bay Shore Note is unsecured. As of November 30, 2023, the total amount outstanding under the Bay Shore Note was $1.4 million. The total amount
outstanding was converted into 674,637 shares of our common stock on November 30, 2023 at a conversion rate of $2.05 per share (after
giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023) pursuant to a conversion agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, we issued to the Bay Shore Trust a common stock purchase warrant
on June 15, 2023, giving the Bay Shore Trust the right to purchase up to 2,439,025 shares of common stock at an exercise price
of $3.73 per share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023), which warrant will expire five years after the date of grant. Upon issuance, the warrant met the criteria to be classified
as equity based on an analysis under Accounting Standards Codification (480) ASC 480, &ldquo;<I>Distinguishing Liabilities from Equity</I>&rdquo;
and will be measured at fair value, resulting in an initial fair value of approximately $5.95 million upon issuance of the warrant using
Black-Scholes valuation techniques.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
with MIRALOGX LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
January 1, 2023, MIRALOGX and The Starwood Trust, a separate Trust established by our founder, have advanced funds on behalf of Bayshore
Trust to our company in order to fund operating activities. The total amount advanced and outstanding as of November 30, 2023, was $1.7
million. These advances were converted into 837,841 shares of our common stock on November 30, 2023 at a conversion rate of $2.05 per
share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023) pursuant to a conversion agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2023, we entered into the Initial MIRALOGX License Agreement with MIRALOGX, which is an intellectual property development and
holding company established by our founder and the inventor of TELOMIR-1, Jonnie R. Williams, Sr. See &ldquo;Business&ndash; Intellectual
Property&rdquo;. MIRALOGX is wholly owned by the Bay Shore Trust, and Mr. Williams does not have voting or dispositive power over the
shares of the Company held by Bay Shore Trust, and Mr. Williams is not an officer or director of the Bay Shore Trust. On November 10,
2023, we entered into an amendment to the Initial MIRALOGX License Agreement, pursuant to which we acquired the license to the non-human
applications of the &ldquo;Licensed Products.&rdquo; See &ldquo;&mdash;Intellectual Property.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a party to an Agreement for Shared Lease Costs, dated April 1, 2023, with MIRALOGX and MIRA Pharmaceuticals, Inc., under which
we have agreed to pay our pro rata share of the operating usage costs owing by MIRALOGX under an aircraft lease agreement between MIRALOGX
and Supera Aviation I LLC (&ldquo;Supera Aviation&rdquo;) based on our usage of the leased aircraft each month. No amounts are payable
by us under this agreement unless and to the extent we choose to utilize the leased aircraft, and we may discontinue the use of the aircraft
and terminate this agreement at any time. Supera Aviation is a company owned by Starwood Trust, a trust established by Mr. Williams.
Since April 1, 2023, the Company has incurred $988,000 in expenses under the aircraft lease agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Review
and Approval of Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, our board of directors will adopt a written policy regarding the review and approval of related party
transactions. Our audit committee charter provides that the audit committee shall review and approve or disapprove any related party
transactions, which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected
to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. Upon the completion of this
offering, our policy regarding transactions between us and related persons will provide that a related person is defined as a director,
executive officer, nominee for director or greater than 5% beneficial owner of our common stock, in each case since the beginning of
the most recently completed year, and any of their immediate family members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of the foregoing disclosures are summaries of certain provisions of our related party agreements and are qualified in their entirety
by reference to all of the provisions of such agreements. Because these descriptions are only summaries of the applicable agreements,
they do not necessarily contain all of the information that you may find useful. Copies of certain of the agreements have been filed
as exhibits to the registration statement of which this prospectus is a part and are available electronically on the website of the SEC
at <I>www.sec.gov</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="da_010"></A>PRINCIPAL
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of December 31, 2023 (the &ldquo;Beneficial Ownership Date&rdquo;) with respect to the
beneficial ownership of our common stock (i) immediately prior to this offering and (ii) as adjusted to reflect the sale of 1,000,000
shares of our common stock in this offering, in each case by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current directors and executive officers as a group; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person known by us to be the beneficial owner of more than 5% of the outstanding shares of our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment
power with respect to our securities. In computing the number of shares beneficially owned by a person and the percentage ownership of
that person, shares of common stock subject to options or warrants held by that person that are currently exercisable or exercisable
within 60 days of the Beneficial Ownership Date are deemed outstanding but are not deemed outstanding for computing the percentage ownership
of any other person. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting
and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable.
The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and
13(g) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the table below, the applicable percentage ownership relating to shares beneficially owned prior to this offering is based on shares
of our common stock outstanding as of the Beneficial Ownership Date. The applicable percentage ownership relating to shares beneficially
owned after this offering is based on 28,609,814 shares of our common stock outstanding (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023) and assumes that the underwriters
do not exercise their option to purchase additional shares of common stock from us. Unless otherwise indicated in the footnotes to the
table below, the address of each beneficial owner listed in the table below is 900 West Platt Street Suite 200, Tampa, Florida 33606.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Shares of Common Stock Beneficially Owned</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Shares of Common Stock Beneficially Owned Before this Offering</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Shares of Common Stock Beneficially Owned After this Offering</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Name of beneficial owner</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Percentage</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Percentage</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Directors and Executive Officers</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Christopher Chapman, Jr., MD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">975,610</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">3.14</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">975,610</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">3.04</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nathen Fuentes<SUP></SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">101,134</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">101,134</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Christos Nicholoudis, Esq.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Brad Kroenig</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,781</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,781</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Michael Jerman, CPA</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Craig Eagle</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">487,805</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.57</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">487,805</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.52</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Talhia Tuck</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,781</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,781</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Hugh McColl III</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,781</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,781</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">All current directors and officers as a group (8 persons)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,710,892</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,710,892</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">5% Stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    McNulty<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,723,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31.32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,723,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30.34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francis E. O&rsquo;Donnell, Jr.<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,220</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,220</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.09</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">*Represents beneficial ownership of less than 1%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    (i) 5,406,431 shares held by the Bay Shore Trust, (ii) 1,853,659 shares held by the Celeste J. Williams Lifetime QTIP
    Trust, (iii) 24,391 shares held directly by Mr. McNulty, and (iv) 2,439,025 shares issuable pursuant
    to a warrant held by the Bay Shore Trust that is immediately exercisable. As trustee for both the Bay Shore Trust and Celeste J.
    Williams Lifetime QTIP Trust, Mr. McNulty has sole voting and dispositive power over the shares held by each trust, and, as a result
    is deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the securities held by each trust.
    Mr. Jonnie R. Williams, Sr., our founder and the settlor of the Bay Shore Trust, does not have voting or dispositive power over the
    shares held by the Bay Shore Trust.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 585,366 shares held directly by Dr. Francis E. O&rsquo;Donnell Jr. and (ii) 1,365,854 shares held by the Rachel Jean
    Williams 2021 Irrevocable Trust. As trustee of the Rachel Jean Williams 2021 Irrevocable Trust, Dr. Francis E. O&rsquo;Donnell
    Jr. has sole voting and dispositive power over the shares held by the trust, and, as a result is deemed to have beneficial ownership
    (as determined under Section 13(d) of the Exchange Act) of the securities held by the trust.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_001"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the material terms of our amended and restated articles of incorporation and our amended and restated bylaws
to be in effect upon the completion of this offering. The following description is a summary, does not purport to be complete and is
qualified in its entirety by reference to our second amended and restated articles of incorporation and amended and restated bylaws,
which are filed as exhibits to the registration statement of which this prospectus is a part and are incorporated by reference into this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the filing of our Second Amended and Restated Articles of Incorporation and the 1-for-2.05 reverse stock split that
we completed on December 11, 2023, the</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> total number
of shares of common stock our company is authorized to issue is presently 300,000,000 shares, no par value. The total number of
shares of preferred stock our company is authorized to issue is 100,000,000 shares, no par value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a corporation organized under the laws of the state of Florida and are governed by the Florida Business Corporation Act, which we
sometimes refer to as the FBCA, our amended and restated articles of incorporation and our amended and restated bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of our common stock are entitled to one vote for each share held on all matters submitted to a vote of shareholders. Accordingly,
holders of a majority of the shares of our common stock entitled to vote in any election of directors may elect all of the directors
standing for election. Holders of shares of our common stock are entitled to receive proportionately any dividends if and when such dividends
are declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. Upon the liquidation,
dissolution or winding up of the company, the holders of our common stock are entitled to receive ratably net assets available after
the payment of all debts and other liabilities and subject to the prior rights of holders of any outstanding preferred stock. The rights,
preferences, and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders
of shares of any series of preferred stock that we may designate and issue in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of our amended and restated articles of incorporation, which we sometimes refer to as the articles, the board of directors
is authorized to designate and issue up to 100,000,000 shares of preferred stock in one or more series without shareholder approval.
Our board of directors will have discretion to determine the rights, preferences, privileges and restrictions, including voting rights,
dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights of holders of our common
stock until the board of directors determines the specific rights of the holders of the preferred stock. However, these effects might
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricting
    dividends on the common stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting
    the voting power of the common stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing
    the liquidation rights of the common stock; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying
    or preventing a change in control of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, there will be no shares of preferred stock outstanding, and, at present, we have no plans to issue any shares
of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends
and Other Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of our common stock will be entitled to receive proportionately any cash or stock dividends if and when such dividends are declared
by the board of directors, subject to any preferential dividend rights of outstanding preferred stock. In the event of the dissolution
or liquidation of the company, after the full preferential rights, if any, on any outstanding preferred stock has been paid to or set
aside for the holders of such preferred stock, the holders of our common stock will be entitled to receive proportionately all of our
remaining assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
declaration and payment of any dividend will be subject to the discretion of our board of directors, subject to applicable laws. The
time and amount of any dividend will depend on a number of factors, including our financial condition, results of operations, capital
requirements, contractual restrictions, general business conditions, and any other factors that our board of directors may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to retain all available funds and any future earnings for general corporate purposes, including working capital, operating
expenses, and capital expenditures, and do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable
future. See &ldquo;Dividend Policy.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
and Election of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors consists of seven members. The holders of common stock and any other class of stock of our company, to the
extent they shall have the right to vote, shall retain the right to elect and remove all members of the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quorum/Voting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
all meetings of our board of directors, a majority of the total number of directors constitutes a quorum. If there is a quorum, a vote
of the majority of the directors present at the meeting is considered an act of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Removal
of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles provide that any director may be removed from office, but only for cause by the affirmative vote of not
less than a majority of our shareholders entitled to vote in the election of directors. &ldquo;Cause&rdquo; is construed to exist only
if the director whose removal is proposed has been convicted of a felony or has been adjudged to be liable for willful misconduct in
the performance of his or her duties to us in a matter which has a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vacancies
on the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
vacancy on our board of directors may be filled by a vote of a majority of the remaining members of the board of directors, even if less
than a quorum, at any meeting of the board of directors. A person so elected by the board of directors to fill a vacancy shall hold office
for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&rsquo;s successor
shall have been duly elected and qualified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
by Shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of our common stock is entitled to one vote per share for the election of directors and for all other corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
of Articles</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FBCA allows us to amend our amended and restated articles at any time to add or change a provision that is required or permitted to be
included in the articles of incorporation or to delete a provision that is not required to be included in the articles of incorporation.
Our board of directors can propose one or more amendments for submission to shareholders and may condition its submission of the proposed
amendment on any basis if it provides certain notice and includes certain information regarding the proposed amendment in that notice.
The provisions in our articles that require a greater voting requirement than provided in the FBCA may only be amended by the same vote
required to take action under that voting requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
of Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws may be amended or repealed, and new bylaws may be adopted by our shareholders at any annual or special meetings at which a quorum
is present. The bylaws may also be amended or repealed, and new bylaws may be adopted by our board of directors by affirmative vote of
a majority of the number of directors present at any meeting at which a quorum is in attendance. Notwithstanding the foregoing, pursuant
to our articles, the provisions of our bylaws that require a greater voting requirement than provided in the FBCA may only be amended
by the same vote required to take action under that voting requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Various Provisions of Florida Law, Our Amended and Restated Articles of Incorporation and Our Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of Florida law have certain anti-takeover effects. Our amended and restated articles of incorporation and bylaws also contain provisions
that may have similar effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Florida
Anti-Takeover Statutes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
control share acquisition statute, Section 607.0902 of the FBCA, generally provides that in the event a person acquires voting shares
of the company in excess of 20% of the voting power of all of our issued and outstanding shares, such acquired shares will not have any
voting rights unless such rights are restored by the holders of a majority of the votes of each class or series entitled to vote separately,
excluding shares held by the person acquiring the control shares or any of our officers or employees who are also directors of the company.
Certain acquisitions of shares are exempt from these rules, such as shares acquired pursuant to the laws of intestate succession or pursuant
to a gift or testamentary transfer, pursuant to a merger or share exchange effected in compliance with the FBCA if we are a party to
the agreement, or pursuant to an acquisition of our shares if the acquisition has been approved by our board of directors before the
acquisition. The control share acquisition statute generally applies to any &ldquo;issuing public corporation,&rdquo; which means a Florida
corporation which has:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    hundred or more shareholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its
    principal place of business, its principal office, or substantial assets within Florida; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    (i) more than 10% of its shareholders are resident in Florida; (ii) more than 10% of its shares are owned by residents of Florida;
    or (iii) one thousand shareholders are resident in Florida.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affiliated transaction (or so-called &ldquo;business combination&rdquo;) statute, Section 607.0901 of the FBCA, provides that we may
not engage in certain mergers, consolidations, sales of assets, issuances of stock, reclassifications, recapitalizations, and other affiliated
transactions with any &ldquo;interested shareholder&rdquo; for a period of three years following the time that such shareholder became
an interested shareholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to the time that such shareholder became an interested shareholder, our board of directors approved either the affiliated transaction
    or the transaction which resulted in the shareholder becoming an interested shareholder; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned
    at least 85% of our voting shares outstanding at the time the transaction commenced; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    or subsequent to the time that such shareholder became an interested shareholder, the affiliated transaction is approved by our board
    of directors and authorized at an annual or special meeting of shareholders, and not by written consent, by the affirmative vote
    of at least two-thirds of the outstanding voting shares which are not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;interested shareholder&rdquo; is generally defined as any person who is the beneficial owner of more than 15% of our outstanding
voting shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
voting requirements set forth above do not apply to a particular affiliated transaction if one or more conditions are met, including,
but not limited to, the following: if the affiliated transaction has been approved by a majority of our disinterested directors; if we
have not had more than 300 shareholders of record at any time during the three years preceding the date the affiliated transaction is
announced; if the interested shareholder has been the beneficial owner of at least 80% of our outstanding voting shares for at least
three years preceding the date the affiliated transaction is announced; or if the consideration to be paid to the holders of each class
or series of voting shares in the affiliated transaction meets certain requirements of the statute with respect to form and amount, among
other things.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
Cumulative Voting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FBCA provides that shareholders do not have the right to cumulate votes in the election of directors unless the articles of incorporation
provide otherwise. Our articles do not provide for cumulative voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Requirements for Shareholder Proposals and Director Nominations; Calling a Special Meeting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws provide that shareholders seeking to bring business before an annual meeting must provide timely notice of
their proposal in writing to the corporate secretary. To be timely, a shareholder&rsquo;s notice must have been received on or before
December 31 of the year immediately preceding the annual meeting; provided, however, that in the event that the date of the annual meeting
is on or after May 1 in any year, notice by the shareholder to be timely must be received not later than the close of business on the
day which is determined by adding to December 31 of the year immediately preceding such annual meeting the number of days starting with
May 1 and ending on the date of the annual meeting in such year. The amended and restated bylaws also specify requirements as to the
form and content of a shareholder&rsquo;s notice. These provisions may impede shareholders&rsquo; ability to bring matters before an
annual meeting of shareholders or make nominations for directors at an annual meeting of shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws also provide that a special meeting of shareholders can only be called by our chairman of the board of directors,
our chief executive officer, our president (in the absence of a chief executive officer), a majority of our board of directors or the
holders of 10% or more of all of our votes entitled to be cast on any issue proposed to be considered at the special meeting of shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
But Unissued Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized but unissued shares of common stock and preferred stock will be available for future issuance without shareholder approval.
We could use these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital,
acquisitions of other businesses or entities and issuances under employee benefit plans. Additionally, we could issue a series of preferred
stock that could, depending on its terms, impede the completion of a merger, tender offer or other takeover attempt. Our board of directors
will make any determination to issue such shares based on its judgment as to the best interests of us and our shareholders. The board
of directors, in so acting, could issue preferred stock having terms that could discourage an acquisition attempt through which an acquiror
may be able to change the composition of the board of directors, including a tender offer or other transaction that some, or a majority,
of our shareholders might believe to be in their best interests or in which shareholders might receive a premium over the then-current
market price of the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
Jurisdiction</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive
forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty
owed by any of our current or former directors, officers or other employees to us or our shareholders, (iii) any action arising pursuant
to any provision of the FBCA, our amended and restated articles of incorporation or our amended and restated bylaws, or (iv) any other
action asserting a claim that is governed by the internal affairs doctrine shall be a state court located within the state of Florida
(or, if a state court located within the state of Florida does not have jurisdiction, the federal district court for the Middle District
of Florida); provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by
the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Our bylaws also provide that, unless we consent
in writing to the selection of an alternative forum, the U.S. federal district courts shall be the exclusive forum for the resolution
of any claims arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities
shall be deemed to have notice of and consented to these provisions. Although we believe these provisions benefit us by providing increased
consistency in the application of law for the specified types of actions and proceedings, the provisions may have the effect of discouraging
lawsuits against us or our directors and officers. We note that investors cannot waive compliance with the federal securities laws and
the rules and regulations thereunder. Please also see the section titled &ldquo;Risk Factors&mdash;Risks Related to Ownership of our
Common Stock&mdash;Our amended and restated bylaws that will be in effect immediately prior to the completion of this offering
designates the state courts located within the state of Florida as the exclusive forum for substantially all disputes between us and
our shareholders and the federal district courts as the exclusive forum for Securities Act claims, which could limit our shareholders&rsquo;
ability to obtain a favorable judicial forum for disputes with us.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preemptive
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
holder of our common stock has any preemptive or subscription rights to acquire shares of our capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liability
and Indemnification of Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of incorporation and bylaws provide that we shall indemnify any and all persons whom we shall have power
to indemnify under the FBCA to the fullest extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0831 of the FBCA, provides that a director is not personally liable for monetary damages to the corporation or any other person for
any statement, vote, decision to take or not to take action, or any failure to take any action, as a director, unless (1) the director
breached or failed to perform his or her duties as a director and (2) the director&rsquo;s breach of, or failure to perform, those duties
constitutes (a) a violation of the criminal law, unless the director had reasonable cause to believe his or her conduct was lawful or
had no reasonable cause to believe his or her conduct was unlawful, (b) a transaction from which the director derived an improper personal
benefit, either directly or indirectly, (c) a circumstance under which the liability provisions of Section 607.0834 of the FBCA are applicable,
(d) in a proceeding by or in the right of the corporation to procure a judgment in its favor or by or in the right of a shareholder,
conscious disregard for the best interest of the corporation, or willful or intentional misconduct, or (e) in a proceeding by or in the
right of someone other than the corporation or a shareholder, recklessness or an act or omission which was committed in bad faith or
with malicious purpose or in a manner exhibiting wanton and willful disregard of human rights, safety, or property. A judgment or other
final adjudication against a director in any criminal proceeding for a violation of the criminal law estops that director from contesting
the fact that his or her breach, or failure to perform, constitutes a violation of the criminal law; but does not estop the director
from establishing that he or she had reasonable cause to believe that his or her conduct was lawful or had no reasonable cause to believe
that his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 607.0851 of the FBCA, a corporation has power to indemnify any person who is a party to any proceeding (other than an action
by, or in the right of the corporation), because he or she is or was a director or officer of the corporation against liability incurred
in connection with such proceeding, including any appeal thereof, if he or she acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had
no reasonable cause to believe his or her conduct was unlawful. The termination of any proceeding by judgment, order, settlement or conviction
or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith
and in a manner which he or she reasonably believed to be in, or not opposed to, the best interests of the corporation or, with respect
to any criminal action or proceeding, has reasonable cause to believe that his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the indemnification provisions of the FBCA, &ldquo;director&rdquo; or &ldquo;officer&rdquo; means an individual who is or
was a director or officer, respectively, of a corporation or who, while a director or officer of the corporation, is or was serving at
the corporation&rsquo;s request as a director or officer, manager, partner, trustee, employee, or agent of another domestic or foreign
corporation, limited liability company, partnership, joint venture, trust, employee benefit plan, or another enterprise or entity and
the terms include, unless the context otherwise requires, the estate, heirs, executors, administrators, and personal representatives
of a director or officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 607.0851 of the FBCA, a corporation has the power to indemnify any person, who was or is a party to any proceeding
by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director or
officer, against expenses and amounts paid in settlement not exceeding, in the judgment of the board of directors, the estimated expense
of litigating the proceeding to conclusion, actually and reasonably incurred in connection with the defense or settlement of such proceeding,
including any appeal thereof. Such indemnification shall be authorized if such person acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made under this
subsection in respect of any claim, issue, or matter as to which such person shall have been adjudged to be liable unless, and only to
the extent that, the court in which such proceeding was brought, or any other court of competent jurisdiction, shall determine upon application
that, despite the adjudication of liability but in view of all circumstances of the case, such person is fairly and reasonably entitled
to indemnity for such expenses which such court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0852 of the FBCA provides that a corporation must indemnify an individual who is or was a director or officer who was wholly successful,
on the merits or otherwise, in the defense of any proceeding to which the individual was a party because he or she is or was a director
or officer of the corporation against expenses incurred by the individual in connection with the proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0853 of the FBCA provides that a corporation may, before final disposition of a proceeding, advance funds to pay for or reimburse
expenses incurred in connection with the proceeding by an individual who is a party to the proceeding because that individual is or was
a director or an officer if the director or officer delivers to the corporation a signed written undertaking of the director or officer
to repay any funds advanced if (a) the director or officer is not entitled to mandatory indemnification under Section 607.0852; and (b)
it is ultimately determined under Section 607.0854 or Section 607.0855 (as described below) that the director or officer has not met
the relevant standard of conduct described in Section 607.0851 or the director or officer is not entitled to indemnification under Section
607.0859 (as described below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0854 of the FBCA provides that, unless the corporation&rsquo;s articles of incorporation provide otherwise, notwithstanding the failure
of a corporation to provide indemnification, and despite any contrary determination of the board of directors or of the shareholders
in the specific case, a director or officer of the corporation who is a party to a proceeding because he or she is or was a director
or officer may apply for indemnification or an advance for expenses, or both, to a court having jurisdiction over the corporation which
is conducting the proceeding, or to a circuit court of competent jurisdiction. Our amended and restated articles of incorporation do
not provide any such exclusion. After receipt of an application and after giving any notice it considers necessary, the court may order
indemnification or advancement of expenses upon certain determinations of the court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0855 of the FBCA provides that, unless ordered by a court under Section 607.0854, a corporation may not indemnify a director or officer
under Section 607.0851 unless authorized for a specific proceeding after a determination has been made that indemnification is permissible
because the director or officer has met the relevant standard of conduct set forth in Section 607.0851.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0857 of the FBCA also provides that a corporation shall have the power to purchase and maintain insurance on behalf of and for the
benefit of any person who is or was a director or officer of the corporation against any liability asserted against the person and incurred
by him or her in any such capacity or arising out of his or her status as such, whether or not the corporation would have the power to
indemnify or advance expenses to the individual against such liability under the provisions of Section 607.0857.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0858 of the FBCA provides that the indemnification provided pursuant to Section 607.0851 and Section 607.0852, and the advancement
of expenses provided pursuant to Section 607.0853, are not exclusive. A corporation may, by a provision in its articles of incorporation,
bylaws, or any agreement, or by vote of shareholders or disinterested directors, or otherwise, obligate itself in advance of the act
or omission giving rise to a proceeding to provide any other or further indemnification or advancement of expenses to any of its directors
or officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
607.0859 of the FBCA provides that, unless ordered by a court under the provisions of Section 607.0854 of the FBCA, a corporation may
not indemnify a director or officer under Section 607.0851 or Section 607.0858, or advance expenses to a director or officer under Section
607.0853 or Section 607.0858, if a judgment or other final adjudication establishes that his or her actions, or omissions to act, were
material to the cause of action so adjudicated and constitute: (a) willful or intentional misconduct or a conscious disregard for the
best interests of the corporation in a proceeding by or in the right of the corporation to procure a judgment in its favor or in a proceeding
by or in the right of a shareholder; (b) a transaction in which a director or officer derived an improper personal benefit; (c) a violation
of the criminal law, unless the director or officer had reasonable cause to believe his or her conduct was lawful or had no reasonable
cause to believe his or her conduct was unlawful; or (d) in the case of a director, a circumstance under which the liability provisions
of Section 607.0834 are applicable (relating to unlawful distributions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may have the practical effect in certain cases of eliminating the ability of shareholders to collect monetary damages from
our directors and officers. We believe that these provisions are necessary to attract and retain qualified persons to serve as our directors
and officers. There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for
which indemnification is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">American
Stock Transfer (also known as Equiniti) will be the transfer agent and registrar for our common stock. The transfer agent&rsquo;s address
is 6201 15<SUP>th</SUP> Avenue, Brooklyn, NY 11219.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock has been approved for listing
on the Nasdaq Capital Market under the symbol &ldquo;TELO.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_002"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there was no public market for our common stock, and there can be no assurance that a significant public market for
our common stock will develop or be sustained after this offering. Future sales of substantial amounts of our common stock in the public
market (including securities convertible into or redeemable, exchangeable, or exercisable for shares of common stock) or the perception
that such sales may occur or the availability of such shares for sale in the public market, after this offering could adversely affect
the prevailing market price of our common stock. Furthermore, because all of our common stock outstanding prior to the completion of
this offering (including securities convertible into or redeemable, exchangeable, or exercisable for shares of our common stock) will
be subject to the contractual and legal restrictions on resale described below, the sale of a substantial amount of common stock in the
public market after these restrictions lapse could materially adversely affect the prevailing market price of our common stock and our
ability to raise equity capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after
the lock-up and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline.
Based on shares of common stock outstanding as of December 31, 2023, upon the completion of this offering we will have outstanding
a total of 29,609,814 shares of common stock. Of these shares, only the shares of common stock sold in this offering by us, plus any
shares sold upon exercise of the underwriters&rsquo; option to purchase additional shares, will be freely tradable without restriction
in the public market immediately following this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus (or 365 days for initial holders
of our common stock that hold 25,451,527 shares in the aggregate), subject to earlier release of all or a portion of the shares
subject to such agreements by the representatives of the underwriters in this offering in their sole discretion. After the lock-up agreements
expire, based upon the number of shares of common stock outstanding as of December 31, 2023, up to an additional 25,617,223
shares of common stock will be eligible for sale in the public market. Approximately 35.0% of these additional shares are
beneficially held by directors, executive officers and their affiliates and will be subject to certain limitations of Rule 144 under
the Securities Act of 1933, as amended, or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, shares of common stock that are reserved for future issuance under our existing equity
compensation plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules,
the lock-up agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if
it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. Additionally, the
number of shares of our common stock reserved for issuance under the 2023 Omnibus Plan will automatically increase on January 1 of each
year following our initial public offering by 1% of outstanding shares or such lesser number as is determined
by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the shares of common stock sold in this offering will be freely transferable without restriction or further registration under the
Securities Act by persons other than &ldquo;affiliates,&rdquo; as that term is defined in Rule 144 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
the balance of our outstanding shares of common stock will be deemed &ldquo;restricted securities&rdquo; within the meaning of Rule 144
under the Securities Act, subject to the limitations and restrictions that are described below. Common stock purchased by our affiliates
will be &ldquo;restricted securities&rdquo; under Rule 144. Restricted securities may be sold in the public market only if they are registered
under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act, which
rules are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the lock-up agreements described below and subject to the provisions of Rule 144 or Rule 701, shares of our common stock
will be available for sale in the public market as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning
    on the date of this prospectus, all 1,000,000 shares of our common stock sold in this offering and all 6,203,696 shares offered for
    re-sale by the selling stockholders will be immediately available for sale in the public market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning
    180 days after the date of this prospectus, 165,696 additional shares of common stock become eligible for sale in the public
    market, of which no shares would be held by affiliates and subject to the volume and other restrictions of Rule 144, as described
    below; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning
    365 days after the date of this prospectus, 25,451,527 additional shares of common stock become eligible for sale in the public
    market, of which 8,970,982 shares would be held by affiliates and subject to the volume and other restrictions of Rule 144,
    as described below.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we, our directors, our executive officers, certain of our initial stockholders (the &ldquo;Initial
Stockholders&rdquo;), and other holders of more than 3% of our issued and outstanding shares of common stock outstanding as of December
31, 2023 have agreed, subject to certain exceptions, with the underwriters not to dispose of or hedge any shares of our common
stock or securities convertible into or exchangeable for shares of common stock during the period from the date of the lock-up agreement
continuing through the date 180 days (365 days in the case of the Initial Stockholders) after the closing date of this offering, except
with the prior written consent of the representative of the underwriters and certain other exceptions. The representative of the underwriters
has advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to
the expiration of the lock-up period. See &ldquo;Underwriting&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the lock-up periods set forth in the agreements described above, and assuming that the representative of the underwriters does not release
any parties from these agreements, all of the shares of our common stock that are restricted securities or are held by our affiliates
as of the date of this prospectus will be eligible for sale in the public market in compliance with Rule 144 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 as in effect on the date of this prospectus, beginning 90 days after completion of this offering, a person (or
persons whose common stock is required to be aggregated) who is an affiliate and who has beneficially owned our common stock for at least
six months is entitled to sell in any three-month period a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
    of the number of shares of our common stock then outstanding, which will equal approximately 296,098 shares immediately
    after completion of this offering; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    average weekly trading volume in our common stock during the four calendar weeks preceding the filing of a notice on Form
    144 with respect to such a sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
by our affiliates under Rule 144 are also subject to manner of sale provisions and notice requirements and to the availability of current
public information about us. An &ldquo;affiliate&rdquo; is a person that directly, or indirectly through one or more intermediaries,
controls or is controlled by, or is under common control with, an issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Rule 144, a person (or persons whose shares are aggregated) who is not deemed to have been an affiliate of ours at any time during the
90 days preceding a sale, and who has beneficially owned the shares proposed to be sold for at least six months (including the holding
period of any prior owner other than an affiliate), would be entitled to sell those shares subject only to availability of current public
information about us, and after beneficially owning such shares for at least 12 months, would be entitled to sell an unlimited number
of shares without restriction. To the extent that our affiliates sell their shares of common stock, other than pursuant to Rule 144 or
a registration statement, the purchaser&rsquo;s holding period for the purpose of effecting a sale under Rule 144 commences on the date
of transfer from the affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
S under the Securities Act provides that securities owned by any person may be sold without registration in the United States, provided
that the sale is effected in an &ldquo;offshore transaction&rdquo; and no &ldquo;directed selling efforts&rdquo; are made in the United
States (as these terms are defined in Regulation S) and subject to certain other conditions. In general, this means that our shares may
be sold in some manner outside the United States without requiring registration in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 701 as in effect on the date of this prospectus, any of our employees, directors, officers, consultants, or advisors
who purchased shares from us in reliance on Rule 701 in connection with a compensatory stock or option plan or other written agreement
before the effective date of this offering, or who purchase shares from us after that date upon the exercise of options granted before
that date, are eligible to resell such shares 90 days after the effective date of this offering in reliance upon Rule 144. If such person
is not an affiliate, such sale may be made subject only to current public information provisions of Rule 144. If such a person is an
affiliate, such sale may be made under Rule 144 without compliance with the holding period requirement, but subject to the other Rule
144 restrictions described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Incentive Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of this offering, we intend to file one or more registration statements on Form S-8 under the Securities Act to register
all shares of common stock issued or issuable under the 2023 Omnibus Plan. Any such Form S-8 registration statements will automatically
become effective upon filing. Accordingly, shares registered under such registration statements will be available for sale in the open
market following the expiration of the lock-up period. We expect that the initial registration statements on Form S-8 will cover approximately
6,500,000 shares of our common stock. Shares issued under the 2023 Omnibus Plan after the effective date of the applicable Form
S-8 registration statement will be eligible for resale in the public market without restriction, subject to Rule 144 limitations applicable
to affiliates and the lock-up agreements described above. See &ldquo;Executive Compensation &mdash; Executive Compensation Arrangements
&mdash; Equity Compensation&rdquo;, and &ldquo;Executive Compensation Plan&rdquo; for a description of the 2023 Omnibus Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_003"></A>MATERIAL
U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDERS
OF OUR COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the
ownership and disposition of shares of our common stock issued pursuant to this offering but is not intended to be a complete analysis
of all potential tax consequences. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state,
local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;),
final, temporary, and proposed Treasury Regulations, judicial decisions, and published rulings and administrative pronouncements of the
U.S. Internal Revenue Service (the &ldquo;IRS&rdquo;), in each case as in effect as of the date of this prospectus. These authorities
may change or be subject to differing interpretations, and any such change or differing interpretation may be applied retroactively in
a manner that could adversely affect a non-U.S. holder of our common stock. We have not sought and will not seek any rulings from the
IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed
below regarding the tax consequences of the ownership and disposition of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion is limited to a non-U.S. holder that holds our common stock as a &ldquo;capital asset&rdquo; within the meaning of Section
1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences
relevant to a non-U.S. holder&rsquo;s particular circumstance, including the impact of the alternative minimum tax, the special tax accounting
rules in Section 451(b) of the Code or the Medicare surtax on net investment income provided by Section 1411 of the Code. In addition,
it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    expatriates and former citizens or long-term residents of the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    holding shares of our common stock as part of a straddle, or other risk reduction strategy or as part of a conversion transaction
    or other integrated investment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
    insurance companies, and other financial institutions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers,
    dealers, or certain electing traders in securities that use a mark-to-market method of tax accounting for their securities positions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;controlled
    foreign corporations&rdquo;, &ldquo;passive foreign investment companies&rdquo;, as defined in Sections 957 and Section 1297 of the
    Code, respectively, and corporations that accumulate earnings to avoid U.S. federal income tax under Section 531 and 532 of the Code;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships
    or other entities or arrangements treated as partnerships for U.S. federal income tax purposes and other pass-through entities (and
    investors in such entities);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
    organizations or governmental organizations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    deemed to sell our common stock under the constructive sale provisions of the Code;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-qualified
    retirement plans; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;qualified
    foreign pension funds&rdquo; as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified
    foreign pension funds.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the
partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner
level. Partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S.
federal income tax consequences to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE
APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP,
AND DISPOSITION OF SHARES OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE,
LOCAL, OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definition
of a Non-U.S. Holder</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, a &ldquo;non-U.S. holder&rdquo; is any beneficial owner of our common stock that is an individual, corporation,
estate or trust and is not a &ldquo;U.S. person.&rdquo; A U.S. person is any person that, for U.S. federal income tax purposes, is or
is treated as any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    individual who is a citizen or resident of the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    estate, the income of which is subject to U.S. federal income tax regardless of its source; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust that (1) is subject to the primary supervision of a U.S. court and the control of one or more &ldquo;United States persons&rdquo;
    (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person
    for U.S. federal income tax purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in the section entitled &ldquo;Dividend Policy,&rdquo; we do not anticipate declaring or paying dividends to holders of our
common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions
will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits,
as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute
a nontaxable return of capital and first be applied against and reduce a Non-U.S. Holder&rsquo;s adjusted tax basis in its common stock,
but not below zero, and any excess will be treated as capital gain and will be treated as described below under &ldquo;&mdash; Sale or
Other Taxable Disposition&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder of our common stock will be subject to U.S.
federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax
treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification
for the lower treaty rate of withholding). A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies
for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the
IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within
the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the
United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described
above. To claim the exemption, the non-U.S. holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying
that the dividends are effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the rates applicable to U.S.
persons. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified
by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult
their tax advisors regarding any applicable tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sale
or Other Taxable Disposition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below under &ldquo;&mdash; Information Reporting and Backup Withholding&rdquo; and &ldquo;&mdash; Additional Withholding
Tax Under FATCA&rdquo;, a Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other
taxable disposition of our common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    gain is effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within the United States (and, if required
    by an applicable income tax treaty, the non-U.S. holder maintains a permanent establishment in the United States to which such gain
    is attributable);or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    non-U.S. holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the
    disposition and certain other requirements are met;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the rates applicable
to U.S. persons. A non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower
rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified
by an applicable income tax treaty), which may be offset by U.S. source capital losses of the non-U.S. Holder (even though the individual
is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with
respect to such losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Reporting and Backup Withholding</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
returns are required to be filed with the IRS in connection with any dividends on our common stock paid to a non-U.S. holder whether
or not withholding is required. Copies of the information returns reporting such interest, dividends, and withholding may also be made
available to the tax authorities in the country in which a non-U.S. holder resides under the provisions of an applicable income tax treaty.
Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not
have actual knowledge or reason to know the beneficial owner is a United States person and the Non-U.S. Holder either certifies its non-U.S.
status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or other applicable documentation, or otherwise establishes
an exemption. Proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain
U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent
receives the certification described above and does not have actual knowledge or reason to know that such beneficial owner is a United
States person, or otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office
of a non-U.S. broker generally will not be subject to backup withholding or information reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a non-U.S. Holder&rsquo;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Withholding Tax Under FATCA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
1471 to 1474 of the Code (such sections commonly referred to as the Foreign Account Tax Compliance Act, or &ldquo;FATCA&rdquo;) and the
Treasury Regulations and administrative guidance thereunder impose a 30% withholding tax on certain types of payments made to a &ldquo;foreign
financial institution&rdquo; or a &ldquo;non-financial foreign entity&rdquo; (each as defined in the Code), including, in some cases,
when such foreign financial institution or non-financial foreign entity acts as an intermediary, unless (1) the foreign financial institution
has entered into an agreement with the U.S. government to withhold on certain payments and to undertake certain diligence and reporting
obligations regarding U.S. account holders (including certain account holders that are non-U.S. entities with U.S. owners), (2) the non-financial
foreign entity either certifies it does not have any &ldquo;substantial United States owners&rdquo; (as defined in the Code) or furnishes
identifying information regarding each substantial United States owner, or (3) the foreign financial institution or non-financial foreign
entity otherwise qualifies for an exemption from these rules. Foreign financial institutions located in jurisdictions that have an intergovernmental
agreement with the United States governing FATCA may be subject to different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on
our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition
of stock on or after January 1, 2019, recently proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds
entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_004"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kingswood
Investments, division of Kingswood Capital Partners LLC is acting as representative of the underwriters (the &ldquo;Representative&rdquo;)
of the offering. We have entered into an underwriting agreement (the &ldquo;underwriting agreement&rdquo;) with the Representative. Subject
to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters named below, and the underwriters
have agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite the underwriter&rsquo;s
name in the following table at the initial public offering price per share less underwriting discounts and commissions, as set forth
on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left">Kingswood Investments, division of Kingswood Capital Partners, LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">1,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are committed to purchase all of the shares offered by us other than those shares covered by the over-allotment option described
below, if they purchase any shares. The obligations of the underwriters may be terminated upon the occurrence of certain events specified
in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&rsquo; obligations are subject to
customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of
officers&rsquo; certificates and legal opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, or to contribute
to payments the underwriters may be required to make in respect of those liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel and other conditions contained in the underwriting agreement. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the underwriters an option to purchase from us up to an additional 150,000 shares of our common stock, solely to
cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions. The underwriters may exercise
this option, in whole or in part, for our common stock, any time during the 45-day period from the date of this prospectus. If this option
is exercised in full, the total price to the public will be $563,500 and the total net proceeds before expenses to us will be
$7,486,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting
Discount, Commissions and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the per share of common stock and total underwriting discounts and commissions to be paid to the underwriters.
Such amounts are shown assuming both no exercise and full exercise of the underwriters&rsquo; option to purchase additional shares, assuming
an initial public offering price of $7.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Without</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Allotment</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total With</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise in <BR>
Full of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Allotment</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%">Public offering price (1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">8,050,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Underwriting discount and commissions</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">490,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">563,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds, before expenses, to us</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,510,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,486,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
    an initial public offering price of $7.00 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative has advised us that they propose initially to offer the shares to the public at the public offering price set forth on
the cover page of this prospectus and to dealers at that price less a concession not in excess of 0.28% per share. After
the initial public offering, the public offering price, concession and discount may be changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to pay all of the expenses relating to the offering, including, but not limited to, (a) all filing fees and communication
expenses relating to the registration of the shares of common stock to be sold in this offering with the Securities and Exchange Commission;
(b) all fees and expenses relating to the listing of the shares on the Nasdaq Capital Market and such other exchanges as the Company
and Representative together determine, including any fees charged by DTC; (c) all fees, expenses and disbursements relating to the registration
or qualification of the shares under &ldquo;blue sky&rdquo; or securities laws. of such states of the United States of America and other
jurisdictions designated by the Representative, including the reasonable fees and expenses of the Representative&rsquo;s blue sky counsel;
(d) all fees, expenses and disbursements relating to the registration, qualification or exemption of the shares under the securities
laws of such foreign jurisdictions designated by the Representative; (e) the costs of mailing and printing the underwriting documents
(including the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers&rsquo;
Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), registration statements, prospectuses and all amendments, supplements
and exhibits thereto and as many preliminary and final prospectuses as the Representative may reasonably deem necessary; (f) transfer
and/or stamp taxes, if any, payable upon our transfer of the shares to the Underwriters; (g) the fees and expenses of the Company&rsquo;s
accountants; (h) all filing fees and communication expenses associated with the review of the offering by FINRA; (i) expenses incurred
by the Underwriters for any roadshow for the offering up to $10,000; (j) the costs associated with bound volumes of the offering materials
in an aggregate amount not to exceed $5,000; (k) the fees of counsel to the underwriters in an amount not to exceed $150,000; (l) fees
and expenses of the transfer agent for our common stock; and (m) the costs of preparing, printing and delivering certificates representing
the common stock issued in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paid a $25,000 expense advance to the Representative, which shall be applied against actual out-of-pocket-accountable expenses,
which will be returned to us to the extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA
Rule 5110(f)(2)(C). We have agreed to pay to the Representative 0.5% of the gross proceeds of the offering for non-accountable expenses,
payable upon the closing of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses of the offering payable by us, excluding the total underwriting discount, and including the above-referenced
advance to the Representative, will be approximately $602,232.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the shares offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to issue to the Representative or its designees at the closing of this offering warrants to purchase the number of common
stock equal to 5.0% of the aggregate number of shares sold in this offering. The warrants will be exercisable at any time and from time
to time, in whole or in part, during the four-and-a-half-year period commencing six months from the commencement of sales in this offering.
The warrants will be exercisable at a per share price equal to 100% of the initial public offering price per share in the offering. The
Warrants provide for registration rights (including a one-time demand registration right at our expense and piggyback registration rights
that expire 5 years from the commencement of sales of this offering) and customary anti-dilution provisions as permitted under FINRA
Rule 5110(g)(8).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA.
The Representative (or permitted assignees under Rule 5110(e)(2)(B)) will not sell, transfer, assign, pledge, or hypothecate these warrants
or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the date
of this prospectus. The warrants and shares of common stock issuable upon exercise of the warrants are being registered as a part of
the registration statement of which this prospectus forms a part and will be freely tradable upon the declaration of the effectiveness
of such registration statement by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including
in the event of a stock dividend, extraordinary cash dividend or recapitalization, reorganization, merger or consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the closing of this offering and certain conditions set forth in the underwriting agreement, for a period of twelve (12) months after
the closing of the offering, the Representative shall have a right of first refusal to act as sole investment banker, sole bookrunner
and/or sole placement agent, at the discretion of the Representative, for any and all future public and private equity offerings, including
all equity-linked financings, undertaken during such period by us, or any of our successors or subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tail
Period</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative shall be entitled to a cash fee equal to seven percent (7%) of the gross proceeds received by the Company from the sale
of any equity, debt and/or equity derivative instruments to any investor actually introduced by the Representative to the Company during
the period beginning on July 27, 2023 and ending on the later of (i) July 27, 2024 or (ii) the final closing, if any, of
the Offering (the &ldquo;Engagement Period&rdquo;), in connection with any public or private financing or capital raise (each a &ldquo;Tail
Financing&rdquo;), and such Tail Financing is consummated at any time during the Engagement Period or within the twelve (12) month period
following the expiration or termination of the Engagement Period (the &ldquo;Tail Period&rdquo;), provided that such Tail Financing is
by a party actually introduced to the Company first by the Representative during the Engagement Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers and directors, our initial stockholders holding an aggregate of 26,332,026 shares of our common stock (the &ldquo;Initial
Stockholders&rdquo;), and other holders of more than 3% of the issued and outstanding shares of common stock of the Company
have agreed not to, without the prior written consent of the Representative, directly or indirectly, offer to sell, sell, pledge or otherwise
transfer or dispose of any shares of our common stock (or enter into any transaction or device that is designed to, or could be expected
to, result in the transfer or disposition by any person at any time in the future of shares of our common stock, enter into any swap
or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of
shares of common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments
thereto, with respect to the registration of any of the shares of common stock or securities convertible into or exercisable or exchangeable
for shares of common stock or any other of our securities or publicly disclose the intention to do any of the foregoing, subject to customary
exceptions, for periods of 180 days (or 365 days for the Initial Stockholders) from the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Sales of Similar Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly,
any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or enter into
any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of shares of our common
stock, whether any such transaction is to be settled by delivery of shares of common stock or such other securities, in cash or otherwise,
without the prior written consent of the Representative, for a period of 180 days from the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale, and Distribution of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group
members. The Representative may agree to allocate a number of shares of common stock to underwriters and selling group members for sale
to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that
will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information
on these websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus
forms a part, has not been approved or endorsed by us, and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock has been approved for listing
on the Nasdaq Capital Market under the symbol &ldquo;TELO.&rdquo; No assurance can be given that such application will be approved.
If the application is not approved, we will not proceed with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
this offering, there has been no public market for shares of our common stock. Accordingly, the public offering price will be negotiated
between us and the underwriter. Among the factors to be considered in these negotiations are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    information set forth in this prospectus and otherwise available to the underwriter;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prospects for our Company and the industry in which we operate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    assessment of our management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    past and present financial and operating performance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    prospects for future earnings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    and operating information and market valuations of publicly traded companies engaged in activities similar to ours;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevailing conditions of United States securities markets at the time of this offering; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    factors deemed relevant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriter can assure investors that an active trading market will develop for shares of our common stock, or that the shares
will trade in the public market at or above the initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriter may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
    transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum and are engaged
    in for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
    transactions involve sales by the underwriter of securities in excess of the number of securities the underwriter is obligated to
    purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered
    short position, the number of securities over-allotted by the underwriter is not greater than the number of securities that they
    may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number
    of securities in the over-allotment option. The underwriter may close out any short position by exercising their over-allotment option
    and/or purchasing securities in the open market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
    covering transactions involves purchases of securities in the open market after the distribution has been completed in order to cover
    syndicate short positions. In determining the source of securities to close out the short position, the underwriter will consider,
    among other things, the price of securities available for purchase in the open market as compared with the price at which they may
    purchase securities through exercise of the over-allotment option. If the underwriter sells more securities than could be covered
    by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying
    securities in the open market. A naked short position is more likely to be created if the underwriter is concerned that after pricing
    there could be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase
    in the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
    bids permit the underwriter to reclaim a selling concession from a syndicate member when the securities originally sold by that syndicate
    member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stabilizing transactions, over-allotment transactions, syndicate covering transactions, and penalty bids may have the effect of raising
or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result,
the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither
we nor the underwriter make any representation or prediction as to the effect that the transactions described above may have on the price
of our securities. These transactions may be affected on the Nasdaq Stock Market, in the over-the-counter market or otherwise and, if
commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, underwriter, and selling group members may engage in passive market making transactions in our securities
on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement
of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid
at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive
market maker&rsquo;s bid, then that bid must then be lowered when specified purchase limits are exceeded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging,
market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective
affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships
with us, for which they received or will receive customary fees and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
RESTRICTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
than in the United States, no action has been taken by us or the underwriter that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>European
Economic Area</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to each member state of the European Economic Area that has implemented the Prospectus Directive (each, a relevant member state),
with effect from and including the date on which the Prospectus Directive is implemented in that relevant member state (the relevant
implementation date), an offer of shares described in this prospectus may not be made to the public in that relevant member state other
than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any legal entity which is a qualified investor as defined in the Prospectus Directive;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    fewer than 100 or, if the relevant member state has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural
    or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive,
    subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    any other circumstances falling within Article 3(2) of the Prospectus Directive,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
    that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
    Directive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this provision, the expression an &ldquo;offer of securities to the public&rdquo; in any relevant member state means the
communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to
enable an investor to decide to purchase or subscribe for the shares, as the expression may be varied in that member state by any measure
implementing the Prospectus Directive in that member state, and the expression &ldquo;Prospectus Directive&rdquo; means Directive 2003/71/EC
(and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the relevant member state) and includes
any relevant implementing measure in the relevant member state. The expression 2010 PD Amending Directive means Directive 2010/73/EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sellers of the shares have not authorized and do not authorize the making of any offer of shares through any financial intermediary on
their behalf, other than offers made by the underwriters with a view to the final placement of the shares as contemplated in this prospectus.
Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further offer of the shares on behalf
of the sellers or the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Kingdom</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the
meaning of Article 2(1)(e) of the Prospectus Directive that are also (i) investment professionals falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the &ldquo;Order&rdquo;) or (ii) high net worth entities, and
other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (each such person being referred
to as a &ldquo;relevant person&rdquo;). This prospectus and its contents are confidential and should not be distributed, published or
reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom
that is not a relevant person should not act or rely on this document or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_005"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered hereby will be passed upon for us by Foley &amp; Lardner LLP, Tampa, Florida. Lucosky
Brookman LLP has acted as counsel for the underwriters with respect of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_006"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Telomir Pharmaceuticals, Inc. as of and for the years ended December 31, 2022 and 2021 included in this prospectus
have been audited by Cherry Bekaert LLP, an independent registered public accounting firm, appearing elsewhere herein, given on the authority
of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_007"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set
forth in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that
is included in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement, or
other document are summaries of all material information about the documents summarized but are not complete descriptions of all terms
of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document itself
for a complete description of its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without
charge at the SEC&rsquo;s public reference room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of
the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington,
DC 20549. You may call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet
website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC
are also available to the public through the SEC&rsquo;s website at http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, we will become subject to the information reporting requirements of the Exchange Act, and we will file periodic
reports, proxy statements and other information with the SEC. These periodic reports, and other information are available for inspection
and copying at the website of the SEC referred to above. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q,
reports on Form 8-K and amendments to those reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of
charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The
information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this
prospectus. A copy of the registration statement and the exhibits filed therewith may be inspected without charge at the public reference
room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement
may be obtained from that office. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The
SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that
file electronically with the SEC. The address of the website is <I>www.sec.gov.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a corporate website at www.telomirpharma.com. Information contained in, or that can be accessed through, our website does not
constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and
regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_008"></A>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc. Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
of and For the Years Ended December 31, 2022 and 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ta_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ta_002">Balance Sheets as of December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ta_003">Statements of Operations for the years ended December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ta_004">Stockholders&rsquo; Deficit for the years ended December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ta_005">Statements of Cash Flows for the years ended December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ta_006">Notes to Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc. Condensed Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
of September 30, 2023 and December 31, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Nine Months Ended September 30, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fi_001">Condensed Balance Sheets as of September 30, 2023 and December 31, 2022</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fi_002">Condensed Statements of Operations for the nine months ended September 30, 2023 and 2022</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fi_003">Condensed Stockholders&rsquo; Equity (Deficit) for the nine months ended September 30, 2023 and 2022</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fi_004">Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fi_005">Supplemental Cash Flow Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fi_006">Notes to Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-16</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ta_001"></A>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tampa,
Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Telomir Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2021 and
2022, and the related statements of operations, stockholders&rsquo; equity (deficit), and cash flows for the year ended December 31,
2022 and for the period from August 26, 2021 (Inception) through December 31, 2021, and the related notes (collectively referred to as
the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the year ended December
31, 2022 and for the period from August 26, 2021 through December 31, 2021, in conformity with accounting principles generally accepted
in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Substantial
Doubt about the Company&rsquo;s Ability to Continue as a Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to
the financial statements, the Company has recurring losses and negative cash flows from operations that raise substantial doubt about
its ability to continue as a going concern. Management&rsquo;s evaluations of the events and conditions and management&rsquo;s plans
regarding those matters are also described in Note 2. The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">We have
served as the Company&rsquo;s auditor since 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cherry Bekaert
LLP</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tampa, Florida</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
  14, 2023, except for the last paragraph of Note 7, and its related effects to the financial statements, which is as of December
  11, 2023.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="ta_002"></A>Balance
Sheets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>DECEMBER
31, 2022 AND december 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%">Cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred offering costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">47,311</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">48,730</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">48,730</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; DEFICIT</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Trade accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">404,221</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Due to related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">581,787</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">119,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">986,008</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">986,008</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; Deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Preferred Stock, no par value, 100,000,000
    shares authorized and none issued or outstanding.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Common Stock, no par value; 300,000,000
    shares authorized, 26,829,269 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(992,278</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Additional Paid in Capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Stock subscription receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(937,278</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">48,730</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="ta_003"></A>Statements
of Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>YEAR
ended December 31, 2022 and period ended DECEMBER 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating costs:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">General and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">20,941</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">11,639</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">833,206</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">126,492</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">854,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(854,147</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(138,131</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="ta_004"></A>Statements
of stockholders&rsquo; DEFICIT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>YEARS
ended DECEMBER 31, 2022, and DECEMBER 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Common Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid-In </B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock Subscription</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Balances, January 1, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%">Issuance of founders&rsquo; shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">26,829,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balances, December 31, 2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">26,829,269</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Collection of stock subscription receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(854,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(854,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances, December 31, 2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">26,829,269</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(992,278</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(937,278</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="ta_005"></A>statements
of cash flows</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>YEARS
ended DECEMBER 31, 2022, and DECEMBER 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from Operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(854,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(138,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in operating assets and liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">385,486</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">18,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash flows from operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(468,661</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(119,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financing activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Collection of stock subscription receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred offering costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(47,311</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Advances from related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">462,391</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">119,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Net cash flows from financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">470,080</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">119,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cash, beginning of period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Cash, end of period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,419</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="ta_006"></A>notes
to the financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>DECEMBER
31, 2022 and december 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
1. Description of business and summary of significant accounting policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc. (&ldquo;Telomir&rdquo; or the &ldquo;Company&rdquo; and formerly known as Metallo Therapies, Inc.) was formed in
August 2021 and is a Florida-based early pre-clinical stage biopharmaceutical company that is developing its product candidate, TELOMIR-1,
a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Based on the Company&rsquo;s
pre-clinical studies and if approved by the FDA and comparable foreign regulators, the Company believes that TELOMIR-1 may effectively
serve as a metal enzyme inhibitor of essential metals such as zinc and copper. These essential metals play an important role in the production
and function of many enzymatic reactions and the modulation of key cellular pathways. In particular, zinc is essential to the function
of pro-inflammatory cytokines such as Interleukin-17, or IL-17, that play a role in a host of age-related inflammatory conditions such
as hemochromatosis and osteoarthritis as well as in post-chemotherapy health problems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, TELOMIR-1 is under investigation to potentially provide a therapeutic intervention against age-related inflammatory conditions
such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways
that create the systemic imbalance of cellular metals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantive
operations began in late 2021 and the Company&rsquo;s Investigative New Drug application is anticipated to be filed with the U.S. Food
and Drug Administration (&ldquo;FDA&rdquo;) in fourth quarter 2023 for hemochromatosis and first quarter 2024 for post-chemotherapy recovery.
A non-provisional patent application is pending for Telomir-1 as a new molecular entity and its therapeutic uses. See Note 3, regarding
this patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America
(&ldquo;GAAP&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, the Company&rsquo;s Common Stock, no par value per share, is referred to as the &ldquo;Common Stock&rdquo; and the Company&rsquo;s
preferred stock, no par value per share, is referred to as the &ldquo;Preferred Stock&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pending
transactions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is in the process of preparing for an initial public offering (IPO) and expects to be listed under the NASDAQ symbol &ldquo;TELO.&rdquo;
The transaction is expected to be complete in the second half of 2023. The Company incurred $0.05 million of legal costs, as of December
31, 2022, associated with the offering, which have been recorded as deferred offering costs in the accompanying balance sheets. There
were no deferred offering costs during 2021. These deferred offering costs will be derecognized as a reduction in offering proceeds when
the offering closes. However, there can be no guarantees that the Company will be successful in completing the proposed transaction and
ultimately listing on the NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a C corporation. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences
between the financial statement carrying amount of existing assets and liabilities and their respective tax bases. Deferred tax assets
are recognized for temporary differences that will result in deductible amounts in future years and for loss carryovers. A valuation
allowance is recognized regarding deferred tax assets, if any, if it is more likely than not that some portion of the deferred tax asset
will not be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and development expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company&rsquo;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains cash balances with financial institutions that management believes are of high credit quality. The Company&rsquo;s
cash account at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes
it is not exposed to any significant credit risk from its cash account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Income
taxes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a C corporation. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences
between the financial statement carrying amount of existing assets and liabilities and their respective tax bases. Deferred tax assets
are recognized for temporary differences that will result in deductible amounts in future years and for loss carryovers. A valuation
allowance is recognized regarding deferred tax assets, if any, if it is more likely than not that some portion of the deferred tax asset
will not be realized. At December 31, 2022 deferred tax assets are comprised primarily of net operating loss carryforwards and IRC Section
174 qualified research expenditures totaling approximately $0.06 million and $0.2 million respectively. At December 31, 2021, deferred
tax assets consisted of net operating loss carryforwards of approximately $0.04 million The Company has recorded a full valuation allowance
against its deferred tax assets generated by net operating loss carryforwards as it has determined that such amounts may not be recognizable,
given the historical losses of the Company to date. As of December 31, 2022, the Company has a cumulative federal net operating loss
carryforward of approximately $0.2 million. The net operating loss carryforwards have no expiry date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2. Liquidity and capital resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had cash of approximately $0.01 million. The Company used approximately $0.5 million of cash in operations
during the year ended December 31, 2022 and had stockholders&rsquo; deficit of approximately $0.9 million, versus stockholders&rsquo;
deficit of approximately $0.1 million at December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has been primarily engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The
Company&rsquo;s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company&rsquo;s
ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations
through related party financings-see Note 4. Additional sources of financing may be sought by the Company. However, there can be no assurance
that any fundraising will be achieved on commercially reasonable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to be able to fund operations through the anticipated IPO, or through the first quarter of 2024, with available borrowings
from a related party line of credit (Note 4). Should actual cash expenditures exceed management&rsquo;s budget, the Company may be forced
to curtail operations along with implementing other cost-saving measures, such as a reduction in staff, reducing the use of outside professional
service providers, or significantly modifying or delaying the development of our product candidates. Because of these factors, substantial
doubt about the Company&rsquo;s ability to continue as a going concern exists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3. License agreement, related party</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29 2022, (the &ldquo;Effective Date&rdquo;), the Company and MIRALOGX LLC (&ldquo;MIRALOGX&rdquo;), entered into an exclusive,
worldwide license to commercially develop Telomir-1 in the United States and its territories. MIRALOGX, which is a separate intellectual
property development company owned by a trust established by the Company&rsquo;s founder, holds the patent rights to Telomir-1, which
are currently comprised of a pending non-provisional patent application. The term of the license from MIRALOGX will continue through
the date of the expiration of the last-to-expire licensed patent or, if later, the date of the expiration of the last strategic partnership/sublicensing
agreement covering the licensed products. The patent rights are expected to extend through 2043, and additional patent terms may be awarded,
including additional patent terms based on the time taken for regulatory review of drug products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exclusive license agreement requires that Telomir pay an 8% royalty on net sales or revenue in exchange for an exclusive, worldwide license
to patent rights. The agreement also provides that Telomir may bring suit in its own name to enforce patent rights. MIRALOGX will control
the prosecution of the patent applications for Telomir-1. Telomir is required to be kept informed by MIRALOGX of patent prosecution activities
and may select identified countries for patent protection. Telomir is to reimburse MIRALOGX for patent prosecution and maintenance costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4. Related party transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Due
to related party</I> &ndash; During the year ended December 31, 2022, and period ended December 31, 2021, the Company received working
capital advances from companies under common control. These advances are due on demand and are non-interest bearing. Amounts due to related
parties as of December 31, 2022, and 2021, is $0.6 million and $0.1 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>License
agreement - See Note 3.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shared
management- </I>Historically, the Company has shared management with related parties on an as-needed basis, to collaborate and pool resources
efficiently. This arrangement has resulted in cost savings and expertise-sharing while maintaining distinct operations and identities
for each entity. The Company intends on reducing these shared resources post IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shared
jet use-</I> On April 1, 2023 the Company entered into an Agreement For Shared Lease Costs with MIRALOGX, LLC, (the &ldquo;Shared Agreement&rdquo;)
who is a related party. Under the Shared Agreement, the Company agrees to make monthly contributions or payments in accordance with its
monthly use of shared aircraft toward rent payments. There is no minimum cost requirement under the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5. Lease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 85.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leased an office in Baltimore, Maryland, as its corporate headquarters. This Baltimore office lease began in December 2022
for 12 months. This space is approximately 127 square feet and has remaining base rent of $0.01 million payable through November 2023.
Rent is payable in monthly installments and is subject to yearly price increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Accounting
standards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2022, the Company adopted Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 842 ASC Topic 842, which is intended
to improve financial reporting about leasing transactions. Under the standard, organizations that lease assets, referred to as &ldquo;Lessees&rdquo;
shall recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. In addition,
the standard requires disclosures including financial statements to assess the amount, timing and uncertainty of cash flows arising from
leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company made an accounting policy election to account for leases with an initial term of 12 months or less similar to existing guidance
for operating leases today. The Company recognized those lease payments in the Condensed Statements of Operations on a straight-line
basis over the lease term. Under the new standard, the Company&rsquo;s lease liability is based on the present value of such payments
and the related right-of-use asset will generally be based on the lease liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6. Stockholders&rsquo; equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Capital
stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the authority to issue 400,000,000 shares of capital stock, consisting of 300,000,000 shares of Common Stock
and 100,000,000 shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors
when a series of preferred stock is designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7 &ndash; Subsequent events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through August 12, 2023, in connection with the preparation of these financial statements, which
is the date the financial statements were available to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Private
placement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company sold 268,025 shares of Common Stock at $3.73 per share, net of offering costs of $0.1 million, resulting
in net proceeds of $0.9 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company issued to the 2023 private placement investors a common stock warrant for the right to purchase up to 268,025
shares of common stock at an exercise price of $15.42 per share. The Company also issued to the placement agent a common stock
warrant for the right to purchase up to 67,007 shares of common stock at an exercise price of $3.73 per share. Both issuances
of warrants are immediately vested and will be exercisable any time until the day that is one year plus ninety days from the date an
Investigational New Drug filing is made with the Food and Drug Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bay
Shore Line of Credit</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, the Company entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&rsquo;s
founder, Jonnie R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan
Agreement (the &ldquo;Bay Shore Note&rdquo;), the Company has the right to borrow up to an aggregate of $5 million from the Bay Shore
Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&rsquo;s
IPO. The Company&rsquo;s right to borrow funds under the Bay Shore Note is subject to the absence of a material adverse change in its
assets, operations, or prospects. The Bay Share Note, together with accrued interest, will become due and payable on the second anniversary
of the issuance of the note, provided that it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at
a rate equal 7% per annum, simple interest, during the first year that the note is outstanding and 10% per annum, simple interest, thereafter.
The Bay Shore Note is unsecured. The Bay Shore Note paid off related party balances owed to The Starwood Trust, a separate trust established
by our founder, in which we had an outstanding balance of $0.5 million as of the date of the Bay Shore Note (which outstanding balance
was retired with an advance under the Bay Shore Note).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock purchase
warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to 2,439,025 shares of common stock at an exercise
price of $3.73 per share, which warrant will expire five years after the date of grant. Upon issuance, the warrant met the criteria
to be classified as equity based on an analysis under Accounting Standards Codification (480) ASC 480, &ldquo;Distinguishing Liabilities
from Equity&rdquo; and will be measured at fair value, resulting in an initial fair value of approximately $5.95 million upon issuance
of the warrant using Black-Scholes valuation techniques.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Reverse Stock Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0">Effective December 11, 2023, the Company completed a reverse stock split of its
outstanding common stock upon the filing of the Company&rsquo;s Second Amended and Restated Articles of Incorporation with the
Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse stock split, and all such
fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number. The shares
issuable upon the exercise of our outstanding warrants, and the exercise prices of such warrants, have been
adjusted to reflect the reverse stock split. Unless otherwise noted, the share and per share information in this prospectus reflects
the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fi_001"></A>CONDENSED
BALANCE SHEETS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>September
30, 2023 (unaudited) and DECEMBER 31, 2022</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-left: 10pt">Cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">2,452</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Deferred offering costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">102,894</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">47,311</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Prepaid expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">963</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Due from related parties</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">130,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Total other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">236,309</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,730</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Deferred Financing Costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,082,292</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">5,318,601</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">48,730</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Trade accounts payable and accrued liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">496,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">404,221</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accrued Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,517</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Due to related parties</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,293,070</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">581,787</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Related party line of credit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,337,914</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,140,528</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">986,008</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,140,528</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">986,008</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Preferred Stock, no par value, 100,000,000
    shares authorized and none issued or outstanding.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Common Stock, no par value; 300,000,000
    shares authorized, 27,097,294 and 26,829,269 shares issued and outstanding at September 30, 2023 and December 31,
    2022, respectively.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,915,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(4,736,927</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(992,278</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total stockholders&rsquo; equity (deficit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">2,178,073</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(937,278</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">5,318,601</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">48,730</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fi_002"></A>CONDENSED
STATEMENTS OF OPERATIONS (UNAUDITED)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>Three
and Nine MONTHS ended September 30, 2023 and September 30, 2022</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I></I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three
Months Ended <BR>
September 30,</B> </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended <BR>
September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenues &nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating costs: </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left">General and administrative expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">102,191</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">3,750</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">204,902</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">11,150</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Related party travel costs </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">589,400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,288,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">262,562</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">229,747</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,370,522</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">355,901</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total operating costs </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">954,153</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">233,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">2,863,424</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">367,051</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(757,173</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(881,225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Net loss </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1,711,326</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(233,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(3,744,649</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(367,051</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fi_003"></A>CONDENSED
Statements of stockholders&rsquo; DEFICIT <I>(UNAUDITED)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>THREE
and Nine MONTHS ended September 30, 2023, and september 30, 2022</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Common Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Additional Paid-In</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock Subscription</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%; padding-bottom: 2.5pt">Balances, July 1, 2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">26,829,269</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">(55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">(271,685</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">(271,685</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(233,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(233,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances, September 30, 2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">26,829,269</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(505,182</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(505,182</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Common Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Additional Paid-In</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock Subscription</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Equity</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%; padding-bottom: 2.5pt">Balances, July 1, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">27,097,294</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">6,915,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">(3,025,601</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">3,889,399</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,711,326</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,711,326</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances, September 30, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">27,097,294</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">6,915,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(4,736,927</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,178,073</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Common Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Additional Paid-In</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock Subscription</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%; padding-bottom: 1.5pt">Balances, January 1, 2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 1.5pt solid; text-align: right">26,829,269</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 1.5pt solid; text-align: right">55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 1.5pt solid; text-align: right">(55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 1.5pt solid; text-align: right">(138,131</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(367,051</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(367,051</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances, September 30, 2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">26,829,269</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(505,182</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(505,182</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Common Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Additional Paid-In</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock Subscription</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Stockholders&rsquo;<BR>
(Deficit)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Equity</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%; padding-bottom: 2.5pt">Balances, January 1, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">26,829,269</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">55,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">(992,278</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; border-bottom: Black 2.5pt double; text-align: right">(937,278</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">268,025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">910,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">910,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Issuance of Warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,950,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,950,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(3,744,649</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(3,744,649</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances, September 30, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">27,097,294</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">6,915,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(4,736,927</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,178,073</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fi_004"></A>CONDENSED
statements of cash flows <I>(UNAUDITED)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>Nine
MONTHS ended September 30, 2023, and september 30, 2022</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from Operating activities </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(3,744,649</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(367,051</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Non-cash interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,517</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Amortization of debt issuance costs </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">867,708</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in operating assets and liabilities: </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accounts payable and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">91,806</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">154,181</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Prepaid expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(963</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Net cash flows used in operating activities </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(2,772,581</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(212,870</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financing activities: </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Payment of deferred offering costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(55,583</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Related party receivables</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(130,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">Net borrowings
    to related party</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">711,283</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">219,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Net borrowings under related party line of credit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,337,914</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from sale of common stock, less
    offering costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">910,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Net cash flows provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,773,614</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">219,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,033</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,330</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Cash, beginning of period </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Cash, end of period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,452</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">6,330</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for interest </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I><A NAME="fi_005"></A>SUPPLEMENTAL
CASH FLOW INFORMATION</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
Operating, Financing and Investing Activities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the fair value of a total of 2,439,025 warrants issued to Bay Shore Trust during the nine months ended September
30, 2023 totaling approximately $5.95 million to deferred finance costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telomir
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="fi_006"></A>notes
to the CONDENSED financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>September
30, 2023 (UNAUDITED) and december 31, 2022</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
1. Description of business and summary of significant accounting policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc. (&ldquo;Telomir&rdquo; or the &ldquo;Company&rdquo; and formerly known as Metallo Therapies, Inc.) was formed in
August 2021 and is a Florida-based early pre-clinical stage biopharmaceutical company that is developing its product candidate, TELOMIR-1,
a novel small molecule being developed to function as an oral <I>in situ</I> therapeutic treatment for human stem cells. Based on the
Company&rsquo;s pre-clinical studies and if approved by the FDA and comparable foreign regulators, Telomir Pharmaceuticals, Inc. believes
that TELOMIR-1 may effectively serve as a metal enzyme inhibitor of essential metals such as zinc and copper. These essential metals
play an important role in the production and function of many enzymatic reactions and the modulation of key cellular pathways. In particular,
zinc is essential to the function of pro-inflammatory cytokines such as Interleukin-17, or IL-17, that play a role in a host of age-related
inflammatory conditions such as hemochromatosis and osteoarthritis as well as in post-chemotherapy health problems</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, TELOMIR-1 is under investigation to potentially provide a therapeutic intervention against age-related inflammatory conditions
such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways
that create the systemic imbalance of cellular metals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantive
operations began in late 2021 and the Company&rsquo;s Investigative New Drug application is anticipated to be filed with the U.S. Food
and Drug Administration (&ldquo;FDA&rdquo;) in second quarter 2024 for hemochromatosis. A non-provisional patent application is pending
for TELOMIR-1 as a new molecular entity and its therapeutic uses. See Note 3 regarding this patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America
(&ldquo;GAAP&rdquo;). In the opinion of management, all adjustments considered necessary for the fair presentation of the financial statements
for the periods presented have been included. The results of operations for the nine months ended September 30, 2023 are not necessarily
indicative of the results to be expected for future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, the Company&rsquo;s Common Stock, no par value per share, is referred to as the &ldquo;Common Stock&rdquo; and the Company&rsquo;s
preferred stock, no par value per share, is referred to as the &ldquo;Preferred Stock&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pending
transactions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is in the process of preparing for an Initial Public Offering (IPO) and expects to be listed under the NASDAQ symbol &ldquo;TELO.&rdquo;
The transaction is expected to be complete in the second half of 2023. The Company incurred $0.1 million of legal costs as of September
30, 2023 associated with the offering, which have been recorded as deferred offering costs in the accompanying condensed balance sheets.
These deferred offering costs will be derecognized as a reduction in offering proceeds when the offering closes. However, there can be
no guarantees that the Company will be successful in completing the proposed transaction and ultimate listing on the NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
taxes </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a C corporation. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences
between the financial statement carrying amount of existing assets and liabilities and their respective tax bases. Deferred tax assets
are recognized for temporary differences that will result in deductible amounts in future years and for loss carryovers. A valuation
allowance is recognized regarding deferred tax assets, if any, if it is more likely than not that some portion of the deferred tax asset
will not be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and development expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company&rsquo;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains cash balances with financial institutions that management believes are of high credit quality. The Company&rsquo;s
cash account at times may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it
is not exposed to any significant credit risk from its cash account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value of Financial Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial instruments in accordance with GAAP which defines fair value, establishes a framework for
measuring fair value, and expands disclosures about fair value measurements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use
of unobservable inputs when measuring fair value. The Company considers the carrying amount of deferred offering costs to approximate
fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &ndash; quoted prices in active markets for identical assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &ndash; quoted prices for similar assets and liabilities in active markets or inputs that are observable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &ndash; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2. Liquidity and capital resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, the Company had cash of approximately $0.002 million. The Company used approximately $2.7 million of cash in operations
during the nine months ended September 30, 2023 and had stockholders&rsquo; equity of approximately $2.2 million at September 30, 2023,
versus stockholders&rsquo; deficit of approximately $0.9 million at December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has been primarily engaged in developing TELOMIR-1. During these activities, the Company sustained substantial losses. The
Company&rsquo;s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company&rsquo;s
ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations
through related party financings-see Note 4. Additional sources of financing may be sought by the Company. However, there can be no assurance
that any fundraising will be achieved on commercially reasonable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to be able to fund operations through the anticipated IPO, or through the first quarter of 2024, with available borrowings
from a related party line (Note 4). During the nine months ended September 30, 2023, the Company raised approximately $1.0 million to
finance its research and development and working capital needs, through a private placement (the &ldquo;2023 Private Placement&rdquo;)
of the Company&rsquo;s common stock. Should actual cash expenditures exceed management&rsquo;s budget, the Company may be forced to curtail
operations along with implementing other cost-saving measures, such as a reduction in staff, reducing the use of outside professional
service providers, or significantly modifying or delaying the development of our product candidates. Because of these factors, substantial
doubt about the Company&rsquo;s ability to continue as a going concern exists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3. License agreement, related party</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company licenses the U.S. patent rights for the use of TELOMIR-1 in human applications from MIRALOGX, LLC (&ldquo;MIRALOGX&rdquo;), an
intellectual property development and holding company established by Jonnie R. Williams, Sr., the founder of the Company and the sole
inventor of TELOMIR-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2023, (the &ldquo;Effective Date&rdquo;), the Company and MIRALOGX entered into an Amended and Restated Exclusive License
Agreement, under which the Company has the exclusive perpetual right and license under the above-described patent rights to make, have
made, use, and sell &ldquo;Licensed Products&rdquo; in the U.S. for human uses and preclinical studies and activities of any kind conducted
in furtherance of obtaining regulatory approval or commercialization for human uses (the &ldquo;MIRALOGX License Agreement&rdquo;). The
Company has the right to grant corresponding sublicenses under the licensed patent rights. The MIRALOGX License Agreement provides for
the payment to MIRALOGX of an 8% royalty (payable quarterly) on the Company&rsquo;s net sales of Licensed Products by the Company or
its sublicensees and on non-royalty bearing milestone revenue. There are no up-front, execution, or milestone payments in the license
agreement. Further, no payments have been made to date under the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the license from MIRALOGX will continue through the date of the expiration of the last-to-expire licensed patent or, if later,
the date of the expiration of the last strategic partnership/sublicensing agreement covering the licensed products. The patent rights
are expected to extend through 2043, and additional patent terms may be awarded, including additional patent terms based on the time
taken for regulatory review of drug products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement also provides that Telomir may bring suit in its own name to enforce patent rights. MIRALOGX will control the prosecution of
the patent applications for TELOMIR-1. Telomir is required to be kept informed by MIRALOGX of patent prosecution activities and may select
identified countries for patent protection. Telomir is to reimburse MIRALOGX for patent prosecution and maintenance costs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4. Related party transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Due
from related parties-</I> During the nine months ended September 30, 2023, the Company provided working capital advances to companies
under common control. These advances are due on demand and are non-interest bearing. Amounts due from related parties as of September
30, 2023 were $0.13 million. There was no such advances made during the year ended 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Due
to related parties-</I> During the year ended December 31, 2022 and the nine months ended September 30, 2023, the Company received working
capital advances from companies under common control. These advances are due on demand and are non-interest bearing. Amounts due to related
parties as of September 30, 2023 and December 31, 2022 were $1.3 million and $0.6 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Related
party line of credit-</I> During the nine months ended September 30, 2023, the Company received advances from a line of credit from Bay
Shore Trust, which totaled $1.3 million. There was no line of credit during 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bay
Shore Trust Line of Credit</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, the Company entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&rsquo;s
founder, Jonnie R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan
Agreement (the &ldquo;Bay Shore Note&rdquo;), the Company has the right to borrow up to an aggregate of $5 million from the Bay Shore
Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&rsquo;s
IPO. The Company&rsquo;s right to borrow funds under the Bay Shore Note is subject to the absence of a material adverse change in its
assets, operations, or prospects. The Bay Share Note, together with accrued interest, will become due and payable on the second anniversary
of the issuance of the note, provided that it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at
a rate equal 7% per annum, simple interest, during the first year that the note is outstanding and 10% per annum, simple interest, thereafter.
The Bay Shore Note is unsecured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock purchase
warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to 2,439,025 shares of common stock at an exercise
price of $3.73 per share, which warrant will expire five years after the date of grant. Pursuant to a registration rights agreement,
the Company has granted to Bay Shore Trust the right to require the Company, at any time after one year following the Company&rsquo;s
IPO, to register for resale the shares issuable upon the exercise of the warrant, with such registration rights being in the form of
demand and &ldquo;piggyback&rdquo; registration rights that are subject to customary limitations and restrictions. Upon issuance, the
warrant met the criteria to be classified as equity based on an analysis under Accounting Standards Codification (480) ASC 480, &ldquo;Distinguishing
Liabilities from Equity&rdquo; and was measured at fair value, resulting in an initial fair value of approximately $5.95 million upon
issuance of the warrant, using Black-Scholes valuation techniques.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>License
agreement - See Note 3.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Related
Party Travel Costs-</I> On April 1, 2023 the Company entered into an Agreement For Shared Lease Costs (the &ldquo;Shared Agreement&rdquo;)
with MIRALOGX, LLC, a related party. Under the Shared Agreement, the Company agrees to make monthly contributions or payments in accordance
with its use of shared aircraft toward rent payments. During the nine months ended September 30, 2023, the Company incurred $1.29 million,
for travel-related expenses to the related party for rental charges and airplane-related expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shared
management- </I>Historically, the Company has shared management with related parties on an as-needed basis, to collaborate and pool resources
efficiently. This arrangement has resulted in cost savings and expertise-sharing while maintaining distinct operations and identities
for each entity. The Company intends to reduce these shared resources post-IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Leases</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s corporate headquarters is in Baltimore, Maryland, which includes a lease for office space. This lease began in November
2021 and was amended in April 2023. This space is approximately 550 square feet and has a remaining base rent of $0.009 million payable
through April 2024. Rent is payable in monthly installments and is subject to yearly price increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Variable
lease costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
lease costs primarily include utilities, property taxes, and other operating costs that are passed on from the lessor. Variable lease
costs related to the aircraft include usage expenses, which includes pilot expenses, jet fuel and general flight expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
August 1, 2023, the Company&rsquo;s accounting and administrative staff began sharing office space with a related party in Tampa, Florida.
As of September 30, 2023, there is no formal agreement, pending a revised lease agreement from the landlord. As such, the Company has
agreed to split the cost of the Tampa lease pending an executed lease. During the nine months ended September 30, 2023, this variable
least cost related to the Tampa, Florida space totaled $0.0045 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Lease Costs</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating lease cost</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%; text-align: left">Operating lease</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">7,416</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Variable lease costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,292,545</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total lease cost</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,299,961</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5. Stockholders&rsquo; equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Capital
stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the authority to issue 400,000,000 shares of capital stock, consisting of 95,000,000 shares of Common Stock and 100,000,000
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Private
placement Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2023, the Company issued to the 2023 Private Placement investors a common stock warrant the right
to purchase up to 268,025 shares of common stock at an exercise price of $15.42 per share. The Company also issued to the
placement agent a common stock warrant the right to purchase up to 67,007 shares of common stock at an exercise price of $3.73
per share. Both issuances of warrants are immediately vested and will be exercisable any time until the day that is one year plus
ninety days from the date an Investigational New Drug filing is made with the Food and Drug Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bay
Shore Trust warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the line of credit provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock purchase
warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to 2,439,025 shares of common stock at an exercise
price of $3.73 per share. This warrant will expire five years after the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the warrants were estimated on the grant date using the Black-Scholes valuation model and level 3 inputs based on assumptions
for expected volatility, expected dividends, expected term, and the risk-free interest rate, which resulted in $5.95 million of deferred
financing costs. This cost was recorded as deferred financing costs and additional paid in capital on the accompanying condensed balance
sheet and is amortized straight-line over the term of the line of credit (which is 24 months). Associated amortization of deferred finance
costs is recorded to interest expense on the condensed income statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value warrants during the nine months ended September 30, 2023 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%">Expected price volatility</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">78.08</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.91</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Fair Market Value of underlying Common Stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.190</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted average expected life in years</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Employment Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nathen
Fuentes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 21, 2023 (the &ldquo;Effective Date&rdquo;), the Company entered into an employment agreement with Mr. Nathen Fuentes pursuant
to which Mr. Fuentes serves as the Company&rsquo;s Chief Financial Officer, Treasurer and Secretary on a full-time basis. Mr. Fuentes&rsquo;
employment agreement provides that his employment will be on an at-will basis and can be terminated by either Mr. Fuentes or the Company
at any time and for any reason. Under the agreement, Mr. Fuentes will receive an initial base salary of $0.165 million per year. At the
time of the Company&rsquo;s IPO, Mr. Fuentes will be entitled to a one-time bonus to effectively adjust his annual base compensation
to $0.25 million annually, retroactively to the date of the Effective Date. Mr. Fuentes will also receive a cash bonus of $0.025 million
at the time of the IPO. In addition, Mr. Fuentes will be granted 200,000 options to purchase common stock at the IPO offering price,
which vest as follows; i) 100,000 vest at 6 months post-IPO, 50,000 vest at first anniversary of IPO, and remaining 50,000 vest six months
after first anniversary of IPO. In the event that Mr. Fuentes&rsquo; employment is terminated by the company without &ldquo;Cause&rdquo;
or is terminated by Mr. Fuentes for &ldquo;Good Reason&rdquo;, Mr. Fuentes will be entitled to severance compensation in the form of
salary continuation for a period of three months (subject to Mr. Fuentes executing and delivering a customary general release in favor
of the company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7 &ndash; Subsequent events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through November 2, 2023, in connection with the preparation of these financial statements, which
is the date the financial statements were available to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Reverse Stock Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0">Effective December 11, 2023, the Company completed a reverse stock split of its
outstanding common stock upon the filing of the Company&rsquo;s Second Amended and Restated Articles of Incorporation with the
Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse stock split, and all such
fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number. The shares
issuable upon the exercise of our outstanding warrants, and the exercise prices of such options and warrants, have been
adjusted to reflect the reverse stock split. Unless otherwise noted, the share and per share information in this prospectus reflects
the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 127 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">1,000,000 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">Common
Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_017.jpg" ALT="" STYLE="width: 225px; height: 87px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 22pt">Telomir
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">Prospectus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Kingswood
Investments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">division
of Kingswood Capital Partners, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
March 4, 2024 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether
or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&rsquo; obligation
to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"> February
8, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 128; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>forms-1_001.jpg
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !) /H# 2(  A$! Q$!_\0
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M?A;Q'8:?I0A\,>+]6T*QD2&?0Y9EEGM;:-R#+*H4;6=6&#^E/P5_X) _LW_
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M[-_P_D_97SAOA7\?P,X;/A?P",#H<G_A8O&.>>W7M7I_P0_X+$_LZ?';XM>
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MR)*R!P0,AN,5]!?LI_\ !8?]GGX%?LY?!WX2^)?!/Q8U+7/ G@JQT/5[O1-
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M^'9['QQX?\.27WB:[\/ZUX<LY$T[24GFND>[TZUO_2OV;_V[_&GQH_X*4?\
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M@*2[ECVRH1(1PR(-VUR#PRKD@]CUK^<W_@L[X9^)/Q(_;A_X)&_L]^ ?CO\
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M-MB=DS*O0LL;',B@C'"LN>YP<?F9^S=_P3:_97_8)\0^,_C;\!['XS'Q;/\
M"_Q#X6\8IX^^/OQ>^)^G^.X;>;2/%]SKOB#P]XZ\5:YH=OXUDG\)0V5KXDTK
M2M.FBAU;4HELY(K@(?Y4?A%_PT+^W]^SAXS_ &O_ !9^QC_P4Q^-?[7GQO\
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ML_\ @J7XI\4Z#_P48_X(3:'H/B+Q%I6C>+?VLOCYIWBS2=)U>]LM&\1Z?8?
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M#O3?!\WAJX\*^-M*F\#V:0WDYO[/PH^F:;XAD"/K,&HGS&'V1^VMJ6O^"_\
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M@NK>(?UYG3TR=TDJMD[EBU#5+>)3W$<$9D2",'A(4D=(UPBNP4,=2CIJ***
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M_AX^.%U/3TUK573PS;Z/>W-U<VZZ3' T:1?$_P ./^"+;Q?'#]E[]JS]I?\
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>forms-1_002.jpg
<TEXT>
begin 644 forms-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "_ IX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ /0UA>*KB6VT&8PNR/(\<.]3RH=PI(]\$U
MN'H:RM?M8[W0[R!R5W(2K#JK#E2/<'!IK<::BTV>/#R[R]0A98'0%EC"YW !
MA\I)![D8Z=?:ND\$7=R=7E65.+B/=N8#<WEE1EL?[X&?0"LYM DMYQ%+8WZ$
MC:5MU\V.0G'S!N2..@;&/UKH_!NBW6FYDN1MDEP!'G<47J<D<9)[#@<#)[=T
MY1:M$Z*]:+P]IM-OL=3(72/")SN_N]>]>2^*H[JZUR\O(9-LT4[0X9L%$
M'_H7ON]Z];NCF(X0I@AO8UQOB'PU)J<OVRR*"<C9-&[E/-7L00#SVY'(QR,9
MKAKTG5@M;:F& Q:PF(]I9-VTOM\SA;&)_.GN[RX0RS%H/+4X;W;I@#CCG^=>
M[:7/+=:7:7$P DE@21@!C!*@GCZDUYKHO@Z\N-12+48X[>'!=URI>100"H"D
MJJD8R<D\G@5ZI&.#]>]81IPA-N":3[_G_78Z\7BY8E)S:;7962VT7?\ X(\=
M****V.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!!VA>-A0X^4$@YR??FI5O-<LTB\Y1-&3\TS , ,9S\H4Y)_V, =ST.@R,'$
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MOW:_W17*:9J\>JV\DP66(Q-MD2;&5.,]B01CG-<[-XPO3-<3V=@&L+=L2.Q
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MRFVYR(K+R856&W6-8%_=A$Z+CC%)<*4655ST(P>W'2H;(A-S[0-S>9CUR/\
M$&KMP )F Y! (_*MNIDM8:[E^_\ )DTV1F/RLH*GWXV_KBJNERXNY8^,L@8'
MZ$C_ #]:CNW"^'K5VR<"(G]*AM?-AU2 RJ$D&Z)P&R,-R"#@=U Z>M<\5[C1
MTSE^\BR+Q%?^,K;4(T\.Z-IM[:&/+R75T8V#Y/&!VQCFLC^U_BC_ -"OH?\
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MAA;?[*R%LGG+L .IZYQ]:V](L6MY;=)F62XGN3/.R]-VW/'L JJ/H*U]2/\
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M+^X*EHH B$$8Z+^M*84[K3\4M*P$8AC'\ IX '04M%, %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>forms-1_020.jpg
<TEXT>
begin 644 forms-1_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V #8# 2(  A$! Q$!_\0
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:5$& ***RE4E-WDSII4:=)6@K$M%%%2;'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>forms-1_021.jpg
<TEXT>
begin 644 forms-1_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V #0# 2(  A$! Q$!_\0
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M9/L\4;7-V1D1(?NCU8]A1K6HO86J)  ;J=MD(/0>K'V K@;ZZ8ZB-*@G9/\
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0M%6+44M$+1115-ZC:U/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>forms-1_022.jpg
<TEXT>
begin 644 forms-1_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U #<# 2(  A$! Q$!_\0
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0.<Y3?-)W8ZBBBBYD]&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>forms-1_023.jpg
<TEXT>
begin 644 forms-1_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ #<# 2(  A$! Q$!_\0
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G1GU]S[UJHB1IMC547T48%+6^%RRAAGS[LFI7G/0****]5LPO8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>forms-1_024.jpg
<TEXT>
begin 644 forms-1_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X #8# 2(  A$! Q$!_\0
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0-Q.,K5W:;T-NBBBK.(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-1_025.jpg
<TEXT>
begin 644 forms-1_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W #8# 2(  A$! Q$!_\0
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>##&L<:C"JHP!116<YREJV93J2EK)W'T445!.Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-1_026.jpg
<TEXT>
begin 644 forms-1_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W #4# 2(  A$! Q$!_\0
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M5[G1A\1B:]3EANW=OUW?J=CX(L9++P['+*NV:Z8SL/0'H/RHKH@ H"J  !@
M45R3M*3DSZBG'D@HQV05DZUX<T_7$'VJ,K,HPD\9PZ_CW'M1133MJBI04HNY
MQ]SX!U>)R+2ZM[I,\>9F-OQ(XJ!? _B,G#06:#U^T$_THHK=8JK;<X)9;AF[
M\IKZ=\/HE=9-6NOM('/D1#8GX]S7:111P1+%#&L<:#"JHP ***P=25363.JE
41A35H*P[K11164IN+LBW)IV1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>forms-1_027.jpg
<TEXT>
begin 644 forms-1_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y #4# 2(  A$! Q$!_\0
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9U8HK&=24_B9VT</2HJT%86BDHK,Z+L__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>forms-1_028.jpg
<TEXT>
begin 644 forms-1_028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V #4# 2(  A$! Q$!_\0
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MZ$/=5CRJ,,7FN(2G)R?5MMV1T'A&V>WT;[1*I66[D,Q!Z@'[H_*BMP
M#  [45X\KR=S]6ITXTH*G%Z)6%/2J.IZ39:M (KR$/C[C@X9#['M112O971I
M**DK-73.>F\*ZE;'_1-1BFC[+<J01^(Z_E47]@:[_?TX>^YS_2BBMXXBI;<\
M:KD> E.[IERV\'*[AM4NVN0.?)C&R/\ 'N:Z6.-(8UCC1411A548 %%%92G*
53O)GI4,-2P\>6E%)>0^BBBI.@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>forms-1_029.jpg
<TEXT>
begin 644 forms-1_029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W #8# 2(  A$! Q$!_\0
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MF-69Z%14-G=Q7]G%=0-F.50PHKZC?4@Y#7IS<^()5_@M4$:C_:/)_3%4?O'
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?<06L0CC'IU/N3WHHKOH86E15J<;#N6****U>XC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>forms-1_030.jpg
<TEXT>
begin 644 forms-1_030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X #8# 2(  A$! Q$!_\0
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>+M_*MD(R<L['+.?4FBBK44C:$(QV+>****9=V?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>forms-1_031.jpg
<TEXT>
begin 644 forms-1_031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X #8# 2(  A$! Q$!_\0
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M W[R3/S.QZDFK]V$'4J;?F=&%PU3%5?8TM_R1U-SK>K7&6FU$6R_W;<!<?\
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+104=BW111691_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>forms-1_032.jpg
<TEXT>
begin 644 forms-1_032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X #8# 2(  A$! Q$!_\0
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/)QE:N[3>AMT4459Q'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>graph_001.jpg
<TEXT>
begin 644 graph_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #2 G # 2(  A$! Q$!_\0
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M_P#A)+(8XNO_  #F_P#B*7_A(K/TNO\ P#F_^(J])_K(O][^AJ6O)/Q<S/\
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M_P"$BL_2Z_\  .;_ .(K3HKE/LC,_P"$BL_2Z_\  .;_ .(H_P"$BL_2Z_\
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MZ\>G'I2W?PI\%:@ETESX1T.X6ZNQ?3K+IT+"6X'25LKR_P#M'GDUU*J%4 #
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MV)(K-DEFB:/*H0QW0'DE<[AQG(KU5_AAX.DGNYF\*:*TUY:K97#G3XLS6Z@
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M' 4]:^M]:T/3_$FFRZ=JME!J%C,5,EO<QAXWVL&&0>#@@'\*LI:P1YV0QKD
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M]S<7*CDW$S?/)YH+([,3D.?05U'PU\-WFCZ3-J.LB,^(]7<7>H^6VY(FV@)
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MID8LY+LSW@$:L$+Y5 ?OY"$C%>F51U#3;:> L;*WGEA!:$21*VU@#C&>G/\
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MQQK%, JC  PG04 :]%%% !1110 51N/^0M9?[DO_ ++5ZJ-Q_P A:R_W)?\
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M#_,U?V7_ %W MT445 !1110 57F_X^;?ZM_*K%5YO^/JW^K?RJH[@6****D
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M_06J[5+4/]99?]=Q_P"@M5P^("[1114 %%%% !5+4_\ ET_Z^$_K5VJ6J?\
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ME_N2_P#LM7JHW'_(6LO]R7_V6M(;_)_D!>HHHK, JII?_(/A^A_F:MU4TO\
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M4GB?Q5<>%O%NH>)])N=-TJXL[>^E2<Z9;.L[1V_G!V9R,MQ)\RC:N6P*]_H
MP9_#^D!F26:5'N'";3>R*68#(4?-UP,X%0_V7X?NM0GL!>[[XX:2U74'\P8P
M0=H?([5\)S^'?#W_  NB;5K>7Q'<6?\ ;9EFU2[\/Q""V@_M4*;R*<W&YIS<
MC[-YVS>(5(\O"@G7\&RZ5?\ QMT'PQINC3?Z/XHN;B76CX26VUV.6*5IF6XN
MFN=QB8-M,OE?/'T'.: /N"3PGI\HE#"Y/FXW8NY1TZ8^;C\*63PGI\GF;OM/
M[S&[%W*.G3^+BMBO,/VF+>*\^!WBBWFOY=.$T<,:20V[W#2.T\82'RD9&?S6
M*QE0RY$A!('- '5:QI/A[2;>2YU2\^P6\C*AFNM0>)-V. "7 !X[=:3[#X=N
MM0DL1J >^E3>UNNHOYFU3@L%#Y !X)%?*>H>3#\%VTR#1;?PWKFG^(C--IFG
MZ5)I[VTHM=P+*\EP"3'(KDJQ#1;L;6&1;\;>&]6_X6)XAD_L:U/@ZYM2\VK:
MU:S1V-L)0@NB6S&[J2TC+MD.,D*,L2H!].6-OX8UP2FRU1+T3/Y3&WU-WRR=
M5&U^H[X_&I_[-\/W#W2B^W,7\J95U%_E9<94@/\ *1N&1UY%?,=KHOA^TL?#
M\UGJ$$L'A]KXV]MIMK?W\3.)8Y'Q)&(Y(@HEX#,VTR'[XKNKS1_AK<>)-:CD
M\-W?V==.N%N[JSM+B%H]UQ&\A9U(,KO(49& +*(WYP<4 >M-#X6N[%+O^UHY
M+2]<1Q7"ZHWERL#@*C!\$Y!&!6I-X4T^?S=_VH^: K?Z7*.!G&/FXZ]J^2O'
MD.@Z5X4^'=@V@M#X5M=2ED?4+J3R;EG1X]TRI*CE8S@$\AR.%QR:^S,YY'(H
M QY/">G3>;N%S^] #8NY1TZ8^;C\*)?"6G3>=N%S^^4*^+N4<#.,?-QU[5LT
M4 8TOA'3IO-W"Y_>@*V+N4<#IT;C\*)/".G3"<,+D^<H5\7<HX&>GS<=>U;-
M% &-)X2T^4REOM.95"MB[E' Z8^;CKVJ"Z\.Z-'+Y5Q-+%)>?NE1KZ13)@$X
M4;^N,GCFM75IHK?2[R6>Y:SA2%V>X7&8E"DEQD'D#GIVKY#_ &8_ YU'XM?\
M)?;ZA<>+1;V*P37OCBTF@UZ**??+;W<;%GB=)$R@\M8/E4@KD8(!]72>$=.D
M,I87.95"MB[E' ST^;CJ>E))X0TZ7SMPNOWRA'Q=RC(&<8^;CKVK:HH QI?"
M.G3&8L+G]Z@1L7<HX&>F&XZGD4DGA#3IA,&%T?-0(V+N4<#T^;CZBMJB@#%E
M\(Z=-YVX7/[Y!&^+N4<#/3#<'D\CFB3PCITPE#"YQ(@C;%W*.!Z?-Q]16U10
M!C2>$=.E\[<+G]ZGEMB[E'R\]/FXZGD<TDGA'3I/,W"Y_>((VQ=RC@?\"X//
M6MJB@#%?PCITGFY%S^\3RV_TN4?+ST^;@\GD<TLGA'3I#(6^U9=!&W^ERCY1
MG_:XZ]>M;-% &+)X1TZ3S<BY_>1^6V+N4?+S_M<'D\CFE?PGI\A<L+G+IY9_
MTN7[O/\ M<'GKUK9HH Q7\(Z=() 1=?O(_+;%W*/EY_VN#R>>M+)X3TZ0N6%
MS\\?EMB[E'R\_P"UUY//6MFB@#%;PCITBN"+GYX_*/\ I<OW?^^N#SUZTK^$
MM.D+%A<DLGEG_2I>G/\ M=>3SUK9HH QF\)Z<VX$7.&C\L_Z7+]W_OKK[]:5
MO">GMO)^TY:/RC_I<OW>?]KKR>>M;%% &,WA/3FSD7/,?E'_ $N7[O\ WUU]
M^M!\)Z>V[(N?FC\H_P"ER_=Y_P!KKR>>M;-% &,?">GL23]IR8_*_P"/N7[O
M_?77WZT-X3T]LY%S\T?E'_2Y?N_]]=>>O6MFB@#$;PWI?G>47F\UHBHC^V29
MV \D#=ZD<^]./A/3R"/])YC\L_Z7+]W_ +ZZ^_6OFK]ISQYX>/Q0T"PM=5?2
MO$6FV5VD^J#6K[3(K>-S"WV=VMH)/,9_E=0V /+;'-?3OAUS)X?TMFE\]FM8
MB9?,:3?\@^;<P#-GU(!/<4 5E\(Z:F=JW"Y78<74O(/7^+K[]:7_ (1/3]N,
M7./+\K_C[E^[_P!]=??K6S10!C_\(KI^<XN<[/+_ ./J7[O_ 'U^M'_"*Z?Q
MQ<XV>7_Q]2_=_P"^NOOUK8HH Q_^$5T_.?\ 2<[/+_X^I?N_]]=??K36\(Z:
MQ0LMP2B[5S=2\#_OKK[]:VJ* ,?_ (173\YQ<?<\O_CZE^[_ -]=??K2?\(Q
MIRLBDW ;9Y:@W<N2/^^O;K5GQ#I+:]H&I:8M[<Z<UY;26XO+)]D\!=2OF1MV
M9<Y![$"O$?"OP'T6Z\9/!J6K^+->_L*R?3KU?$5_-=66JK=6Z>8Z*[D*1MYV
M]"2* /9_^$5L..+C[FS_ (^I>G_?7ZT#PM8+MP+CY4V#_2I>G_?7MUKQ?]GS
M3O $?C+Q#?>#_"\EC;3%ETW5H="NK2WDLU6%9$%Q(H24M.LC KU7&,@5[_0!
MCCPKIZ@ ?:>$\L?Z5+T_[Z_6D/A'36\O*W!\L;5S=2G'_CW7WK9KC_BEX.C\
M;>&X;.;Q+J?A6"WO(;N6]TJ]-I(Z(WS0M(""$<$J<$<X/:@#77POIP(0&X)1
M-FW[7*2%/_ O;K3E\+V"E2/M&578/]*EZ?\ ?5<!\"_ =CX?&M>)+*\\1RKK
MQBC:U\374EQ<0?9GFB!#R,6VOG<!TQ@CK7JU &0OA6P7;@7'RKL'^E2]/^^J
MJWVDZ'H\*W%[=M90J/*$EQ?NB\]LL^,\?6NAKYS_ &HK?P__ ,)CX-N-1N["
M;6/LM['9:/K7A:YU^SN$S"991%#@QRIA 'S]UV&.<@ ]SA\-Z;)'%)$T[Q^7
MA'6[D(*G'.=W/;FGQ^%]/CF@DV3.T)!027$C $'(."V"<CO7FO[*KZ=_PJ98
MM+GGGMH=5U"(B73VT^.-Q=2;XX;9B6@A5LA$8Y"@9KV"@ HHHH **** "BBB
M@ K/\0:38:]H.I:9JL:RZ9>VTMM=QNQ4-"Z%7!(((!4GD&M"LWQ+#8W'AS58
MM3M#?Z;):2K=6@B,IFB*$.FP<MN7(VCKG% 'S7X'LOAZOQ6UG3?"&L76L:UH
MNG%]'NK#5;W6S8[HG6?S5ED>W1SM"(&(+98>M97[,]G]H^+EWK<6@:KI<VH6
ME[)>P:KI]E9MI[-,A\N-4E:3+MDL%1 2N6YQ6K\'M,T#PO\ %[0H/AQI7C31
MO#MW9RVFI:9K%A<0Z;:V\,;O;^3]H3=&1([ *C8PYXXJM^S;\/=!L?BM-KD'
MACQ+X:UVUMKVSO([ZP@^R2S&90TC7:*'D9HUB8(Q']XC<22 8WP3T,_#1/!_
MC/1_&$!T;Q=J%OHT^CIHMO'<W+&>=EEN)%G)>X!=A(^"P'4?(<?9%?#_ ,-;
M&[T?]IN)'O-#\<:C+J,S7&O>!_#5D18JQ;<FH2;,P.0=K/'*[L>JC)K[@H *
M*** .*^-&MZYX=^%OB34?#:DZW!:DVS+&DC1DD NJN0K,JDL%8X)4 ]:\A_9
MVL[KP]\4-<L[&Q\6Q:5JU@=2U*?QCI]M;7,E\LB(LB-$%9PZ%L@J0IC&",D5
M[=\2/ ]M\2? ^K^&KJYELXK^+8+F$*SQ.K!T<!@0V&53M(P<8/!KE_ _PQ\2
MZ?XZ/BSQCXKM?$>IP:<VE6<>GZ4+"&.)Y%DD=QYDC.[&-.X5<' Y)H ]-KS+
M]H"[ETWP;87\FEIJ^B6>JVT^M6K6,5X_V$$B1DBD!#$$H3M&[:&V\XKTVO+/
MVDO!</C+X7W9N;CRK71YEUF6!M-744NEMPSF%[9F590>NTGJJGM0!RG[*=IJ
ML$?B>64RW.@R&U^R:A<>'8=%-U<;'-P884AB=H%S&$>5=Q._!(%>_5\__LA^
M(+F;PWJ/AQ]8U#7-+T9(!I%]?:6ED)[)C((Y8]LCDH3&P4.%;8J'&&!KZ H
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MX%ZEXD\6R> _ ]T6DFO((?#MW+'>0HT<,9MX6GC6,)^[=^64$MCC.:POV5=
MTV;XB7FIVZ>)-,$JWM[;Z7JEC8P?99)3%%*TTL4K232%88^70=RV3BOJKQ5X
M>C\6>'=0T>:YGLXKR(Q-/;;/,0'NN]67/U4BOE7]FF\T]/C1<1I_I-S?6FH
M0_;K6>^LQ#<(C_VC%':Q-!)(2"OSD'Y@0>M %+X9:;X)\+>,+:;PS'\/?'$5
MGJ\5LUYIL)TC5+:XFF*"7RU#0SY??\ZB,,0<9-?9M?+%TN@>(;[X7VVC_"_4
M[&VT/7X(])U[4KJS%O!"LCF1(I8[MGD&%;;&0P)4<948^IZ "BBB@ HHHH *
M*** $P!T%+110 4444 %>(_M9ZZ;/X;S:-<^'=4UO2=8Q#<W.D-;O+9LLT)1
MFAF8++&<L7'3";6P'R/;J\=_:DT6VG^&=YK=S/J"KI*%OL]F\$<<PE9(SY[R
MPR[85SO=@O"JQYQ0!XKX8\(ZG_PK_1;'3(KK6K+^V5N-3GU+^S+&;$$,4$20
MP,\L&Q8B6^;<2T8^[D$>L>'='\17G[1UWXBDTK4+/0OLC:<TMS%%\TB*2C(X
M&3 R_-G(_>,!R%./#(]/TN?X,O-!-HL]SH_B1[634&U1'TNZ5K=99!;W$$$:
ML<*JX9"=ZL@)+"OMW2V,FF6;$@EH4.0I4'Y1V/(^AH M4444 <9XX^';^+=0
ML+ZSUFXT"Z@*B>>S@B:2YC1BR1LSJ2%#%CQUW,.]=G110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;ZA'J$%C]E\A?M#.))\HS$1;1&00Y;:>,U[I5:^TVTU.-8[RUANXU.X+/&'
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MW!=O/'TI\5-2L]'^&7BV^U'3%UK3[;2;J6XTUQE;J-86+1'@\, 5/!ZU\Y?
M'Q+H$WQ.\):3$/ &MW7]E7+6ESX+LIK>;2"B1J\4K,[>=&R$*';:VY/N\\ '
MUM1110 5Y'^T@]E'H'A,W.I3:#=GQ):+8:Y&T0CTZY*2A991*"C(5+Q[3C<9
M5 ()!'KE4]7T>P\0:;<:=JEE;ZEI]PNR:UNXEEBD7T96!!'UH \?^ C0_P#"
M??$E+CQ&WC'Q!'+IZW^N1)#':NODL8K>.*+(C,8+%@69CYBDGD >V5E>&_"N
MB^#=+73= TBQT33U8N+73K9((@QZG:@ R?6M6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^5_VJM-3P[XBLM0MYM1L!J5O//-?2W^LRVTL
M\0016<<%E,HB>4$G>1CY#@,:^D?!\\UUX2T2:YL9M,N)+&!Y+*YD,DMNQC4F
M-V/+,IX)/)(KY=^/'Q*MX/V@=/LM3U36/!^G:3'_ &:^JZ'/<+>2QW,*SM,8
M_LTD+P(\<:<MN#ECT'/U;HLD4VCV,D%S)>0M!&R7$WWY5*C#MP.2.3P.O2@"
MY1110 4444 %%%% &'XZT.]\3>"M?TC3=0;2=1O[">UMK^/.ZWD>-E608Y^4
MD'CGBO-_!.C_ !)U;QQX>O\ Q)I.F>$](T&PGM98M-U>2^_M6601JIVF--D:
M>66!?<^6 X^8GV2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>graph_002.jpg
<TEXT>
begin 644 graph_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L )8# 2(  A$! Q$!_\0
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MJ5YI&L#XU_M1Z]\4K6S\4P1O%XA^%OP?^#NI:9=/871\SXS^%7@>W\>?L_\
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M3XB?!34_A'%IT>FMI$VH^//!/C,:^]TU\+^.*/PA?7CZ:=+6VLW=]0\M;O\
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M\7:S\:_C#\+]"\+>)],DU[1(W\.W.IW%]JNIZK;Z5HBZA)9ZW-I(![M\3O\
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M$/ W[,G[3W[-7B7X0>(O!]KX@T?Q_HO[2OB_]G;Q'JE_JNI7^IM81:3I6F?
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GC*\'P\CL'^%$GB!M DB\;M=KKR:4-:M3I;:CJ'Z<44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>graph_003.jpg
<TEXT>
begin 644 graph_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $D Q$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4ZS/$7B;
M2?".E2ZGK>HV^EZ?&0'N;J0(BD],DUIUR/Q6\)W_ (Z\!ZIH.G3VMM-?Q^2\
MET9@JH>I!B=&#=,8..QR#0!+XR\32:?X9LM4TFY@FCN+NS5)E DCEAEF125(
M.,%6X8>H-=37F'B;P_/X3^$OAG0_M*7DFFS:39O<-'L$@CFA0L%7A20.!T%>
MGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5YQXP^)T]O?3Z=H20O);G9<7UP"8XV'544?>8=^<#I79>*M0DTKPWJ=W"=
ML\-N[1L1D!L':?SQ7R/XT\:1^&=%U'3Y6E?4$@9K=;$F3>NPEC+W!8Y'U-?)
MY]F-;"QAA\-)1G.^KZ)=O-]!QA*K.-.#2;:6OF['I6C_ !BU^\O(5CU2.225
M?,BBNK6,).!V'EN64XYP><5ZYX)\;P^+()8I(?L>IV^//M6;/!Z.A_B4XZ]N
MAK\P=.\031ZQ-J-A<M&T;9)CN!\HPH&-N#D[L''-?5O[.?Q#N=?O-%EGDCEN
M[&5=/NKA9MS7 E7NN.,$H<D]5->MB\-7RR=+%T*LJN&J-0?.K2C)W5[I6MS+
ME:O=.Z[#Q&%Q.7XCZMB6N:R;M).U[=+WV:>VJ::/KBBBBO6)"BBB@ HHHH *
M*** "BBB@ HHHH **** "LS7O$VE>&(;:75M0M].BN9TM86N'"B25SA4&>I/
MI6G7RY^W9KEU8Z#X)M;(;I8=6_MB;&.(;5=[G_QX?E7-B*WL*4JG8][(LM_M
MC,:6!;LIWU[63?Z'U'14%C>)J%C;W4?^KGC65?HP!'\ZGKI/":<79A1110(*
M*** "J>K7+VFGRRQG#KMP2,]2!5RL[Q!_P @F?\ X#_Z$* -&BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\4^*+/PGI;7EWN<D[
M(H4^_*YZ*O\ CV%>&^)/CIKD<[-%?6%@@5G\F/850 @8:1NK<C@+5+]J+XK:
M=X!URS?5C)]G58[>!5^Z))"6=CZ *JC\Z^2/C%\5E\?:]!/:&U5DC:.7[([%
M&C\P;/F('S;?R_&BGCL'AL72P^)BY<^]NBZ;V7XW[7/H,!D.89DHNA2DHR4F
MIN+Y%R[W:3MV\G:^FJ^X_A[\>&UBVAGU)X;S37?RVOX$"- V<9D0$C;_ +2G
MH<]*]J5@RAE(*D9!'0U^6'P_UC4M*\::';1:Q!96L=ZD!AMSE+R-R 58=&QD
M#VK](OA7>277@VVBE8R-:N]L&/4JK?+^2D#\*]K-,$L)5?(FHO:_]='=?+30
M\%*/LHS4U*]]KV\M=FI1:DK;)V=FFCKJ***\4D**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ JEJ5U):FTV8_>7"QMD=B#_A5VLS6OO:?_U]I_(T
M :=%%% !1110!QOQ6_Y%>#_L)6/_ *4QUV5<5\6Y/+\+6QV.^[5+!?D7.,W,
M8R?8=S7:T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!1US3?[9T6^L=WEFXA>(/C.TD$ _@>:^7M:TZ]T]C=:7H5C-XBBW
M6=U]H4*4/ ;=TW CH?<'I7I.M?M8>!O#6L>,;35FU"PM/"Y5+W4Y+4FV:3?&
MC1JP).Y3*G# 9!)&0#1XS\:?"S7))[^3QQI6D:A;7$5A->)=QC]\^=D,JMPQ
MX/!Y [BOF<[RNKCXTZN&ERU:;NK[/NB)>TM^[DXOR[=5Z,\"L+#3M+U)7T3P
M$KZM:PLDC3Q*(IW;[S$@'&TY /OQ7JOP2\(B/4M)M8].ALC9LU]?K$BC:2S&
M)&(ZL20?^ 5##JVDW%]#9-KUQ-+)K<V@+!9VB"9[B*)I25W2$!"J$!L=2*D\
M+?M->&_"_AK49$^'WC32[:POY+.Z,^G++*9(UW7$LC+(>(U +$GN N>E>/@,
MIS&M7IU<Q:4*;NHKJ_\ +KZFT\3C,3=XNJY[;MN]KVW?G_E9))?2%%>>^ ?C
MAX?^(WB?5-%TN*^CDLU:2&ZNK?RX+Z-7\N1X&S\P23Y#D#FO0J^^("BBB@ H
MHHH **** "BBB@ HHHH **** "OG7XN:&/B-\9-9T5@7@TGP->D;1DK/=,4'
M'?Y4KZ*KQGX1K_PD'QB^+NO.,I'>VNB1@\C;! "^#Z%I.GJ*Y,1%3Y:;ZO\
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M<YKBQF$^N*/O\KC_ ';I^NSTUMZG;1S#'X7E6%KR@E>UFU;F24FK-6;6E_\
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M^%/B;4O&/@'3-:U:"*VN[TRRB*)E8+%YKB+.UF&[RPFX G!R*\[_ &D+/?\
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M_;&0*7UA1^*+2[M!'(:M;3#5J=272,9>\_))I7?DM7T3(1^WS\+VY&JPJ/\
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M3_\ 28-?B?8,WQ)T>%06%[]/L<@_FM49?B]HD?'DWY/_ %[$5\D^+/A9\?\
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M"?[Q^8CI5"?PCJ?BW4-)\6_&*)I+:2Z1=(\%V?SV=DQY62Z8D++(!_>^4'@
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MT$=S$T4T:RQMU1U!!^H-244 1K#&FW;&J[<XPHXSUQ3D18U"JH51T"C IU%
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M"%:-9WB#_D$S_P# ?_0A0!HT444 %%%% !1110 4444 %%%% !1110 4444
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M;\5O^17@_P"PE8_^E,==E0 4444 %%%% !1110 4444 %%%% !1110 4444
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MC$8#!H20?7F.@#M:*XM?A]J(4 ^-->8@<MNAY]_]72_\*_U#_H<]=_[[B_\
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M ,10!V=%<3)\/-39HROC?7D53EE#0G>,'CF/CGGCTI__  K_ %#_ *'/7?\
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MN*]+^'OB=?&W@+PYXA6T.GKJVG6]\+1CDPB2-7V9P.F['X4 =!1110 4444
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M+J<D<;+)>^, 1JD[;VRTV><Y^Z.R[10!Z!1110 4444 %%%% !7$_%GXB/\
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M;,4$:(TK,[' (]17T9\-];7Q)\/?#6K(;EEOM-M[D->*JS'?&K9<* N[GG:
M/3BNA95;!*@D>HI0 H  P!0 M%%% !1110 4444 %%%% !1110 4UU$B,IR
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>graph_004.jpg
<TEXT>
begin 644 graph_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #^ MT# 2(  A$! Q$!_\0
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MG?[2FJ/I7P+\9-"-UQ<V+64*]S),1$H'XO5;]E^^ENO@9X6MKD_Z9IL+Z9<
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M )!Z_P"_)_Z&:OU0T7_D'K_OR?\ H9J_0 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT444 <9<-+_PN"Q!1!!_8DQ#[CN+>?'D$8Z8QSG\*[.N0NO^2L:?_P!@>?\
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M ZKZ^J>#-)T3XH>'8M>\#^*],\3:3+PL]N_W3W5QU1AW5@".XH P!<'<"(Y
M>QQS7E'B[Q%J/QR^(-KX+2\:^^'?A2\CO/$D#,76^OT(>WL&'>-3MDD&<$A5
M-=[\<V\0^ =%TO1-#%M<?$#Q5=?V7X?L<E\2$9ENI,=(H$S(Q]E'>O6O@O\
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M?X<ZAX<M=6UK0=)\166LZA:LDUS;6\JO);JPPN_:3C.#76:3_K-0_P"OIO\
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M623D^RDN7>ZDK'D-G^RE\/!8R#4]-N-<U>X)>[UV]NY?M]RY'+-*K @?[(P
M.U?/^O?#G7?V._&VFV^@>/-:\.?!+69EMK9Y5COK?PS?R-PDRR@XM)F. X(\
MMS@\,#7W#69XE\-Z7XQ\/ZCH>MV$.IZ1J$#VUU9W*;HYHV&&4CZ4+#TDK1C;
MTT_()9UF%2:G6JN=ME*TEK_=E>-O*UMNQY;_ ,(G\:=4F_L^Z\=Z!8Z3LR=6
MTO2#]NDS_"$D=HUX_B /TJY:? ?P'X59O$/BB63Q'?6P\V36O%MY]H$6/X@'
M(CC ]E%>7^%=%^/OPIO+SX7^$]-TKQ#X6LU670?'7BB]<_8;-L@6<T*?O+B6
M+&%;*ADV[CD5U>G_ +)&G^*KZ'5OBYXFU/XKZK&PD2RU/%OH]NW_ $RL(\1G
M'K)O/%"P\+WEKZZ_F7/.\8XN%)JFGOR14+^KBDWZ7MV1ROQ$_: T+XY65W\.
M_A;X.D^*4ERAC?6-K6OA_3F4\2->X^9D."H@#,2!@BN>^'OPG?PA\5-&MOV@
M=5F^(6OE8U\+:]J!/]C12*HS!';'Y4N00<22;G<<@@Y%?8&GZ=::38PV=C:P
MV5G"NR*WMXQ''&H[*H& /I69XT\%Z/\ $#PW>:%KMFE]IUTN'C;AE(Y5U8<J
MRGD,.013J0?Q0^+\_)F.#QE.*^KXQ.5)WV>L6[>_'I?35/22TT=FM34-0M])
MT^YO;N58+2VB::65NB(H)8GV !KRG]G[3Y_$%OKGQ(U.%H]1\73B:UCD'S6^
MG1Y6UC]LKF0^\E>?>)]-^(,LFF_!?5UNM9T;5[A=OC!1\SZ5'\\T%QCI/@+'
MNZ.'SUS7TU;6T5G;Q6\$:Q01((XXU& J@8 'L!64).M/F:LH_G_P%^9ZF*HQ
MRG!.E":G*OUB]/9IZ>:YY+5.SCR6:U):\B_:(A?0--\.^/K96-QX2U*.ZN-G
M5K*7]U<K_P!\L&_X!FO7:H:_HMKXDT/4-)OHQ+9WUO);3(PR&1U*D?D:WJP]
MI!Q6_P"O0\7+L4L'BZ=::O%/WEWB])+YQ;1<AFCN88YHG62*10Z.IR&!&016
M7XL\4:?X*\,ZGKVJS>1I^GV[W$S_ .RHS@>I/0#N2*X3]G+6KJ[^':Z#J<AD
MUKPO=2Z%>%CEF,!Q&Y_WHC&WXUD_$@_\+6^*>B_#V+]YH>D>7KGB(C[KX;-I
M:M_ON#(P_NH/6LG6O24X[O;U_P"!U/1IY4HYC4PM>7[NG=RDOY(]5_B5E'NY
M+N7O@QIDGAWPKJGCKQ<\>G:YXFF&IW[7+A1:0D;;>WR>@CC*C_>9O6O2'\2:
M5'/;0MJ5JLMS&984,RYD0#)8<\C'.:XOQI\-]5\3^))[NUU*.PM9H(8S*<RS
M(R2J^45E*+T[[LGMWJE??"?4[6>:UT2]MK?3+G:999R_V@ 1,ACX&UT8MNP<
M;23@5M3@J<5%'DXW%2QN(GB)JU^BV26B2\DK)>2.\T_Q=HFK?9?L>K6=U]J+
M"#RIE;S=OWMO/./:F>,O$3>$_#MWJJ6;7WV< F$2"/@D DL>P!ST)XX!KB]!
M\#^)[&3PM;WHTF?3M,^>X+74\MPT@R(V1V3)4 D[3@9/H*]'O;&VU*V:WN[>
M*ZMVQNBF0.AP<C(/'6M#B/*]0\<>*]/UB\EM9['5[ W5F+>Q2S:.7R94>1@)
M/,.YPJ87Y1D]JK:7\8=2U'5+G4D59?#5O8+<(T=L DLDDDB1JTQDW(Q*J,>6
M1R<D5Z_]FAW;O*3=D'.T9XX'Y5&^FV<EO);O:0-!(NUXFC4JP]",8(Y/YT 9
M_@_Q)'XP\,:=K,4#VR7D0D$,A!9.Q!(Z\@ULTR&%+>-8XD6.-1A408 'H!3Z
M "BBB@ HHHH \E\0?!6WUN\/BGPOJ4O@[QIN?.J62@Q7>'.$NH3\LR^Y^8=C
M5/1_CIJ7A">/2_BOHG_")W32>5#KUL3+I%UV!\WK"3_=DQ]:]7T7_D'K_OR?
M^AFK%[96^I6LMK=P1W5M*I22&9 Z.IZ@@\$5S.C9\U-V?X/Y?Y'O4LS52FL/
MCX>T@M$[VG%=HRUT_NR4DNEKW'6UU#>6\<]O+'/!(NY)(V#*P/0@CJ*EKQVZ
M^".I^!)WO_A9K8\.@L7D\-Z@&GTF<]PJ9W0$^L9Q_LU1\SXJ_%J1](O; _"[
M1K<^3J-];W*W-[>L/O"T<#$<1_YZ,-WH!BE[:4?=E!W\M5]_^=C5970K?O:&
M)C[);N7NRCZPU<GVY.9=VCI/'7QLM]%UH^%_"NG2>,?&K#_D%V;@16@/22ZF
M^["OL?F/85G^#?@E=W/B1/%_Q$U5/%?B5#OL[14*Z=I)[BVB).6Z?O&^;CM7
M<^!?A[H'PVT4:7X>TZ.QMBV^5\EI9W/621S\SL>[,2:Z.FJ3FU*KKY=%_G_5
MD34S*GA82H98G%-6E-_')=O[D7_+%W>TI204445TGSP4444 <'\5/A:GC^UL
MK_3KUM#\7:2QFTG6H5RT#]XW'\<3]&0]1[BN1TW]I;3-%T.\M?&MK)H_CC39
M5M+CP]:H9IKV9A^[>T4<RQR8RI[<AL8KVJLFX\)Z->>)+7Q!/IEK+K=K"UO!
M?O$#-'&QRRJW4 G^OK7-.G+FYZ3LWO\ UW/?PN/H.BL-F$'.$=8V=I)[N-VG
M[DNJMH_>CJY*7E6G_#GQ#\9+R'6?B9&-/T!'$MCX(ADW1#!RKWKC_7/W\L?(
MON:]HAA2WB2*)%CB10JH@P% X  ["GT5I3IJGYM]>IQ8S'U<8XQDE&$?ABM(
MQ]%W?5N\GU;"BBBM3S0KRGQA^S_8:EK UWPCJUSX"\0M,LT]WI4:M!=D?\]K
M=OW;G_:P&]Z]6HK.=.-16DCNPF.Q&!FYX>5KZ-:--=FG=->331XY_P )E\4_
MA_\ +XE\+6_CC3$ZZIX5/EW0'J]I(>3_ -<V/TKI_!?QQ\%>.K@V>GZU%;ZJ
MG$FE:@IM;R,],&*3#=?3(]Z[RN0^(7PG\*_%'36M/$6CP7C8_=7:KLN8&'1H
MY1\RD'D8-8\E6'P2OY/_ #_SN>HL7E^+=L71]F_YJ?YN#T?I%P1T.MZ)I_B3
M1[W2M5LH-1TR]A:"YM+E \<L;##*RG@@@U\R:?XFNOV(M3CT+Q9?W%[\#+I]
MFB^(KHM+)X:D/*V-TW+-;GI%*<E3A&_A->B>%O'VL?"_Q#:>"OB'=F[M[I_*
MT/Q:ZA([[T@N>R7 '?H_4<Y%>LZOH]AX@TZ;3]4L;?4;"8 2VMW$LL3@$$!E
M8$'D \^E:TZBJ+3=;KL>=C<#4P4TI-2C+6,E\,EW7Y-.S3T:3/FVS\,:]^V)
MJ%MK/BZSO/#GP7AD6?3?"MP#%=^(\'*7-\O5+;HR6_5N&?C"U],VUO%9V\5O
M;Q)!!$@CCBC4*J*!@* .  .U2*H10J@*H& !T%>2>-/C!J&L:W<^#_AI:PZ]
MXGC^2\U*8DZ;I&>\[C[[^D2_-ZXIU*D::NR<'@:V.FX4EHM6WI&*[R>R7Y[*
M[LCURO./BY\ ?"/QE@AFU>TDL/$%F"=.\2:5*;74]/?LT4Z88<_PG*GN#6-!
MI_QXA0!]8\!3MCEFL;Q<_E)3GD^.MK&Q$/@._< X"M>0Y/;KFLO;=X/[CT/[
M)5[1Q-)_]O-?FD<YI/[-WPG^#-K_ ,)EXTG?Q5K=F@,WBSQU>'4+G=C&4\S*
M1D]EB4'ZFKW]I>-?CXODZ0EY\/OA\XVMJ,T>S5=3C](4/_'O&1_&WSD= *UO
M"?P5N]8U:T\5?$R_C\4^)HOWEM8(I&F:6WI!$?O,/^>CY;TQ7KM3RSK?'I'M
MU?KV]%]_0V]MA,JTPUJM;^=KW(_X(OXG_>DK=H[2/%?@[--\*?%U[\*=3N)9
MK)4?4?#%[<N7>XLRV9;=F/WI(6/U*L#VKVJO/_C/\/[KQQX;@NM%E6T\6:).
M-1T6[;@)<*.8V_V)%RC#T;VK5^&'Q M?B7X-LM;MXFM9WW0WEE)_K+2Y0[98
M7'8JP(^F#WITOW<O8O;IZ=OE^5B<Q_V^DLSC\3=JG^/I+TFDW_B4ME8ZNO$?
M'W[+.BZMXDF\8>!-5NOACX^?YGUG0E407I["\M3^ZN%]V ;T:O;J*ZCYP\%^
M!?PA\:V_C[7_ (B_%N\TK5?'#I_8VD_V.'%E9::F"6B5\LDD\F7?))&%7.!7
MO5%% !39)$AC:21E2-069F.  .I)IU>'>)-0N?VA?$5YX3T6YDM_A_ILODZ_
MJ]N2#J4H/-C X_@'_+5Q_NCJ:RJ5.1::M[(]/ X)XR;<Y<M.&LI=E^K>T5U?
M97:EM?BQXX^*-Y?K\.-"TV'PY#,UO%XKUR=S!<E>&>"! &D4," Q8 XX-75^
M -SXI82_$'QGK'BTDY.FV\G]GZ>/;R82"P_WF.>]>K:=IUKI%A;V-E;QVEG;
MQK%#!"H5(T P% '0 59K)4.;6J^9_A]W^=ST)YPZ,G'+::HQ6S2O/U<W=IOK
MR<J[(P_"O@?P]X'LQ:>']$L-&M\!2EE;K%D#ID@<]3UJWI/^LU#_ *^F_P#0
M5K1K.TG_ %FH?]?3?^@K72DHJR1X-2K4K3=2K)RD]VW=_>?-'[:$6AS7NA2F
MX\/_ /"26=G<S);ZO=2+++;M@>7%$)HU8NP8#.22F .N/HWP.KKX+T!9+>&T
MD&GVX:WMT*1QGRURJJ0" .@!Z8KQ/X[:?X*O_B$DVIZ#XEU;6],T^'4;FXT*
M^^S+:P))-Y4A!E3>ZGSL;02 3ZBO:['Q#IEOX,M=;CGGET@6*723&.265H=@
M8,5 +LQ&#C!)-,R-RBO+=!^)NJ:S\9ET0-8GPI>>'!K%B_D2Q7FX3+&QE$F-
MH(;A=H(QR>U<WX!^-7B/Q)\4K33;U=-;0-7NM<L[2UMXG6ZLCIMRD&^5RY#B
M7);&U=N4&3DT >CW7_)6-/\ ^P//_P"CHZZ^N+N( /C#8S;Y"6T29-F[Y!B>
M,Y ]>>M=I0 4444 %%%% !1110 4444 %%%% !1110 4444 9'BSP['XJ\/W
M>ER2"$3@8E,8<HP8$, >X(!![&N0U#X,6NIMY5QK%Y+8[92;>1$8M)(@21R^
M,D-C<5/&?RKT:B@#S[_A3FG2>*+O6[B]N+F6:59%AD1"B*N[:G3D+N('H,4O
MAGX2V/A/Q,NM1ZC*^R$1K&T:*3B)8_G<#+#" A>@/->@5Y-XM\!^)O$UQX@M
MQ.S6,[N;4WDZMMWV\D9"(,@("R\,,GG.: /5(KF*= \4J2(>C*P(J6O'5^$^
MJ^&;U+O2IX7AC>UCN(HX4@$T$66++%$H19%?E0  0S ]:W?@?=ZI>>&+N76)
M-3FO6NF+/J.<?=7B('D*/0]\T >BT444 )7"0?%FSOKVTAM+"Y9+B;R=TV(V
M4^<L1.WDX^;/.#@=*[RN5G^%_A>ZL[BUETF-HKAS)*WF2"1F+*^=^[=G<JG@
M\8% %J\\6(NK6=E8I#?+-/+:S3).,6\R)O",HR<GOZ5R\'Q<.FS:5;:[;V5K
M<ZCJ<FGQ-:WFZ-E3"F1=ZJ6'F$)@#OGI7>+I-HL=HGD*1:#$)8DE/EVYR><X
MXR:SKK0?#^GV82YMK.VMC&+4><0J[2VX("3W8Y]<T ;M5-3U:RT6U^TZA=PV
M5ON5/-N) B[B< 9/<FH-'\0Z=KWF_P!GW*W/DX#[01C.<=1[&L75DTSXDZ7J
M.D0W<UN]M.BS-]GVRQL#N!7S%XR.CCZ@T :>D>+-.UR]N;6UD=I;<$ON0@8#
MLG7_ 'D:IM/\0V>IZMJ6G6[.]QI_EB<["$!<$@!NA( YQTS7/6_PQM+746EC
MU"Z:QFB>&[L)A&Z7(9W?+,5W@@N?ND9[U?\ #/P[T+P?J^I:CI-H]K<:@%\\
M>?(Z$AF;(5F(!)8]* .EHHHH ^?_ !UXRLO@#\8-:\0:AE-"\4Z,9PBC_6:E
M:#:L:_[<L;* .Y6NX^!?@F^\+^$YM3UX!O%?B*X;5=7?^[*X&V$?[,:;4 ]C
MZUO>._AGH/Q(DT%M<MFN?[%U&/5+4!L 3(#MW>J\].^*ZJN2G1<:CD]NGSW/
MJ,9FE*M@*="FFJK251]U#2FEY6MS=W&/8****ZSY<**** "BBB@ HHHH ***
M* "BBB@"AHO_ "#U_P!^3_T,U?JAHO\ R#U_WY/_ $,U?H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH R/%GA+2/'/A^\T37;&+4=,NTV
M2P3#(/H0>H(/((Y!'%>/V/C34_V<[R/1/'5_-J7@.0[-)\6W +R6?'%K>D#K
MCA)?XNAYKW>JFJ:59:Y8RV6HVD%]9R@"2WN(Q)&^#D94\'D#\JPJ4W)\\':2
M_JS\CV<#CXT8O#8J//1D[N-[-/\ F@];2_!K22>EO%O[4\6_M$,8])>^\$_#
M=CA]3*F+4]83N( >8(2/XS\S \ "O6O"'@W1? 6@V^BZ!IT.F:;;CY(85QDG
MJS'JS'NQR36RJA%"J J@8 '04M$*2B^:3O+O_EV1.,S&6(@L/1C[.BMHKOWD
M]Y2\WMM%16@4445N>0%%%% !7BWB0?\ "D_BM'XFC_=>#?%LT=IK*CA++4#\
ML%U[+)Q&Y]=A->TUE>*O#.G>-/#>HZ%JT N=.U"!H)XSW4CJ/0CJ#V(!K&K!
MS7N[K8]7+L7'"U7&LKTIKEFO[KZKSB[2CYI7TN:M%>&Z!XF^)/P=T>TTWQ?H
M#^-]&LT$*:_X<)ENUB7A3/;-AF8*!EHR<^E>D>!_BAX6^(]L\OA[6K:_>/B:
MV#;+B$]Q)$V'4_44H5HRT>C[/^M?D:XO*<1AHNK"U2DOMQUCY7MK%OM*S\CJ
MJ*PO&?CC0OA[H<NK^(-2ATVQCX#RGYI&[(BCEV/95!)KR]8?&WQYYN1??#SP
M#)TMU/EZQJ:'^^?^7:,CL/G(/\-.=51?*M9=OZV(PF73Q$/K%62ITEO)[7[1
M6\I>2VW;2U)/&WC"^^+?B2Z^'O@C47MK2V.WQ+XBM3G[%&?^76%NAN'&02/N
M#)ZXKU7PQX9TSP;H%CHNC6D=CIEE$(H((QPJC^9/4D\DDFH?"/@O0_ >BQ:3
MX?TRWTJPCZ0VZ!=Q_O,>K,>Y.2:VJ5.FTW.>LG^'DOZU*QV-IU(1PN$3C1CK
MKO*764K=>B6T5HKN[91116YXP5G:3_K-0_Z^F_\ 05K1K.TG_6:A_P!?3?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:>$)XRDGA71)$/56TZ$C_P!!H U/^$@TO_H)6?\ W_3_ !H/B#2QR=2LP/\
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M_3_&O+_C)!I/PU\/VFM:3\)K#QBRW(AN$L[:WC:RA8$M.V4+,@(4$("<'.,
MU7^ EUI'Q?\  ,?B74OA[X=T5+BZN(K46@@NXYX8YGC$@81CKL_KT-(#UC_A
M(-+_ .@E9_\ ?]/\:/\ A(-+_P"@E9_]_P!/\:RW^&GA"1D9O"NBLT9RI.G0
MY4XQD?+Z&G?\*Y\*?]"QHW_@OB_^)H TO^$@TO\ Z"5G_P!_T_QI?^$@TO\
MZ"5I_P!_T_QK*D^&GA"8H7\*Z*Y1MZ[M.A.&Y&1\O7DT[_A7/A3_ *%C1O\
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M_!?%_P#$TV7X:^$)EVR>%=%=<@X;3H2,@Y!^[ZB@#4_X2#2_^@E9_P#?]/\
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MI69_[;I_C1_PD&E_]!*S_P"_Z?XUEQ_#7PA"&">%=%0,Q8[=.A&2>I^[3O\
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M5IEGIHG8-*MG L0<@8!(4#)QQ0!HT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %)2T4 ?*O[,>K^+-6^)&M1WWB2YUWPZD]Y<P:CY
M=X\6HEO*CPKRPI'&B-'(0J,PRY"Y'-?55?('[,^K:'\/OB3<^$==UG3]*\4,
M;D1:;J=]?V]]="2X9T=+:9_LQ# \&$<]@,U]?T ?*?P-TRYM?COKTNK6/DZF
MVJZH4FO-(OVNC"7/ED7K3>0R%<8 B'RX4<C)^JV7<I )4D8R.U?)WP+L!IOQ
M^U^'5+!+?6VU75)8Y)_#ZM<&!F)0_P!HF<LRE<$ QC@A<  5]829\MMN=V#C
M% '@>A_#CQ-;>-M#TS5OBAXDUG5=*DBUF[CFMX8;"\@,LT:Q9C16W_*"5W$<
M X((KWZOD?1?$/B?6OBYX1T3QIKVL,L6K/<6UC=7NA*K3PHV0RVZ^:=OF#Y0
M<Y('K7UQ0 4444 ?,'C>SO\ 3+KQEJ.O_$OPS+9KJ<UR?"?C 6]]IZV:!3&%
M48F@D #'C>,X^4U].QD-&I&,$<8KQ#XN>!/AWHT.OZ]JOA_PW/87GG7GBF:[
M@22[,"6I4O%_$)/DC'RX)QD<\U[=%M,2%/N8&/I0!X1\0/BW>-XKM$T'P7XG
MN?$.FW?V&VDN$ACTV5998XYI)")PQ58PS*<9R.G.*]ZKY0UGX#^.-:\876MC
MPMX.TZZTG5!=VMY!IEB\NN&2\5M\[-%NB2*WW=#YC2?-G@9^KZ .7^('CR/X
M?Z5!?2:-JNMB680^3I$4<DB\$[B'=!MXQU[BN4_9_P!;O-1\.7>GC0]1T70-
M(:&QTHZQL^VW$:Q*7DEVR.,[RPSQG&<5N_&#P"OQ&\#WFF1:?HM_J:%9K#^W
MK)+JVCF!ZLK*V,KN7<!D!CBL3X"_"K4_A/H^K6.H3Z1,EY=+>(FCZ?'9QQ.T
M:^8@6-%&P/D)G)"@9)/0 ]1HHHH **** *FK%1I=X6G^S+Y+YF_YYC:?F_#K
M7R+\,_&/BIO'7@O0]9\<C4M*NCI=Y%<6^DWL:2#[ PAA>=W*J\ZJ9F5@<M7U
M]?,([&X9H3<*L;$P@9+\'Y<>_2OC7]E_5-(UKQMIEIXAD\103V"QW?AK09HM
M1;3--,D3AK?,\"_O8%R@+.5 <;,4 ?:-%%% 'R)^T8^K1?%J"XU^>QU+1[73
MGFATJVAU61;*V\X9OKDVS*J'C82=W"\#@U]9Z>R2:?;-&RM&T2E60DJ1@8()
MYQ]:^-?VNKD6GCJ)?$NFZ1KL,EDZ1BVTS4%>#3V=F\NYECU"%'W&-SC;R5Z<
MC/UMX(T73O#_ (3TJQTA7338X%:!9)Y)CM;YOOR,S$<]V..E &Y1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\H?LTZ7/
M#XRCLK34M)\0:!B\O;W4(?#<MM)=7AN/D_TMX]EPL9W!7R&_W@ 1]7U\F?LP
MZ/XMTSXF23R:.]IX/OK*XO+9K.\O);"WWS A%,MR\9??YN0B#  88#8KZEUR
M^&EZ+J%Z9[>U%O;R3>?=$B&/:I.Y\<[1C)]@: /@>Q\;:%\/_P!HFVU.#PO=
M6GB2UUFZMI;>20;;N.>>>/S&D%OO\_$@VP[RK*\9+945^@U?*/[/?QQU?XL?
M&&\NK:\\%:IX;OK;;)J5E?R1W5W) &\LVEG)(SF,;B6D94! &,XKZNH XZ/X
M/^#8O%%WXC3P_:KK=W=17LUY\V]YHP0C]<#&XG &">3D\UV-%% !1110!\<?
MM%>!5TOXD7][;Z WB"^O(AJ@CA\%Z7<IY*;O.W74L#.SHJ+A6.YC*@7N1]B1
M-NC0X*Y .&&"/PI]% !1110 4444 %%%% !1110 5Y7'\ ;,?$<>,)?$FMW%
MU#?M>V=G)<#R+174B:% !]R1BI;.3A%48 KU2B@ HHHH ^<_B1\8_A]K7Q$L
MO"OBI;>P?3-8DBO4U&S6>*[ACM1)$LFY#B-I;A'7_;MZ^B8722)&C(,;*"I'
M3':OD'XK>"O&?Q,^,FM#1]#\46OA33KN&*ZU7PKXMB2ZOIECC=H?*ENHTM$4
M,H8"-F;.01NKZ\M5V6T*E67" ;7;<PXZ$]S0!+1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7+_%#6M9\-_#OQ'JOAZS_M#6[.
MQEGM+7RS)YDBJ2!M!!8_[(Y/2NHHH ^3OV=6T=?C=J1\&R:/J7AJYM[NY==(
MM[M!IH:5&B$TDC[/.E9I6,00%=OI7TMXVAN+CP9K\5I<_8[M]/N%AN A?RG,
M;!7V@$G!P< $G%<#\.?@&? /B[_A(9/%NKZU=F.:W9+M@$:!F4Q1E0<'RR&.
M[&YF<DGH*]9H ^7?V?/'&MZG\2'LM5L="*7D9EBEL]&OK6>W$<"(P5Y;=%P[
MJ7.6ZN0,U]15Y7X?_9\TCP_\0HO& UG6+_4X+BXD@6\N Z00S+)NME  _=[Y
M6DYR2P7G"@5ZI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\L?%SX7#0?'6M7ND_#B]\<:EKTIUEM2>^N(+:V:-$1X&$+#YMD*[!@EGD
MYX4U]/::[2:=:NT#6K-$A,#G+1\#Y2>Y'3\*LT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>forms-1_010.jpg
<TEXT>
begin 644 forms-1_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )G!$P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#\SZ***_U
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M:W?=+7MH244W>OK^A_PH# G /Z&@MPFM7%V76PZBBB@D**** "BBB@ HHHH
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M%9Q<U2J<J:3?)+=Z+HM[$E%1>8O]X?\ ?R#_ .+I?-7U7_OY#_\ '*7MZ/\
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MR.+C_@7)\=@LNS3):2HQG5E1KQ=VXRI32E>5-*+4]>5-76E]-N,\3_M=>#M
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MM=4'))]=G]*<2,9[ C/Y^O4>H(S^(HV@C'3//''^?H>E,E^6-V0YE4# /S8
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M!Q&@(V@!0H/OYS^R=<ZAX3_:4TK0;:XD41ZL^DW48+,LMLUSW'&6 4([,-V
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M2O:3*\ELGER$*S0#8X!7]V0K<8K[$_;S>:U^$^E.R1M$VKRPPB5%>18FMC(
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M\3W7AWX5M#IDUU;1W-S&DY6:0/)')<2+(DDBMN=9$0)(I)WJ I&W@>&_L1?
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M[())STQCG'#=>MDF"G&TIX=W3BKR:5WU5K]OFA\%\<Y7A,WX@RVMBDH9Q?\
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M=J\S^!7@G]D'Q;X%M[;XB:U'X3\66.G"34[S4GAA%[>PD&1[5HLRMO\ X0<
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MS^POJWA?PSJVH>-+73)Y='+ZKI\TD:W_ /:$5DRW$5O'N?YC.61254988R0
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M>/\ 97\>I3_AAS]G;!(TK4<#O]MNA^8()!]LGZGK6L?!?B!W_P!FCM_,_O\
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M_B[Q(S'C"IB:>+Q%:.'E-M4%*:I<NL4H*6BT2O9>;;;;:CCJ#C.>3GU]<'
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M-OV[00/X=W3+'/H_Q=^%5I\7="&@7/B#[(EO(9H6FM$(!(8E@&V\Y)49^;"
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ML^Q6_P!4H4-&H8')!49R #7ZY?M%Q7%U\#OBC!*@)L?#EG&P&?EVW<+8!(P
M5.X<C@YZ]>:^"/[,?@WX&0G4QJ U?Q9<6\D7]I^0A6VCE7+I% I?!+%<-N^0
MKG/4GU+QSX2MO'O@K4/!4WB,VDFI@QW$DEM'O="5;$@5L2JKHH4,=W#9' )]
M'AW@W,5E.8XNM2:>*A.5162YWK&SNKZ6:3717[GC<9<?Y5B.)N'L+A<0EA,M
MJ4:,6I7<HTU!.4HWY8WMIRWM:^[T_/C_ ()MV?\ Q4?C*)<*92TA!P2/W#J,
M=.IW=<9.0">#7SW^T%$Y_:AD_<,WE:K8JWR-R1J*,P/'=><'&<_2OTW^ ?P
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MR#VP?.(_,$?G7]''_!*__DSSP?\ ]C/XU_\ 3Y-7\XPZVO\ US_]D>OZ.?\
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M=BL/1Q4<75Q%:O.;J*2;;=W'2W72WD];^=RG MKM+&R%I--AC(,@(?N@@'+
MD+D#(.>W JS%'<S,!/J$,L<6?L\;X+/P< <;1L''/(P 23B@J)9$@.2TV2,\
MG"J.<DCD]#SP.G;+0JR VO(FCY5@>%R.#D9P<9&<GOZ@G:=##0=W9*RO:5GO
M?1K5?*QA)XFIFE.2DW"RCM[L4KZM;7OI=ZZ?=9NXA<HL-Q%$'B7.P*QE*\'[
MR,N,=N<D$ <@U3AD:6%FT5-/TV2#*RW%\I&[G#(67>06!.U<9)Y/ Y>);FR4
MW$B"<HWES2JV\C=R 0HY!!SSC )/:II7A@FB94*PWZ*[+C<I+#)X.>I]03D\
MT\-6P5.HTJ,9SM\37,_1MK7;J[]CMQ^48KWJ_P!<FU)IJ',VDFOA4;VW[=]A
MH!&T,=Q"CYE)V$CDLAS@J6RW)R 5!Z4UE#+A@&5EVD-DK\O(P .')R,]Q@ \
M'+Q@8"\+SGCG.2 #CZ @9YW8RP(I,''<88\_D!P./8X!XR.P%.MCDYQHJG&,
M).S?*M4V^N^FWRMN9X"A4IIV;<EJNVO5=$_3=M[B?:959XS;P/'@?+M)&W Y
M!'*CN>O.>3W?]JCMC'<)9VJ>0P20F+=N:7"H">2>> 3GG([@%.IY&#G@'H"#
MS@]]W?&>>>F* $P3<1DVC-_I+XR(B,^4Q.&P22"-N<'OVKEQ%#!QJ*T::;U;
M:3DKN[M)ZVN=N$HXNIC=*M6S3]WF?+N]XWMY#RXTN[FO+BSLO-G0,8WC^:-#
MP'R/X2".1[<]JB^QK:E?-$2Q7A-RT4 !54E^9",J5 8' '<$_A'<1&&"60A[
ML280;@7DB@8#[P(W!,XPQ'.1@\X,BQB!4C60RCRXR6+,Q5<$I'@XP$SR.#@#
MJ <==+$8*G&=-TXU'-.*NKK7316:]##'Y=CXXM5*=2HN5J7Q/3E=TUKHU;IJ
M]O6>9;;:;6RM-/7=D&:]C\PH&*MM&T [FPWS$-\H!]ZN6S7-KJTET\\#&2W\
MH6XPT*_N?*!C##Y5;J!]X$,>]9V.,L?EROIC.6 ;G@\Y/XCMFJJ)'<J;%C+_
M &@K JQ8G*;MZ9;D8/S<<D8YZXKEGA,$Z56*C"BZJ=[V6]^FG<WI9ACJ^)IR
MG*I4E2G34V[M?NGHDM4KVU[VU/SC^-/[+/Q4U_QSKOBCPN]U>6VJW,L[P6+,
M)8896,C0X+J,-D_4<C*GG!^%G[#?C"^URS\0>-Y;;0M/L+JWNY].U99EO]06
MUE$@CBC(=6CF12I)8A]R@$Y%?J+]JN;M1;6OFPM8E6NW!D F4?=7<&!R<X.[
M.%&1@FBY>Z\D;F)C;!QO=E4GD@#><D$E>, X)/!-? U?#7!8S%O&RG3E)U.>
MSDVK\W-\-VEV?1]>A^O0\7\QP&$IY=&$H*-!4(N%&G'W5%1M=13NN^KWU6MX
MH8;>P@M-,\-)%I&CV=E#%]BC0)&\R##':"2"P[8R /3.7M$-P(M[ R@$LTZ,
MRN>,DCKGD=CQD X%2$0M"F  Y.&7.2&/5@>H[DXS[X.:CV*!W[=R2?SSUX_P
M%?H^7_5<KP3P"C2J)P4)14(NZ45&VV^F^_R/Q[,Z^*S'-GFDZM2+<G-.3;?,
MYRE=7>BU6UUN.* B.>5+=;J"0O$; >6F..-I.20%!Y]R,XIMQ&SW U4SR&5R
M"T>XY & -N<*,EMIXQM';/(ORN" 21QR1T/!X'<8Z9/3IZ(,XX&.!W&.>G&,
M\].3]3Q7,HX2G)\M"$.JC):KK>S76]_GU)G/&8JISO%2E&FE9WN[-:W:E=ZW
MM>[2LEHD-=Y;K,*6UK D@'FN8\EP'SER!DMR2>^3Z5)&\T9%N+/3Q';-OCF>
M'*%2/NX//R_>R2?IQFFD DY;CZ]>_P"'!P"/JO6C[JXV[B.=IS\P SSSDX&X
M#GVXYI^WBO=C3LN9M.W\SWO;6-W=)Z))=#.-"K5J*+K2:2O:[3;W;WO=]>MV
MKV>T";_M,FI6<:$ES%=RH";(%AL; +#"_,,94@\#KD5/+&MC#Y*Q1K;RDW>Z
M!1&TDZ9QR#@KM=\@\Y QU-6"AN[BWMH,1V31A[DD[4%Q@[AGC.,<!LG/7%2P
MKA);:X"!;=W:"3<&#1A6"A<CYMS'C!).,8R:W>%KP4I*M2NUJE**OKZ]WT^X
MNDX-JA.-5P5E%.,G;U;NWIN4DE"6AU!)#O5L>2W+9(8@=",#G/0X/.1@42-+
M<0VLSH$,\A9E.1^Y!(&[! ^9@V..@&/NBG6[SQ164AA+6QDOA? !6V(JP^0Y
M P1\Q*Y( .2".!35&T;@S-&ZAXE8YV(W!C!Z@"17QD<@@GJ*F,JT-:\Z=2E9
MQY6XRU=N5I=+-/5?J;5J5&BDL.JM.J[)-<T-[WOM?TZ_(5+>(33W2^1YR(8X
M2Z%_E8!<$GDCEE/."!CJ *BB%K;JFZWNVFGQY@3RQ$!]YBHV@A226&,  *!D
MX(EVXYV^^. !WZ_GGC';H!2G/.=H)& Q.&&>N/SQ^&<5+K4(V=.G&]V_=23V
M]-?T./"X6M@9SK2Q$FZM[)S^%N[=KO2ZE;OZ#YC#YBPQ1L+,Q^9*V"6,A!.
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M:Z2-<C5+>V0S2$Q&U(A0*54*6.TDDG#&\48F->T*:<%=+7M;9?III;N>QE7
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MN9&*PSK9;7N7WL5&$65.G)[>_P -3ZO8Z9H7[1.@ZGJ@TW6KG5[GR8'>/%Q
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M\:B>+PKXDLM;N[&);C4+.".:WGL82'*M,LS 2JSH59HN5"[N"U?)?BW0]/\
M"W[(EKK7AFSNK/Q5K>NZ5'J.HZ3-=W6G3V,D-V9DN[TOMA1L 3)G;&8AQ\H*
MW?@1\.-</Q.\,^(8]2\*VFA-\/+62_TSP[KT.IP:K<S:7>NYU9HF)L9FE822
M$DN&".#\V3GF/%V)IU*48TEI).Z_O-MN_77<]+!>'^6_4\1-UDY*249-+G24
M8OHG:Z=E9VYDU?2Y]*WGQ-^'MA)IUM=>+-,COK^_33I+7=)NL)97,9N)BJ,G
MEQOSRQ4JZ;\G->=?'_QAK/@^W\!#1KI#IGB?Q#]FDO(R6CU"W@DM"BP9Y^99
MF8Y )#*.@P/D+PWI/PSOO WQXU/QEY:>.M%O-4_X0Z-M3ND)F$<SP"W'VE&G
MVR["K;<N0K$EL5W_ ,49-1NOA-^S#-JD"Q/)X@?[0JSO+<RJ(],VO-'(S&%0
M 2C!BS9P68FO-J<6XFO.2BFI)M7NTU[W*]5?S7EU[GI8+@'+<%..)=3VMTY-
M32:3E3E.R=]4FT^EFD_(^O[S6=4M?C6VDV^IZ>^D:GX6B:'26BE\ZU8-$#*X
MR222S=6VAB/EX!%W6O'_ ((\/ZS!X=U/Q-I\&M7%Q%8VFF['>>ZN9IEBCA5H
MLI&Y9MJM*%')SVQXQ)=(/VL)3'-(MI!X/6&)&SL$Q6$E53("ABRDJ  2<G[Q
MKB_@/H/P\\3>(OB)>^.6MKSXF0^,ISX=M=:U![1VMXM9D*K:V[',LOD)B)(]
MKML7:<)@]='B3$P=G&[OH^:]K6VZ[;?/<YZO".6XB<YU*S@E#51LMU)+3U6K
M72W5IGT_XP\<^$/ NI:=H?B;7[/3M4U!HXY+64&4V44IWB[N)8LPA<-%'L)4
M*7R<DC'(_%WXJ:)\,K30[RXN(V?6;BW-GJ4.\6\UJ[H);A0F7>.TA</+D@,'
M 7YPQKYL^/VLP^*_$/Q&\*Z%I6C>$KCPWX>GFU>\U[47MKZ^DAN+9Q%IS7[&
M=I'#PM&D;8;Y,@X0BCXYMK;6?V:_A!KWBV\34Y(O$4.F3-YD7FQ:6NK6UI=N
MSQCDPVR,3GG[I8_,**W%=:K=26D%O?1N]M4G?>[_ ."B<OX"R2A/"SE6<U6K
M3YX-*\_<G*+;:Y6]N6][-)GU5XP\5W:0?#G6="U:S.F^*+VRC>6**2./6H[B
M,,_V;S#S(%PS)(0!'RH#FNM\2^-_"O@G3[:3Q)XAL(6NPCVZ1Q2K(XR6N62*
M1FDV6:E1*S#:V=R$9KP7XWV-GIVC?!73- U)1X7@\<Z8WA^:!U:3^SDLP\&'
M^\0Y!8KG:2?SPO%,7@G6OVA?$R_$EKJ'0=.\%B/0](&\6MP9-$C_ +0NPQ_=
MQOO59R%4!W;C&T$=$.+,32PLW33DWIK)OEWU6JWVTU=K'F8C@O+,3B<*I5N2
M"I59R<5[TVJ\H13TU:C;5Z12UW2/J6;6M!M-+LO$ UBTE\-WUM'?'6D8FV@M
MW +-)C=L5>1M8&09'<$G.T7QSX&\2ZI:Z/X8\5Z;K][<QLP%IYL:H8MB2%O.
M1-V]W &.!@;05KXIT8M)^RM\5XXKF\DT6'QQJ<'A>>8N;A--7^R_*M!\Q/D(
MCR%64@*6.T#)J>T\/>&/!'C?X$7O@V2[TZX\1Z-_Q-MQDD,MXTEJ3N8D<.Q)
MZG'7 S7GX3C'$2Q,7.%[M-W=[W=GW\^MSJQ_A[DWU2HZ6*GSQA)Z+7W8.35[
MW7FEM>_6Q]VWMQ'8075S*P,-EO%R^0##C[SL"0NU,,5)/S9;<3@8Y&U^)/@"
M^U*ST>Q\6Z7=7]XR0P0(6#_:,<12,7\O<7)&% Y''M8^*]C,GPQ\>--;VPU.
M'1S)YKW+)(R,9/G5 1N<AL,Q.0,#OD? -KI/PTA^#/PRUKP\\<GQ?D\:V7]H
MJNH3M*]L-7N%='C5@55$6 *><(^W[H&/5S'BS$QJTW3HQ;J\OWI1C;KOO^G4
M\'(> L#BJ&*J5,94C&%907O:6]Y.[;5DW'7>][]-?T%\0>-/!_AB_FTW7?$5
MGI]_#%!(EM(C^;<27+B...- ^_:&(4LH^;!.<8(G\0>-/!G@O^Q[GQ;XDL-$
MM]8L6U&R$T<LC7441$?D0QH_F*[9#%I.><# )Q\G>./"NG>,/VL/ 5AXF22!
M)_"?AF]N=.B>5K>XOH[1YQYA+8VO<*&DRIR5Y)Q6GKVF>!-4_::\2:;\<M\W
M@K2/!FL)X6TZ:::WL8=1C6S-BHD1K8 ,3.0,,&.&<L<$\U;B?,HT6U247>R<
M6DUI^'DM]M=4>U3X R.AF-&G'&U)^THJK*#3Y4Y)-1@F[-+OHK)I)M-OVOXJ
M^*!I_P ';_Q-X6U6VOC=7OVBUOK1G 6VEN -I=6VI)#'\K!L'&<@L:L?#'XH
M>"O%6F^#_#O_  E=CJ7B=T@74(HDE!1PP4QLTI <J&"%UZD@U\D:#+JC?LI?
M&.&Q6RE\-VGC34(=(N9KZ5[NTTYM:5((+92X+H(\!75E##C& 15*UTSX?66H
M_LM2_#T)#XVU>ZT-/&;6-S)</<6\VHNMS<WL?G2"'(6-),J,H=A(  KS?]9<
M?:_-4>E[.<N_J?1O@/*G[L%3=:,G:?LU>345*TI-;6O9+6^NJT7UAX0\2:[?
M_&SXC^%-_P!JTZTMM,^SV2$_NHR;IY+B)7R NX!I6/4!5Z 9[;_A._ 7_"1S
M>$5\7:8VNI<FVCT]5<.DA9F>-YF/D[T;.R,<LQ8'(P!X;X1@O(/V@OCO/I\^
M+W3?!5M_9TQY6::2UNS@#I-('0X1@P)/S#!&/D;X?>&?%/C?1WFM-3TG3?$]
MCXZ:]O\ 4=:U6.PUNYUG*R1Z?;6LQ\R2"2W2"543"O+NX.P8Z*/$N8-W4')V
MD[-M[6OO=:7T?W'+F/ >4U*;K5)0HJE",7R04??DFHS?*MTXO5:WDKK>_P"D
MOB#Q[X3\(P3'Q=K-KH%VMS'!;:?=[YKN\B>79]KBCMW#+"%VR,678 2 2N*G
MM/'?@+4M=TKP_IOB[2[Z^UJT%Y8B)R!)$YP@+/'Y:3?*^R(L<YRVX#)^9_%7
MAC3_ !-^U??Z?XJ\.0ZJD/P>U)[O3&N[H6<.IVW@.>6+5%=F8>:MU''>N%&6
MDVD?,H-?/OA_P3X;T_X">&O'-L^HP>-X/B[_ &&NNJ]V4CTI-,DN%LX7+B$%
M)0)HN0Q&XG!<Y(<6YC[>,/81<7+WKVT2<5M\W?IM\O,Q? '#T\$JBQ=3VL:*
MDDHM\TI1G;[6NL/5KF:7NV?Z>+,C('8M&!+<0, K$0R6\ACP^1N9IEPZLN$
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MS;3^^G_?]/\ "O[#O^(>7]E?_H=_'/\ X :7_P#'J/\ B'E_97_Z'?QS_P"
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M9V=I&MPW*!F_=\<'&.>*_MB3_@WC_994'/C7QR2>YL],/7V$H Q^'OSS3_\
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MIG6[@%Z;Z$3 ,C;AA";IE"_Q;6?.,U_:M'_P;O?LMJVX^-_'9&>AM-+(./\
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MX/U/P-::/'+X>U*2>=K:_EM[J6UDN',I^PR _P"BLC,0FX@H0,<=,[P5\+O
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M[)9V($\9R0L>3M& <$&O[0E_X-WOV6T(<>.?'1QD\V>E,#ZYQ-^&/TYJP/\
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MA9\/?"_A7Q%X+TFRN(](\5J\>LW$ES VI,DNP$1W&X_*A0$@?P\CTK^TX?\
M!O!^RVS%3XW\=X4@J/L>D]NN!YH^7G&?7CK1_P 0[W[+! )\<>.QR 6^Q:5C
M)&>3YO8GDXP#P<=*QQ7B_P )5ZSK?5<1>[^P]4W=KI^.WYO ^$OB)A,*Z%'%
M4HP;NHN3MIL[7MZ:7/XLI/A9\/I-+T#17TTR:;X6EFFT2&2X@?[++(Z/-,"6
M.)+EXT9P<8*@Y&,T_P ;?#'P#\0Y+&?Q+IF^]TY$C@U"WN(%OI(HU"(DUR&
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M<E@6*R+D#(%8OB/X-_#GQAXFC\6ZQHZ_VG;RQR>18R6<&FWC1X&Z[M=P:=0
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M7)^4?8M+9B.GW?,X'3TSUZ@UC+Q;X.E%Q6"Q33W]Q[+5=>GIH=D/#'Q(3O\
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M[2LSYM9P<0R(TI/F$X8[AGBO[/?^(=G]E7K_ ,)QX[R.G^AZ7_\ '?85*/\
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M_P"U#_.C_B'E_9;'3QSXY [?Z#I9P/J9<FNA>/\ DZ27L,3HDOX;Z)+LS/\
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M8,.*_H\_X)/I->_L:^$)Q$RK_P )9XX1 9 #Y:ZW)Y9.3R2A4Y''I7V7;_\
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M%/B&[CL-&T>[.GVDIMEOKIRGVF?RH((T9Y6Q@U^$?[=?B?XN? 36;+P%JO\
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M]AI7AHZ)9W>I-:6TFJ(]Y:1WMY/I $CI(T5L)596?/F'[9'[77[5O[)7Q_\
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MOCSXC\2PPMX2,DUNMS!K5IIXFMKK3GD=E6:,D;E)#;D_M->G_#!9]X_^ ?\
M /ZC96OS'()%<V\4#12QQQ,EW=NL05Y[<H/,$>[[N%9\@')4U5$NHQ) EM$7
MMA9P-#>32%Y[='''VJT)$KMC*%]F 0S9 !K^+']G3_@L[^U[XK_88^-FG_$3
M5[^U_;/TW]JKP'\&OA9HMQ&B>+]8\-_%;5-0_L+5]#TQXU6ZT>TTV;34FNF7
M:"%8+EL5N_MT_M'_ +2_[.7PW\2_%>S_ ."B?C#Q%^U5\*/!OA&/Q?\ !_X7
MRZ'K/@W0]976[+3M;T'XFI-86MWH>I6TC7EGJ-K"+EX[P E&6E\V_4+/O#_P
M#_@']/OC']LSX4>"?VP/AK^QEJ]Q>)\4?B;X$\1?$G1XA/<*SZ;X4NK*SO'C
M481X!)J4660^4 X1AE,5]HJY6=;9%;Y 7D+G(VL6YRV<YP3Z<\8)Y_E<\&?%
M>+]H'_@KG_P2<^-/B+2R?&/BK_@GW\?;C5+]$!M;N_7Q7X3$LS-&VUY$D,H5
MMB%/,D78H(Q_5!%-&URRH8O.C=A=!"6=$51Y8?IC)W# !'<4!KV@_/E]2Z(D
MW!]L>]00&PNX!CE@#CH3_@,=*4( <@IG@9X)P !W'MDXQG//:I<,>^/; /\
M7OUHPW][_P =%%Y?S/TLMNPK+^2GY^Z,X_O#_O@?X4<?WA_WP/\ "G;3_?/Z
M_P"-&T_WS^O^-/YK[O\ @!:7>'_@'_ &\?WA_P!\#_"CC^\/^^!_A3MI_OG]
M?\:-I_OG]?\ &CYK[O\ @!:7>'_@'_ &\?WA_P!\#_"CY?[P_P"^!_A3MI_O
MG]?\:-I_OG]?\:+^?X?\ +2[P_\  /\ @#>.Q!/;Y0/U(XII!(Z@?394H4@Y
MW$^W^33J?,UV?FUK^(_>7\C]8%<(FXEE0[@ <J&)P"!G&1WQSSUI52$;CL0,
M[!W(4\L,8/3J,"IR >H!^M)@>@_(5+;?VI+R5K?*Z8N6+UE&+;WLDE]UB(J&
MSG9CW'^(SU]Z0(%R1L'T&?Z'_P"OCVXEV]<<$_I]/K1MXP3GW[_UZ?YXIWVZ
M^J5WW>UA6=FU&GS+2/NJ_+TUMV&<#^(?]\#_  HX]0?^ #^N*=M/]\_K_C1M
M/]\_K_C1\_P_X!5I=X?^ ?\  &9'K_XXO^-+UZ%?Q"@_R-.VG^^?U_QIP! Y
M.:6O\W_DL?UB&J_D?ER_\ BVCUC_ "7_  HVC_IG^2_X5-11>7\S^Z/^0[O^
M6G_X"0X [I^ 4G^0S^=&1Z_^.+_C4I&1C./>F[3_ 'S^O^-&KWD_NC^D1:O^
M1?\ ;O\ P!F1Z_\ CB_XT9'K_P".+_C3]I_OG]?\:-I_OG]?\:+/^;\%_P#(
MA9]X?^ O_(9D>O\ XXO^-&1Z_P#CB_XT_:?[Y_7_ !HVG^^?U_QHL_YOP7_R
M(6?>'_@+_P AF1Z_^.+_ (T<'CY?^!*H']>:?M/]\_K_ (TH7U.[V/\ /DFC
M7^9_<O\ Y$-?[C\N7?\  CVC_IG^2_\ Q-&S/&$P1Z+WX],_C^N:EP/0?D*0
MKGIQVX]/3'^?UHO+^=_='_(-7HX4[/?W5MUZ$!@0,'*)O'1C][C/<^F?PXYX
M&)0Q ^Z?\?TI0F._!X(QU_6G]*=WUDY>JM^0-).RA#E_NQ47?S6@45XS_P +
MS^'_ #_Q-EX./]8@S^O^?RRA^.G@!>?[44^WFQGKQT!_&M/85_\ GV_O1'MJ
M7_/Q?=_P3V>BO%S\=_A_CG4@/?>@_K2#X[?#X]=5Q_P-#_6CV%;_ )]O[T)5
MZ3=E.+?E?_(]IHKQ;_A?/P\7C^U5..Y9<\\]JA/Q^^'0?:=7&3Z.F/Y_E^N*
M/85EO3:[:I_\,/VM-;S2^1[?17B8^/GPY)&-8'4?\M(__BZE_P"%Z> "1C55
M(89SYB<#J..H)_'CZYH5&L]J;?W(3KT5_P O(_B>ST5XT/CE\/V(7^UU&>_F
M+T[GMTIDGQT^'L1(.KYP>THY'KU_^MC//%#HU5O!I_(7UBC_ ,_%^/\ D>T4
M5X>OQ^^'+-M_M?!]Y$_F6]Z<?C[\.@2/[7'!(_UB=OQI>RG_ "O\/\RO;4?^
M?B^YGMU%>%']HCX:IUU=?7):/C]1BF_\-%?#-N/[849]'CSQSV8FE[&M_P ^
MG]Z%[:E_.OQ/=Z*\('[1'PV)"_VNH'9MZ<G)[Y],G&.W7M5M?CW\.7&4UE6/
MIO7_ #[CO[#G%>PK_P#/M_>@5>BW;VD3VRBO&T^./@*12PU0< MCS(^F6SW]
MN,<X(X["&3X[?#Z/EM5ZYS^\3V)P-V.#QT'MP1E.C67_ "ZE]Z'[6E_S\7]?
M,]JHKQ+_ (7W\._^@H_YI_\ %4\?'CX>GIJCGIW0]?HV*%1K/_EU+[T/VM-[
M33^]?F>U45XN/CO\/P>-28YZY,8Q[C+#/O\ 2AOCM\/L%CJRCM@21_7/7.><
M8ZYQQCFCV-5;P:8O:T_YE^/^1[117B0^/_PYQSJR@C@_,AZ>^X?R%+_PO_X<
M?]!9?S3_ .*H]E4_E?X?YA[6G_,OQ_R/;**\0'Q^^'1;9_:_(SSOCR>_/(Z?
MYS3_ /A??PZ_Z"__ (_'_P#%5/)4_D?WH/;4?^?B^YGME%>(-\??AT,8U8MD
MX^5XR1[X#=*G7X[?#Y@&75>#_>=%/Y9/^>U-4ZK=E!W]4'MJ/_/Q?<SVBBO&
M?^%Y^ /^@H?P92/SS3)/CO\ #Z/EM4;GH R?_%#'^>*;HU5O!KMMJ'M:7_/Q
M?<SVFJEZ]Q';LUM&LDV^,*KLJC!==Q^8J"57)"Y!..#FO&?^%_\ P[Q_R$WQ
MC^\G_P 5FGGXY_#V=-JZQ)&3@[@Z#IG(W%B0I ()'.".0#1[*I_*_P /\Q.M
M17_+R/XGPS\)_P!@K4?!G_!1/XJ?MXW'Q2M-?7QM\*;SX57?@>R\--I$MG/+
MKD/B!KV74C,\-W)"ULD.]8ER2#N(.*^)_''_  2E_;U\ ?MA?M+_ +4G[#O[
M=G@/X#M^U!_P@K^,O#GQ ^"Q^)UGI_\ P@%G<VMK':Q3:YI\27$RW4L;705@
ML4DF02=J_MI)\9? 4AD?^U51C"8$57B>%@V>9&.=Q<8W9&!CD5-'\:O TD!:
MYU.+SL;716C\J8 L,2J00><MM(.<C/WLT_85NE-M=[H/;4GJI77=+?\ $_&G
M]JO_ ():?M=_M!>-?V:?VCO#7[9GP^^'G[5WP \(:/H6I?%N;X-IK7A'Q/JU
MA>:G<W5W!X&;6((K)+B?5"V[[9+@D_PA(EQOCA_P2._:2_;*^#O@&_\ VH_V
ML]#U7]M3X(^+-+\9?L\?M+_"KP#/\/-)\&IIFN6NJ:EH?B#PAI^HF37M'\42
MV-M#J5HUVRM9(4<,KOO_ &G?XQ?#@QM#+J$,L4C^9)&S0M$C@J1M#?*,E4)&
M!R /X5PR7XS_  ^(F8:TBNH0VL+2JJ1R!!%Y,; G$4J!5D_AE7APW I_5Z__
M #[?WH7MZ?<_%+2?^"3'[6W[07QL^#/Q0_X*;_MG>#?VE_#'[/FOIXU^&OP^
M^&OPN/PJ\.1^+U@DL?-\6Z;#JNIV?BLQ6C2K.)X85D9Q/E9%60?5G@K_ ()H
M1:+\7O\ @IOXY\5_$'2]=\,_\%"[+PMI=EX4CT#9'\/8/#?PV;P!9/;(9W1E
MMXBMX!;)!OF03,?-4-7W1%\7OA[;7-O=Q:I H.V6ZTV)@]K:WCC$]_8HH#?:
MF4NK2N TB%M[<DUKGXV_#E7:6WU"VC?S%)<.NZ6(#]ZLF<A<*3M4Y'S$]<X7
ML:G\OXB^L4^Y^)?[*/\ P0N\(_LK_P#!/W]H_P#84T;XPMXA\9?'6^O;O5OB
M]>:'<0W^F>#)]6TR_P##OA4&2Z\PV>E3:?GRXIT,TEP[$9<%?<? W_!*;4O#
MGQ8_8.^+4WQLT^]D_8U^$7C/X5:KIS>&WMU\:6_BOQ-:>('N;=&NR-&(6UCA
M=V#.Y!>-U$F#^F]W\8OAM=*8IM9\NP603O!$R,ER4V&&&Y89*0121QL@!P"%
MP,A:;%\9_A\9;F^>^LDOY(##%%'.RVDH "QF[<D*%140*2"HQCJ!@]A5>T&W
MV312K4V[77WGYT?!'_@E3H/PO_9L_;)_9S^*'Q"M/B%X*_:M^-GQ;^+Z60\/
MO%9>%S\1]7BU;0[*2U>>?[;-HE];6KO<*5-P]JDI)RP'OO[!W[$R?LK_ +)O
MP6_9T^,FO>%?V@]?^$NG7&A:7XSUSPM9W&II;2ZG>ZE96S7=\U^X^R12V\ 9
M%B4M'N1$&%KZD_X71X%CGM)WUM(6BB42Q6KQ".\E,15XY?,!+VT19O)GCPY.
M4SG.Y8OC+\.H$$%C>QVEJ["62;_4W7F@ AUC?HPPH!'0 !> */85EO!KU:&Z
MU);S2N?D%_P56_X)E_ME_P#!0RXT_P"'O@?]M[X<? K]F[3K[PWK?ASX8/\
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MJG4HQ:I%JFHO=VI,?R!Q&1Y64/T'^RO_ ,$L? /P3_8G^*W[$WQ2\3:E\0_
MWQ?EUFV\7WUI-/HUU>:=K$-M%<+I+&2Y;2I5D2.5&B=F*H(T1&!DK[]3XS^"
M5=YAJT0E9A&UFKQ/;Q0HP;"*?D\P)M8X4'<%)!.<R2?&GP$[,;C5(YK="KIM
M,3,2#D=1D[9"Q7)^4\CGD'L*W2FW\T+V]'_GXOQ/Q<_96_X)I_\ !0C]DQO
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M;XQ_#QH5CGU&.X8HIFCW@033*!M,C*<;(^B \#/RC[V6Q_&GP +=42_MXXU
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MM3AOK$_;;>.!?+-O&HD8!!'N2OZ*!\:_A];R2.NI!_,(9IW,;S"0 *"!@MN
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MKR'_ (77X _Z"Z_]_(__ (NFM\;? *C(U8,?021__%&I5.JVDH.[\T'M:?\
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MVGW(/JE/JY/UM_D<W'X+T$C']BV.20/O)C/ _P"?=<<\=5_WAVD_X1'1N?\
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M4@?NH1SSGS.G;KSC.<]LXJ'C6VWRI:]G_D'U+S_\F7]?U\SEAX&T(G']DV)
MP2O[@< ]_0>_:G_\(+H _P"8/8CMG=;\9X]!QSSZ]*WXS$K-\O7.W)8@G  #
M>@R.<?AW))+B-004AW#L=^,@CON]>AQGH0.16GUV7\H?4H]E]Z_S.<D\':%
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M@Z+I^3G^.#D<#_GA[?YXJO-X3TD8W:+8>@PT'? Q]Q!SDY!#< 8Y(%;+SPE
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MQY8D,H4$98@'YL@'MQG'4#DDGM-*<12' Z<?,V>H';U'.,Y&">0< ^OU//\
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M6U[_ '/3^NU*4FDXSYV].5/X?/3ITUZEV2]EE(^<@L<$%N1D8//3/'RCKR<
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ME_+^!*<[ZRT]3NXU&S.P<*S'< #U) #'ABW(4 ]0<@=!%N +8RN6;!(P2>X
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MD_[0)SP.223CGVP<#D;PHS'=@D#\V X'3D'N<XR#S@"BU/\ E?W+_,.>7?\
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M63#D DE1S6-3"NDFY4K66]GIY[)/?_@'71Q"JZPJ)J_2VNZ_X8Z&YU,^82)
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MP<#G!()&.W/1V^J!1EB^."..K XZGVR>HX/7UNU/^5_@3S-]7^7Y&C=P8#;
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MM<J-&MP6Y#2#L>X_SW_H/+[I@9KDC)_=+\IZ]0=O'7D 'KDD@=J[_P +H_\
M8\'SGEY#P?4CV/\ ]?KUYHY:7\K_ "_(=WW?WFIY[,PWC!ROS XX!]!G@$YZ
M >O6I6\N1-F26)!.#U(.2?I@D]/3OUQ_/D]O?AAGV.%Y'L?4^M)Y[CG '09
M(.2<#G:.YYYZ9I"-8VT0_O?G_P#6J&2W'\(8X'7)7C)X^HR#G'/(XJM'=NI)
M8D9&,YP.#T&.1WZX[].15I+[*G<W XSDG' & 3TZ]N,XZD< %"2U#$ED)';Y
MB..PP.I' //)&2:S9K2(.[ $%>0/3)'&"><9.">.,X/.>@:96RR,2A]6.T=
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M<#J<DY)S55823ZXZDYR/4;VZ#!_A]<^IJY' 1CL1RO;'')QT!SCECNZ?Q8H
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M 8AGS"6;<PA/D$*?/B90<Y^<[JPX+V*Y/AZ.Z>2T6_N432=.!8C52 &6ZE'
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M]TUM:2WOEV]N+H&X,L,+*"K2=1@ D&O@CX$?\%:? OQV^-^NZ!?R^&?A_P#
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MV(8"5W$8(('/(P> 3GV.0HP,^Q &-;W1WD[B.^>1CD#/08!/U]6!QD;8NL*
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MO\%_AKX0T7PS/:B73;[7M7DL&M+MHBXANDND(AO()ODF5HP%DW?*5"Y_'?\
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MYS581L,;=H'!R!@>GW<'/'7E<@X[5HN>%7G(P?;&TC@]_P *I@X X)X'09H
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M,/PINWTOQ#X;U&V2_P!+O6,\]_?17(NEB-K<K<I! SQ(LLL9#(&&,Y%?V_\
M_!.[_@L)\/OV[/%NN?#ZQ\!ZUX*^(_A#1M+?QE/]GF?2];G>WFG-S;3O,L2L
MKP3ED6V4$RJ 0" /X@-8T][S7KI](T2PFUJROA=W5^L$/DQQJ-DA"!@HVN =
MPQM"EN!7TM^P7^VGJ7['?[17]JV^E6%YI7CJYL=,UW6H45%M"I-LD9:,Y509
MI0Q;C&/7-?BW&N"P.)C7J1E'W5*WO[MR;VOJOZW/VS@G-,TP\\-0;?LY\JLT
MUM:/5=K_ -7/](C1O$%M?Z?;WRR&1)MB;,@RAY?F_>#)*JH(;GD#G."*VM3$
MDEJ^F*AF6ZN[*]>2$$PK#9R+(R37 ^57=7,:HW4 L,9-?!WP8^,NE^*-/\/Z
MUIE]'=Z9XCTZUO(\2*T<4MQ$C; %/R,H?G<.F..U?8VG:[&+&!+FZD-@\B1W
M@@<B=WDD'E(K+D@84C(!P ,_>6OP:KRK%^SA\+DHO?1);^CW/W^FF\,I2=YJ
M/.EU;EKHOT/&OVO_ (\7O[/'P"^(WQ[@T<7/B+PU:W7ASPC"%!L-*AC6%H=7
MN92=L10SR^8^2%6&,YZU_*M^U_\ &BX^&WA"X\)_L]?'>\U_QI\5O#^I:_\
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M^9:736NO8^HP%:M@U&6&K2;C*-E.+VY[KE]UW=[==M3^M+_@DK_P5T7XF2^
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MK,<^8[#,>0V">D$%^MAI+P1Z/8SWKL@,=TR7"QE3M>:&XEC<JT84&&./H3D
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M/-&D<]V;VU(^S1)-*/.^SN7(+$8VY< $M7H7]F*0, D<]U^G?'6I8[1(05*
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MH>V>3W/3(YQG YXP!VH\IB8F5PN."S$  DX))R  OOC'WN<U<\O&0<DYY(.
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M4%1@'@D^GW<CCMTZTW>V_&1C)')[CG=GN01]  5ZURG427$:,6/8ACGZ!?\
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MY7'!S_>0 'J" 0>G(Z]L#U-84MTR,,D=2,'H<+_$0,$D<C  QZ\4_P#M!CC
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MP>YQZ5:B0G(/ .2<>H487/J "21[>N*;Y2AL GAE Y/?:>G3C-7XHP=OON
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MY[=P0Q&<CGW-4()2ZG:2"I&1Q@_7ZXYQQW&>IO1DD$X&"BD\^N[CTZ9Y/?%
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M^?L4Z,H:Z_:"\"78;)8:7XFTJY"8R"DC"? ? !QGA2IS@BOXN1^R/^U3XPE
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M-,$DDYY&?8#C^\<[0W)[D]:AL8 B(B@G]UR>IY'!&<$X!Z@#' .*?<G:IW'
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M:;?ZYJ^C:AX=T?2+"6*;3[M[ZPRER\L85F +="6P&0C)!KSGXYZK;6GC:_\
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M_P!&O(3 OF_;8HXQ\DDTJ,PP$49JI\'/VF/&GQ$^$VHO\._#LL?BC5/$U_\
M#'6KG4+,QP:7XMT^T:YU[57N)K<+;V\=F[R+.615V@*PQ@?,GPW^'.K^"/CK
MXC\.V/Q U!_ =QXMT#Q!=?$6Y6[$WB.\AC1]4TJ'4&E^T7T=O?"ZLL^:\?DH
ML>/+ 6IY8+6*::U6O4IU)N*BVK==-_ZZ7/)?'VAVOA;]KR3QE\3TU;PG<-<7
MT_A*V\V:'0KJ]MC>31+J*W'[J&"22*-0L<+$QDJ@3J:7CWXD^(_&4'ASX_\
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MUGQ19>$+;PSH'BNXL/!GC/0=3A;3)[>Y4VV;A[-?-+F)D947RV1XHV'*E$Y
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ML>$X(QC(Z @9&, 8K\#?V>VUZ+1_#3W-]%J"QZ/I2O/#<B4.PM$,CL Q8.[
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MD/0'/H<X^NG!K>J+M47,13&=C6=FP!)&00T)SU)*XP<=/3E;IPDC8X(!*Y!
MR,>HQ@;1]<XJG#?,21G&T=R<8R,KW'(P0!U'L10!W,DL<SBYN;'3+QQD,DVE
MZ>Z$-UW(;;8QR#AMO!/&,9K@?%'PX^%7C"%U\6_"[PIKT;Y\Q;K38UWKR2&-
MO&N1DMP&&-_0<&MI=2*KN+@ \?+\IR.3D+@Y/&>Y( .2!6?<ZI$4<><P.&R"
MQ)W<\]?7\"< =: /D[QW^P#^P_\ $B6RB\1_LS^$WCM?/<RZ3;7BR*9=Q8S
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MDVQEG!++L)SEB>8^%7[57QY^#.J6MY^SY\</'G@B_P##\YN+5?#6H?;[6:=
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MZ=7A&TI(S,,1@E0OLUPT0-G?:E-_9]C!-B(7"'4C?. $2(6QW200,5QY8PA
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M%9ITFT:3>HY*?>*X;/R[B.,]2?4$9.!0!SMAHLETI+*!SP.G'& .,Y^N/;J
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M4XQ)Z'G@T ?O?^QM96-K\.?"5]:ZRT\.KPC588MZ_NH[T17$2'!^\$D )Z#
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M.4W@9"C@#)R00 1Q6G9EM1ELF=H8#F2?9%<>0M^D:>88;AU8"$*A#G>O+<,
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M>F3GDGMDGKV)Y-5I=.4A@  !&6)' XR"![X.,^_I6RQ60YW\CT[[NO48&,#
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MG7OV:5^(MOH(/@GQ8T6CZM?:QKCV(ATYK:)I5DBBN=0M\QYR5+"3. 5_G_\
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M:/X8_MS7XWO)GT^;[1H,=T$TVU733$LMRNJVSX@0LR[70_T)?LG_  PA\"?
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MZJ8GFC8?=)8D]P%][_8YU2+P-XOUWPH5GO[;5YV>6]D)F,'G>4/E<Y"N!%R
M5)&#QD9\FT*V\2:+<R:YJ,&G:G;"TGMH8H]02YFO;=8P(IF;:6A,2JA"[R"'
M(&T@8])_9Y\;1:3\6=*TG4_#*6NE^(_*>76I;@*+"221D945AA]BQHXD?*'S
M-H'RD%Z[7;]6W^8679+T21_1-\"HXH$L+BS9%FTN;9:K)A3J,-[(&F.T\LT;
M-Y>#G!C.WDXK]%_$'BC7_!O@64>#]$GUGQ)XG@1'2UC9C:;QN+H%&8E#,=^
M, 8/ Q7YI_ F5FOM-N$^RWFFQS0_V9<"Z"&1!("^Q,8DVR,<>I[=!7[9?"6-
M8HK.?4$@MKF2$?97O(8YHD)V8/F2+M0D@8QTY)[4FK]6O1V _G<^(?PT^(.D
M_$3Q)XF^(7[*/Q@G\2Q3Q6'AGX[ZKI=FW@;7(]5A-S'-H5Y]I-R(M)GD^SS(
ML49$B$NW( ]Q6QU.\\*63W^J3ZIK=M!#96EOH>_[=8:E9I#<7;R!UP)(T23[
M0VXG:&^9ERI^N?VS?%/QC\3?M 6W@Y?#TMI\._A_X>GBO/$R:A(ND:OJ5_']
MOL#96L:+9/- K^4SQ@%Y2!(YQ7@?C;XE2_#[P/J-SH7AT>+O[!\-)KL^H:?:
MK)>S:]JD;6EQI\MO"DC*]G+*K,['9.4<;E7*EK3J_O8?UY?<<[XZ\3>,-+^"
MVO\ B'P3XJU&ZUV]\&ZWI-GJ^D7$ALDU"XCVP0S$1B47$,XC$Q6,9,$F&R01
M\G>(Y/%GQ-_9BM/A5+XNN= \5^&]%@\7?$WQ!X#NA9ZS=6NK6RLMOJEQ(6E6
M3[3!(C;C\XX 4C%?3_P,^)]]I_@'PK<:KX:M_%.O^()+FXU_[7_Q+AH$!O9/
MD_L5H6AF6*-U!(4*G)^;S./$/!/P#UO5_&?QF\<^(=<MO!\/Q36YT#3-"T^Z
M:_EU#3-"FDOK"22Q/V9K3S1<E%AB5XPNYND@6,N^[^]_Y@TGNEZI)/\  \&_
M9A^'/BKQK\(?'$?B'Q-X,L_ .GR3:CHFN^,))V\97;V$$ZY6[5<R&6X$O"D(
M0%8@GIYQX>\<?#GXR?"KX@^*OCAX:\9:[XJ\*7FK^!? /B#35A?2=+/AUIM+
MTF^L7D(DB>YRB*X R) <E17W':_"RRM_V<K+P4-!NK+5I].ODTR\CO9[:\UO
M4DGN(;?3I-/0D)'? %S."Y4N&"D94?$-MIFKV7QMU/X$^+-!D^$O@^Q\(>'-
M?_L?2(!XKN]?UV[@^U7,UPFV&6RWSVOFRO\ *$,C$@X%.[[O[W_F.]E;3:VR
M_P CP.;X]ZCX3_9OT_3/'5[XLU/QOI*RS>#=&N9$>ZN+I9)5TV[VG]X7AV>4
MF> &R"-I%?*'P@O=1\?>$OB9K.O:A/I'BJS,6HS?VW(WV^*6[N'<AFPS;(I2
MX4!A@%<'BOHG]LZV\/\ CKXI>#-"&NVO@33]#\$.EA?^'8(O$L][XIBU.86.
MDZQI\!!TA[BU$<K+.\DJ%R^XJ0!X]9:)HWP^\#>/]/\ 'EFNG>*?&]OHMAX<
M%O?--_;*0E8KJ^N'!B%G(ZM)-Y"(^V0[6!4,"KON_O?^8CYZ\4IJNJKI^J>)
MM<&LQ+ 8+:*&:1P5WE4VY7E@=GS X4(=P ( ZSP3X;M/"JW'ANUD.B^%[RYL
MYK[6+LK"1<ZSLVNLY(W"&60O$S'<K9Y Q56ZTG1/"<UI96\&K:KH6@Z2U]K&
MIPVDUY-'(DN/(AL]Q^T!1/"6?,8+%CMP !Q,-EXL^(?B>^NO[26[\ V4=K=0
MZ)+C3=3U".!6E!2T&96DM#$O <D.74E@H( /Z#?@?:2>%_#G@K3(=:37].L]
M(TW3(M1BF,_GW$<0*R-*K$EW5AN9NA4J><9_8GX RS-;P%UZ,N[N<GAAGGV!
M)Z#G([_A]^RYXN\!ZIX>\*Z3H$]S830:59V[6&O*]E+/JB8):Q-TS27CME@"
MBJ,;5 &"3^Z/P*A:*QM=B%E8C)888#C'8<Y.#D#)&!QS0!^B?AJ\$.GP@-M7
M8.K8X!.#G@XY ]#P:ZC^TUVCYU'S>HZ@-CC''&0.Q  YX%>=Z-&YLXD8[1Y>
MXXP>2PP.1]<<=B.V3KB.3[HY&1DYR>HP?4':3D#OC;UH Z$ZFQF"1G.,GK][
M.#QUZ;CDGJ,YSC%=/::BQ4,6P0"",\\X')[XR,\'(V@9XKS^"WE\Q=J$@_QG
M@\@CG' Z'IU(]SCN+"P.U2[[!P&RN2=H4@C  R&.W! R!T- &\L[S$98L.,9
M.00>3R#CC;DC';%6E>--P<#E67DKSEMW0^F>1CDD'L*HL8K2+>LB.0N GW3G
MWSQR<D=\,?7:.;O=;*EL1#.#SYN<-QQ@+G(Y 'IC!+<$ W=1U*.VC 1U"X.0
M2!Q@\X)ZCU/)(SUKS'6=<$C;0V=K#D'&?OD<]>QQDD],<&H]4U-Y@3\R@9]A
MT!YRQSP0>V>A(YQQ%U-ND4;BQ++D8QCAR<<]<#C/'S<XYP >EZ+J#%X6!Z;,
M<C'(8>N,C&/7) SZ>IV6J[U(>0 _*HRV1@!2#C'.<GTR..>17BNBRQA(S@@A
MER .F.><G@'UQQ\V>",]?'> N#TP"N ?H<Y!/)+8(';\B >L0W:.-PD7.!DY
M!SM&,D<Y/T[]<]G-,<G]X!@D8SCH3S@$=?Q^M<%;7Y51QGK@YX)RW&=PQ@'O
MR>N!TK3&IJ?^6))'4[QC/<X)!/K@@$]"!0!U(F.1F0,/[N[KZ=6(X.#_ /7H
M'  ] *YZ._0D?)SD],#((/<GT.>?R/>Y_:@_YY?^/K_C0!INBR81B ,@X;HW
M7CTX]^Y'T*?8XO[JD=N!T_+\:S/[2R<^60!UPRL#GU&>@]O>I4OT;C'?^$D
M =<$D=N0,#TQ0!8DM8QD;5P &Z?7Z9Z''3KWJNMHF[H,MD=.^"<G\CUSUQT)
MI[78Z!3M*D')^8 Y]3UR3V/&.].28,<@J"&(&<X.00/Y_P O6@"[%^[*8P,+
MM'8 \'OT!Q@>A(ZUL07852Q) +9(]"%Y!XX YSGL!VP3BJP903CGKSQ].>_K
M3@Y (!4Y&,D\X]".AQ[\XX- &E)*DFX ALEL]@-^"N3GGD'H3T]JR[F(%=H(
M.Z2(CU/SOSGLW;/U/KAA!))$N,\GI_C]>]-)"%2\F[]Y$1Z8RW4>W/3)Z<4
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M;XA_"_4?%E\MW/\  CP+H_A/2]8F(:^U^QT"TFMK)%>0*]S-LF6XDX+;XR,
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MFKE_I<;%RL+\'@8QU &!WP0,=#QP:P7TZ2-LQJP"DY!)XR"#M]LGD#@]^.:
M.LMKUI!D<=,$8ZY.<#OP1G.0<8ZD8UX+KH68,0K#MST.1C:1G!'!&!CT-<(C
MW,(!+$$$;0S'G .XX/88Z^^.N36Y;RY\MBQ8O@L5SS\Q &>>5VC!SC&<'F@#
MHW=9=V!L/'&W.0!C #9/J?J>3Q@PX(.#CU&.A!)Z>@]NPQ3(F1B&)&X@8QR>
MOIGC@!@O +'H35WR8V )W-D9R23UY)YZ9[XH J>=Y9 RI&<C/\()''IWXZ$
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M>>VFF@DUF.$WH,;S*N^"62X1FE,K.!F0YR%\0^,VFZ'XWU>#QJ/#FO6GB-?
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M"\6W L@8KBWD@$941*BP 8SD!<D_Q%AC;D5^T7P@CO4M[5'\T1(N6 RIX5"
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MT'8'GV[>>)KY=1D@D';U[\=3TSD^WL*O6MP9[F'+.-Y)XZ=F]\< #!';ON-
M'J-D_P#"&#*0>_(R>F.G<#UP">]6+P;8-X.6"D[00#DC!YYQM!XX[<YS7/Z?
M<",$LI(R<'.2-RC'(.>!U)]?7!JQ<3%F)W$*3G;D$$?7'' P!W(/K0!Y]J]X
M8IWR3NSG YSP2/F)'0=< \@X]!GVVH.VYE(QC(.1D<CJ/7'(&?IS5[Q#:L^Y
ME5N-W(R>"&QUR<_-U/?C@#G@DF>V<KR<?>R<$DGD@<<<'C.>2.N" #TQ-48
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MS$EO#<)LWDL=QD!WG +'&, '\2GQW_9^U'XY?%SX6^.O%6KS7%Q\#?B.]O\
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M*L=S*=X48<J2>G8@ '/J6Y]1VR*[O[-"K)P@ QC 4!?+&[)R#G=R"?0 'D4
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MXZ\01W_[/7@37_!FG>&9=.MQ!KFI>+]$T[3M?U!G4F>.2_O].%T!;E(X_,
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MOERVX&X=/7.<+CGMCOCG&6/;-0?;4R=Y.>,>H[]?E/.>P_$]* .B-R ,NZ
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M /![8XS^>>0#I_#44[[Y,,%68YPW/11G.0?7J,8)SSDUZ ,.Z$'@%L<'ABH
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MU5 ,;@0JG@J0./,&U.X,;$,RE@1@8(W9( Y).,^WMGO4*WETXX<A@1R"P!Y
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M:P1)/8QO))\PAB.Y Y(14<@5\G>%_#FH:%KOQ)U?5+;3?%UQ;V]W::)XZO\
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MM(>*M0M[;1[_ $6";2=/BL[=+V]>S@UG[-.;,6'F.LLT$DHCF7:0LF.<'/\
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M:I-I?BC]H[5/^%6^'KNVF$5W'<V-S::C<BW(*LDDMI+(JN-Q56E X<D>C?\
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M@/P%\0M?M)++XQ_'CXF:%)K7CNX"BP^SP:K)HDDL.H;BKQF"-6W21JQ'#%@
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M^T(RNC?9XF1<(Z2#"E-NT9.?1/$WA#Q%/XF\?-K3-#HVBR3>-_"^@PG%M?-
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M)D",D9?)R2I4DDDD_9O[6/BWPUX*^+OABV^&WP\/@NQN_#L6F1Z);VSQ*S7
MMVBGE7>Z.TP9G4EVR&. .B^+^'O FG:S\(+[XGWN^Q\0>%_$_B42V7"H3J=\
M;8NT9) \M"'&1\KG';% 'B-U:3V'C"RTO1]-6YL[;3Y&21F268%7 &Z6126
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M_9_T>>[FMY+MX[")9LP11J UR$?L"I/.[ "GD#([T ?J7\.6EFTFWV,.$!4
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M.[&,OY9R0VVFT,L:Q/<(;6XD)$VG9WI"@'#I.H 8 G&X*$;;E3S7^>]^R?\
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M/I]QI"_*N:]];W[W_+L>U:#=^8%=QG#,5;@XRPQP3ST]1W],UVR71.3N'?\
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MGQ\_X5OHGB":U\':5I7C70/%%[I=V9HX9KSPWJ$4$4GR"0I]K$;2L" I,A+
MGF@"W\$?V6K;P?\ ";Q!H^D:')#XT^+A_M7Q?\1[G40&GN7FBURY,<(42Q0*
M\!>*V\S,3R."235NRO?"_A[3I-$_X3#4OB9;_#ZZBO\ 7[&_M;R33].U>V4R
MP,@O9)[>[@AA<F6%0GF8;Y>*^@=?TOQ1KG@.[L]%\=QZ#9>&=9DMHWM[C9!-
M:7=U'IZ1#,.YE"R[  1M0LQ'>O+/BMXK\!?LR_#7X@>'/%_@_3U.JM"9?'D,
M;M-J6J76GDVNFR71DR);M%$B1"'&UMPDR650#XD^*7B7XA:)\;_#OCSP9;6M
MYXV\=V-OH_@ZVAMHKNWL=+U2VDMTO8($<K8QZ=87@ECBV![=8B$8(JFN8^.G
MP2\-_LH>&+K5O 6N0_$[XZ:VLM_\8/&LRF^E\+-*F^ZL[ 327,\:0>9;2Q_9
MVBP\<A/RCGT']C3PQXL\(ZUKGQ1^)VJ#Q!-%9>(]4\)27&UU\%>'/$EE<)X9
M1#\R1-]DN88=TB%SMCQ\Q5J\GTS1IX_$WB__ (3#Q'%X>T*[\'ZW?>)[K4W?
M;XSU/[;$5\N63S PFMRMM%'$R$B$D]2* /CSPOX;\*^)OAQXV^)GBGQSJP\7
M:K?V$FB66HV]X]O<OI-YYTJR6L\@\S:2&"%6!C.2>*Y#QW\4]$\3>,/!_C'Q
M!X9DM;'3/!T'A6^\2VEELTF:2.\W>9%9P1B")I1M=G=RX)/8G/TA\3OB3X:\
M0W7PA?0?A':V7AO0Y?$NE7,%O921KK4-S!#9?VK(/-Q(88%^UQ.48$L6.3@C
MY]^,5M\0C8>'OAWX/\/Z2? &L:[!J%G)+%)]KGL7@ :!) P"L"K [V4*Q&T4
M 9?Q<T[1[K4]#U+18K;4(H)-'U*W*RQ6<SQQ/;R!# [,\B@ $1Q@9_BZK7M'
M[(OC[2M>^-_B-YG;P^4@VW,6J(=-M+AXKK.;<W+11,&7:!@$9#'.>*^=?BEJ
M^D^)/#_AS7]$\+ZMH&O^&M;T?0C<QI'_ &9,T%R;:Z:X)WNX!M5+!0<*<L<,
M!7KOPY^&EEX_^,D<OBK7(M1T>#3+9[C3O!DNV]4M,[LMP)2(PZ;F)"-R/0C-
M '](?[/FKP37>GZ@)UDM9+F%'N()(YH/*B9441-&3&<J@.%/.2#SDC]?SXZT
MKX9_#F3XAZS#-?6 M5BTK1[<N;G5+EDW)$CQY-LY51R$;.[G(&#^'O[)\&G>
M%[K1;&S\^]\-Z7YFFZ=HMZT;WDTDK>4+B=EX,D,BLXP2.1G)YK]T/ 5IIVJ>
M'QI'B;1TUMYIDN]&T^52\>EJ#E6(!VG8&4+DD@+GOP ?E7^T-^T-_P %&-6\
M'M\3O#_PKTO1?V6O%-U)H.K^"=;U33H=?T2SN9'LY==&IWD$-R8/))O&M4A.
M!('#;=QKRS2?AK<>/&\.^+]#CT;PGJ'A7P]I\@U_S[7;)H%O ?(NA-%L2[GN
M[??$S1G$ID4*<-D?>7_!0K6]<UKP)X>^&L'C;2XI?$-[97J:!?N(=,U/0](N
M6M[O1[".W6+=(T;-!,9F#/(2 Q;!K\]-%T77I]/U2;04LSX3\(>&CI]IX3OY
M+HZ7J.IVL4\,?A>+RY%N772Y_(ECC\PLIV@R,I.X X&Z\+^%_%/QAU/XHZ#\
M2-<@@\#Z%?6LWAJ6_O8+2XU/,$T=_;:0]TBO;PB!P!&A\TW0! PI/T);WWC)
M]!C#3:5XITC4=&U75K_6=:\.V^[28+_3WVQ6,5X90+FT=%=@DBEF)(&[+'X3
M^#Z^&K#2M$L?C%<^*])^/_Q(T+Q9<^'XK$6T6B2Z19ZE]E:>2)XFG86D<=I
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M03GW^F#4NH8)%+;48#'7 .1N.>.^"0?8@@8!% 'BB:1<R;1(H(!.>64$,1D
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M/A7XGTGXNZU_89UJWO\ P)>:D66+6_$$>FQ&Y;3--F8/&[M&HN?G5(\/L#9
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M >57$ZVY(<,!O(.3R2,$G/.3N&,]>2 >#6-=7HD?#-O..,GH#T R."<@YSP
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M-JKC/4@<D#!! '6@#$LU.ZP8*1FU89]T9P3^A!/8GUKZ<^&%P?\ A$[?E/\
MC[N^O!'[P=L_Y]37A]GIKM!;!(6S%;N'7/*ABV.@ Y)R!T*D#)ZGV_X=0_9/
M#%M%.!%)]HNF*2=0&<8Q\O(('4\YSGT !4$D<4>0V,!LYY&0,XYY &.,<X!]
M<UR.I2QAV<$#&_ODY;<.^1@C&/\ =[<UI7PD@C)WJ<'H.I4'G@=5W \8Q[<\
M\3=WK-(\1C;EB-X)Z99NI/0D=^,]>,"@"K<W3B3Y3N.[' '&<\X'7)SQD\CU
M K9TA9+LMYISL&Y<CH1CH0,'J!@YR>0*R8(!/(-J8]S@@AL=._/!)/&!@],5
MVNFV_D@#*HV.3@!B,# W#D]SU(R?FXS@ ZVPLXUB7&#E5R<D_3OQTSQ@G')]
M</Q' !'-A0#Y8(;)]&ZG.1G&>".3SGFNEM05B10Z+\@[8'(&?3![],$'(R,F
ML?6HQ+ R##%A@'_@)('L!_"O0<#  H \)N)GCG?;D#..@P1N88 VGDC\2 <]
M!6]:RL[1A@6!"*1DC[P'0@@_FS9/(S@TR]T[]ZQ)4X8'[J\@$]>,YP,<X8 G
MH,UH6UJ8BKG;A53 )'IP<=CZ< C)/3- &U:V:$^9C&TXY+'&2.""QP<\'IR!
MS@D&2>P27=\NX,<_Q8'...1TQ[XSQQFEAND1<' !^G4'/(!R2>O<9&03\IJ]
M'<0_>9NY&W.1C STXZDY/(/./6@#$M]$1Y65EQ@@]"<9&21W.1S@GG\:M-H4
M"@$KG('][)]P 0".I&!SS@'%;JWL"CY5SGJP&"Q[DX7MTZ\8P.,56GOHB",D
M;3QP<#:>,8]NI[@=NP!SOV".)"I &0>FX#)R/[P8@@#@D@XZ YS=@M%W!2<@
M; 1D_P > "3USSG@^OJ<LDN(]P7(\Q@JG(R%!XR.H'7)P>H]>FG:PLY5MZY)
M0D8SZ8R.>/FR <CY<C % #IK&%(RRD9P#CDX'<C.[(]"<XSGC&*Y#4%FB+^6
MIPJDG&2,@D9^8D=,<=/;H1TWG/')+YFYU#C@$\#).?0K]/T)!-@I;7,,IV<[
M#@$#^[P!D9/7CCMGN,@'FT>JSVY(<%1P,G&<DY^F20?4<] ,59;Q!*J@[B.!
MW'.!GID]AG _#TJ76-++C=$<8!.TJ,D?>Y]<X& ,X QQG%<FME<;RC@;0@ '
M &.N0I. 3@9XSG!X)H Z1]?D!([8P0"...>1\PX[@Y&>HZ4NF:PUQ*68J,<
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MGQ_XA\<ZEI/B'4KCPMKFEZC,XB@FC0OX/L#,@>TM]'MY)',;NL$<+$1H <$
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M SSQSV/;+<GISDG(YKJ[68["A)<D\8/S#*C"AB1R /7C&.XH XR>*6V>,J"
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M[-@BB;!#!?+P,;F!_3"VFEM;PW4Q:Y,T5S<:?:J RN)8F"Q6X8'YGW!0N ,
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MYM'U7['VJ3:+\%?VJ/AW>RS_ -G>%;G58M&\1322M:PH;V^MS&N7-J6\L;2
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M>\JE.\VW>^MWS.^K:>MSY7%XFW"-/#PG*4X5O<@VW'6,E:U[+9+T\CZ"SO\
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MEO'%/*RNP4*N>68EC[\G /!_'DGD5.VF02YP5//][MDXZ$<?K^.:Y9-0\O\
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M,V-QQQC'( 8]<CN2>.AQW*\$ Z:/49&.T8 7&02#@=>F.G3W&00#TILE]*>
M >3@!L< ^F/<?7DXK/1"BJ4."1\VXC)P>,YSTQTXQC@#)%#1L<?>^J]_J<_-
M['COQSP #7CO=+LX3Y0<$XR6 (XZ8Y/H<CIFO0M'?<@+,,%5!')#*>,#('.
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MZ%AC)(%>4Z;?+M"R-M#.H/.<H0<@_-P..#UR3P<UN+JZ-%)($WRVKLMNTV6
M7&&*C(P0#PWL<YQ0!Y5^UO?^'M,^!'BN_P#&ELVHS6YBGT.U@R7EO86GEM(\
MJ1)\\A*#:"=P/05_+[\%Q\4/'/C?XEW7Q1\-P^'?A+*;JYT.VU1Y1LU&.474
M\HCNHXPR-:J5!+YVKR21S_3+^TGHFL>,/A-K.D^'C:W5\;.XU KJ,8N3#=6:
M3/$T#'_5(F=YV8P/O<XK\5_%'BCP_P"-_@EXAT:VUW39/'.@V+^#M0M0WE6Z
M^*+-1#J&(Y-GF-YDNQCE@L8?YG"98 P_"GQ;\$_%+P=!?^!T:S^'D6A:_P"&
MEMY+A[*S$KSS6L[K+$<#;=6@>W53N!&!@C)^:?A[X^\*>!/V:/'^M:C\-M-\
M3:?8?$KQIHOA*]O]9N4EMM2MK>UAN;MV='Q#+%*ZQODJ=O)KU'X6? +Q-\-_
MAYIO@C5=7\//'=7 FL]'TS3GA6W74)9+N22]3<\4TF^65LQ]<\#) &5^T'8?
M ;Q'^S=X]^$^GZK-X.UG39KJXUY--N/LICU1)((_M]E#&IFMI;]T5)7'R2\J
M>,Y /CW]B?Q-\$/%]SXRL?&VGV/A.S\-ZO(NFZS/<"Z\GQG*\M]H LI=1="T
M-N7/SP,(RBE512*PO#7Q \7_  D^*WQGUSX2V4;^(/&$&G^'-!^)%\%:QTG4
M%U-XM?U!3,KVJ^9874Q1FDV!"02&!)]!_9?T3X>_%O\ 9M\<^%/&7P_@\!:]
M\,(KO7_#6JF*&RU/XD7>AP7,^FZXERZAFC5HO*F2;<CNV['.*X;1/BAX<OO@
MQ_PA>FZ4-)\7^.?%E[X5T^SU>SEU!K>9+N#^U-3BN$C\F-I(/G4!ML:%GP,T
M >4?%O2_@GX,\,_&J&+QUKWQ$^+?C"X73_%WBRWMVET*_P#$VI:9&_VO3I[>
M\:V,5K 8;=WB 3?&Q !XKDO'>K:'J.C_  Q\-:9%/9))X/\ ">F^+]:D7]XE
MMIMA!'>7+RDD+*8HV6,R."1G<V1SZC^U6GPN^ _P7@_9XMM%L=0\6:-+;ZOJ
MGBW2E2/5]4CGBDN)-]UM:5F#SLI;KF,*/E&#X)X4N;C4O@WXY\465Q8'PS:>
M'O#NFVDVOVANM5DN\-;WUO!<D!!)'@+*Q4N9&PV&8T ><7%]X&T_Q!XE?X3>
M)9O$GAOP]J+6-A]L18GO;01PM(H DEWJ9I)6;:2"J/R3U\ZNVTB/QU>>*?$<
M_D?#GQ1X:U>UU/36^Y!J^G6%U!II+DA$8WLT;J6"D!1\O%=%X@MM \/Q>'HO
M"?A5M)O(=#9KI].C2"RN/$_VD- MW$/E>W,0W26YP9(P5&,Y'CFM"UN_ :^$
M?B!IFIS7&NZU>37,VD7'V(6SSSQM$X=?E2+;M#H,# (Z9H _4G_@G.;D? X2
MW.I+J-OI6O>396PD,L\=J-K)$02W*EI%V] >#A>:_6SQEX&\/ZY_86J7-LNH
MZCI)TV\T*!I&/V!ID\R=9(E)&6W/\S?-R1Q@"OYP_P#@D]XM\26'QE^._P (
M[+Q#:^)-'\,2ZI>Z!HSQNTY:U%ND<+ZC)MLRZ1Y0D2 LX)8@MFOVY\$^//%,
M_BCQ7X@^,&K0>&?#,)L].T;3=.@DM+BQN1(MO"9K^ -!<DA6)P[<-D #&0#Z
M^U(S>*O"<C>-XQ8)X<GF?3+>U54$^FVUJ&@5MH1MK232@G)RP<#.,U\>:#JG
MBZ[\$?%KXIV.N3^!+"'1_$)"R[Q<ZFNCQ7EG:Q6 N63$CK$%#H23G<,8P/J^
MW^*'A_QEI]YI6B1P:_<Z%X>2.UEB9 EU)'*^5N=Q!>1U'[UF'W3D *17F.J?
M%_P5XB^ -WJ__"&V5CJSW-]HTFA:HMO)ID&I)=7-C:NEDY41Q7LH#W,)WBX+
MLXSP% /RK^!/PM?XO>*_''[5VL^+M07P]\(_A9IGB"[T2_C"ZGXAUF;4&L+N
MU@A>X-RY47OVB)2KL$A8D< UY-XL^(^J^-Y(?A=X0_X2;5$M]5B.DZ3?:,;'
M1K72M0G:]OY4\2%6NKB>&2[;S(G(16 08!S7WK\*/$4_Q#^$7CBU\%>#=-TS
MXB?\);J'@U],MK**+P_>?V>;:5[6YTX,L<ULQ0.0K#YCM&,\>,ZMH%]_PM&Z
MT^'P_=:=XG\+_#WQ%K'C?PUH$L5C#X/U+3X#-9W]]&':"6SN8H//:"V)>>+"
ML5)S0!V/B:Z\3>'GT_QS\ KSQ'I?A3PQ\/=,\&_$>SOM!^P6/_"0:1:&TUZ?
M3;L.'U=6D:4QSNV.5? +FO@WXC6OPNT;X;_#_7?"USXKU/6_%_CK3=;\=V$^
M@OY][9V-Y>0WHM@)96V!9SEA\H4;MIR37VE\1OVCO"OPS_9%O-#_ +7O_$NO
M>.;&S.F7>D-/_9\^MZNMNEW%';1Q/L:T-P7E.Y=SH 22P%?,'A?P*OA#PAXD
MT+7?&VCW6O>"? FKZK<W^L+)<'3X+N*+4XX[0,\317RI.$61%P&&%.=U ')_
M'/XD:I=Z)X#\*>'_ (%/'X$U#4[Q-'U'5;2:SU"&\@CB:XN)/]"+/ \) 7]Y
MU4 '& ?/?$^KQ6>G_8+W4MEI::E;/%HP8&.+3U7;<0*" 60D;%<JN4 )5?NU
MS-IKGQEU!?"4_B'XB?V_X=:26[\+:;'%>K+9V]Y%)YD\TCJT<RO;QDQ9W#85
M&<@X=XMT[P;=Z?*+B2\?6HX)+>:07(&V1QO=\'J%8D*S YSVQ0!?TFRTNXU6
M77M#A:SO[VTEM[NT !BBM85&R<#@[Y,;I=P"D#@FO8_V3/!7A/6OB'XEU6?Q
M!+K7B>RFD.G:%=C%M'-%Y014(D8",,?FPA)Z+UKP_P #B\TY('MD^U"[L[FT
M%S.XN'D6UB9[:%F4D':/]:1\S<>Q'US\ O"UUX5T?0_B3J^GZ=I&I:GXCMK.
M]O=/LC:O)921EGD,C$DRY5 )!\N[@C!.0#]0?AQI-W-J-M$Z$.C%9$V\H^[]
MXF#R K<*.,"OV"^ >B316=@V"FWR3@*1QCK_ ./8R!Z''>OS@^$NBK=WEG=I
MYKI=;+B-SRTB39=)7;D.[*1N88SP>2,U^Q/P4T>&WTV$NI.R*-COSG@*3MZ=
M2,]/4'TH ^M/!Z-;VD2N-Q*X(Z8YD&<8XRH&?:O2$59(E)!4 DY/N%(..@R.
M<<C/'?GA=&7;$A X8%AZ %F*G /4@C(SR#CL<]I9$R1G<6/"8&3[]>IZCK^/
M3 H PM8L3*KE"0#R,J3E< G//M@XP217FM]:W$4A "XV[A@$\<#CT!Z9&<@9
MP:]JN(HW5"02,9R3R0=HY[\[L\$ <\<D'C-5M8RQ8("%C"D8&20PYP>HSP/;
MCIF@#QVZ$RMPX_B]N>HSZ =#UZ#!R0!EQO<>?D_=WJHSGGD9.>A/]?<<]S>6
ML>\@QX'/N1G R>AQ[9.2..^:::-&09@I&"2!R,%1T//7MW['O0!OZ#<$)T_A
M0'GD$YSDCMD=><<<=E]"L)M^>IP>@'&,#/IGY> /?. " /+=->>&0QJ0 3TP
M,@;L\\=<G('Y$8KNM-N9,-T(ZG@9/RJ>A!_A[=B<=!0!V*IYRL"" \9'(_A8
M$DX[C@ ?7O6!JNFH(5BC'W?W@)X .X'.>2#C@#\AG(K9@EE9U#, L:C'&<@>
MO?'R\\]>AZ58F#-\[C<5R0"N.,@9!QGC/1CP.HS@A:;6UW4NB>UO7J-.VC5X
MO1I?U_P#^<7_ (.&O^"='C?]N#]FOPK\0?@N([KXX_ W4;75="TK ^U:AX?T
MM;FZEM8 JO("]Q*D@*QN 8^^<'^/31OV_;WX;:%!X6_::^%GC3PK\4O!D=OH
M3SW&E7Y@O/[*5;0.?M$,,9!,4C;D!4KM*L<Y'^HU>6_V>:2XA55DF7$KGAI8
MW),EM*2IW1RJ,?*%8 G)((KY@^('[,/[+'Q3U9M4^)7[-/P2\8:GYRM-?ZYX
M*M+VYNS\P#W#R2AG?#G+$C>W.,LQ/T'#_$^9Y'B95:,^6+TVOMU^?Y;WL?+\
M2\)91G]*C3Q%%3C2ESZ;W=FU=?DT[-736M_\Y7_AZK\&)=QE\(^(]YR3)'I[
MB-\D@%0IV#Y<9VXYX/S$TS_AZ-\#)"/-\*^(]Q.3MT^;(SZY.#[D'G;CI@C_
M $-W_80_82ES%_PQY^SK'&OW53X<Z8JJN. !OXP#T_[ZZ5DWO_!/K]AAW#)^
MR'^SZ !@?\6\T[(R3@K^\)XQP<>]?<_\14SV-12A75K=$M/+^OQ/CY^$O#%1
M+FP%-W2NW)W?F_=T;N[JY_GL'_@J;\$ENG%YX:\0JMG\NE.EC*#E?N%P?X"<
M X('3IWMI_P5#^#>K!Y=6\->(9+I3FWAMM/,;&*/!CF8Q#YO+ R=^6;<<= :
M_P!"33_^">O["\IBBN/V.?V>)53:%,GP[T]V!S@_-Y@X[]#R>HY%=U8?\$\?
MV"H1S^QY^SXIW(XE7X>:6LPYP$20-Q$0,%>C* ,<UN_%W.ZMU6FWR:Q=EJ[I
MJUWK;T382\(^&HTXJC0Y6G>UW>Z:_NNVW=H_SG3_ ,%4?@[I<LK:9X>\3"6Z
M 2[CFT=GP#E<,7Y  + ,/F.>N<40_P#!4#X&6XVP^%O$R*?](G']DNT9GX^Z
MKY7!&,=LY YK_1^/_!/O]@=C)(?V./V>#(PV,P^'.DEF Y!/.2<DGKG&>1FH
M_P#A@+]@H1>2?V._V=_+0$C/PYTDYXQD\YP<$'+$=P1BN6?BCF\[M3<7KNXJ
MZ[;_ /#]#NJ>&F12ITX.BVHI1:OZ*[7+KY_GW_S@K_\ X*N_!^\$<\FD>(TD
M0^484T%%(@'R;0T6TYV $^XQU.:6'_@J?\'X4 M_#OB"6TD.%271@TBL>2P#
M XP/4YYRQR,U_HX']@#]@5&\Q?V,OV< ^"G/PUT<Y!.1Z#H,G*Y' !P*&_8#
M_8%9(XW_ &./V=%"G.$^'&E*.!D8(8'DGG))ZXYYKA_XB7G3J7E)M*UM.M][
MW[?\.$O##A_V<80HVLVW[VCNK-6Y-_/\#_.73_@J/\#XD5V\->*)W.#AM.D$
M2]!E8VX0Y.>.@&.],'_!4KX-QF80Z!XDA6\&VY8Z=G^TT;CRD QY)4 J%!PQ
M_P!VO]&J7]@S]@=HS&_[''[.10*PPOPVTE6;CA690'(.!G+XR!R>M<W/^PA^
MP7'"L:_L;_LXE80?)#?#G3LPD%A\N)=Q)'1B20>N2#7?#Q7SJ%HJ,9*RUE:Z
M:Z;ZIV,/^(5Y!*[:J0:VY9:-?.&GRZ=C_.V_X>??!(K#%'HGB)?LCK-';-I\
MF;$#[Q9Q][<  0R@ )QR2:4?\%3_ (.R:G)JD>D:U(QB%NUQ]@&R()D\JO7&
M[.YOF/"] #7^@/?_ +!W["AEN''['O[/6Z7"NZ_#S3R[JV[*.!)A@.JC'&?3
M %"W_8-_8-2'[*G['/[/*0%P[A?AQI49E) 4LYWY8' 4]^/4BMY^+F=VLJ=)
MWZ+T[]//OMH0_";AYMMNM]_W]/2W;7<_@#/_  5*^#Q39<Z'K,]E.[R7;+IW
MRSMO8IE,E<(<*,9R%#'DE:;'_P %0/@\Q>[ET/6WD0F.U@%E((A$S9#%1P!@
M+QVSC'&#_H0P?L,?L$O$(1^QG^S>D:A2L8^&VF",LC?,"IDR-S'>^2=SL_&.
M!:/["_[!ANX[S_AC?]G(/&-JPK\.=,%OCH"8_,^\!C!XY 8\\UE_Q%3.I*\:
MBIR:NT[64GJTKWTOHO*W0YZWA#PY6TE2;2TYFVFTN_NO5[WO\D?YZ3?\%2_@
MC;S*(_#6O&*7F]MS8/(CMDEF"G[RG&/F[< 5</\ P5,^!>H,#?>&?$-M:VRH
M+.VATQPIP1\Q5=K;R22 ."V3QD8_T'4_86_8+A,I'[&_[.C--)O>0_#?2S@>
M@ DX'&3CDG''7*S?L-_L$SW-K=O^QM^SKYEGM,:K\.=/*N4(^_'YF'+*,;>.
M3D#/-8OQ0SNSY:BYK.UDM[:=#J?A1PS]7A3:JODU2E+1^3?+HGJNOH?Y_=K_
M ,%,/V>=0F6QB\.^*6CU%UM[.[U+3YH+5;B3<JB.:1BA3=P&R3E?X>@^[M&U
ME->T;P[J=O9I+8WVC6FM:7;!B%O+>[0E=P&,A50,IP>3U/?]&_\ @Y9_9U_9
M7^$G_!.NP\8_"7]GWX7_  P\8Z-\3O >EIJGA'PO8:-<+I6M^(8A?1PRPGS)
M)2!LC=V=D$CX(& /RQ^"4MLWP4^%NJ7&IQV&ACX>Z-%!>ZA<1K=6#V\4KSR2
MW$S+YJ^4T>(P< 'Y06)K]5\.^.\9CU-X^K!*-V^9J-^JW=GL_P 4?C'BAX;8
M3"TL(LDPTHW<H3C).2G)<NNUU\4;7T;V/2+-9)Y9'M2ES(F6ETJ0_NX./,90
MV68(@(W9  R1R%!KQSXO?M _"3X(:'<:]XW\2+!-*&M$T31DAO[^.Z1@IBMK
M4RK*?,8A))57**2^,@5\I?%+]LWQ%XK\71_ ?]DSPI>_$KXIZY>C1[+7-(L)
M+FUEN;AEMY<IY2[?)D)@>6601F6%F#*K*!^W'[ 7_!N3>#5-%_:/_P""E6K:
MSXI\?W1MM7\)?!RQOVM--T#67DCGF/B^T)EM=4TK[-*ZBRA:+S9D4EB5W#3C
MKQ.CA8U<+@VW4=ESTFI7MNK]>7?OOJNF7 '@S5QM"E6SN/)A92C)T;-.=I<R
MYXMKE@]E)];M1EI?\B_V>/V.OV[O^"P_BNRL_!VB7O[.G[)>EWBRZGXNUB6Z
MLOM]D9P?MFDW=]#:3Z[>7,1D,=B;SR(W&S#;LU_:3^P#_P $N_V5_P#@G;X-
MTG0O@]X3T_Q5\4;<G4-;^,/BVRA%[X@OKQ?WLMK;WD=XML\9#1"UM[GS%&SR
MR.:^]/!GAOP_X6\,:/X(\'>%M!\*^"="@AATSP=X>T]=+\,PF*,1+<C3(BZ_
M;MJJ_G"3:&)&W(KO$TY64"9 T0R8;=U+P6SD -+;(I'E2S$!I'&3E5*8 (/\
MWY[Q#F>;UINKBJTJ5762M>U]&M-M-TC^I<CRK"Y!AX8+!8'#TJ%%*%+V;NG'
MEBN:;T;E=6UZ;62L<I-<7<T]W*][<VNHR#$EEK$2PO*N J_V:MPYDP(AB*.*
M-550<'&T#2LH;E?+:161F56*MD$8*K\QR<?,"S 8 .[&2<UH-910YDN1_:EU
M'\T%[J3&\N[,=0EO-)]R)E& I4D *,]#5J(KO4$Y+JK%LD[B3ECSTY!PJ\8)
M.!S7A1P^'H14H-U)3^*_Q7[M6TM_D>S)N3<FHIOI';Y?UN=MI<A6(K@D,I)^
M@(4<<=E'.<9K U-%^V/P22">O.XMV]#R,5J64ZX;!4#;C;@=01D^O7M]T]3R
M35>^1&<2 $MR?QR>@YZLPQ[8Y[U6G31=%V0CE'MM]QM!."N.V5!['CW''3T(
M(%=!9:*70$DD$8!"]3QP.2#P/7C &#VS@,2B1^,$ ],L<J"I&.[ XQZGCFNV
MTR0% HVCC&XXSGY1P>2,@=CD$DYZ4 90TF:/.T [1@[EYYY&!QG/<_3-498+
MB/)  /RX"K@9#<^I/'IU!/3OZ+;*IA/(;+,"2!U!. HQ@XSTZ$JN, 5FW=E$
M<$#=USMZ8&>..H7 )..F#DGJ <M#<R \D-P!@')&!\W\QTYY!P<8.G&+.:.1
M[QB+;9F\9#\\<+<EHSTR 0'S_%WZXIRV85F**PY)ZL,<8SP>YSGOC\JN6$3F
M6&)H5N+=W"S1'@,K'I(S' RQVC<?3.><@'YE_P#!37X0ZG\1/A;X+M+6\M-(
MMAX@N]0L+N&:)=1N-'C@CEMY)HQC(N%A=(W!VMS@YYKX,D^*VC> ]/\ A)I)
MM8-!T3QUH=SISZ[$L/\ I.MQ7 TVUCDW ))+>3QE02P??@8.2*]._;<^+O@7
M0_VJK'PWXYU[XCZ?XG\9Z/!X'\"Z";W4IOA_816$\["8Z;;63V'VI[:9UEN(
MI@<K&"V,UX5XL\/>%_#'PTO=*>6W\:ZS\)%F\6>'="U"&2]N)[BQ6;68[&S+
M K%<7%P"MJTI.-VUEVO@ &E?:3XRUC^U/A?X&CBT.Y-R?$5_XKM@D?\ :"23
MK>&.3Y2K[FA*LH?Y6DYQG R/&>E+\8=<\'^"(+Y;B;P/<VWC;QGII=8+R?4-
M!GV&YMRA$[VYB*"8-^Z!WD88R&M.Y^+4<W@'P]J-UH>I>!O&7Q$TYV\.V=Q<
MQ0/8ZI;6K:C=1:BX"V\EIMVQ1P9&UE$; ^:,?/O[,^H:AXQO/BIXL\9:HVA_
M$FYUD^#K!]-S:OJ%IJ-CYK+:B(,L<<C1J"F&B$[2L&W.=H!\O^'OAKJ'[8&C
M_%'3/BQ\3+C_ (1#PY\2/%.A:%X-LXK03Z;I6G>(9;.VW+#<Q7$@2"",AWC4
ME5QV#5:\+>*KCX5:)\?_ (#?#*:+2_!'PR\!:W%>>+M/@@U&_P!9U.W6TV/<
MP7&^2SNGCNG5=L[%O+<@8 ->O^/?A/JFM_M#?"CP_P# +P=XBT#P_:ZA<W?Q
M2BLK^WAN]0U>WMC<7%YK5U&JF6"]U%6FFMYFYCD9 RJA \]^*H\&VJ?MC>#+
MBW3POXVO8M1\21:AH\B6=G<-9:99V8M9(;8DW"2Y#2@DK++ER<XH ^5XO@+#
M?MX0D\6:W?>(+B&+3=?&H$RWEUY7B,13PH]E-<20016_1V12!@DC/*^8Z'?W
M7AKXS_%7P;X5M]-N#<:Y?67_  D7B2=(+72-+(3>NE_:X;A6D+IO18@N<D!E
MYW>\>!?CJ-+^&EU\3M1AL+_3]#T;POX3L+.VM6^WWETH_LZ_E,S(XPC[)(XR
M $)X*U\K?%SX'?$#QK\7/ OC_P +WUQH&CZE-;:BUG-?6S:??R33B:8:E;"4
M-=?(YCD7@KE@#F@#S3XG>)?AKJGQ!V:]87UY9VT;V5S=;9/LVM:I%!) MS:G
M<(62TN 9%:%1NW,&QA:P_"GAS1="FU5('\Z#Q#>3V=FV\,\=S)"98PX+$JP,
M((],KR#UV[:3PE\/)?%EO\6(8?&&M^'7NI_"FG:'$T$$$EZ9Y+IY#(LBRI:S
MO L8!)"/N8X*5YQX8\4Z;K?AC7=;\+QR:1XIM-7NO$FDZ?X@9+BS\V6*"%8V
M@^0/ 8XRRC/RR-(.F 0#]:_^"=OB7XE2?"14^(Z++:Z9XFN;?2[ICNF73HM7
ME00$LBR8-HHCR3\H7H!C'W#^TAX>M]=TOP1I?AY6\)2:KXA74BL4KJFN636[
M-;Q3@[<+-*NT8##<I&/7\Z/V*_BCJ+?#NQU_XG2VFEZ(6U1C:64D4$6LR0SS
MK(]E&I;RV5U\M40;@Q49RPKZXTSXVZ!\8?BQX4T#18-3OQ%ID.C^$X7=GCTT
MPMN6YO%EC"RRI'N57!W1GYLX H ^K/@M)I^J>)O$D'Q$^WZ=JM]I%OJ.@:!:
M1S-865QH-@EG9Q0N#'AM2FB%Q,5099U&#DFOF;7O%>O_ !D_:.\)?#3XSV=[
MX?\ "WP]U1/%OA:*-)1'J@N2UO8(\7^C(PN7CB1RQDZG*MD$^_ZG\2M.^'WB
M70OA9K.EMJDT>H6=I=>(8F27Q&-2U699+.V;5?G=+2-2R+:@[FPK$G(-<CXU
M\(ZA\2?VR=#TVQU$6</@#PAI6L:I<W/G3((;6*X"QW4Q"$^1)&LN$;<KH6"D
MJ<@#?CGXC^(/[,OQXTGXA0RIXJUG]H2YL?!.G_!@S1_9_"?A_5DBTR3Q6X4S
M&.73_L\%QLDMXT6.:8-( PS8T_PQX<\#Z%\2OA_>:EI0;QA+/J/B'XB16EI>
M7\TM\_F+X/2%D?S%TN:+9&D<RA!/N$:LQ+>2^!=$USQ[\0_CC^U)XZTWQ?X[
MU/X<RMX;^$FMQ:Q#::!:>%Y+>&35]:U#3+IEEOK;3]2TRT5VC7?Y:@(P\UL]
M^T)^*_P7U'P1X%N=#F\4>.]1776N9((UU*POC/;7>H7VG3O)%<0P7AB'V=$.
MY 77)CV@ 'PGK?A;5OVH9=&^!OPZ\#V/AO4?V:+U=4NKF37+S2)/'<.CW3ZT
M]U-:11P*XN[>9X2JI="/<$&2"*^?/'FO_MA_%)O&'PAT#1K/PU9Z1'91>(?#
M<4$:7<VC:-=&3S[/4$L([^]EOTC(12HR@8DYX'9?&#Q[XL^%7[4.D6'PKN-2
M\.>.[F-?!WC6;4[M+JUU.WNWC@NYK*VB"2+<)%M>WF)=B#R>,UW6OZQ\=?V=
M#=_&BTU"+XC?M&_&AT\+^'O#9VMHOAOPQX4D-Y-?ZEIEV0);O4=,D=6N("C/
M("S@@XH \:^)J6/B/X4?"SPC\./AYIOA#Q+X<M8]>^(MUX@N'MM5N(;&ZEM]
M3M8$OK8.Y=8VD01E6W2*V<-BO!-.\;VFI2>*;[X4Z.-#\."/3=/UA-14B?2]
M7LU^SZQJEL)@"!J5R'F1UVAE P>1BI\4+_QO\7_&/B+Q'XIU;5/#=[K?A^>)
MM%T*[;3#;B29DF3:C,IS<>:1L<$[,CC@<UI'BF[T30;'X>_8;&'2&4C6/$\M
ML);[4/LP 6*_ND4R37$(4AR0OSNP8DXH R;SPEX9MWGU*XDO7U'4O$*N+V$R
MA]5E>!G\@NK%1'(^'( 8G P,*2?M;]GCP'I/B>\E?Q/H@FU%HTM]/UU5/FV@
M6,QQ1.X4 _9W1UW$@]%P,5\8^)9#K&DVLVA6E_<"QU-+BTN+60PP6LJV\T8G
MB#C&" -X.2Q''0Y_4O\ 9$2\3X:H=0C#737+;I)55IU83$2!Y ,L6;<W7HP4
M< X /T"_9_\  USHPLM&O=6.JVUM<12P"8;S%_"%R&.<=..G SP*_9WX4^'8
M[?3;-U08P3G:>N .W3YASC ZXK\U/@?HRS7.D$0H'EDB#LJG)3J"3ZY/0=#Q
MTK]B?AMHZ1Z;9*R$@Q@Y.>N0.3T'/7C R<#GD [^R9[?9&JL0D8 QW.#GJ>X
M/.>G(QTKI+.\+$9  / Y'S$G.T# YP&/X8R#G$&HVB6^WRUP0N6([ X#<^F"
M>>N1UX)K%M99#,BAL?,2/?;N4@?4,2!^ Q@9 .MN9[?;$' \PN&P2.A88_+
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M3VVU074R0<,1R00&SS@'/!]^>/3GFKNN1$F7KEE)&#V#,?PR,=B>IP>:XO\
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MK0O?,&0[#'!&1@]"#VY_^M0!%<61=V(7<6;/L,G*X^N3QP><X&<%8-.E4D;
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M@J  >J0?"OPU\(?A[\;[3P_JOVKQ9H%U?ZYI!MV69WT<K8P6^2A)$0N/-C+
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MYK(U:>(XV@* &!/!)X&#VY!'I@@GIWQK34PA9 > W4$@G..,@XP ?3GK@9H
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M!4;@,'' QG.",\9/3&<GICN,*SU$)LS(2!@8R!D #.?KG)QTV@<]:UAJ"/M
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M_#_PLU#PMIGB3X3ZD_BJT\-OJ_Q"\2>)M(@GT(6H\16SOIVG1I=1O-#!97,
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M8/?DLP!&,XX!';&?>M"XN8RKX(!"XYZG(W \?W<''KGJ.V'+<KL;>=YW8SU
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M  )A>>N01P..I/';J1GS;5[2\M'PL85!D9! S@GG(/0#^?;I0!JQ7\@(V\9
M'8'/09X')P0,\<X!Z5-]MD]5'K]W(]?R^M<A;W+X&[J <C(R#D9Y/'((/_?0
M/-6/-<\X7DD\]>O?CKZT =+_ &@QXW#GCC&>?P'\_I4,]R2, C!(..#G<<>F
M0.< \X  !^\:PA*S G)')SDYZ8).0P]1ZFG;GQD-GTQGGMC.['/2@#4MXE+L
M=@ (ST;![MU)Y(( )QU! Z&NBMK>W*G*A0I()W,,#@@YW=,8S^@&#7&)?.I
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M/#5[I?B/QMX]70K/6-+\-67]ISV,VK>*;<EV>U^S26F^*Z?>I\P!0I+'YL$
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MTC1O!_Q+\%6R6GB^ZO/%&M:9#<:7:7>L64%S,1+:6%Q?7%R9+= D)"_O%Y-
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MC+\;XM0OM/MM&UIO!6EZ1YUG?^ _ TSBXU^]D>$22W#).D4\,D925(IE0$J
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M^F#T'84 ,M[DIA4/*A>1WP"<XZ'/S'..H&!FM W+R(P9B0R$8&%RK(Y[8/)
MR>HV\'FN7W/&5QN&XL& )^4+CK^.3COGN<5HVXN)MP"L<I(#DDY/E-WR3_%]
M5)]S0!#U6T)R3]D/4]]QR<=!DDGVSBOH7X8;?^$3MLR8/VJ[XP./G'M_GKUK
MP)+.X,5F2A)^Q]<D@\G.?H,\ <GO@9'NWPQBD7PI #CB\O/?_EH!ZC'TQ[T
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MIQCIZDT >H&ZB=.,@' ;)X"GGUP.V.".HP1US;_3;2^AP%!8@[>AY(!W$\<
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M.>O=>2!P,9 &<5H0VSSW "EN0 0.G(V[<8.-W4#.><Y!H HQ6)D(7U9<,<C
M <L ,9.0O.,GIP>AM)ISM&052+46,0L=';Y-2U.)C([36D<N(I(8(D>>0X#*
MBN=PX%=U8Z2J1B5EX12XS@%""%;)QD95S@CD\9XQ7XW_ /!<+]JGXK?LX? +
MX9_ O]F_6K32OVFOVS_'+_"'X;ZP]G!?:IX6M;-;74M8U6TFG62>R\_1'NX8
MY(#$8WC9UD#R T ?J!;R^']8U*]TGPKXK\.>--<TF(W&M:!X8O4O]7TC<GF/
M'?P&9EBDBC4F8#<%8.#C.*T+#35N+^PL%98KR[3=);S%0VFQ!#();]5RJ HH
M.Y05+<*"N#7\DW[;O_!-^T_X(W^&/V/OV[_@#\>_C'K'Q*OOC[\(_AW^T)8^
M)/B+XJ\1:'\1KOXD:G;ZEK,MII&H:E-96MNL32626RK,B)AEV-+(J_TA?\-[
M_".;]L_P?^QU<>%KS3_B'XS^"6G?'ZY\03)<Q07FB:WX3U3Q?<:*,08B.F:?
MI<J,D4@ "K@*'(H ^M;'21=V\DRXB\O ,3\2/G R!CGGY3Z$'M5N70I@MN]O
M;R7T4[&)IK1=Z6;X7+7+#[@53N;G!'(/7'P-\"/^"HG[,_Q[_9P^.G[4J&Z\
M(_L^_ C7K[PJ?$]])<6TOC5+9+NXO(]$\]8KC4M3,UG<0VT%@TES($S$A("5
MA?L%_P#!6W]GG]O?XB_$CX2>$/"GCKX6>/?AYX8LO%>G^"/&FC:_X8OO%?P_
MU.TN;KP]XGTLZW96$EU;ZUI5M+?6TZ1R&9#E'E4;B ?HPVAIB\6TE@O?LL+3
MXMF$C3JNT?NAP"P<E6YSGZ5F&SCGC1K;,ER^1-:)DS6("DLTZ_P8VN<>@Y/:
MOS%^#'_!9;]DS]I+]J75?V,OA58>--0^(/@#4;R+6]?TWP[K:Z1I<VFW1M[G
M2KC4HK%K6]WS;O-FEE96"OL *&OU2\3P:A8LJK8WFAW>I-''=7<5E/.S62-A
M[F=/+!@ @9I99"@91C(QT .(-U;)+()KF*TA1#(;VY;;:L  %4.0 -P(&#C+
M\ $$4Z&^8_;E2*=I;)K=?(C0F2\CO,&"XLUZF,AN'& R\D5^*O[8'_!>?]B[
M]C+XM^+OA$OAOQ;\;HO FG/;?$3QYH.@ZY?^&? >KR74,,_A;5)K2QN=,.JP
M/<+<K'<S17VZ41QH(RE?<G[2W[=/[.7[)G[*WA?]JGXT^+K^/X=?$/1?#.M>
M%OAYI6C7#?$/Q-+XJMK"Y\/VNB1VH.ORPK+J,$06W@9%B4,P"\4 ?:#WRA'=
M=\BP86\*#Y;61R542$<*<JP .1P23C!J%S+((TE,<#3*\D*3MM_<J-SW9P0/
M(B0,\C@X"\G%?C_XD_X*U>$=>_X)J?&_]N7PU\+O&7PZ7P -3\/^!/#WB;0M
M:M==O-;AM[.[M_$>O:/JEE!<26-S;R?8P+N#[/YQ"Y&XFOG;]F?_ (*-Z#^U
MM_P1N^+G[0G[36M>+?A;XDL[/Q5X/^-/Q"MO#VJZ'=FP\27>O:=X4E^'5O;P
M6KI-::#';1/=^&2"US&LCLS-NH _?O3;VTG>>XL;RWU.WLKW[/<S6,GVA;=5
M\HFX:1&=?L^9!\P)7&2&(!Q[)H]P6DFL<@8MVN8;W_ESN+6)4-U-$YQN6W!
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M2-<-A>>(]0T^&/5I(A<7K10NSH)&6(@J$WB0H0?E)( GQ@^(/Q!^+-A>^$/
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M?B7HP\SPS>:'+J&ERIJUNXBCF=7V;6FDM%D,<;'.&45\O_\ !53Q?X0\(?\
M!%C]C7X;_#-=)\=Z)\5?B#^S;X?\%>(O BF7P^+^^UG3=,\00-+B&5IFU6YF
M@O$FA$?F;HVD/%?NG=?L2_LX^+?V;+3]D#Q+\(HY/V>Y+;^R](\.?\)+/<26
M'AF"V58(9[[RW=)8I-NT2#><#!#$,'/^P)^RLOP<^$_[/VJ?#:YO?A)\&M=A
M\6_"#P[/XCN[J72M>TG5X]9M;VXN6_>[;76(Q-!!( AC 7D@,0#\'?\ @MYX
MQE_8J^$'_!+#]HJZ\)W#ZQ^R5X\M;+4M$TN!1)IVLW/@'5/![%528.((;G72
M=L"3@R*K!5 !/GNJ_ OXF_LN_P#! +]I3XB>)+S6;3]HG]LR]?Q9\8=0N3+)
MJ<G@_6(O$,NF)J7V5)KE=.LO"VI117!#!A$\<9;*.I_H[_:6_9K^#/[6_A6S
M\ ?M.?#Y?B#I%CJL6NQV,>IOI=O8M;2126EY<7,,3QLX>W1F,J$,Z-ZUZS>^
M!?"7BWP5JOPVUGPOI^K^!?&'AL> IO!NI21W-C%X1^P+H\K6^IW*31I+!8*I
MB:/RY%SO9&#1[0#^83_@D9^Q-<?%3QE^P_\ M,?'+]K_ ."/QIOOV6_@%\/=
M0_9R^!/P?UO4=0N?!%P=!NM)2\\9V=]86R6VIOIT[073173E9X]L@7;Y:?TW
M:A<WVIW4MS'=2W=^[O-J<FHF-9F0,WE0E4"C9&I"JJDD[?OG&3\Q_LG?\$U?
MV*?V)O$_CKQ)^RIX3O;'Q5J-A/;>)?$%YXUU#Q%IVE:58227,FAZ5IEY+)9V
MKZ<K2M]CLFA=!'YDKJ7*+V/PR_:"^#/[1_AK7?&7P$\:0>--$\,^(ETC6=<M
M5C7[5*C21WXDA68QQO!<13@6XER< [F"X8 ]@?4");<V[!K*(M'J4C8#1N45
MT,2X^52V%"D]LYQP+46I33HS6?ER/:;I;M'P'6WB9E:5<G/RC&TX(&?8USK#
M$>N:?99F6>STZY<C<QC:6=V+':"PP?E< ,> !WSXYX"_:!^$7Q3^(7Q1^%?P
MX\5V&I?$?X*W \,_$K0K:ZMY9[">XT^'5I#=(DQE@D2SN(G>*>))%&<;LXH
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M+#G.,'^(?7OR3R<4 6K:\>,@<'[P('499L<8[YP,_P!X=JZFQO/-X8KQMQ[
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MX4>#?%OC/QAXET_0M?\ '5II]Y-J6D:A>7\D UBVNY-BI8P(5F9Y-W24&0#
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M\N@:!K=^[VUBVG6%VUS:VVNL8B@2(31FW2#<PD>4CA@!]1?':YU3X.->>*=
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MSQ+F>ZU#5/!5I )5*:PUS,J>=*B-$%S$TA5E\0_9J_X.0_V@?V5[W3_V;O\
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MM_86_8>_9_\ ^">GP0T[X(? /1;#3=4:&R_X3CXG:A;V\>O>,;ZT0(L,NH1
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MF(VI!X-NP(YR/WC]>.<XQCKTP>,U[=\,8R/"EN%4,/MEYR,_\] /7KC&?\:
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M/MG[Q&#D8/3&3GB]8TJ2*0MLQRW/S#Y=Q.#C P.AZX&>1C->U^4D<#'@L!@
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M@AGQRO4<#'/(QUX(Y///%5+**1Y6+#@J,C/H0/0C[H.2,]>N3BN[TVV4O#D
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M21I]G(D=Q8$7Q8$#<]R1<3(LF0Q"D;=H/95/  JO;ZF-,*W]JBW$\ZN;^QD
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M+[PK\/M4\6RW.C--:WLL5Q:2Z/:VADLVE%N6B,@KX/UK]I#XV?LM>'O^"O\
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M:I?^"_#BQ3I]K^T6-U?3(VF,D3VDK RAG9L?$_[/GA#XK>"?^#:G]I3Q9<>
M_$5A\3/V@_#/Q;U\^'8],O/^$AM-(BU;Q1I+-J&F/Y5[:W!,0DMGNX4::.1&
MC)1@0 =]_P $O?VL?VV/AI_P22^-W[3?[1WPXU;Q7KOPZU^/XA> /$/B&R^T
M7/C#1?'GB?2X+C2;CS;AFN+'P_87T<]I;K"!:H[#(R,?>VD?\%5M5\9>/?\
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M!SUR<<C..>Y'ID9 .@ED5X9Y5BN+R:WC+P06_P"\4R'"XN027*$'/R$$?>R
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M9EFRN0,YR .<$<\8QG(P,,/KQ6]+8[2-JJ% ))W$,!].^0",9^A'4OMUAC8
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M'#Q /"\-SI>O:_I7P^^'UQXA95@T&TU&YM=,FGLS,!YZ:9);OL,,@,\87T(
M/'K;XG:!)X8B\,PWD7C'2+R\@OKWP_X#2?1-#M[M(2H>:QU!)7.,L"&*_*<;
MJR[UO"6A6>D3Z>UWHVH:?_:-W>:-%<0R(MM<9ELX+I+=2&;R_P!T2RC!')4X
M)YB2RNK.5_',$D/BBWO-!GN->\*V,,%I96UP+G8?LUQID$4SDQ!E R -QX->
M5:_IT>FQWWQ#\!:#>Z1'XOM'M;OP[=3W]Y81'2X?])N9)[]IY+:5C)^[6)E6
M1A@[0,  R/V1[OPMK'Q8_:"\2ZCX!URW^(0&L3?"FZLM0TVWMKOQBLJ#2W6
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M_P#9U_:;U#36DN-<TJTMHO"OQ#U&,O.ME>I<21Z9ITTTH599M.@26(/@\ D
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M?]E+X7(FMV_@JPMK77/$#@$WNM2[KJ=PX5-S227L\A8DDE6.> ![%>WD]K%
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M202"3D=0W09'!/08Y) '% &K8*LF 5(8?,0>Z\8.?4 X'3C(XSQU<<)V \@
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MX(XY!&" 1P,'\:W8;98V*R@(QY =N2.,$YZ]^.PR,?,30!A'3F;:SDD$XR5
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MGT[PLD<MOO.<B!0%;!P <E1G')P2   /Z&?@9K*SV<) ";TC?:,84LJ,RC&
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M^G?^7'8^Y+/LBCN.>@P.3UQG'' /- N >=[?B$'XCC!'(YZ9(]13O/4$%G)
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MC*\<$B*"O7:<XSFOZ!?V8O&FC^(-"\.7VFW,,31V\$-Q8LZB6-D5<DH#N&[
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M5U7P)JUM&^R2UT_PY]H2SM(VAQ'"AB,<2!%#2*@%?Z>_[9'_  3P_9%_;PT
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MP,'!(;@$]LGCDX (SR* /'([.:)F.P'(QCH1C'.?]K .,= ,\BI?)F_YY_\
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MXQFDM= L[C3H6<JDAB^5T."7W%CP48#K@$>N20#VJYUG2-/5FUC68+-XU+!
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M],<]2 <GC.../0KF6-SA>"01T^4$E@,XS@#<5 /7KT S1.F_:, QY!P=V[(
MSGH1SGIT.<]Z /'WTZZ!#8;[F>_'^U@ =NG;.3C()-W3XI8V=9"1CL>.,%<
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MU501\^1\QS@X'KD'KTYQG-<S<WX+2$2':<X W'C;S\IX _\ U< Y !5ELS*
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M .?F( QR%.">:TK4)/"-Q$\%_K?@F^B;<);F[U6WG@D!&]7C:=HMQ88V ,O
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M/O-G#''1N0,\#N,=*_)&3_@L-\/\.FE_"S6+QW'#7E@51,  '(N#QP.@XR<
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M'4@Y]NO%;\=Y&@ !V\Y&.<\ '@8QG@C/.=P(&: .P68 *WRX4?=SGJ/XAZ@
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MHZFFK:C9R::+:>\E;4--T^.TO"SW?V.WE-JN[(<H1 J]#O6'Q1@D\?O\5O\
MA&]'GN?#EF/ SZ/K,4JMK,.GL5@$-K@K+.SO&2B1><ZL6.2"#+\/_!?Q>\6_
M%7Q[\0OC7X6L?!7A+P[XG\.ZEX*&MI<6*^(+=K*#4?L\#(0L\"2R);0+(..5
M*]FJ-&K;WN5?-_J<=3$JG55.2LFTN;5I7ZM]$OZ9Y%\8_@K_ &/J7PXTKXL6
MQ\77?Q&UW4/%%IX*\/1'0[B^TG4[&34]/L[IH5D(2V"1,=\1$I0XVYKE/'6G
M0:5\*OAC;6I?5D\>>.M)NM4\$_,M_8>'M.N[G3]0T^[O@&P&CDCB7S(E!0(V
M,DY])_:$UKQ)XSNO'?[7FN?$C2?",/P\@B\%> =,M;YUGTJ?3;V&QCELXI4:
M%9&L[PPLJJ[$A$Y&2OD7C[3/A]H/PKT?Q9KOQ$^*C?%3P]K.FZG?Z=H\6FFQ
MURTFS?O$D31>;&9T:V!6)(U<J>A!8Q.G5BG)*+23?5[+R9TPG2FTO:)WZ1WU
MZZZ:=?P/"_&6D6VD7UUXMT32;+X?^#/[=OM$TSP^;FWN7U.]T>;S;Y9UB6'>
MCV^T,)%;D@ = /,I_B#>Z]XH\4:O>:(;?PE+8746EPPZ.SVYN!;[%E\R% F^
M0HV2Q.X@D9'S#U+X._ '4/C@WC_XP>.O%>IZ=X*\'.?$&D_#_7I#%=6<VJSM
MYVIW%E&%4#4$1=K#(D:1@2<'-/XG_M4V.F>![OX=_#WX6^'S;6TAT*[U"UM)
M#?/JDOF1VKB0D/YI4@J@"A\Y  VXPI5E.7+.,EKO%?YW-ZE)QUBU)6OND_S/
M&(3X<^)NF3Q6MM<:6FCW$6S3X[66!+J>,@SR6Z(%60OMV_+N)SWZCZ0^ U]K
MMK\4+.VM;"#2_#UO9B*Z=V6.Y;$JMEHV EWNH+?3^\,@^$>"-3DO;*/6M4NV
M\-7TBPVNBZ1=>1;;=2C %[/Y2JI+,^W8W..< =:Y_P"('B3XD^&/'/A2T\'W
M,FH>(M8:#^V=1MRS+:VS2% )2A\N/Y<$EE&5(^@[_J>)LY>RGR/6,K-77]=C
M@6+P[G*FZL(SB[.+G&[?=:[=/4_IP^!.OF/4[<A9%A,D(1F! V$'9EN &9<'
M)./6OV,^&NJ"XTZV?( $9R^?0*, \X[Y(SG!R *_G)_9)\2_$*TN](TWXB33
M7"2P6;Y=L[E:%=A4D*5)R#D<XQ@\@5^^?PIO(+G38XK5@D,,2R*A<_,"B=QR
M0.3@\<YR3BL73E%/FTDMU^1T)IJZ=T^I])SW#!,8!/#9]=QRO3T'3)R!R2O0
MYAU"2)UQC !&02>0#TR<], ]^OJ#4\7SV@*CYBB@YSQNYRISR22.,XZ#H*SY
MK-A$I,3%C*Y4YZ\YW ]LCD8..XSBH&=19ZOE>7P#G W8(SGKGTY/ Z@?2M>+
M5@^"6SC. 3G.0>#_ %Z]",C(%><I RE3AF4$<Y;G&#G:< _E@XXQ6M"O )+8
M[89LDGD=\\J1Z<\= , '73ZF,@@+QD=><\=.?EZ8'ICWK!N+\EG.,$Y P" 3
MDCU'/!SU)Q@8ZTD:XX&2Q !R3CCMD^F0.Y)(SR:JSPLS8VDG=SUQR<KR!Z,0
M1[_0T 26]X_GH "0SKDD$=",CC)X.1SG@#C.<]_97!3*D !2 "3V 52?Q&.W
M0]3]T\;9V3,Z=!@@CT W#H2.I)!'L>, XKJE&WD'#$DD]02<9XXXX_ XH WE
M,4_WL*Q&<#H>!VZ@8QP&YYS@\5C:C8JZG:ISG&<YR .2  ,D$YP>" <XI89
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MM;MF&#YD=Y%:94Y)R% #$<\8Q[AIF1."I;!<84$JH[D!?3'],9[:>K,<)@D
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MB@&38@7>I&0,^N,9Y/WA7&2X1U;L[#'<@;=O7\!WR#R>:W]-F+;EQPJ1DX)
M* +SC/4C'!YY- '>VDZA%#@-)@$-Z$CY3@_G@\#:#QDBM,?OHF+')((48SE2
M%.T$^P()P<GD<#%8-N-W(X'EJV1P0-C\CW&:U[=BJ!03NPPR<D=0"W/?(Z>_
MIF@#+N].20@\D@>G.0<$#'IR/09&#TJ!=/2-5//R@$\\9ZD'KSQZGU&:V)F9
M6  '(X/IP<GWY/(/4A<GFLBY?:'"NPR,KCU)(XZ\8 4$=CCH10!)NV!0N>^#
MNP<Y.X< @XYSVY&.U-:1?+8L,?,23D'G&3GZG)SCG[IQGC):YV"12_&!@]P"
M V5/3GD\=,#L *J-."B@-N!0%L,22Q YXYYSS_#@=P * 'W-V48JI#8)#=0,
M\Y)SCG\<=?50(TOFW-\RY^4@Y(!/IC/8<\9Z8/)%4+L^9" N3\_)S@MDE3SD
MYY[^F,^M8Z;E<8+<')!8@$<8)Y/9EW=L9H [RVNF=1N*[OX1C/(8@X]\%2!W
MZ8-=G8N&VNI1B2P4,>!A=VYC_>)8[??(YX(\WTQU"*Q/1L9SGCYA@<\G.#@<
MXQ@<5U<-RNPJ2'8* 5W;0<,#G@\!>N<9SD'& *.5R]U.UWKZ=1/1-]D=9#+)
M$?[.M'1I)I#>0W]RP1[>Y('G19;&(=O$?JPQW-?G!_P41MI]5\-Z9/XX\3V?
MAWX)^#(Y=:\4:5#JD=KK?Q!\4V0-YH.B+:+*FH3:5J&V>SOB;>XMRP3E8@#7
MWS?7EI+'J GE%WYFD0)8W08A8;^&X++9Y5@=_P!WIEF& <=*_,C]O;Q3\#K>
MZT-?$G@"X^/_ ,>[SPOKWAW0?A5;PRZH= .K0Q6T'BB;1X'CD1-*PLS73K(;
M=)MR#. /:X:2H9[@W4Y9Q]K3T=OYU=;VVV_4^;XKYZF0XQPNI0I5>5QWOR-:
M_+M^&Z_ ^?4;KQG-KWQ*\.>%-&\-^"-1U*[T&Z\*Z;#9Q7%AI=NR'2S]NA10
MLC3S#<[K@9XY(KBM&OM?^'OC3Q+XDUZ]@T[2=(\-ZK"-"N[M+QM0O+FW,NGK
M'>R,JS"6)D4IM(R  IP .FGC\164-_\ #RWTW3?!>J7LZR:_H3>;!(CP2M<2
MHUM,2Z,SH%.5!"J/3%<!\59O"7Q(\.^*YU&G)+X*O=.TV%A<2LD^L0V$9B$C
MJXWAY%*;6[DKT&#_ ')A8S^H8*5'2$J,)226B>B>UKZ6WN?PCBZD5F.-=?WI
MJI42YF^\K;^?0\1^''Q:UG3O$OQF\<Z'X+2VTG7_  S8Z?-HLML#9WNI/=RH
MUS&Q1;:20R2>:H52^2!P2*Q]2O/$'[._[/-SXY\2ZN^JZ_XUU@^,-'\.7\,D
MITB^@%Q#I^F06TC;HK5P@9UB54VN2HW%J]+\(:SXC\ >%_"_PO\ &>D6#:YX
MUU-M7T7%L6E-A*JZE 7!4MY<:PG8RC:@!&2&^7C_ (^KI?Q(\375YX]\5^&=
M \/^!8HKW1M,N+EH)-2N;&&.6.%8F CD#AV5XMRA64#:223VR5-.W*]HW]>5
M7Z]'?U.&G)R;OMS=VFTY7M?IIHOR/-9-7^+/A[X9>%[O[79:YXV^.3:OJFNG
M5X1!!X7T2XMAJNAP:4MX=Q>TBN,6J1E7&T#:&(SXE\*?!UIX'UB#6O&WQ"O[
MWQ,LTD5KI%U97<$D,[GS/)FCN9&((8;5PBJRC( 7IZU\5==U34O$7@2\NO%V
MD:E8_P!DB7PQX>ENI%M]*^R::)+6\"6ZJT<9V6KQN2P$<)&T#(/S)<CQ9KG]
MK?%SXD^-);C41XUM(X;G3YE6RUJ-;&9D>P0Q*#" A0!5Y< '^]7)B=*;E"]-
MJ_P[NW5WZOR.VC24YJ#BK.SOUTV^_P OT.4\;>)]0^*/Q:?1;W5I+$6374C2
MV&G2S)-#8I)*D5P\.8DDE4;<O_>!ZC%<'XON-?L?MYU[5Y;/0=;$FA>&ULTE
M:ZL85&]9'"OO@.1("&4*&(R.QZKP4+J?Q-J%UHVJ7^A6^KW=W--)(L:RW$D"
M.^XR.ID*3%PK(N!LYY!P<O6M0L+*\UBZUZYCOI/[1DX7;($98\!E0_(K,<L=
MJC)]B ?!K2>*@XSG;2R=E]SO>Q]'AZ"PTHU*=-*3DN]EOJK=?)JWZ8NCQ+:Z
M*;2%%F2Q@>"^U*1P;Y_.0>5(6R7;=MD,FX':-O'3'[*_L(^'8[/X5W3V]U#<
MR7%P"EO%(DLA62VCPVQ"[DY8*>,9SW!-?C!H6M:7J^LZH^GVY6)Q;6\D90NA
MAF7RW)1<Y=L#;U(&2OI7] G[)/@SPOHG@GPA/X0MCIVK7MO"\\Y,B!F=,EF1
MB5YZ ;>!QSDA?QGCC#86#JM\CE%6NK7=^9??LW8_<N \3C.6E#WG3E+JGI\*
M6W2]UZ>A^@/PA\(W5Y,$L64:VT<D^G6&3 KM&K,US<7;';$EN1O:+:JSA!&P
M&2:^0;_7/C?K?[2&O^*9M5@\<Z1\.4N=,UJ7^SUT+PWHNFV4K".S6">26SUZ
M^AE:,".U,<VX!Q'MSC]*_@[ISP1M<2VSW=U!-&NH$)_K+:3;]K5B.?+>&3 V
MXSG/')'U)\1/@_X*D^"WB.Q\,>#M!T_0[9[SXCZC/?H]N+W5KJW,!A%S&1*[
M!@LB!I&3#,I0FOP[!8-U\:XQ;4?:JR5K.\[6/WK&UWA<"JG*ZCA2<DEO=1O[
MU^ENUM;WN?SY?'#]H[XP7WP U?Q;H6M:=J_B"?XC:#I_A*2]\(SO>MX*CO9(
M/%6LW%K,TDUL/#C+Y=K*RG[1'&98=L> >=\5:WH7BGP5\//@W)<0)X4^)=Y!
MK_C77/#=_#H=SJFN7,*:I<W5QY#M-%>W=[;1M=I,TK[)!D*<UE?$'XD>(/%?
MB33K76M3TGX8P:AI?B3PYIX@D:TL]3CFNI; 21*\;HB^1$@8@(Y<;@VZ0FO,
M_!WP)L-/T[3[G4O'WA%M2\"Z]>Z[8V%UJ<V;QYD%L@$9?(>?:K!1\H,F!]X"
MOZ?X%X'P*5#%U://.?)+WHT[?#%_RWW_ .'/Y3X^\0,9)XG"TJDJ*AS0<>>:
M;M*6J2EVT]=CT3]H#0'2#5-1U33;>6>[\'W_ (=\)+:ZE;WEY9Z_<6OEZ'-Y
M:AIO*V0*9[DA6,DJYVD9'.:_?^%/ ?@SX&:/\2K";Q#+!IT4U[#]M^T1S:Q)
M9J+JVDF?<K&"5 6C/SH6Z8(-4? >@:9XF^+6A:EXJ\616MY_86LWC>'GN#Y*
M?9+N%(9DAEW( T<0",<L48XQD"O(/B7XR\):WXMG^#WAZ:\\6^+8M<OM5T*V
MTU1=M92WT21W4K.05$-DD"/,=T8BA3<N2"#^USRS"T*,Z=.,8-Q25K1Z;626
MM]6?AM/-L5BY2G4<IN[<G[SLD[+5W>RU;T^5CR/PCI$-[\>OBKX^T[PG::9;
M6TSVVAVU[>6MJMPDUC ]NL(FCC\TDX4&/=CN000>9E\.7'Q(MGU#4)X?"MUJ
M&N:A;W&H6-RLSP1Z7,L\0'V9HV4. /D8Y(&.IX[S4/"V@^#_ (EZ'_PF?CBV
M\66VC:9=>)-0M_#=U]JT"WN-/<3_ -E>(&&9HY1S$\*,N2&V';M-><:K>Z[X
M;UG4OB%=> 8]"^&7B>]NX?"-I;07B>&M5U9V4N]K+,QN'E=9H96$9PRNW&5K
MCA".%I\JBFVM6VUK:^G*UOK^(KRQ%53=27NV2BE&W+YWN[K3K;[S@]7^&?B;
MQYI_B:]T3Q#+I1\%Z[#:IKTTS6MUJD<=HDI8HTB3-%A@P9G=1GEL9%<!\*HM
M=TO3[Z?Q5K^G_8;F_O[?4;60V]P[1+,5%P)(K@_/=)\S@JSEF7YAR#](^(O
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M5R+5V.-S<'@@EL@=/[W'<=.#DT <]JFGE""L8 4\\GC //0$=!T!Z#IUINF
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MZ\NUE!BA93#$XF\PD=2 3@=<L GM93=X@*.%B*@#*[CN)W9)SD9((]L"O/\
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M#R&X Z8R?H;X]?"R7XE_LU^-_#D6H:IHT^E^'V6W.ARW,US?-;HP\AXK5XY
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MD')R!AL\9Y!QS6%>(PW@+UW*/8X7'_H.?3;@YS@592[9%PO&<D\'D].06XX
MK/NI]Y;!'4]SU).#W/&22?0$'@C !35D/R$\L01SST4@9Z@]QU';C.:G6 MR
MH;&,@ECSTP,=1D9/0\8X.>&PK&7'4GH-V.#@==NTD8Z'.!CT-;,,:[/O;1Z
MCT[$@^O/JW(P#R 9!MR,%B5!YP22>,9'. 3STX!SWZT/#'Y;A<$E6P0O 'ER
MC.3W!'/8<=B:V94C Y)/!(Y&%'?'&>X &<G  (Y-49" L@4#!0XSG(_=R]2"
M#S@'U'3M0!B6\$BK9]#_ *'V/^US@=<].N/3/%>^?#&-_P#A%8/E)_TR][Y_
MY:CO_GVXKP^'I:>UEGO_ 'B/7T]*]Z^&;%?"EMCG-W>GG_KL1_("@#YQ1RI
M:+ 8\EN,+P#@@@X R>/4UHQM"ZKC:,E!@ $YR"P[X&.H'JV1WK4U#364<)@X
M^]D<$;B"._0*< ?UQA0V<IN%!8+\YYY/.?3GUR,#('4]<@&W9J'E*^7P1C(7
M<0-PP"#D#Y>H'.,9SQCK['3HWZY4'H-I'  '7 ^ASSR>?FYR=.LMI#$="/FY
M/<'MUQDD'.2.20>#UD$JCA>"#@YZ9P!@]R#SSU'&0!0!M6EK%&L9 1OE4[2
M2 2.2!R..>OTJGK$<8B9UP6 W+&, YP6!QP3MSP&Y ' '6D^TB-03G*]LG(
M[$9QT&!@'(P3MSFJ5U/YT3;P<,05(&2023CV(7@CIU!P,9 /-[B^F@E9/+8
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MDD 9 4<-@9P3GKGC/(YKSN> K*&/!^;M@@9^8#C'0$+@_=YX[@$T;E> I;/
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M[)QP>6?KT)[84XZG%932G!7&54D8/J,@D_-G)SR>I)SZ5V-[I4J(QVC\AD\
M=<>ASU'!_"L!=-D>4CY>,YSCJ2<< >^1D9P<#T#$9KQER=O\0VG &<XQP.@X
M*\ 8].:VM/TOS SLYSYK DJIX4%@.G; YZD8!Z8K1M=/"@%T'7U!/4DD9Z]N
MX.#] >CMH8XHV?9]V1NP/&, @>I)P,9&2<D8% '/W&F&$ B1CV' XR1G&.W
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M%U&?PQ;2^)=5T_7]>CF;35;3; -.\$WEM))((\0XVNP& /I+P=XQTGXA^ /
M7Q.\(O+J'A'X@^%M%\=V-W-!):W=GX2\26BWVB7]Q9O^^@GND.)+:?#Q#<64
M'85_,S_@L-^T/\'_ -G3]A?PE\=_$OP%\&?'KPCXX^)OPSL8/ .NZ-!J>GW6
ML^++-[[3]=CM9YXD*:89 CW#2KAF& =PS<_;N_X*!ZU^PG_P3J^#'[5?A7X3
M:3+_ ,)/X"\"WVI> -+M+:VT;2?#.L6UE%IVA01&Z,,*Z?#=%(XTD*1*%1 H
M0@ 'ZB;DFN)8XG<PD 6UR\4BVU]<,NY4@F(V/:@'8\@;(=-N\9P:EJB3W:P
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M[@DL!&0-QR1N*G)7H2& )P1^9'_!0#X._"_7_A]K?C?QGIVA:!JFA:9<V_\
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M^@?AC;AO"EN2W2\O!TSC]Z#S@CU]*^?K0_)99/6T;&?8C'7T.<>AS[U]%?#
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MB09;)4X)RPPN2,\GZ<51O]+C87,D<:%[B>YN91(OF1O<R#+;K>3,91W8A0H
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MDRR>8')7DJ"<8/0K@#&<?*2. :5IQ_>4YJ$UIJ]7Z:?(.6,O<J.\):NW2_\
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M,9&4$_*NT9R":_67X-^!F^'$&K:%I5G96^DQ^9!!%#8P1S#]T(D N(45VR%
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MM+;=X*PC[W5!NXRH_ Y-?S,_\% GMM)_X..O^"5YU'[((88]:8Z*;T&6<O\
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MM/GNGN(PMR(HS)Y,2[CMPH!^.7_!4K]H/X'?'W_@NS_P2ETCX,>-?"WQ"O?
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M#$$Y:/&.<]0 #R?PZGC'O7,3X+2,.GFDCT/S;?ZDCW - $D!^8' R4+ GJ,
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ME**0.F0K!><Y"[=BGL=H!R,[C7>"Q8D 1=3CJ#U]L5>BL(\ R!5!S\IS@#'
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MC!_+=BB1 &10#DX].&QC'H<<_4^U,N%&%SU;<IQT ()P,Y]@,YX ]\TFUL[
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MSC%6+9]HPI 7?N"#B%L.9 QC^ZTB[@L;/N"[.!QBLQ2\G*$%C_#CH%PO7/7
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M9&2<$8SU//7@ #H-*NLG;D JQ  ZJ?E&" >0,D'@9ZC% 'K$<Z&+<S;B4"C
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M$!< '.3QG)8_= ). ,_J #SF^TR0.Q '0'!SV&?P'7!_ETKD+FT<8&,'YOF
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M9UDBB<3 %Q+&DB.%)PI5QRC-M++G:V , G->LQOP-Q49 ()!ZMDMC!'<^_&
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MD<<US2_F?S;?YL$[/2*CYK?\V: CVJI!R. N1SD9)R23WST[8P>.87X8D\@
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MP,E 3PO4*,=N!P.!@>W)R44 49?O8P#F1 <@'C:.V,#\ ,=L5@ZD +@8XQO
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M *U2(" <C!)SUSV _I110 [ SG R>IQR<<#]*0J",')'IDX'T _/ZX/8444
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M&,59A'RK_P!<T_4MG\\#/T%%% %>106Y&>9.O/1@.,YQ[D=3R<FF;0.@ [C
MQ@^HQWX%%% #L K(QY89P>_" CI@<5!-CODC:^1DX.,=LXS@GG_ 444 5)K<
M2*N% !;'!_NEL#KQR"<XQ@D=>M$6*,0" ,N 1^:\>G.!QT '. *** .FL='A
M+(2%PZ@@ 'MCGKU&3VK>AT:)BQPIQ'(I!&!DQEB.".N!@]L8SR<E% $QA%M;
H68'7[*Q(!(!RKGL?49/N!UP#7IGPY9CX8@.3S=WO<_\ /<T44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>forms-1_011.jpg
<TEXT>
begin 644 forms-1_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )@!$P# 2(  A$! Q$!_\0
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M /DF@#ZKHKY4_P"&X/V3?^B]?#;_ ,*C2_\ Y)H_X;@_9-_Z+U\-O_"HTO\
M^2: /JNBOE3_ (;@_9-_Z+U\-O\ PJ-+_P#DFC_AN#]DW_HO7PV_\*C2_P#Y
M)H ^JZ*^5/\ AN#]DW_HO7PV_P#"HTO_ .2:/^&X/V3?^B]?#;_PJ-+_ /DF
M@#ZKHKY4_P"&X/V3?^B]?#;_ ,*C2_\ Y)H_X;@_9-_Z+U\-O_"HTO\ ^2:
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M (;@_9-_Z+U\-O\ PJ-+_P#DFC_AN#]DW_HO7PV_\*C2_P#Y)H ^JZ*^5/\
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M ,*C2_\ Y)H_X;@_9-_Z+U\-O_"HTO\ ^2: /JNBOE3_ (;@_9-_Z+U\-O\
MPJ-+_P#DFC_AN#]DW_HO7PV_\*C2_P#Y)H ^JZ*^5/\ AN#]DW_HO7PV_P#"
MHTO_ .2:/^&X/V3?^B]?#;_PJ-+_ /DF@#ZKHKY4_P"&X/V3?^B]?#;_ ,*C
M2_\ Y)H_X;@_9-_Z+U\-O_"HTO\ ^2: /JNBOE3_ (;@_9-_Z+U\-O\ PJ-+
M_P#DFC_AN#]DW_HO7PV_\*C2_P#Y)H ^JZ*^5/\ AN#]DW_HO7PV_P#"HTO_
M .2:/^&X/V3?^B]?#;_PJ-+_ /DF@#ZKHKY4_P"&X/V3?^B]?#;_ ,*C2_\
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M /DF@#ZKHKY4_P"&X/V3?^B]?#;_ ,*C2_\ Y)H_X;@_9-_Z+U\-O_"HTO\
M^2: /JNBOE3_ (;@_9-_Z+U\-O\ PJ-+_P#DFC_AN#]DW_HO7PV_\*C2_P#Y
M)H ^JZ*^5/\ AN#]DW_HO7PV_P#"HTO_ .2:/^&X/V3?^B]?#;_PJ-+_ /DF
M@#ZKHKY4_P"&X/V3?^B]?#;_ ,*C2_\ Y)H_X;@_9-_Z+U\-O_"HTO\ ^2:
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M_P!_/_L: +_VW6/^?S4?_ FX_P#CE'VW6/\ G\U'_P ";C_XY5#?[R?]_/\
M[&C?[R?]_/\ [&@"_P#;=8_Y_-1_\";C_P".4?;=8_Y_-1_\";C_ ..50W^\
MG_?S_P"QHW^\G_?S_P"QH O_ &W6/^?S4?\ P)N/_CE'VW6/^?S4?_ FX_\
MCE4-_O)_W\_^QHW^\G_?S_[&@"_]MUC_ )_-1_\  FX_^.4?;=8_Y_-1_P#
MFX_^.50W^\G_ '\_^QHW^\G_ '\_^QH O_;=8_Y_-1_\";C_ ..4?;=8_P"?
MS4?_  )N/_CE4-_O)_W\_P#L:-_O)_W\_P#L: +_ -MUC_G\U'_P)N/_ (Y1
M]MUC_G\U'_P)N/\ XY5#?[R?]_/_ +&C?[R?]_/_ +&@"_\ ;=8_Y_-1_P#
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M ..50W^\G_?S_P"QI=Q !/F@-]T[^#@_-_#^ QT/6@"]]MUC_G\U'_P)N/\
MXY1]MUC_ )_-1_\  FX_^.5!%#+,3LW@*I8[I1DX&>. 1^1STS4!?!()DR"1
M_K/3_@- %[[;K'_/YJ/_ ($W'_QRC[;K'_/YJ/\ X$W'_P <JCO&,[I/IO\
MSYV]OZ_7";_>3_OY_P#8T 7_ +;K'_/YJ/\ X$W'_P <H^VZQ_S^:C_X$W'_
M ,<JAO\ >3_OY_\ 8T;_ 'D_[^?_ &- %_[;K'_/YJ/_ ($W'_QRC[;K'_/Y
MJ/\ X$W'_P <JAO]Y/\ OY_]C1O]Y/\ OY_]C0!?^VZQ_P _FH_^!-Q_\<H^
MVZQ_S^:C_P"!-Q_\<JAO]Y/^_G_V-&_WD_[^?_8T 7_MNL?\_FH_^!-Q_P#'
M*/MNL?\ /YJ/_@3<?_'*H;_>3_OY_P#8T;_>3_OY_P#8T 7_ +;K'_/YJ/\
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M*/MNL?\ /YJ/_@3<?_'*H;_>3_OY_P#8T;_>3_OY_P#8T 7_ +;K'_/YJ/\
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M*/MNL?\ /YJ/_@3<?_'*H;_>3_OY_P#8T;_>3_OY_P#8T 7_ +;K'_/YJ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?H!_P $J_\ E(U^QE_V7[P'_P"G&O\ ;FT[_CTT
M_P#Z\[;_ -$FO\1G_@E7_P I&OV,O^R_> __ $XU_MS:=_QZ:?\ ]>=M_P"B
M30!I4444 %%%% '\0?\ P>B_\FX? G_LHVG?^D&M5_G#2??;ZU_H\_\ !Z+_
M ,FX? G_ +*-IW_I!K5?YPTGWV^M #**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** )8HS(Q 4MM4N0,9VKU."1GZ#)]C4T%I),48(Q
MCDE2%=HW.[R,%58XP2\C$D#"@\D=3P6VBDRA@<>6#*020&5"-R''.&!P?;(P
M:_5#_@C]\!O#/QY_;4^&UOXRLXM2\*^%=<LM?U[0;B-9;:_M5GV1V\L;KM,7
MFXR"#R%.WY<$ ]0_8[_X(1?\% OVQM"D\5>"_A/J/@SP8\MJMEXL\963P6NJ
M07,1E6^TP1R+<&U12N6,:,-P8Y(4-H?M<_\ !"#_ (*!_L<Z-?>,_$OPRF^(
MW@?2;5KK5O$OABS>ZT_3X(HGDN7G6>4SA;=4D,FT$[%8JI( K_3,^&OQ)\-:
M%I,&B^'--L_!WA71[6QT[0=,L)$BAN+3[*L5Q++&J(%:)XXR,J"0"F0N<YGQ
MD^(7A[Q7X0U3P1XJBM]?\/ZW"\5U%/Y4J20W)(E5HF7:SG)\L/D ?*25)H _
MQF[B*>5[F<6IMT21DEB"B(0.F \;1L0P*'(*E00>#SD54>-H\;@1N4,ONIS@
M^QXZ'G^OZQ?\%D_@9X3^"'[<WQ)TOP/!::7X4\5:G+K6F:-8I'!;:9%(MM&\
M,<4;%4#R2%B!@ Y(7&17Y52+D232D@(WEPJ0</Y9VGG/3 _/C/.: **HS$A5
M)(Y(].GK]:0@CJ,?Y_\ KBKD[F4JY2-"5&2K@$\8P0,#.0.<=CQZ(67R"OV7
M!S_KM[G;UXVX*Y/3L>O3)( *=6H(MP:1P5@C.'/))8XPA ()#-M!Z'GKUJK6
M_P"&+5;_ %_1;&8[H+O5].AGCQD/&]S&KY'0Y4L"!@]^3B@#] ?V(_V-M9^/
M?B:W\3^*+>?1?!.CSI<"YO%:.TO4B,16!1C<RN6;& H;823TS_59\._!7BOP
MO\,(_ G@S6?%UCX0\-Z3>CPWX<\/7WV?2_M1CCDED^R*HW+=2B-V;JY4YR1B
MO@7X*_V/X&\-^&_">A64=K8WNCVDMQ+&H6 RLJJVX'(&< @9P"OY?KQ^S9\4
MO#OA2WMXKJ"#4[Q-ZRQW4B^2RX4( SA@%P..!@=.M 'Y0?##1?BF_P 6[3Q#
MXOT'58=>TO6+MX/[;C)LC:P&22.>X1]J.CMF(]AN7&#6[_P5U^./ACXV_L>6
MNA^)O"/@W0?&?@77;$6<6GZ;';ZE>0J96FN ]N ^':/JQ.?O'GI^EO[2_P 4
M/".N74EQ8Z)8:9>DD>9ISIO?]X7 )15(0L/F')*\'(8U^-'[46BZ5X_^&'BW
M1[YT?4&MY;B*9T1W*11R,BH00^5+,,Y'4<^H!_+Q),XMGE\R$&Z40BU0$&W@
MCR5;:0%"/_RS(^8MSG/7(K8U:R.F:EJVG,0QLKN:U!YP1#.47 /( 53USR>2
M>IQZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+;9/FH"VYU52%X;"D\U]%:-\:GMX(&T_4C#:^4J;TD*W#R(&\U@_#$$LI7G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'Z ?\$J_P#E(U^QE_V7[P'_ .G&O]N;3O\ CTT_
M_KSMO_1)K_$9_P""5?\ RD:_8R_[+]X#_P#3C7^W-IW_ !Z:?_UYVW_HDT :
M5%%% !1110!_$'_P>B_\FX? G_LHVG?^D&M5_G#2??;ZU_H\_P#!Z+_R;A\"
M?^RC:=_Z0:U7^<-)]]OK0 RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#$*0S)@YSE<9/ /'/4XZ5&>O7/OSS^>#0 4444 %%%% !1110 4444 %%%%
M!115F.TGE@DN(XV>*$KY[JI(A#DA&D('"M@X- %:BM!M/GC7?+B&(H7BED4A
M)@" ?+(!9B#Q@ GTR.:KFUG'*Q2NO7>L4NW& <Y*#L: *]%2-'@@*ROD9^7(
M/\7&& .1M)QCN.YQ3U@W%1YB;F (&<Y!Z<]"?49R#D'H: (**<R,A(8%2.H/
M!_+J??'3O3: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/T _X)5_\I&OV,O^R_> _P#TXU_MS:=_QZ:?_P!>=M_Z)-?XC/\ P2K_ .4C
M7[&7_9?O ?\ Z<:_VYM._P"/33_^O.V_]$F@#2HHHH **** /X@_^#T7_DW#
MX$_]E&T[_P!(-:K_ #AI/OM]:_T>?^#T7_DW#X$_]E&T[_T@UJO\X:3[[?6@
M!E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;YDB@@X ^8%2,9) ZY-?TG?$[XH/KUW<W-SJ1O))W:0K(RNJ/O:5-N,8*D8
MZ<@9-?AA_P %)[ZUU:+PQJ1G9[]F>.958%2@E"\9!? [ D#G!S69H?DJS!ER
M>&!92.VW:=HQ['@<GJ3R.D%7[M(]_P I( MXW'H6. ?S)'N<\],U0H ****
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M];^9MW[7NW9K2S[: W=MI6N]%VVT_ FXP2._/7\0.>@]/2O4_@SXRF\#^/\
M1M9BD:-!-Y$FWY20<*JD8)Z$#C!)/)S7DV3Z]L?AZ59B:0 N"0%D1A<='BD!
M#!E?EE8A?EP>NWH<&G.:VC?E=DT[.U]'R]K7>W;05K?,_H&\/?%-FA@OYI6
MU%(I=V2N7<9.1NV\[ < 8&W(SDY[V#XFK%&6?4 KY+#?,!D'. !O0''3&#@8
MS@]?R:_9D^)+>(_%VA^"/&.LW,=K<K%::=<WDS.OF,62-CN#98%\Y/)49#$
MU^Y/[./[-L7A'XE:+)\:X]+UWP3K^I6-KH*W)6Y34EU*X6%$D$KMN,8EMR@9
M<*)&Z#FL.2DG>/Q>FO7S[7#;8^:O$/Q5B!#F[C(8[=PDP/F#*1N!=<Y]1GGI
MTK\K_P!KWQY/XC\466D^89(+.+S.JLI$CY4AE5&()'^R.HP.E?TL_$O]F3]G
M+X>_%KQYXF\=_:=%\.^$KG5M4M?#%P]K#HES8Q-<6UI"MKGR9(%F:+9&&4*
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M,CKDX'7&":E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*&C,R.@0(I&.2QP<@GD\]_Z;?A'J6B7^H65Q?&-8]_DJ'[11A53@DJ @!*\
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M-Y6X(9-I\L,0"%+XV@X.<$YK3MH[RX) WRP*R-<AGSYB0G+*0<R8VJ%5=N.
M,#!K]D/^"0__  3ML_V^/C=>S^*=1AT;X1^"-1@N_$UG=N^)8T6.8QF)=T+9
M3B1'7&'P68<  _,OX>?LY?'?XI:3)K?P\^$'Q'\8:,N\-K/AKPEK6L:=NC)4
MHUU9VLD'#J0?GX/<=^5\<?"[XG?#)H[?XA> /%O@Q[QC!:GQ-H.HZ,T\@ EV
M1?;8(EDD\M&;8I+%0QP0K8_V1OV6_AC\&O@5\.?"?PQ^#_PO\%^#O!^BV<=B
MT5II&FVL>NK8H@:^G6(H)WU"023R2OM<$J0F<@?$W_!3[]BS]F[]N/X7>(?!
M'CKP#X2\,>*[!+B/P5KUOIEA#>0:W'9S"WFM[JW#2@L))V$C/&OEEANW%8W
M/\E%[2Z1E5[:X1G4,BO#(I93T905!*GU'%0$$=01@X.1C!]/K7T+^T7\(O%7
M[/\ \9/'OPA\574DNN>"]6GL+>4R.Z/IKGS;!U+L<;[-HF(^90> <#CP2XC:
M%%21<22$3;N0=C+\H.>A!)X[=<X(R 5**#Q[_2B@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** )XRP'R-M)ZMGIV P?0<\=0?\ 9P9DF:(,
MA2.4R#:KD'>F#G*D8^;KC.<>N.E*K%N)-S-&@<K'(3GI&BC+R<D ;0?7N1CF
M@#T#PMX_\6^#+FR;PUXJUK3)9+J SVZR2Q0!-Z8W*\K*RXX.T(K#)&W-?W$?
ML#^*_!_C'X'?#G6[W1++5]=.A?8KV\NH8WFNKA[J1VN(Q*KLRG&,C=TXY(K^
M*#X0? [X@_''Q&?#G@72KC59)8X_M.H20XM[?8N!B25DRH8%?D&> !QAC_5Q
M^P7X:^(W[+WP8\->%?$RQ:UJ,-V)XI9=ES+I4)N9I#9PRR."L&\A@@8JK8&[
M S0!^)/_  67\&'PI^V1KL[0RQ:;J'AO0KBQ$:YM1,8I'DMUD"K&&BW .BC(
MXR %:OR0E9G=F<AG8Y9@<C.!\H(R#M&!P2.P) R?[!_VK?V0OAA^UKXQA\4>
M.M5U_3+ZVC\^0:?<RH0S0,92FV*0,2-RJAR &RJD#*_EK\6O^"0?B"PG^T_"
M;Q6FMV.I!9=)M=1DE:^M[?@&UNF98%+EFX)50"&P2 2 #\/L45[[\9O@G\1_
M@;K,G@[X@Z!:Z3/$SK'JL=N&2XV@G8EPC,&+X("@]& .VO!ODSC'X\X_4Y_/
MGUH CIQ5@VTJ=V<8QSGZ5+!&SN"$9U4@ML(#!<C<0?7;G'!YQQ5[[*Q*7:QW
M!M#*L1/FQF??PVU%5FDXR,_)P3QR,@ RRK#.01@@'(Z$],^F>V>M&TXS@X)Q
MG'&?3]:^W?@-_P $^/VP_P!IHFY^"_[/_P 0/&FD3M$/[1MQI]E;P"9'DBDG
M?4[JTDD1PA\L+&P!R2>21]<>(O\ @@O_ ,%1/"^E2ZMJ'[,/BZ:UAB61(;2^
M\/\ VAQ@, ,:K@N-XW$@#/7D 4 ?C64<$ JP+8V@@C.?3UHVMDC:<K]X8.1C
MKD=>._IWKVSXM_ ?XM_ KQ._A3XR^ ?$WPXURR*?:=/\11F24%U62-8I[(W5
MN6='39LD*X9=Q'./+TBMXXYY&?8LA'E6[@-?3;^,K(JNNPGEE+KG!![D@&#1
M2D<G'0>O\OK_ ('DTE%@"CKTHJ_:)*\4P"H(,*)IW ;R1R5*C.5+'Y00.3CG
M@4 4"".H(^O%:D*BWBM[U9Y%E#S%!;L#)#*F&B9B"K("<$\@XY!&37H_@'X4
M^/OB?>Q:7X+\-W>K/*P2.\\D>4[!S$"))@J9)SGYB5';(P?M[PY_P2X_:E\1
MZ4;F?1-.T-)61Y[2Z,7VD0@GRICY-S(?WPR0I #8!)ZT ?JC_P $?/A7XH^/
M7P@\?7WC[6+R?1]-CO5T8S\.T05(P(B_S2_,&P, %5 .<9/<?MU_$'2_V+M-
MT]M/TK3?&US?JHM(+^_DLW9<@O$JP!R_EY(DP1M*@]P#]@_L!^#;7]FGX#V?
MPW\0RB#Q,\-PL]W;A@WGR"4@J!D.NXJ"K$#G'50*_ ?_ (+"_$^Y\<_'F#0G
MANK&V\'0(MJS1W)L9?MMO$'>)O*,9E>2#=E@  SKZ!@#P;XL_P#!0WXJ_$OP
MSJ?A?2M,L/!VDZY:RZ;?PV5Q)<M]F:3S&"33*LD&0%7> -PCVC)!K\_9+EKE
MY;BZN)Y+QCDS.Q9FR,G<3RQY(!+$GZ8Q-<2+>!I%"0/#!F4(0%N#OD;("E@&
M^;H<$CJO3&2?\_Y]NE $SF$QC;O,N]BQ;H4VC&,>ISUY'.>*AHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _0#_@E7_P I&OV,O^R_
M> __ $XU_MS:=_QZ:?\ ]>=M_P"B37^(S_P2K_Y2-?L9?]E^\!_^G&O]N;3O
M^/33_P#KSMO_ $2: -*BBB@ HHHH _B#_P"#T7_DW#X$_P#91M._](-:K_.&
MD^^WUK_1Y_X/1?\ DW#X$_\ 91M._P#2#6J_SAI/OM]: &4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'U'^R!\ ?$G[3WQR
M\"?!C0HP]MXD\0Z=)J[OE(HK&*=(9V>91E"T4[*JE@&/?.,?ZK7[!W[$O[(_
M[(OPU\)^'? OPO\ "FH>*M+T+38O%?B/7](T^_NUU:2'RKB:W@O8;B"Y$=QY
M>.5!/+ @;3_G!_\ !%'XD:!\._VP+"Z\1SV=M:77AR^^Q3W6Q=NIQ7%J;41N
M_ E+-F/!4@AL'+8/]^_P]_:2M;>:TDOM52:&]:20_P"D;E$>0T0P68Y+[6)]
M>!M.: /LO]K3]DW]E']I'09_!7QO^$W@SQ/:ZEI-Y':>,8]/L=%NM*N)BHMY
MDATJTMX%:) ,*7&%&,A\./\ +?\ ^"EO[)MM^Q=^U5\0?@UI%YO\ SSIJGAZ
M[MP+E$L;KSKJUM4FD)9_+3RT($HR'SMPJ@_Z+_C#]J#3/L5_;W%V;F.:VDGM
M;-YR0]Q"C1PPA6.%+!@Q!.,_/V(/\WG_  55_P""<O[1O[?"Z?\ M3_ 'P[H
M7B&'PI::CI^M>#DNM+34YHM%@%L]P8[B\MWFS';R/&NQRRG 4G!H _C%,9P&
M!!4G:#UR<9 PH)R5QQZFO6O"GP%^+OC:WDNO#7@+Q'J,"(CK)'IEUB82'Y/(
M_=DR9!!R!MYQGJ:_5[]B[]A"W75O$.L?M)>%FTG4;&YE33O"%U':/<+<0R6X
M1_(C-TB@L)2IR"H'.1@G^BGX4_". :7I6E>$/#6FV6BQQ1QQO9V,7VNTVIA-
MS08+ '#,2F 2<$#@ '\.GB[X#_&#P+ ;OQ7\._%>C6@SFZO-'O(H ,D9WM&!
MV^G3GFO,X+;<CO(QV#<K1("9PZ]C'C( (R3V'4#D#^]CXP_"#3M/L9-.^(]C
M;^,-'OH#&+.2T\YK7.7W/YX<*4S@ +@=!QC'X<>.?^"77@#Q[\:-*U/1O$UO
MX*\ ZI<7MSXC^9;7^S8T8-#&@C"/&]S&[*&C1B",'@&@#YE_8/\ &GD^ ]2T
M@V\_FV]P726&/<I1&#8DD(150#"DDDY.<'&#^LGA'XEB%8I[>^M_(556(QS)
M]Y$4L<C #K(Q5Q@_=!/4"F_$/XE_L=?LB_">\^!_P.\,^%]=\3R6WV+4O&^I
M6^F27DDRX$C1W4D4=X[/(BL?F(8*3C(%?GAX8\=3P(SVZK)%)<37(6*5#%FX
M=I7$>UB-H)(55 (&,9R#0!^N4G[0=[-IS:=_:Y&U"H5I@%90N BG)PW'R]>0
M.#7S_P",/B/E$O)KA62!CYDEZZ1J%.22K.2&YS_$1^'%?'+_ !*3<1-:RC&-
MN#P& P#TR2.WUQTQCAO%WQ+F@T[6+[5'BN-,CMW"6MW*C2$K&6 6-B,J#PP"
M '@ >H!RW[7WP ^/OQ[M+#Q]\-?ASXE\<>']"$<E]<^%M+NM8E0&,J9$BLXW
MWA%!8X;^':!GFOR7NO OCC1O$0\%WOAS5[#Q1<S"W;0KNQGCU%"[>7B6W*&2
M/# B0L/EVG/3G]??V;/^"I_C#X'2W.CZ'XKN_#?AMKMTN=-+:@\%U9DX:+RK
M4>4RLA*8*G@GG%?I%)^U1^S_ /M1V>FZYI/P>\)P^/(1$+SQWIFCZ=!J4DS[
M6\Z6Y2)=1.9$9AO+Y8D.V"00#\VOV7/^"6%YXNMM-\2?&"_ET2UF6*ZL]*L0
M)[J]5UWM#>PR21-;H4(53AB6W9R?E'ZQ:5_P3-_9WMM%EMI?AM"D@M55-:5[
MEKK)08<12+Y6<X; R2>Y ('L_P )]61=6T:VN+N*]@BF@B:>=5WA5(#1XE4?
M*@.!D#ITX-?L1:R_#D^ 2WF:>;S['&&^6%7)$>22  QP> >OIP#0!_&;^U)_
MP2R.C6WB/Q9\(-4O]2ET^ 3?\(]<6\44\A";F2*.%I9#N*.L9ZN6!& ,#]1_
M^"(GP'_:)_9P^$GQ!^*'C/P)'H'@;Q+>%9[C5+B[T_4)XFM]DI$+HJ,H6-<
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MS22,P!)=R23N&0">/E_*G,I1(E(P"K28R#R1D=N!CMQC/K0!6HI3P2/0FDH
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M_*1K]C+_ ++]X#_].-?[<VG?\>FG_P#7G;?^B37^(S_P2K_Y2-?L9?\ 9?O
M?_IQK_;FT[_CTT__ *\[;_T2: -*BBB@ HHHH _B#_X/1?\ DW#X$_\ 91M.
M_P#2#6J_SAI/OM]:_P!'G_@]%_Y-P^!/_91M._\ 2#6J_P X:3[[?6@!E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!VO@+Q
M/JG@OQ)H_BO2FN89]"U.TOFN+;>&V12*_P!F=T*GRYR@#J2 0!7]&_P1_P""
MD/@/QCX8ME\2>-[[PGK\%I';M92/$MNTT;C)$TLBOF0 ;MHSAC@9YK^:"WVF
M"4->M!\T>(0)2LG+<L4^4;>O((YR>:6%(TD$DT;2PJ0=T#B$G')VDCKZ$#.[
M@9., ']/GQ2_X*1>"_#?A+5?L?C>?6O$4=ZEWIS6SP36R;8<+90RB3,MK(0K
MO.OS"8*H!;&?B_X#?\%C?VC?!?CR>#2M131-$UVZDMS;6UW=318OI&MT=K:Z
M(MV8^>SD%0N78<X!/XJR[7_?A96M5(\N-W>4IE@"&;[J G/!(+'& <G'1>&=
M2@T3Q1H>IO$)H([FSF,:X9@!.AXQW4J!TS@' [T ?UH^$O'][XBU0^(_%&I3
M:GKVH.);K4)HHX9)'<!V4) JQXR1R 1@XR:_2_\ 9U^-FF>%Y;UW\@220!/-
MD9<*I0(<*P(' .2!D\<\5_/U\._BG'J.C:3?PW,6QUC49="% C  #!L8..F>
MQ'?-?1>G?%#4+=RMO>K$CJ&^5E W!$)4#/48)(P,\G!R: /U_P#CQ\8])UVP
MG-@T$=PQ!>55$FX[CD\@D*?09X(]0#^57Q;UJ.]\+:XUO-)IU[]BN66^AF/G
M.Z^>T;!05"%6.0"1@\9)P*Y#5?BKJ$\<B/?-(A!;EEP ">ASV_, #\?G#XF?
M$]X]"U8O-DK8W)R&4G_4D@8'.2#['G&.<D _#+XB:_K>J^-_$5OKNKWVK?8=
M6O8+>2XN'C9?+G<(V(RS' X&25YY8':*L^$_C7XQ\)R1>1=&\@MR!':W#OY:
MHG10V68YR021QC(SD@<)XGO/[4\1:WJ,1W++>SW!(/.6?#-P2<;NIZ=!QFL*
M5E$C?(#T'.>#R2.WK^'3I@  ^MV_:W\23Q*)O#VE*Z@_,ES.2?E*J6#)NSD@
MGMG&,\@^">*_BCXN\7W,T^IZC(L<I<"W@9A$B,3\G+98!?E!(S@#C->>E@3G
M;CC& >/U!IM &I%?2N(;9U0QH9"P*@ER0QR<CJO8Y]^#7Z/?L!^([;1[W64B
MO);2^DEB*D[7# "7A5D(100< @Y!.>>0?S2AD:.17'+#D \Y/8'ZXQ[@X[U[
M+\%/&=WX)\407ZW0MK;S8C(&;:K$%L$'/(!/)!(');&* /Z9O"WQ":RDA,Q/
M]JL7>*56 6<C<56;HL:8(*XY))!.!7M!^.NOP:6T*ZF7OR!&UD7(@B0# )._
M#$?,.N#@<'%?DQH/Q9NKZP34]+N$NY+^%%$B$R?9@&!:0'+  @A2<\ KG@XK
MT71O'/C'4]:31_">@7WBN^>V\W4391R320(JXD8M$DIVK@ ]0"PR03R ?87B
M_P ?23R)))=+=27*HTI219%@F*H'(8LWW6.?]DDJ0>WY ?\ !0'Q=-K%AHFB
MS7WG0Z?<^;'B*,N65>(RP(;:O(!!R!SZY]TUOX@7>CC5[G5YI]*-I->Q3V-\
M[Q/:W%NS+(KH^-NV8,#T(R5.&R*_*KXV_$>_\=>*KHO=">PB=O*.04&"P9L@
M8P<'!S@=!0!X@\\;,K+;QH%4*54MAO4DGN1D'\/3!;YQ5GV#:CX#(.A4#@$?
M4 ^YR"2#4)ZGZFDH F$H$;Q^6OSLIW_Q#:&&!]=V3]/?AC.S[<DG:H49/0 8
MX^O?U_0,HH **** "BBB@ HHHP?3W_ =3^&#0 448/I[_@>A_'(HH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[
M[P9X+UWQ]KWA[PIX2TRXU[Q7XEO8])T'1[*-YKJ>^.,[XX@6\O:2P.UBHPY&
MU6K@:_J,_P"#;?\ 9]\">)?BIX]^.WC30+/6M1\!Z5:P^"CJ%I'<V5CJ]Q/]
MEGNP9H3&)44J7(<F,NI8@LIH _6S_@D=_P &[_PF^&GA?1OC#^V[HS>._B!X
MCAM[K2?AO+ 3I.A1W$"& WTNZ.X9T=O,=W1<[@.@ '],FB?\$[/V#K2QB@@_
M96^',2PC:"K7#&20 !SO#YVD "-#G(R<@BHOAOXH=9;"*[U.34O$FHZ=)K6I
MS322/I]K:1R"T^SZ>&/D0G8D+ 0LQV!B!@D#Z8TSQA9BW(#_ "@ @ J5R5X*
MGIAAG:5P" <' & #\W?VAO\ @D)_P3O^-/A'Q+H&K?LZ>%/"QN=/N<>)=$><
MZIH4CQ%$U*SB=FADEAE$15)BD9/RDG/'^=Q_P5 _X)1_%;_@GMX\UR[N+2^\
M1_ SQ!J-R_@7QFULT=XMLUR#;P:C;0J+6 0[A 94D9&"X/*$G_4N\8>,+9;#
M4)ED4PP(TEW 3S>P9"FU7;U#DAR/]@8[BOS#_;5^&'@#]IGX/^)?@[X\LK76
M;'7](O+C0+W48XY9?#5Q#&98O+:Y*F C=M&T[P #C'% '^4A/(\@A#X(CC5%
M92"-O\.XX'(YZG/;.013!&"T84LX<G*H,R#G'"C.2>P[X/2OI_XX_LV^/?A?
M\6?B/X(T[P=X@U'0_"'BK5-%L[ZWT^]FAO;2WFQ#<PSK"WFQ.L0 <9&?E!.<
MU\^:II-]I4J)>Z+K&B2K(JL=0MKJ)@VX'*B:*([EZ@+R3TY- '/NNUF7!&UB
M!NX; /&Y>Q]>.N1]!<9&[.W<N['7&><>^,X]Z'R68[B_.=QSEO<Y.1^/3I3H
MV9'1U RKJZ[N 2A! R2._4 YYH MQPEH9I8WA"QLQ)D?;,.4'RIWR&QGU+#C
M&3^S7[#>JFU^%Z+8PN(TO8'N9)%QN*F0LPP,$A@0#DC !!QU_'W0M%U?Q-?_
M -DZ)I-WJ^LZC.$@L[.(RR*[9P3'AB#N8X)VC.5R&^6OZ'?V'_\ @G3^T'+\
M*-2\4^,S+X'\/V^EWNM1:=J,8MIIVMHI)( ,RPE3*\61\G);G/)H ^BO#OB=
M+F_5+>:>4.NZ=;@+&D;< LAW'<!SM8@9!SU.:]R\->/VT^8K#>K&;1TA*(Q*
ML[*&W$Y 4DG(R.3]:^ +/Q)=6FLZIX>O9DMI-%NFMWNT<(9RCNK$/&QW%V3.
M7.<$[CDDGNM.\:0",B&1E:-V621GDS,PP"XS@$'KGG@ =P* /T<'QGU!+=H1
M>;@V%P9>IQOS@$\DJ!SD<_2O(/%'Q!EUBYE>6Y<^407*EF'R@G..O8#W[8Y(
M^78_'",O,Y8<G =F^[Q@[N,?SZ#@UAWWC&YA,FV8+%.-H^8<*<_>.20<>O4]
M!D8&E)T%.*JJ]WOT6J,JD)33Y9<K2OLWT\FNNYZIK6N3ZS<B/20;NYD8Q+&Y
M<*SOD8RF7^9B. /8CKCX*_;J\$_$"/X=QKJ/AG4)"(DQ]CMIITMPVX@J67)'
MS,P. <.Q([5[)J'Q,G\)2C4;>6,F%TGE;(9XTC8DLH!R0/3T![]?3-*_:UTK
MQ+I<:^*=(MM>T6<;9/[2LDD&U%!W?Z1;X"@#DAV'/7&#7Z5PWPU@LW25J?PI
MQ32NU;1ZM6Z]SR:U>I0ZN36Z2:VWZL_ C]F;4K;PE\?/AEJ&J6S*EKXGTV.9
M9 R21R274.UQ&V K)CY=Q )8$XK_ $"OA?\ %F6^LHHFU-8[ Z=;2:?(&5I9
MMVT^1-\PPN_Y<X^7/L*_G/\ B#X-_9DUK0G\7Z!X1TC2?$UK+;7UA<6L5O"R
MRPMYK "&+AF=  <J?4YXKZ5^"GQGU"^\/:):/J,D.J6BI-!;JS[FMF^9$$;
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M<1V5B=4,,X\N&65I@^8U54<9)X"J6(!.<9..37X%_$75!KGC/7]21MZRW\C
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M_*1K]C+_ ++]X#_].-?[<VG?\>FG_P#7G;?^B37^(S_P2K_Y2-?L9?\ 9?O
M?_IQK_;FT[_CTT__ *\[;_T2: -*BBB@ HHHH _B#_X/1?\ DW#X$_\ 91M.
M_P#2#6J_SAI/OM]:_P!'G_@]%_Y-P^!/_91M._\ 2#6J_P X:3[[?6@!E%%%
M !1110 4444 %%%% !1110 4444 %%% !)P!DG@ =2?2@ HI2""0001U!&"/
M8@XP?:DH **7!'4$?A24 %%%% !1110 \.P4J#\IZCCG\<$C\* [*<@GN<=@
M>N0.F0:910!*L\JQO$KD1O\ ?3@AC^(./7C'US3 S*RL&(*D%2#RN#D8^AYI
MM*.2,\"@#[+^!GQZ&CQ6WA?75_<D".'4))>8 60;@67 QUV[@3G@@ Y^[] \
M77-_=VEKHFM1ZB=0DB2&XD=/+B$C*A4O&^YMNXIZX''3C\3XQ&"2C3*% )>/
M<0#DX)*]-O'7'4XKW;X*Z7\7_%7BO1="^&D6MZM/)J5I-NM[>YDMH$M[J.64
MRW)1XX5"YWH[9(R ,XH _=3XQ? +XF_!?X::9\5O&.IV47ACQ%%%]E>66411
MBX1YXBLDB$ [8WRO/(QN.X%OR&^,GQ^DFM9O#/A^2*ZDG5VO-3BF+H%DX5%&
MS!&T< ,<9P<=OZ;OVHO#/BC]H[]AOP9\!_[.*_$#0K.SF\Q;A5)EM;>2%]\C
M;4^9IB2A/R[&R .1_-#\2/V /VF_A5H=WKNM^#UN=+MRS/+826VH7+0@XR\5
MLTTZE1DE3DD\ A<T ?$AQY;)#NFGFR;AQG 7<KE>F>7 .[O@\<X-6?8DK"'<
MJX&0W4'OU]_8?E5UX;V":1&MIK.9"4G@>%XIDR>289%$@QCIL&-ISSDFA.J+
M(1'*9EX.\JRL21R&#<Y'^?9Q7,TE97[Z(",DGK24454H.*3;B[NVCN Y%WNB
M9QO95R>@W$#)^F:N3F(-'''%DI@,03^\(XP>F-W3.>!SC)JD"01CKV^O8_@>
M:G1G16VG#9!;(RX "G)ST4''.#S@#K4 >L^"?BKXO\(O/96-V6TR2,*]K.Q$
M-NJDM^[< L"V-ISUQP..?W__ ."+WQLL_&GQBUVPU^QMO#MN-$N474I%2XM]
M0N'"*8WDNX< LFT%8R2,=VR*_(+]D']DO6OVA/%Z/J/F0>%-+6"]U:Y=S%!<
M0.69K>*=RL<D@5<.D;,5+*"!D9_J*^ ?[.7P]\$^'M$T3X9^$8K74K.2*"XU
M>W"I>2B, .6D"%B&;80Q.20W7(H _G9_X*'Z7\7I_P!HOXKZ=:>'-3A\(Q:[
MJ4]O=Z-;3/87MI=3S.)6DVHN6PHD"@;2KD'&2/S*,)#E80XDAPLD,XVSLX.U
ME*-RI&6&S&5'<U_?1XR_9XU/3K"YNM;\%:5KEM=0O+J-U?V=K<7+QR1AG8RS
M!I7P9'V9SM! 7Y5%?A1^VC_P3Y\$^)UN?&_P:@CTCQ4KR2W6A0E(;=W7>2L<
M0VI\K+M7:#ZKP<T ?SO."K."NP@D%3G*G/3\/?M30"<X[#/X5J:QI>HZ-JNH
MZ3JD$T&HZ?>W5E>13*ZR+<6DSPS AP&(#H2#@@@ @XYK-4'G@G(*\#N: &T4
M4H4G. 3@;C@9P <$G'09QR?4>HH 2BG%64@,"I..&!!P>AQC.#[#GM28.<>^
M.XY].<<_6@!**4KQD<CN0#@9XYR!WHVG&<''T]: %4 G!(&?XB>!]?8]/_U5
MWGACPAJOCC7-.\*^'/#VJZIXMUB6TM-"TC1[<W0U*>67:SS( 90H3.3!UQDX
M8G/"(KL2$0N>X"D\#UQR ,9)X]SQ7],'_!M9\(/#&N?M9:A\<O'.FZ7XB\._
M"G2H[O\ L_6+&"[MA<7\5WIJ.@N ZM+!--;M$L8W(P#8W4 =1^RA_P &M?[:
M7Q_T'2O%?Q$UCPM\)=%\3Z7%J6B17TTXNX7F+K&EU!=V\<:H=JB7#%HN1EBR
MFOD+]O3_ (("?MP_L&Z%KOC?Q=H6C_$#X=Z+=2[_ !+X':^U";^S5N3"MY-;
MBT,( C!ED,4Q50C$,Q*H_P#IG^"?BK9WVB&QO;M[>368+B+1U%SMM--T=V"2
M06MF%$=I-Q^[F"JR_>5P5#5Y9\<_&7@'XA>"_$W@#Q>KZO\ #KQ!X<O?"%Q:
M:E,;EWU5-.ELFN($D!>/S+]XI%F7Y44!G+ $D _QP;RV:W< QS1JV[RUG $@
M"LR,"!QE74J0<$8''6J=?9_[?OP-T_\ 9X_:@^)GPST>W>'1])UZ^?36>\%Y
MYT%Q,9_,4AF$2GS !'G@#':OC"@ HHHH **** "BBB@ HHHH **** "BBB@
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MWDD'F^4P"'<(D)(W*0 0&P.2,9ZC)Z]36OO&E]<F./3H5EAN2S7MY=,R-IA
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M.!,ZAECRR[E"K(4?&<$@8QS7=_$SQ:FG>&=:FB==TMO<1+N(()*;"N,[B<$
M'OU.37YF7<CW$TEW* L<MQ(SE2-X!*N<#@]@>V?;BOX_^D1XCUUF=3#8'$/F
M=5KFC=Z>TJK>,]]O+R/T'@_)TJ+J5X-\L8RCYWC'>ZUVZ6/HW7/VH/B!K5M:
MVY<6303^=>+#*Y6>T4C,)#C/S(RJSD[N^"!7VQ\+/%DVM>$M-\66%M#96=Q^
MXDCWNPN[F ;IQ^\VKO7.YR,Y+$'';\E5E,DUPR+N5[=H_F8 ]% )R,?PXY.2
M><BOUK_8,USX8?$SX=^(/A!XUO%T;Q5HDD=]X&>.9D?4[_49V2Z1D#*"JQA
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M2>3Z]J &T444 %%%% !1110 4444 ?H!_P $J_\ E(U^QE_V7[P'_P"G&O\
M;FT[_CTT_P#Z\[;_ -$FO\1G_@E7_P I&OV,O^R_> __ $XU_MS:=_QZ:?\
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M=PI6&U#3RG).,1Q*S$\ X^O'2O3M$^"?Q&U]2^F^$=9E50,A["ZAP".,^9$
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M'&_L!_\ !.[XY_M__$%/"?PQT!G\'O>6UMKWCK4;=V'ARW4HDS12Q[8P8AO
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M1P2V$3GY0%RM '\EZSKNMELUS>D>44M@2DQ#LH#&15;YN?N] %8DAAC]R?\
M@B]\?]2^''Q#\<>#K>RN[+1-6T^TEU.[ME8QV\\-Z)YEF8E@I#((@K,P&-PP
M"-OM/Q8_X)#?#.[TD3?#KQ#?^&M9M[.Z*17%I?3++=+N9%,L\FT,R,BJ0IP<
MD-DX7[F_9C^$7[/7_!.?]E_4_&?Q"73?%?BC6H]5/BC5;M5:]TY;BV"631P-
MYC./M$H7;&K!<Y ! "@'ZV>'?VR_#Y-A]K\1R6*2VC$:F;@Y,"-L-DQ:,E Y
MRHQCJ23@Y'*>/OVRM.BTG5M8CO(SHVC6^H3?;9YE ?=$P:1%PJ;B,;7VA]Q7
M.XU_(GXF_P""H>J:1XJ\2V^@>#++6O!LMU=#PT\UYY+"UE;=%,Z&%W5HGW*J
M.QRO+KN KYG^,_[>GQ/^+-I)H=G=S>%/#]W:-%>6MI)O9G,8)4&)$.QG58R1
MCY6+'I0!P_[<GQ=M/C9^T;X^\<6+B2UOM3F6.0/O#D,5;:PR-B[%P"21NQDC
MI\A59N)5D"##;UW>;([LS3.S%C(V[.&.23DDG/4U6H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OT#_P""8?B*P\)?MD_";Q#?
MSI!'8:C>Y>0H%S-9O$@RZL!N9B,C:W3##D'\_*[CX?\ B^]\">*]!\3::[17
MFFZA!<"42%-J),H=B,<LL?F;<G:2V64E02 ?Z;WPR^-&G)%Y+7JM!/'%&A\X
M'"2Q1.V6 R2Q.X9."">#7T];_%7PWXD\.:AX:\26R:MX>OH&LY_#C^6ZSYR!
M=QI*&4$D>8." AQMS7\OG[-W[4,7COX?V.NZ/J=OJ'D-8O+''=1&^6*.!8Y0
M+-'\\F.2-DV[3OVY (<9^T;#]I&$1I>C5QI\FU-ES.H1E0*"$>$X9753\Z8!
M5\JQ!H Q_P!J#]DA?!_BF^\8_""\35M$UN6>YNO#<+%_^$661F:2<1Q(@A51
MC* D $\9QGX7&OC3KV;2=1U'9J%K\NUGP0R<!]O97)W#.2 #D\\?>>I_M(1-
M)Y6EW66U-3!JETRI/%?Q2!@T91@XMAGJQ/'*K@D$_CGXQ\1PR_%[7[J_F,,$
MMW=FR6+,D; -(R+F)BJ(-H8'@C&!PS!@#Z8\Z]U2:*X%P)F@F\Q.3PRD;" I
MP0<98$D'CT.?1?A/X O;_P"(UEXM\0WL9MK*<7 5FVD*OS$J,D=\*H&..0.2
M/G#P[XFN+:T,D;1'S7^7,BL2K*.<9)&,Y(/K@<#CU'2_%]W;1QO'J#I,IRT2
ME0IR0=I/ ^O7IWX( /W.M_CUH3^'X+.R>-(K&,61#,H:1D0(SC.<#Y1C'?.[
M-?%GQ;^(=IJ5Q,R.I\Q^&RK88Y 89)'7MZXY-?'Z_$V[C@56NC!E0'19 58X
MZX'.>F""#GN!DCCM>\9M>YW7+$[6(#$  JN1DYR!N SU&/49H TO%>M07, R
MQ.-4N' W;07*#' .-N>0.1GCK7YW_MPZ6GBGX.Z\%Y.G1_:L[B&!MXGE(/.,
M$H%(P,@<$9X^G/$/B)52V43<)>23R,""H1D"C)Z\E3W[$?7XS_:>\1(/A?XM
MC\]&34-/O/) <<DVLZ <'C!)QW[G.: /P;_S_C12GK^ _D*2@!>O8<X [>GI
M@9^OJ2>>:DCX!)C#(05).<AB.""""""./4]CG:8NE2(QQL+%4SN. #R 0#@]
M3T&.@Z]LT >C_#[XE>,OAAJL6N^#M;FT^\B(9=DD@"L"KJ[(C'&&C7!7 )P"
MV"0?T)\(_P#!33XDV.CV]MXF\&Z=XAU**$I+K4@G^TWI1ODEF8OS("0#A0,9
MQS@U^5N5!.,E>_8D<'T..1^E79)H=L4<8FB" +(_G.RR-C#$)PJ X'W<9&>G
M%--K9VON*RO?J?</QF_;M^+OQ7L'T>VOW\)Z8\4D-Q;V=PT(G@=61X#N)+JZ
MGG<O4<-U-?"S2DEB2"6)+$[F+$@C)/?&21ZDGIG@DDRP7(= >/E ..PR &)!
M[YRW<GK4%3%<DG*/NR>\EO\ K^0-)[FWHNH'3]1MKM&*F*:-B22/EW L"00>
M1D=?KZ'[U\+>,+;7+/3#9RH7@BC23+;0K  D#:V2?J3GGM7YZQL@8YZ,IP,<
MY((Q]<\CTZ 8)KL_#/BW4/#DRR6\I,;,&8'+*1Z8X.,="&&"0<5^O^&O'*X>
MQCIXJ\:/-&4IW:4(J2O*U^FST]=#R,URZGC*3DZ2J249):7DW9V2UW[77=;'
MZ4Q^)'MY2K$DX4;B<Y&#@<\9!+8 SR>I%:@\6(\9 ;@@ D$ C&#C@C&./0XP
M.,8'S1X=^)/AK5K%!<:BZ:CNBBDAD1XAODRJ^60ZJ03D9 ;'XXKUT>!_&;VL
M.H6VAWT]E<IYT-Q!#-.ICD V,2(V13C)9<?=()Z"O[1R+Q&P6=475PV(NJ-.
MG[\IM+W4NTEJM/7KY_G%?)9.O-3PTH1NU><+)7TMTWZ'83>+8D4*K?O#QU8C
M/.,?48.>A.<]*Y74-<NB#(#A#DDEB%VGDD\Y(Z9''&,<5PVM:QIWAQ5&LW!L
M[R+=YMM*#YH.=H+QLP=3G:P!4 AN%(85XMXS^*]N\?V;1;DRL05<F':HSE2P
M;[O"\X.>V1C@^!Q1XKK!TJ]*GF"E*$97BIQ]VR]W2U]7IJV>A@^&'>#<4J=T
MU&W_  ?3K]Y:^,'C*QO(O[-T^0.&)67!R-VTK(1M*C/7;D'D\@]OF>=EVA5/
M<D>V0.>#URN3P1R._1]Q=&:>26:1I \CN&8Y)+L689^I!/ Y&>!P:99&+DLP
M"@[0 /F.?E7)YY!.3_L]<D&OXUXTXL>?XJI6K<LYN4N5IIZ\\WSW5M7>W:R6
MA^A8##1PE%4X:75G9?925H^B^^_4@(;)Z]^1GG./PQQ76^"?%.L^"=>LO%'A
MZ\DLM9T>9+FU9'9#*N=LD9"X+8'( /W@"0=N*Y7>/?Z>G\J59"C(Z'#*25)
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M[9&  !CF?%?Q*L[O3=0LI=82TBD#36$\97S;C4E*F&S.U@1"W#.W& &YP#D
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MVGO"&D?$SX=>+O"&LR7;.;.66R6(@KN\PW"8&1P! #D#@L"??W/QI\>=7\2
MI/?&*,Q$*KW.Y$)W?,6R>O*X&1A1D=2?E_Q;X_NTNKBXGGM(;*/3)4D8^3/Y
MH:TF3YLELDN0 2!CCD8Q0!_+5XNT?_A'-?UC0 )-FG7TD(,X'G +NVC@X *D
M9[GJ>ISR]>Q?'BZMKWXH^++N!E(GU*1]L:*J8(Z_+QG/;)Z=,&O': "BBB@
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M\HY]ACGI0!]Q:5X[EME0"XD$@/1&V\<X..021].O7 KH9_B-=31JDEQ,8U)
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MS?A#\/+*6:]\:6'C+4EM7FM?#MG>QRPF>/S#'.U[93L5<,AC*!6<@J3N# @
M^G?VZ_VI)O"7PJ\7IK-^+2XU_3Y(]%\J=6,K/!<PQA@K!B!YJD*,XV@C'%?Q
MW:A?7&I7UW?W;F2YO)Y;B>1LEGED9F8DG))8GDDDYY))YKZ=_:2_:D\9?M#Z
MZ)M5DEL]!LY'&G:;YQ*11;B8@QP,B./ &02>,]L_*[X+MCD9X/J.Q_'KZ^M
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M.::C>-DV_)_U_6CY)W3Y9:-7T?>_38[/X;P?:?&WA6$ $OX@TI0#TW&\C(Z
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ML9?]E^\!_P#IQK_;FT[_ (]-/_Z\[;_T2:_Q&?\ @E7_ ,I&OV,O^R_> _\
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MW_@F_P# ?4_&OQ-L_B5K N[71_#6_P"Q3$R6XG98FC3/E@"4,"5.2>2><G
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MQCD_7OC&:[[PWX+U_P 9:M;:3H&F7FL7ETXCBL[6"265@6"&0>0&(3Y@20"
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M!GWK?NK2ZB,D87RY(V99(I(PF6&5:/Y0/FX);C.<XQT.(Q=8I1'A,\3H>QR
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M=G)OFE%126VOEHSYW,Z]%>Y[9)I.:C>S:4E&RUMULGZ=#\]O^"I'Q'2YGL?
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M %%%% !1110!^@'_  2K_P"4C7[&7_9?O ?_ *<:_P!N;3O^/33_ /KSMO\
MT2:_Q&?^"5?_ "D:_8R_[+]X#_\ 3C7^W-IW_'II_P#UYVW_ *)- &E1110
M4444 ?Q!_P#!Z+_R;A\"?^RC:=_Z0:U7^<-)]]OK7^CS_P 'HO\ R;A\"?\
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MX!R063I@]V/ :OS \8_MT?'G0OB1/)9^*KTZ)X8U)TM].>295N8TFVHLBO(
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M,N''W P#9S@[Z_4+X=_L1_#WP]$'\17":W<_*OE['<,X/RLHD@*8*;6P&/+
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M\?\ !)_Q'_P43^(L7B#QA/+I_P '?!<T4^O.#L6_MH9(WEL4>5"@,T1EP(Y
MS$9&,$4 ?A_9:!KFHAWT[1]4U%(C^\?3["YO43!(Y>VCE0#(Z[N.:A%O<6UP
MUJT,T4\BM$T5S$]O(,G RC@LN[!5<@?.,'C(K_8 _9J_X)=_L _ KP%:>&/
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MY-7XGD<Y&3OD+[BH7(!.[&1D9QC'8C&/ES_A(EVE%D\E22 C$?+G!(P".-I
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M('0 9XSWXS\V1^V7_!+']JJT^&EKJ?PZU?4)K:XN[^-M(@,XB5[@X"A@Q&2
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M.=-S;45.25E&:VY[-6>GWV=C[C+<JI82"Y8I66UDK-6?96?3H]R%I&)YV]^
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MU71'VE->X[VNGVL][==3^/ZBBBI*"BBB@ HHHH **** "BBB@ HHHH ****
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M)'^'J*^C?V:_$GB33_BKX7M]/\2:Y81-=PJT=EK-[:QL PPI2&=8R@! *D8
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M_>8' +$^ZDGD#';/'&1QGT->Z_M'^)%\1_%;Q#=^<LT8NL,8SG#X&03T^4
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MU6,JP\J"4LD0(('RJIQVY%>65<ME20JC3"$+(7+OG:JD 9R <,,<<8R1UY%
M'Z>_#WXR^&?B/J>CZ!8B;_A,]=>&P2!))5MVNKAEAC2#=$(E8R-@$X&X[BX7
M+5]4_'GX&?$_]E_X=Z!\4_BAIMVVFWTX6S0%D62%XP5!2,EBX67YBZX..,9&
M[\V?V*_@=\:OC7\>OAEIGP/^'WB3QAKVE>*M(N]4?1+1YXK:SCU&.::ZN+C
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MXA^!;)4%IIOB*^M;<;%5;:**^E5(X=ORJ@4'[O ! Q@5X?<#R6DM\(P60,)
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MP^!/_91M._\ 2#6J_P X:3[[?6@!E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $L3,C%E*YVD'=C!!ZCU_+GCM4BBW"?O"Q<Y(VG(
M [ 8(&2<Y!!Q5:B@"SB)0I4)(K9)$CLC+@] 591^)#8-(&0_=BC0\?-YCD@]
MN"Y!Y&<8(.*KT4 .88./3 ZYZ >W_P"NFT44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#P -L1AXXV-11:4I149)R2MS.U^SUOHG>QCBJ/UBC6CO>G*ZZO1I^6OH]S]
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M^2/SRI'DG**?,DVE+NKNSU[I)_,;1113("BBB@ HHHH **** "BBB@ HHHH
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M4445QFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN[N_+\$E^@E%+@^A_(T8/H?R- A**7!]#^1HP?0_D: $HI<'T/Y&C!]#^1H
M2BEP?0_D:,'T/Y&@!**7!]#^1HP?0_D: $HI<'T/Y&C!]#^1H 2BEP?0_D:,
M'T/Y&@!**7!]#^1HP?0_D: $HI<'T/Y&C!]#^1H 2BEP?0_D:,'T/Y&@!**7
M!]#^1HP?0_D: $HI<'T/Y&C!]#^1H 2BEP?0_D:,'T/Y&@!**7!]#^1HP?0_
MD: $HI<'T/Y&C!]#^1H 2BEP?0_D:,'T/Y&@!**7!]#^1HP?0_D: $HI<'T/
MY&C!]#^1H 2BEP?0_D:,'T/Y&@!**7!]#^1HP?0_D: $HI<'T/Y&C!]#^1H
M2BEP?0_D:,'T/Y&@!**7!]#^1HP?0_D: $HI<'T/Y&C!]#^1H 2BEP?0_D:,
M'T/Y&@!**7!]#^1HP?0_D: $HI<'T/Y&C!]#^1H 2BEP?0_D:,'T/Y&@!*4<
M$?44NUCV_I_.C8WI^HH EBY=C[]?8Y_F<58#!9.O!&,G/()XQTY) '\ZK1X4
MG<0,D 9SS@@^G3W./YXD9EWCYEP,9)/3J3T!.<8_^MS5*',I25[QB_3OKWVV
M1<K2HN#W<D_/:5_EMT\S]%/V5Y1)\.OBII65+WFD':O.2%LIP=N!UY')/M@C
M.?@;6E>SU"Z@90-D\R#C[P5\8."1UR<CD>_?[K_8YCFU!/%UE DDQET>X+HN
M"O\ QZS8YR<G .  <[LYZU\=?$/3Y+'Q5K5G<H(9X[^Y38<G!\QPI!P"%X'S
M>^0.]>%EN)J8?,:[@Y1E=WY7)*UWJK-:]_S/C,FQ.)IYSF>'G*;IREI%MM12
MU2BG=+KI8\^,Y)/S$=NG_P!8?TJ(R$^_OT'?M[9II4YXY[]1ZD<],'CI2;&]
M/U%?43QM>JK5,15:_EYYV7EN?7Z/7]%_D+OSP< '.<9]/QIAZG'3M2X/H?R-
M&#Z'\C6$IWCRN2=D[-M<W7S&)12X/H?R-&#Z'\C6("44N#Z'\C1@^A_(T )1
M2X/H?R-&#Z'\C0 E%+@^A_(T8/H?R- "44N#Z'\C1@^A_(T )12X/H?R-&#Z
M'\C0 E%+@^A_(T8/H?R- "44N#Z'\C1@^A_(T )12X/H?R-&#Z'\C0 E%+@^
MA_(T8/H?R- "44N#Z'\C1@^A_(T )12X/H?R-&#Z'\C0 E%+@^A_(T8/H?R-
M "44N#Z'\C1@^A_(T )12X/H?R-&#Z'\C0 E%+@^A_(T8/H?R- "44N#Z'\C
M1@^A_(T )12X/H?R-&#Z'\C0 E%+@^A_(T8/H?R- "44N#Z'\C1@^A_(T )1
M2X/H?R-&#Z'\C0 E%+@^A_(T8/H?R- "44N#Z'\C1@^A_(T )12X/H?R-&#Z
M'\C0 E%+@^A_(T8/H?R- "44N#Z'\C1@^A_(T )12X/H?R-&#Z'\C0 E%+@^
MA_(T!6/&#^5 'W__ ,$J_P#E(U^QE_V7[P'_ .G&O]N;3O\ CTT__KSMO_1)
MK_$:_P""5BLO_!1O]C($$$_'[P'_ .G+'6O]N73B/LFGY(!-G;X!SDXA[<8[
M^O;Z4 :5%%% !37Y1N_RD_B!D?K3J9("48+UP>!@$@C&,G@?7M0!_$9_P>BR
M _LU? F,,1GXCZ>6 !(XL]; )QTZY'(]*_SB)<*Q4R-."S+MRP(*G&<D8Y(W
M8 QT))R<_P"S)_P5L_X)$_#;_@K-\/?!/P_^(OQ2\7_"^T\%>(K/7X-3\(Z1
MIVJW&H-;)<Q/;R17Y:-(9A=R(\JD/ %WCLP_".3_ (,K/V39B2W[5GQD!4X8
MKX1\.H6;:A<G##@L25V'9M((.2: /\W')&?E?/?D=N.Z'T]31N/]U_S'_P ;
MK_2+'_!E+^R7V_:M^-'_ (2GA\_^U*/^(*7]DO\ Z.L^-'_A*>'_ /XY0!_F
MZ;AU*,1Z$C'XX0?SZTFX$\(0,<A6/7L>GY^O'I7^D9_Q!2_LE_\ 1UOQH_\
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M !RC_B"E_9+_ .CK/C1_X2GA_P#^.4 ?YNFX_P!U_P Q_P#&Z-Q_NO\ F/\
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M/C1_X2GA_P#^.4 ?YNFX_P!U_P Q_P#&Z-Q_NO\ F/\ XW7^D7_Q!2_LE_\
M1UGQH_\ "4\/_P#QRC_B"E_9+_Z.L^-'_A*>'_\ XY0!_FZ;C_=?\Q_\;HW'
M^Z_YC_XW7^D7_P 04O[)?_1UGQH_\)3P_P#_ !RC_B"E_9+_ .CK/C1_X2GA
M_P#^.4 ?YNFX_P!U_P Q_P#&Z-Q_NO\ F/\ XW7^D7_Q!2_LE_\ 1UGQH_\
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M_P#_ !RC_B"E_9+_ .CK/C1_X2GA_P#^.4 ?YNFX_P!U_P Q_P#&Z-Q_NO\
MF/\ XW7^D7_Q!2_LE_\ 1UGQH_\ "4\/_P#QRC_B"E_9+_Z.L^-'_A*>'_\
MXY0!_FZ;C_=?\Q_\;HW'^Z_YC_XW7^D7_P 04O[)?_1UGQH_\)3P_P#_ !RC
M_B"E_9+_ .CK/C1_X2GA_P#^.4 ?YNFX_P!U_P Q_P#&Z-Q_NO\ F/\ XW7^
MD7_Q!2_LE_\ 1UGQH_\ "4\/_P#QRC_B"E_9+_Z.L^-'_A*>'_\ XY0!_FZ;
MC_=?\Q_\;HW'^Z_YC_XW7^D7_P 04O[)?_1UGQH_\)3P_P#_ !RC_B"E_9+_
M .CK/C1_X2GA_P#^.4 ?YNFX_P!U_P Q_P#&Z-Q_NO\ F/\ XW7^D7_Q!2_L
ME_\ 1UGQH_\ "4\/_P#QRC_B"E_9+_Z.L^-'_A*>'_\ XY0!_FZ;C_=?\Q_\
M;HW'^Z_YC_XW7^D7_P 04O[)?_1UGQH_\)3P_P#_ !RC_B"E_9+_ .CK/C1_
MX2GA_P#^.4 ?YNFX_P!U_P Q_P#&Z-Q_NO\ F/\ XW7^D7_Q!2_LE_\ 1UGQ
MH_\ "4\/_P#QRC_B"E_9+_Z.L^-'_A*>'_\ XY0!_FZ;C_=?\Q_\;HW'^Z_Y
MC_XW7^D7_P 04O[)?_1UGQH_\)3P_P#_ !RC_B"E_9+_ .CK/C1_X2GA_P#^
M.4 ?YNFX_P!U_P Q_P#&Z-Q_NO\ F/\ XW7^D7_Q!2_LE_\ 1UGQH_\ "4\/
M_P#QRC_B"E_9+_Z.L^-'_A*>'_\ XY0!_FZ;C_=?\Q_\;HW'^Z_YC_XW7^D7
M_P 04O[)?_1UGQH_\)3P_P#_ !RC_B"E_9+_ .CK/C1_X2GA_P#^.4 ?YNFX
M_P!U_P Q_P#&Z-Q_NO\ F/\ XW7^D7_Q!2_LE_\ 1UGQH_\ "4\/_P#QRC_B
M"E_9+_Z.L^-'_A*>'_\ XY0!_FZ;C_=?\Q_\;HW'^Z_YC_XW7^D7_P 04O[)
M?_1UGQH_\)3P_P#_ !RC_B"E_9+_ .CK/C1_X2GA_P#^.4 ?YNF[U1S_ ,"Q
M_)11D?W'_P"^S_\ $U_I%_\ $%+^R7_T=9\:/_"4\/\ _P <H_X@I?V2_P#H
MZSXT?^$IX?\ _CE '^;S$<EN$'3_ %I)R"<<<=N>WKDYYJ3.<\1=\XCZ<?[_
M /GI7^D*O_!E1^R4O_-U?QE.0,[O"WAPX_ R<>XZCH>14H_X,J_V2\\?M5?&
M/KV\*>&^Q[_O,8]\8]*N$W!O7W6FFM/1%Q:NE+6*3LMK/H]/Z[G\!WP"^+^I
M?"J[U&ZL4M91J%E-;R+)&2 S0O$"&(."I8,!@G((Q\V1XOXX\0S^*?$-_P"(
M)S"ES=WDLDB1@8/F,Q!XQP .I /(R."3_HP1_P#!EK^RFF%@_:N^,<6-_ \*
M^&E#;^Q+OS[8((["F?\ $%9^R<N&?]JKXON02?\ D5?#&6)SG=B;YNHX(P"!
MQFO.I87V>)G6Y;<S_#7>[?X'EX++X4<=BL54LG55H>NNME?>ZM_P7?\ S:25
M&#C)8$\/M'+,<8]NE&Y,<ID]\L"?7KQGC_"O](H_\&4G[)F23^U;\9SDDC9X
M7\/%0">!E)<<>_.,>U)_Q!2?LE_]'6?&G_PE=!_^.UWMIMM;?\,>CMI>_G\V
M?YNN2/X7_,'_ -DHW'^Z_P"8_P#C=?Z1?_$%+^R7_P!'6?&C_P )3P__ /'*
M/^(*7]DO_HZSXT?^$IX?_P#CE(#_ #=-Q_NO^8_^-T;C_=?\Q_\ &Z_TB_\
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M/]U_S'_QNO\ 2+_X@I?V2_\ HZSXT?\ A*>'_P#XY1_Q!2_LE_\ 1UGQH_\
M"4\/_P#QR@#_ #=-Q_NO^8_^-T;C_=?\Q_\ &Z_TB_\ B"E_9+_Z.L^-'_A*
M>'__ (Y1_P 04O[)?_1UGQH_\)3P_P#_ !R@#_-TW'^Z_P"8_P#C=&X_W7_,
M?_&Z_P!(O_B"E_9+_P"CK/C1_P"$IX?_ /CE'_$%+^R7_P!'6?&C_P )3P__
M /'* /\ -TW'^Z_YC_XW1N/]U_S'_P ;K_2+_P"(*7]DO_HZSXT?^$IX?_\
MCE'_ !!2_LE_]'6?&C_PE/#_ /\ '* /\W3<?[K_ )C_ .-T;C_=?\Q_\;K_
M $B_^(*7]DO_ *.L^-'_ (2GA_\ ^.4?\04O[)?_ $=9\:/_  E/#_\ \<H
M_P W3<?[K_F/_C=&X_W7_,?_ !NO](O_ (@I?V2_^CK/C1_X2GA__P".4?\
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M\/\ _P <H _S=-Q_NO\ F/\ XW1N/]U_S'_QNO\ 2+_X@I?V2_\ HZSXT?\
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M7/[.WQ@T[5O$%G$7U+X<^)KNQT[Q]8F1WA$=[X=:3[5%Y;J=X#RR!1GRVP<
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MIQBN8V7<I0QY?!P: /K'RY/[R?\ ?+?_ !5)Y4O_ #T7_OG_ .O7YT?LT_\
M!3G]EO\ :R^ 'Q,_:C^#'BVZUKX4_"34-3TCQM?7$4$/V.32;5;V[N8!%+(C
M.L<G!=ANBR_W6%?F1J7_  =)?\$OM#UBYT>]\3_%>?3+36GTC_A,X_"L,GAR
M6[2]-M<QQ:K!=QP2VFGS!HIWV/Y(#HX#*0H!_2=Y4O\ ST7_ +Y_^O1Y4O\
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MIRV\C^5.C1I<6\F(I55UVU^NES=2R2P+;O#Y#"5[ZXMYM[Q& ;BBLC?*?E)
M)4G/3)- &QY4O_/1?^^?_KT>5+_ST7_OG_Z]?E+^W[\5/^"AGPJ\+^)/BY^R
M[X9^"&N?#7P)X-U#Q9KEEX[\1:KI7B"_;30]S-'#;6EL8I&DM4VJKW(+-M54
M9SBN<_X)3_M\?%W_ (* ?L 67[5/BKP'X>\*_%&YO?BEH5IX#TN>\.CWVO\
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MG_Z]'E2_\]%_[Y_^O4VQ?3]3_C1L7T_4_P"- $/E2_\ /1?^^?\ Z]'E2_\
M/1?^^?\ Z]3;%]/U/^-&Q?3]3_C0!#Y4O_/1?^^?_KT>5)D$NI SQMX/IGKG
M!Y__ %U-L7T_4_XTH4#.!C.,]>V<?S-  %49P ,^@]/:EHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *KSQ@Q,0H=T)= 2!AMV1@GH
M,_3/K5BH9Y/+0D#G'MZJ.ASG[U 'F_Q)DS\,_B&TQ,=R? GC!CP=A\OP_J#
MD '=@*"0O)QQ7\MW_!K%YVN_ ;_@H%I/B#1[#4],U/\ ;)\;/=65Q!!-INHR
M7>CV\=U:7MM-')%*LT4$:DS@KTR" *_J;^)Y#?#;X@;B-Q\!>+^@P<'P]J.1
MCMG.00!T([D5_+?_ ,&IJE_@Q^WMBZ=(K?\ ;2\73F,$;6;^R54$LPXVX"D
MYR>F<F@"U_P=!_LZ_L\^!O\ @DG\1_$?@#X&?"WP=XFN/BO\*8K?Q!X:\&>'
M- UZT^U^*&.HJE_9Z;#>/]M4/#.XF <.7(*E<_K#_P $R_V;/V?+']A_]C#Q
MY8_ OX3Z;X^M/V?? .JV7BM?!7AN;Q39:K<>%XC/J2^(!8/J$]]*7D>>\>0M
M)+([>=N?%?G5_P '5MP\W_!'?XAWU]IXM;]?C+\([19;R/8H1O$[*D^$.?)C
MB*EIM@4!& /.:_7K_@FC&L7_  3S_8Q17BOR?V;/AY:F]L&\VVV+X3C<RPSG
M"F-GB$49)&6=23WH _C$_86_:P_8%_95_P""IG_!2FX_;ETCPA86OBOQCX:G
M\,:WXZ^'=Q\3$A&G6&N0W=I9QP6&I-I!O'F5XMJKNXPK+N(_KV_8._:,_P""
M=_[3UCXP\;_L)Z9\/(7TJRU#3?%6H>%_A<G@>\N(<.##-<#3M.^T1+?,CLI+
MEA)\P Y/\NG_  2P\"_L<_$7_@IU_P %5-,_;)T3X5ZS:6OQ!\#'PW'\3KI;
M1'5;'Q'YR6ZR7<,3HLBPF50RJS*A(P"*_KB_9:\-_L+>"(O%GA+]C2U^#NF1
MMIU[K'BO2_A1J4-].L5RTL"SW$%O>705C=!%4,%PX"A59Q0!_./_ ,$+[9D_
MX+#?\%;)@L 6'Q]X($TT*B ;IO#FMXC$!8NT9PQW(-L>,L<R 5^@W_!RS^T]
MXK_9P_X)C?$^Q\%7TNE>,OB_)IOP^TGQ)IEX;&]TP:CJ^E6=PUI-"K.9O)O9
M%7:P*CG! (/Y4?\ !&7XM_"OX8_\%</^"K$GQ5^)'A'X>/?>./!XTT>,M;LM
M&U+4X8]!U:.ZCMDN9DBD0DQK)G]ZN 8\DD#[@_X..?"/@C]LK_@F3\1->_9P
M\8:)\5];_9[U;1?B+<>'/AQJ<'B:Z2WM_$&D"[N+NTT^2>X,,,,,DKH%9VVG
MRQD9(!]8_P#!'[_@E5^S1^RW^Q5\)AKOPD\#>.?BY\0O"]GXF^)GCSXB>'=.
M\5:SKVKZOYMXEN+C5HKN6V@:WO5BBC1W8@,Q# JJ_A=_P56^!OP]_P""4?\
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MV5FZ;_@Z]%TG_!)G5H)+F]$0^*GA)$_LM%E:]TF'1-:5?MYD5U17.R662-N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+1]<\&?:%TO5[O1H-"M-0TP:!K)T_4OLLMU?7D,<<:0[=D;H^Q7R/A/XG_\
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M/V5OBKHGAC3[:2VL;)H8O".HFUT"WBG.3/>?-!!#;J9&>7<@V[P?Q5_X-_\
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MPR17K?[&G[#WP*_8+^#UK\!OV:?#VJ^$_AYI_B/6O%5K!KFMW'B*\DU+Q/J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 8^[C R,KGUSO3'X8W$_0=*_AF\"_&KX@?L%?\'$7[8_Q
M!^)/[-_Q/\6>!OVBK*Z\*_#KQOX9\/Z[J^CM;7E[I%W!->:AIVC7]MI]MYUK
M/'.)V8"  *0[;J_N8EX1F 8E1D!#\W&<8!R">3U!'?L,<[')'+=1%A8#@!EO
M8$^V=20%8(JK@DG Z9XX P ?GA^VW_P39_9(_P""EG@CP?HW[1?@._OKJRBT
MW7?"_B?1KRXT'Q7I"NL%]=6,&L6\)OM-G2%?LY)<2(#E7WKN'QSX-_X-M_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>forms-1_012.jpg
<TEXT>
begin 644 forms-1_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $S!$P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!(Z@Y]^.GT/-+34  X/7!/KD@=1VXQQ3J_&-'L[KH_P_3]>IVA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444A.!GKT_GB@!:*C=CP%.#C)R,^_
MKVP<_P#UJ8<G^->./NG^A/KWP?:L_:PNTFKK^:\8_P#@3BUZ=^C GHJO@_WE
M_P"^6HP?[R_]\M2]HN]/_P &K_Y6.WI]Y8HJO@_WE_[Y:C!_O+_WRU'M%WI_
M^#5_\K"WI]Y8HJO@_P!Y?^^6HP?[R_\ ?+4>T7>G_P"#5_\ *PMZ?>6**@^;
M^^/R;_&CYO[X_)O\:/:>=+_P:O\ Y6%O/^OO)Z*KX/\ >7_OEJ,'^\O_ 'RU
M'M%WI_\ @U?_ "L+>GWEBBJ^#_>7_OEJ,'^\O_?+4>T7>G_X-7_RL+>GWEBB
MJ^#_ 'E_[Y:C!_O+_P!\M1[1=Z?_ (-7_P K"WI]Y8HJO@_WE_[Y:C!_O+_W
MRU'M%WI_^#5_\K"WI]Y8HJO@_P!Y?^^6HP?[R_\ ?+4>T7>G_P"#5_\ *PMZ
M?>6**@^;^^/R;_&CYO[X_)J/:>=+_P &K_Y6%O/^OO)Z*KX/]Y?^^6HP?[R_
M]\M1[1=Z?_@U?_*PMZ?>6**KX/\ >7_OEJ,'^\O_ 'RU'M%WI_\ @U?_ "L+
M>GWEBBJ^#_>7_OEJ,'^\O_?+4>T7>G_X-7_RL+>GWEBBJ^#_ 'E_[Y:C!_O+
M_P!\M1[1=Z?_ (-7_P K"WI]Y8HJ#YO[X_)J/F_OC\F_QH]IYTO_  :O_E86
M\R>BJ^#_ 'E_[Y:C!_O+_P!\M1[1=Z?_ (-7_P K"WI]Y8HJO@_WE_[Y:C!_
MO+_WRU'M%WI_^#5_\K"WI]Y8HJO@_P!Y?^^6HP?[R_\ ?+4>T7>G_P"#5_\
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M_P K"WF3T57P?[R_]\M1@_WE_P"^6H]HN]/_ ,&K_P"5A;T^\L457P?[R_\
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M/^&E?^"I7_1._AK_ . VK_\ Q=?:OGS_ //6?_O\_P#\71Y\_P#SUG_[_/\
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M3^>?_@7_  #XJ_X:5_X*E?\ 1._AK_X#:Q_\71_PTK_P5*_Z)W\-?_ ;5_\
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M_BZ/J.4?]$UP_P#^$,O_ )(/:U/YY_\ @7_ /BO_ (:5_P""I/\ T3SX;?\
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M7;?5Z2T6^W3T&Z]35<\^JW]4?%G_  TI_P %23T^'?PV/_;KJ^?R\S/XT?\
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M86V+N.W+[?FR.@)J9X3)8?'PYP]!/9_49R3^YZ![2K_//[V?%'_#2G_!4O\
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M\WI#//C_ %TR^YE<_APQY^N!ZD5\U]3R;_HF^'__  AFOSDB_:U/YY_^!?\
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MJ+I^D:MK$_P]^&P@T>QGU&95M]7#2);H69,%^00"QP<[E7'6OM\/.#D3S?\
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M)_\ !4K_ *)W\-C]+75S_*2OM(S7&/\ 73'V\R0G&>GW\'C\Z:9YP.)I1G
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M;Z[<>/=8F_M"2(--&T]P]HQ,JQLK.VZ1@A)%?MW\1/\ @F7X-^(?_!0CP?\
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MN;33F%F+/1+_ $FUU:* L5MYHI+Y;M!"@=&6-E8$<?:Y-Q%X787,\XHPIX;
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MIZ/0YSQAXAM_"7@SQ5XJN@&BT;0=5F@48W+J'V*_>R(3:6D87)ADRJ\DA0>
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M_P#QF6(_^=@?5*M[?6(WU_Y=J^F^F^CT?9[VV/YCO^'UG[.O_1*/BK_X#_\
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MX?5_L[?]$H^*G_?@?_*^OZ</^%8_#/\ Z)UX"_'PCX? ].]A[?I[52U#X?\
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MN,L0[*]KNV6.RNTKNROI>]DU]3J_]!$?_!:_R/YEO^'UG[.O_1*/BK_X#_\
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M3G_CW'4]3_R#Z_IO7X7_  S"@?\ "NO 1Q_U*/AWN21PNGJ!GL, GW.32_\
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M^'^GKG[!T]^A[4EXL\&O;@/-'K;3C.N]5NM,M>JZK==@^IU?^?\ '_P5_P
M_F-_X?6?LZ_]$H^*O_@/_P#>ZC_A]9^SK_T2CXJ_^ __ -[J_IQ_X5C\,_\
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MROYTE^L6?*L/_!=3]DV.>.1O!OQ (5T.-H(!! R!]C ..1U&1D\9X_*_4/\
M@IU\#]8_X*W:/^T-IGA#QC>>$+?X*Z1X6?3(H VJB_@UNXN9+B51 5$167&T
MHQ(.>^1^_P##X+\"^?&/^$#\#X$JY_XI'P\2!L&T<Z=C!]R.>,BO@[]F[PMX
M2?\ X+IQ:<WA#PJVEM^SKI3C3&\/:/\ 8$G/B?409EL6M# MP<?Z] 1D  UW
MX;#<"Y!E7%V;1X=S24L/PKC[TY9_4FL1%U:5\/=X=^SE4M[M:R]G9VE&^LWK
M5ITJ?MXKFJPUY$MF^ME_PW8];D_X+7_L[232N/A3\5-K2R2!?LP! D=B"O\
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M2OS*'&>)@I7LWSJ.704KM)OF4KVU']3JM)/$1:6R]FK+O9-.VRVMLC^8]O\
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M3_PC] _^5]"\5^#5MP#FB].,:ZWU>V6+=Z^NH?5*UK?6%;M[/3[MOP/YCO\
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M'_#ZS]G7_HD_Q5_\!Q_\KJ_IR_X5A\-3S_PKCP)^/A#0,_KI^11_PJ_X:_\
M1./ G_A(:!_\KZ^*7BSP=96X"S5*RLGQEB4TK+1IY=)W6UG*3[R>[T^J5?\
MH(C_ ."T?S&?\/J?V;Y-CW'PA^)\QC<M&TMLDIC./O1@Z?P>.2 #D8#=*<?^
M"UO[.Q/_ "2CXJXXQFW'  X&?[.S@=!DDD 9]OZ<?^%7_#3_ *)QX$_\(_0/
M_E?1_P *O^&O_1./ G_A(:!_\KZ7_$5>#.93? .:.45)1D^,:[<5*W,HWRQ\
MJE9<W+R\WVK@\'4=OW\+KK[*-_OM?\3^8T?\%K/V=?\ HE/Q6'TM_P">-/']
M>_3N?\/K/V=?^B4?%8^YM\G]=//'X^O'K_3E_P *O^&G_1./ G_A'Z!_\KZ/
M^%7_  T_Z)QX$_\ "/T#_P"5]5_Q%G@[_H@LU_\ $RQ'_P [ ^J5?^@B/_@M
M'\R47_!:[]G1)8G/PH^*@ WY!MQC(Y!(^P ].!TP<XSUK\K?V;_^"FOP<\&?
M\%(/VJ/C3J'P_P#'MQX?\>6UNFE:5;P!M6M&A\,:7IY:\7R#A6EMY"IVD*C?
M=..?[O\ _A5_PTS_ ,DY\!@^_A#P^"!ZG_B7YP/7I7\]G[(?A+P7+_P6K_;U
MTF3P;X1DT^!]"AM[!O#.AM;6Z?\ "$>'V8VT']G>5 DC%C+@[I"[,<EL5]KP
MCXE<&XS+>.E_J1F=+V/"&*K.+XKQ%;VJACL)^[36!I>S=[OF][F^&VQE4PE7
MFI_[1!>\]732LVE;6WEMZ6V9Y!_P^N_9V)_Y)-\50&#$?Z../G)[6!YQ]<YQ
MP:4?\%K?V=AT^%'Q5_\  8?_ "NK^G#_ (5C\-20/^%=>!3GM_PB&@$=,]?[
M/Y_/.<#%+_PJ_P"&G_1./ G_ (1^@?\ ROKXB'BSP<XI_P"H.:QONGQ?BH/2
MRUC+ 5&KVONE;[*Z[/!U=/W\=M?W:_R/YC_^'UW[.^0?^%4?%7(S@_9AW_[A
MU(/^"UO[.PX'PH^*V"03FWSDCD$YT\\CL>H[5_3C_P *O^&G_1./ G_A'Z!_
M\KZ/^%7_  T_Z)QX$_\ "/T#_P"5]/\ XBOP9>_^H.:7[_ZXU[_^JP/JE7_H
M(CO?^&M^_KY[G\QW_#Z[]G?_ *)1\5<@ #_1QVZ<_P!G9'UZTC?\%K?V=<C_
M (M/\5,$_P#/N!@<#.#I_P!>,^_>OZ<O^%7_  T_Z)QX$_\ "/T#_P"5]'_"
MK_AK_P!$X\"?^$AH'_ROH_XBOP;_ -$#FG_B8XC_ .=@?5*SWQ$7ZTT?S''_
M (+6_LZ ,?\ A5/Q4/'3R%]1Z6!/Z=ZR/$G_  6F_9XOO"?BO3HOA/\ %)9+
M_0+RV1Y(%6-&EMYE!8_85')8$Y9<JA],U_41_P *O^&O_1./ G_A(:!_\KZX
MWXB?#CX<6O@/QA*GPZ\#@CPUK/RIX1T!0^+&7"LW]G_* <,#T!7CYMM;X7Q5
MX-JXO"P? &:RY\5AHK_C,:\N63Q%!1J<KP%)25*5JK@YI34'%J7-RR3PE51D
M_;QTA/\ Y=K^5G\1O_!*G_@IY\&O@+\%OB9X:\4_#SX@:Q=Z]\1]>UJUN-)A
M'DPP7OB#4+Z*.51!.-\<3J),LF21^[ ^9OTQ7_@M;^SL5#?\*H^*IW#(/V8#
M(/(X_L\X'H,],'CH/HC_ (($>#?!NL_L\?%H:KX,\(ZBR_&KX@A9;SPIH4\P
M1/%>LI'"6ET[<L,2;42+[B[2RC)S7[U_\*O^&O3_ (5SX$(' _XH_0.G;_F'
M^GTKZOQ"\3>#L%QMQ!2?!69XR4JN!F\7'BBKA563RW!)6I1P=3V:BFHN/LX)
MM<UVV12PU65&DOK$=(M_PT^KZV/YC?\ A]9^SK_T2CXJ_P#@/_\ >ZG'_@M=
M^SN>OPH^*O<?\>PZ$8/_ ##N>"?\17].'_"K_AI_T3CP)_X1^@?_ "OH_P"%
M7_#3_HG'@3_PC] _^5]?'?\ $6.#M_\ 4+-+_P#998C_ .=AI]4J_P#01'_P
M6C^8V+_@M1^S7!=/>P_!_P")T=](C*]VMB@N&4\8,ATXM@[5]A@#D#EW_#Z_
M]GC+?\6I^*HY/_+N.=Q9CQ_9^>I/<_7@5_3A_P *O^&O_1./ G_A(:!_\KZ/
M^%7_  U_Z)QX$_\ "0T#_P"5]2_%;@UN[X"S63Y5&\N,L1)J*VBG++6U%=(I
MI+HD'U2M_P!!$?\ P6?S&G_@M;^SL>3\*/BJ3ZFW_P#O?1_P^L_9V_Z)/\5?
M_ <#_P!QU?TY?\*O^&G_ $3CP)_X1^@?_*^C_A5_PU_Z)QX$_P#"0T#_ .5]
M4O%C@Y62X"S1);+_ %RQ%O\ U6!]4J_]!$?_  6O\C^,#_@HG_P5>^!WQK_8
MR^+WPK\.?#CXB:5K/C#2[C3=/U+58%6PMIKF-6BFF_T-"$CPAD)90$3.X 9K
M^I3_ ()KQ-!^Q#^S=$Y5G3X8^%4=D^ZS)H5BI9>>$)0\?W\G/45\K?\ !:KP
M-X%TC_@FE^U+=:;X'\(6%W%\.]5DAN[/POH=M>6\RK$8Y[:>&QCN+>XCR&CF
M@=948*5.0I'U!_P3-8M^PU^S.78$CX5>$\G.1C^P-+P<].!P<G(.<]35<:\1
MY/Q'X4Y9B,HR7%9/2H<9SI5(8K-?[5E4E++5[_.Z&'Y'>*M[K44GRVNT*A1G
M2Q23DFO82VLMO*[?WGWG14<7W!GJ,YSUZGK^&/PJ2OY_G'GCRWMJG??8[PIC
M\KQSSG\!FG$9!![@C\Z:$"*P&>AZG/K^'?M^.:<G:,G_ '9?D_\ ,-C^<+]E
M;/\ P_:_;!QT_P"$5UD'_P !="/\Q7V#_P %J?AM\8/%?[%'Q(\;_ 3Q]XN\
M"?%7X9:6_B7P]<>%M1N;$:A;VS0S:E;7\=J#+<(;2&;RP =N",?,,_'_ .RL
M/^-[/[87_8JZR?RM="&/KDBOZ$?&/AZS\6^%?$WAB^AAN+7Q#H.K:)-%<(K1
M%-2L+FU<OOR,+YBL1@XVY')X_6.*LR63\8<%9C.E3K4\+PIP;4K4*R3I5Z/L
MJ2JT:BEHX5*3J*2W:AIKH\*"?LJL?YI5X2\E.<K:]K6?7]#^3#P5^W3\=?BG
M_P $&?#?BKX*>*=?UK]K/Q!X=G\(^)+XZC)>>(='\7,;^%M1::/_ $NU6&*W
M1@[A3&H5Y"N<CZ(_9C_:9\=_M[_\$L_A@]E\0-?T']H?3O'VC^!?$FH:#K$]
MIKLMQX8\1V.D>+VN)ALNG)C@N6G$J*=ZY+,"<<#_ ,$:/^";WQ__ &7/VJ?V
MX?#'Q<T29?V<]8\:>((OA?I^H(9]*NUU-8I;;5]+$D"1Q>4ES>6@$4S %59L
M.6 C_P""4_\ P3=_:!_9A_X*&_M.R^,+;5+3]E_2]>O?&?P;TU_-.F7>N^-M
M0O+SQ%*%,:JS6TKV\P7>RQL2%.*_4\[J^&$J7'&$R[&8:GB\#C\)QUDN:<U&
MI2QU>M@%1GPU@H5(0J>RI8BK.48NE&/[B,I324)U/,Y<?"G2E%2=2.(5%T]$
MXX925ZM^9*UKO=O1^Z]#PS_@K_XT^(_[+?[87_!/;X1^$?CM\5/#?PY^(FM^
M$O#?Q6N/^$INHYM2TNXN=134+HNL;;)7\F-W8JW&5W#=NK1_95_:>_:2\(_\
M%K_%7[-/P&^(GC3]H']C#3_A]%KGB/4?$;ZGJ1T779_#D=]]DM=8O7ALO,;5
M96MT\J AU+ RH,++H?\ !<SX!_'_ /:&_;P_9!\1^ _V?O%_Q&^%_P &O%6@
MZMX[U33M)UMK>_L+2\N);R".[L8PH54N  T<T9^3);&<_P!/'P:^%7PK^$?@
M:SU[P#\,--\'W=WX>T^]U*VL]-+^(;IX;%2MO<75UYVJ3S1MO1(7N6QET,9;
M!'GYIQ3P_E'AMP=6Q-'!<0YSGF79[@<WP$99;]3C6Q%5T\OQ>9>R3QN'QM!3
M<\%B,/5@URN%54IPA,VG2K5,=B*,)<L&\%7A65[34)MU:::[26O-%:NZYE>_
MQ%\$_P#@K!\)_CI^W!XY_8>\+>"?%&E>._AYX4B\2>)M7U::Q:S1WU>;3)+&
M"WB83 H561I&.!\H ZXZS_@JK\6OBKX _99^('A[X!:G%IGQQ\4>&-:E\&7,
MMRMN;:VL;:8:A>0GSX)3-% XDC$1)#KQDGC\.?V3/A5^T=X8_P""Z/Q^_:D\
M1?L]>,=&^$GQ%\*2^#/#WB"7P_JUM US%KT^IK?7#_94B3S8W*-*961F"9V\
M9_3?4/#,G[;7[:.J:+\>_@)X]LOA%\-]&UW3?"6H:I:^+/#^E:ZU_:Q1RW#W
MME<622KO)VK$[)(-I(*]/F,5PQPEP]Q+PKF6%EA*^29?PS@,YS?"4<93Q=7&
M9JVJ^*R_V&(Q,^>O2BW2ES5)4JGLU+GYING'HA4KN6,A*+C*5:5+#RM=1I25
MG4NGI&\I3[ZK1/;FO^"!?[=_B?\ :T_8ZUK3?B[JL^H?&KX!^)]8^'_Q"-_>
M+>:EJ+^'["W:36<AGD>"YGW)O=G)=@A8NI ^XOV,_P#@I#\$OVW_ !I\;/ G
MPIT_Q)9ZK\"?%"^%/%CZ[:/!;W%^V\"6P8PQ*\ \N1@5=PVW"-EA7\Z?[%?P
M%_:7_P""=7_!6/\ :)_X5%^SUXRN_P!CWXZ#4-/BV:9KM]IFB:F-4OKU+^"6
M2.9SYZQ0P27$TTGF*T8W8!+_ +.?\$OY/VH9/B7^U&_Q[_9[\(_!GP[<>.+2
M?P#K7AZ,PWWC+27BFD-[J*?8;8O+$) CEWD)8$!CN%+Q(X;X,HXWB7B#(\;@
M)Y?FF"R/-N'<)1QN$=7"5\QIO$9SE>*PU.JW">#J3ISC3M*G#FY*4Y2A*,.?
M"3KT*%/#5%*I4C7JQ]LUHZ?M)J+])0:UM>S6BZ_:W[<GCCQEX3^ OBG2?AI?
M?V7\4O%MA?:?\/[LN52WUG38DU*1W"M'(ZR6EO-'A63.\)N)(!^9O^"7_P"V
M!JWQ?_8\/B/X[ZQ;V?Q3^"K:[I7QPGE?*:9?6NIZIJ%E<RJ\LKQJ^@?8YA$2
MSJH"L-S;3!\0O%OCGXU?ML>%_A/XI^"_B]_@SX.MWU$>,YM-UNUT>\U6[MKF
MVN(VOHEBC,9CVJNR12=PV-N(S^;]Y\!_C7\/?VQ_VV/V=OA)\)/%VC_LY?M8
M^$-4NK;QA;Z=J[:/H/CR?P7IGAW3F@NYDD@AM/M$MS//<23GRN7897GQ,ER3
M),9PX\@Q>(R["9M4E1XCCG%6O3C##X.56E0K93*HIO\ ?5H5'74+<BY$Y24C
MMJ<W/3FI/DC=RIV=W[LDEMW:7_#6/UVC_P""D7P3BU+X=MJUEKFE^&/BIKWB
M7P_X*\6O$MQH^HW7A;39M6U6XWP1.T=G]@A-PCS",,"-I9FQ4-Y^W_\  OQ)
M=^$/#>I^']:O?!7Q>UB'PKX-\4B%;W0/%#7\SZ<)[?[-;2LMH;J.:U+S,NPV
MYD=E1EQ\-_LX>%OC3XB_9XU;]B'XA_ FZT;QYX&T76_"^A_$W4=*NCX8\JWT
M^73+/7=)\27-GY$E]J)ME6XEMVB)BG5W9DZ]3^P-J_QL^"GPE\+_ +)/Q5_9
MSDUOQA^SM%JECHWQ!N='NK_PWK]@-7N=:@U;3?$$EB]J^M12:HT,45H4D>..
M(@@[]V5;A[AVE#%2PRI5\90QE+#X>A3SO!T88C!N$V\RIU7.HHN-6$(.C449
MISYK2BK2F-2HY46VXQ49<R<=I=(NU^G5?@SXI_9P^(W@;X;_ +('QLTOXMZW
M\4;;P1-^U[XYTO1]=^'_ (@32M7T-F^+UO8Z#8FYGBD9-+:X>VLG@&%%FTRN
M%23=7ZBS?\%0_AMX8\6^/OA-I_PN^(_B;Q%\(?"IUW7#9W6E//<Z%I]M9[K]
MY9$0R3L)8_,."&RQP2"!^/GAWP5^TA8?L2_'OX>7_P"SAXPE\9:Y^U3?>/\
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MHU3CIIM^1@@YQ;2<<=.O>M*33KX=)Q;^M8;2ZZ8B@^_D)M6>J[[KS\S\"/\
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M_D+13<M_=_\ 'A1EO[O_ (\*+^OW!==_P?\ D(5)<MV\LK^.<U_.=^Q\"?\
M@M_^WP>ROH.?_"'\._XBOZ,LGNO'?D&OYSOV/#G_ (+>_M]X_P">F@G_ ,L?
MPYCUXX'/OT YK]#X&:67<?7O=\&XFVCZ8_"OHG;?K8PKZJ"6KYX]_P#)']%R
M]5^K?R%2U&H. 1S@G ]<X'7MTIV6_N_^/"OSUO5[[OHS=M7EYNZWVLO(=129
M/=3^8/\ 449/H?T_QI7_ *L_\@NOZ3_R%HIN6_N_J*,MS\N.#@Y!Y[<<47]?
MN877])_Y#JX3XG?\D^\9?]BUK/\ Z12UVZEP<-@Y!P  #P1[].?Y5P_Q./\
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M7[[_ %=<91INUY*/M:KDEV:BUH];FBGB];4Z=T[?$W?S2MJNE]/0_7$_M'?
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M_@0!C_A<'P_/.<_\)7HI/7I_Q^$XQQ[9SUYK\CO^(=G_ ()Q?]"%XG/(R?\
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M?ZL5W%WZ.RC*W31IVV=[,.?&_P#/NC;K[S3L_P#MW]3]<3^T?\!CQ_PMOP$
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M:&% )! "_P!H)]T# /8$]\U^29_X-V?^"<)Z> ?% _[G7Q:?_=@I!_P;L_\
M!.+I_P ('XJS[>-O%H_' \0?K3CE7A*DY1XRXC?V5+_57%.7*W>5^:K?1W<=
M6MK6*YL5TITO_ KOSZ?\,?KD/VD?@,!S\7? 6<YY\5:(<=< 8OB.,\D') QF
MFC]I#X# @GXN^ 25)PQ\5Z-]UL$J0+S!!(!Z9X 'O^2 _P"#=K_@G#DY\!>*
MC_W.WBW/YG7SG^G2F_\ $.Q_P3B!Y\!^*<9Z?\)KXM'?I_R,.,]NF,]NU3+*
MO"1/E_UQXD:27+S<+8N[73X:TDI6M?F:2>[T;1?%?R4?_ IW_P#2=_P/UQ/[
M1_P'(P/C!X !R#G_ (2O1^Q)/_+X."#@CIP",$9H'[2'P'!!/Q>\ ,0&&?\
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M26'[-?P/M+[XF>$;2Z@\&".XMI=4M%EBE:_F?RI/,FA:-]@_U<BHQZY YKW
M?&CX,]_BGX/Z8_Y"^FG_ -OQU[__ %JYO]E;_@@=_P $[_B3^SI\(O&6O_#S
M6KK6M;\+6E]J-X/%'B*(7,[RS!G,,>I1P(<=%CBC0D@X/%?0/_$.K_P39)./
MAMK?4\?\)3XA^O\ T%/2OW#%>+?A?@L7C,)'-N(7[+$XB#:R5N+E2KSISY6Z
M]W'GNH.T6X*+DE)M'GK UW%27(DTK7;OLEK[KMLK_HCR/_A='P8_Z*GX/_\
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M_EM1_P .:_V*?^@9XT_\*_QA_P#+:J_XE]X)_P"B\S;_ ,1N?_R8O[0G_P!
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MD_\ %V_  _W?%.C8Z=LW7^33O^&B_@4>!\6/A]D\#_BJ-''7W^U\?6OY(_\
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M'_R_H_XAV/\ @G$.O@/Q5^/C?QA_\OQ0LK\*K_\ )8<2?^&*I_\ +P]IC/\
MGW2?DJD[_C%+\3]</^&C_@+_ -%:\ ?^%1H__P GT?\ #1_P%_Z*UX _\*C1
M_P#Y/K\C_P#B'9_X)P_]"'XI_P#"X\8?_-!2?\0[/_!.'_H1/%7_ (6_B_\
M^7]4LI\*6[?ZX<3?+(:K_!5K@JF-?_+FFO6I+]$W^!^M_P#PTA\!BP7_ (6U
M\/QD@9_X2C2CC..>+MAWSU(]:_G]_9(^+OPGT[_@M#^W?XBNOB1X0@T749-#
M&GZG/K>G0V%[Y?@?08Y#;74ERJ2F-XY$(C#@LF-X!S7TFO\ P;L_\$X X+>
M_%;8P !XW\7\Y[9_MP^N,Y)QW]/QJ_9L_P""/W[%?C;_ (*F?M=_ +6?#&O7
M?P^^&ZZ2GA?31XD\20SP?:O".C7LI:]BUF.]D*75W,P::XE\P':P,02-?O\
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MUJ;?5?%$4T[I!J=G:R%H\9". JC"X7:\7>-?C-\$/B3K/C'6]%\+?M!?L_\
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M=&O?A?\ #CQGXXUFPT34?&7A[2=0DCN9/)#7MY TDQ2$;FBA$F0IVHB] 1M
M'L]O/;7D,5S;7*3P3)YD4\$J/%)&1PP<9!]B3Q@\#D5_+S\-?'GQ/^(?[0?B
M_P""OCJ;PO9:)J?[,6G6'PPE\8ZO?Z786NFRZLR6.O: 87C6?4LLY5F+J\8<
M?=8"OW%_8B\"^(?AI^SKH'@WQ9\1&^)E]HT^MN_B\3QW1DM;F]N)TLXY4)#Q
M:<CR00^8S,H7+#@5\UQEP/2X=>*JSQF&J3GF481PM"%*4?J]>I)TY490G)U'
M07+3KQ=N2:LM.5NL/B)5(TX233T7,^K2Z[63U?7HM=3Z6U+XA>#-(UNV\.:A
MXBTRSUF[ ^S6<\Y02RD;Q")55HQ+L^<QLP)7(Z@BOSM^"_[5OQ#7]KS]I/X+
M?%_Q/X8_X0'X;W6A#P7JB6T.FSB'5M(MM0"7LSR"2X4"Y*F5@T;%2ZG@FOS:
M^(OBGXL?!CXP>)?&^M:;X2_:2_9@\0_&C6[:;Q+;:MJ5Q\6?AEXHD9#?Z'I6
MBZ?,FFR:5I,1A\IKZ0LXDERF X/5ZMX#^'GQ1_:V_P""B&N>(+F9WTSX0#5=
M'M7FE@GLI(_A[9S6EXL=O-$!=VHE5=@)1'W!2V2*]S+N",KPD:WU^I];PF,R
MBM66(H4*#JX/&<V#A0<*?M)N52$\2HSC/DM#GJ/X&FZF(<83=DIPFFHM64HK
MFN[VTVZ=?6Y^T?[0?Q$^*7AWPMX5U?X'6?AWQ-<:KJL9U&:^U?1[:S&B%(7%
MS:3:G?6L$Q?=.P\EV.% P %%>D0?&?X9M:6DESXZ\/I-)-9V%PK7ZH(=1NHE
M06\Q(VQ!G<'?)A N78@#-?S#WOB/4?$'_!,WX :KK7C?5I]3\*?'37]#TG4/
MM4WVJXTJRL-)$&FW12XAD-O''.V&+MGKG/7T?X4_#CX9^./'/_!2BP\8:W<Q
MQZ'X.74M#MX[^;SO#FH67PYLIH]4T=3>+&+N"X,\R^9A=[+DA22-J7AM@GDV
M8XK&U\?3>5X_%X)SP6$H3G.K'%8/#TG73JMPH<N*A4G6BVJ7+)6G%MQQJ8N4
M*E*/+=58<U]5RV5]%9WO?JUL?TG:E\1? >D:E:Z3J?BG1K&_OH/M=G#<7T<0
MNX"AD,EM(Y$<Z[%9R87("@<=!6>/BW\,QHT?B ^-?#@T>:XCM5OFU&V,<=S*
MQ4P2_/E"K$#<W '(.P9K^7+P_8>)/'FD_P#!-_3_ (TZKK"W#?%/X@^&M)U2
MYFN;;4O$_@FQ\.Z,N@'5%\R-3')#+,TLA\U=\R$$$$CTVT^#_P /_P#A/_\
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M&(]J_P!]O^^S_C1M7^^W_?9_QJ2BE[-=W_X'4_\ D@N^_P""_P B/:O]]O\
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M2.@_"IJ:Y QGLP/X#K42IQIQ<HI7T6BY-Y+K!I_+85WW1!@$MG&[Y< #(Q@
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M9-V=2^F=XWK[3KUV7E?4Y:3;EB==ITWMWA!V_$8$^HY/&6]3_=&/RI=GN?\
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MX5^$?_3!IO([<DMD]R?>O"O^"WG/_!,W]J/';X=:MG_OW"*]S_X)G#_C!?\
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M<  Y'7\B/^%#?\%B?^B\_!;_ ,&OB7_Y2TO_  H;_@L1_P!%Y^"__@V\2_\
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MLER)>QLHZ)M:ZI.^E@<HR33I7NK/1:_.]WMU/T-_X8M_9^C\$67P_3P-;_\
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MT>ZT:-^;^Y(_;[=)_<'_ (]_A1ND_NC_ ,>_PK\0/^%$_P#!8O\ Z+S\&?\
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M]4UF,ZQX@'A?3KH7FG^5I\ADLTMYHHC*ZJ1)&R@M]X_JH?\ @FG_ ,%.\_\
M)POPO(/<:GKV/H =()QZ98\8&:^LXUX[X&PG$N8T9<8Y-&5.GEZM*EF-[2R_
M#U-7]7WO)?)HBEAL1*FFZ,HOF:W<KK7I;36^OR/:C%+Q^Z?@^@]"/7WI?*E_
MYY/^0_QKQ3_AVG_P4[_Z.%^&/_@RUS_Y4T?\.T_^"G?_ $<+\,?_  9:Y_\
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M/ZCA(<C(0#N0ZD_^A4_S%]1_WTO_ ,57\MW_  LW_@KS_P!%9^"?_@[US_Y
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MJ\69!2J4:V"HSH5'B934H9=@TY<U*G+1<MK6MJG>]TM,')O#TFX2NU)]NO\
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M@_=3NVE9IJQ@FWBU?_GQ+[V]?RV/NN/HW^]_[*M/#!LX[$J?J.M,CZ-_O?\
MLJU&Z,&.%+9).02,9)X//)'KZ5^.G26*8_0?4?IS_G].:?36 P<]@3^0I/1/
M_#+\F"/YPOV5FQ_P79_;!7 P/"NM%20"5S;:$6 8C.UF8L4)*@\@#O\ L/\
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M7X#G /\ Q1%D-NU0.))\'A1SP.>_4\U];E3_ ',^@]N>1QQD ?YS7R3^P?\
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M?_8B^$?_ $Q:97I%?'XZ$7C\;=7OBL4WK+5K&8JS?O=#1?#'_#'_ -)B0O&
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M[)&!/W> 17YSC_@OMJ/?_@FQ^V<#[:1X7/0D]?[7'H,>_P!133_P7VU+H/\
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MY8ME5!+G&?O 5:##C@>O"_R^;]:_G6'_  7WU'//_!-G]M#J2?\ B3^%N_8
M:N1@=CD$]2*0_P#!?;4<G_C6Q^V;^.C>&,_C_P 3BOB)>'/&_/4G/)H)U).;
M?]J8#5N[Z8MKJWZOT-/:T8I)R7EO_D?T3>:P'W !^/'Z8ZTGG-_G'^%?SM_\
M/]M0_P"D;'[9P[_\@?POV_[BW_U_3FE_X?\ &I?](V/VS_\ P4>&/_EM1_Q#
M?C>6L<EC)+2ZS7 JWE_OJ*5:@MG%_?\ I$_HC\YO\X_PH\YO\X_PK^=S_A_Q
MJ7_2-C]L_P#\%'AC_P"6U'_#_C4O^D;'[9__ (*/#'_RVH_XAKQS_P!"-?\
MAVP/_P VC]M1[Q^^7_R)_1'YS?YQ_A1YS?YQ_A7\[G_#_C4O^D;'[9__ (*/
M#'_RVH_X?\:E_P!(V/VS_P#P4>&/_EM1_P 0UXY_Z$:_\.V!_P#FT/;4>\?O
ME_\ (G]$?G-_G'^%'G-_G'^%?SN?\/\ C4O^D;'[9_\ X*/#'_RVH_X?\:E_
MTC8_;/\ _!1X8_\ EM1_Q#7CG_H1K_P[8'_YM#VU'O'[Y?\ R)_1'YS?YQ_A
M1YS?YQ_A7\[G_#_C4O\ I&Q^V?\ ^"CPQ_\ +:C_ (?\:E_TC8_;/_\ !1X8
M_P#EM1_Q#7CG_H1K_P .V!_^;0]M1[Q^^7_R)_1'YS?YQ_A1YS?YQ_A7\[G_
M  _XU+_I&Q^V?_X*/#'_ ,MJ/^'_ !J7_2-C]L__ ,%'AC_Y;4?\0UXY_P"A
M&O\ P[8'_P";0]M1[Q^^7_R)_1'YS?YQ_A1YS?YQ_A7\[G_#_C4O^D;'[9__
M (*/#'_RVH_X?\:E_P!(V/VS_P#P4>&/_EM1_P 0UXY_Z$:_\.V!_P#FT/;4
M>\?OE_\ (G]$?G-_G'^%'G-_G'^%?SN?\/\ C4O^D;'[9_\ X*/#'_RVH_X?
M\:E_TC8_;/\ _!1X8_\ EM1_Q#7CG_H1K_P[8'_YM#VU'O'[Y?\ R)_1'YS?
MYQ_A1YS?YQ_A7\[G_#_C4O\ I&Q^V?\ ^"CPQ_\ +:C_ (?\:E_TC8_;/_\
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M()F/0 _4_P#UA3Q(?XA@^P+<?4']*_G8_P"'^^HG_G&Q^V=^.D>&/ZZO2?\
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MBG9:?VAE53KNW5QZE;I9)QZK5LEUJ71KY<W_ ,C_ $A?^"^ W3?L4 9('QT
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MP<>F#G//L,U_/9_P<5*?^&;_ (  #/\ QD5X;R #GFQD';/KCOS@<CBO,/\
MB)&\'\D?L"?M=CM_R#/#&/J!_:C'//7V[<;ORC_X*X?\%F- _:T^#OPB\(Z9
M^R-^T/\ #NY\/?&72_$G]H^-]/T"/3]3-G9LATNP:SO;F8ZC,KM)$9(TBRJC
M?G /V_AMX0^)&"XYX;Q6+X7Q.%P]#&U)U,2ZF7\E."PN8-U)N>+J*$59WYY2
M5]WM;*MBL.Z4[5(ROTO[S;MNOPZ=/4_M]^%!/_"K_AKN*D#P'X1."!G:-!LP
M23T&/EQ@]<<YP:]"+(.@.1V!Y_#GM]#7\U_@C_@O+J>C^"/!>E-_P3?_ &R+
MM-/\*^'K!+RUTKPK]GNA::1;0?:;<MJJNT%P(1)"Q4,T;(<9P*ZD_P#!??4?
M^D;7[:&3ZZ5X6/<#_H*^]?G^8^&?&[Q^+:R5-/%8N47]>R=*2>*Q,E)..8.2
M34HM-*ZO[JT26L<10M%>TC\,=+^2T^'\KZG]$AD/8/\ B?\  4GFL.Q_$_XB
MOYV_^'^^I?\ 2-K]M#_P3^%__EK2_P##_?4O^D;/[:!^ND>&/Z:L*X?^(:\<
M_P#0C7_AVP/_ ,VFBJT4]X_C_P#(']$?G-_G'^%'F,><-^!/^%?SN?\ #_C4
MO^D;'[9__@H\,?\ RVI/^'^^I?\ 2-K]M#_P3^%__EM1_P 0UXY_Z$:_\.V!
M_P#FT;K47UC_ .3/_P!M9_1,&<D @@$X)W= :7< V <X('U)^7'?OP,=,_E_
M.Q_P_P!]2_Z1M?MH?CI'A?'X_P#$V'\Q2'_@OMJ./^4;/[9W?KI'A=>,<C)U
M< 9YZ$'/3WF7AMQNDT\DBK\ED\UP+O\ OJ7_ %&-^5EU:Z-M)5:5WJM5Y_\
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M5Z*KD_RS7!__ #:+E?37Y/\ *US]68LF6$_[,G4$'DMZ]/IG/X5^//[+(/\
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M]1W!!*#PMX9WX_X1O0QP2$.D6.XC(RP'E= =O)7J0,^O\BG@']MS]HOXQ?\
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MEL/_ (Q7D?[-7[0W@;]J+X1^%/C'\.YI7\.>*K:6>VAN2#=6S6]S+:7,%P5
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M/_C%='L7T_4_XT;%]/U/^-'ML3_T$8G_ ,#E_P#- <L/Y5_X#$YS_A%/"_\
MT+^@?^"6P_\ C%'_  BGA?\ Z%_0/_!+8?\ QBNCV+Z?J?\ &C8OI^I_QH]M
MB?\ H(Q/_@<O_F@.6'\J_P# 8G.?\(IX7_Z%_0/_  2V'_QBC_A%/"__ $+^
M@?\ @EL/_C%='L7T_4_XT;%]/U/^-'ML3_T$8G_P.7_S0'+#^5?^ Q.<_P"$
M4\+_ /0OZ!_X);#_ .,4?\(IX7_Z%_0/_!+8?_&*Z/8OI^I_QHV+Z?J?\:/;
M8G_H(Q/_ ('+_P": Y8?RK_P&)SG_"*>%_\ H7] _P#!+8?_ !BC_A%/"_\
MT+^@?^"6P_\ C%='L7T_4_XT;%]/U/\ C1[;$_\ 01B?_ Y?_- <L/Y5_P"
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M3;>FWSDN7GE963;5EONTNEBE_9>C\$:'H /;_B369Z^P3G@'GIZ9H_LS2?\
MH":#_P""2T_^(J]@]PI_$_U!X]NU&/\ 97_/_ :YHTY<JO+$7UWQ$K[OM4%I
MW_%%'^S-)_Z F@_^"2T_^(H_LS2?^@)H/_@DM/\ XBKV/]E?\_\  :,?[*_Y
M_P" U7LWWK_^%$O_ ),-.[^]?Y%#^RM&/70M#)[D:+9X_4"E.EZ,.NA:#CO_
M ,26S!_ F/&?3D<]Q5['^RO^?^ TA''W5&<#(ZC)QZ#^=*5.2C*TL0K1=O\
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M_C7+[;$_]!&)_P# Y?\ S0/EA_*O_ 8G.?\ "*>%_P#H7] _\$MA_P#&*/\
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MP\W_ &#!T_:4^'N0<C%QJ .[!&1_H?7!(S@]:7_AYS^PA_T<GX!_\"[_ /\
MD"OBLVR/B[-<QQF95N%,_HU<;6E7J4Z>39K.$)2C"+495<-[1JU..LKN]SIH
M^RI4XTU434;VZ[NY][45\%?\/.?V$._[2G@'_P "KX_^V(H_X><_L'_]'*>
MO_ J^_\ D*O/7"?%3_YICB+_ ,,F9?\ S*S3VE/^=?B?>M%?!7_#SG]@_P#Z
M.4\!?^!5]_\ (5'_  \Y_8/_ .CE/ 7_ (%7W_R%3_U2XJ_Z)GB+_P ,F9?_
M #*'M*?\Z_$^]:*^"O\ AYS^P?\ ]'*> O\ P*OO_D*C_AYS^PAV_:3\!'_M
MYOS_ "LQ1_JEQ5_T3'$7_ADS+_YE#VE/^=?B?>M%?!?_  \X_81_Z.2\ _\
M@1J'_P B4?\ #SC]A'_HY+P#_P"!&H?_ ")1_JEQ5_T3/$7_ (9,R_\ F47M
M:7_/R)]Z45\%_P##SC]A'_HY+P#_ .!&H?\ R)2?\/.?V#_^CE/ 7_@5??\
MR%1_JEQ5_P!$QQ%_X9,R_P#F4:JTGM4BS[UHKX*_X><_L'_]'*> O_ J^_\
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MG@+_ ,"K[_Y"H_U2XJ_Z)GB+_P ,F9?_ #*'M*?\Z_$^]:*^"O\ AYS^P?\
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MI)_:5^'>!DG_ $ZX7MR 3  .W<8XQ6<N#.+Y."CPKQ&_>A_S(\T_Y^TG_P!
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M:4W3BJD-9WNFFERV>MM=>CVN?UEK_!_P*I*^"C_P4V_80R,?M*?#X =/]*U
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MVV'_  4X_80&0?VD_ 0(9@1]JOQCYCZV6?SK[+Q.X4XHJ<=Y[4I\.9Y6I3>
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M6\2:#Y,33N+R,@.I:%3)$HR9$!91R,4N(..FG+^U>*5344_:RS+,^3WM(?\
M,3>TGHG??2RN@Y,.E=I+IM'?ML?&O_#G?_@G6>?^&<O#_N?[7\0_K_Q,Z/\
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M#\/KUK].J8W1OJ/Y+4SXQXLA"4H\2Y]>*O\ \C?,-=5I_O5_Q#V5.WP1_P#
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MX>,Q_P#FL.2'\D?Q_P S\Q/^'.W_  3L_P"C<]!7W75_$.?I_P A,<51U/\
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M_-P>RI_\^X?^ K_(_,7_ (<Z_P#!.?\ Z-M\-_\ @QUW_P"6='_#G7_@G/\
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M'$UO:4KXW"<SI25:+A*6D923NXJR[FN&2GB*2EJN9Z=]-M]M#]>S_P $=_\
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M>Q_YXV/?IG/:OZ"_#7_(OZ%_V ])'_E.@.>GO]:_GV_X+Y))))^Q.ZQLR_\
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MF''_  5-_:4(R,$:?X+P1C)((T\DXSC!QR#^'RO^RJ0/^"[/[8G&3_PB>LC
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M(Y.!S4KBW-9:?5>'WZY%EC?XX"^VJ[K:^X<D.KE_X%)_^WGXY_\ #O/]M?\
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M/VV?^DI/[2?_ (+_  ;_ /*VC_AWQ^VS_P!)2?VD_P#P7^#?_E;7['X_VO\
MQW_[.C'^U_X[_P#9UYW^M>8_] _#O_ABR_\ ^8C2T._XS_S/QP_X=\?ML_\
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M^]/>.G-*RM"/6_RZ]^R/R*_X=Z?MKG!_X>F_M+#(&<:?X*P"1SC_ (E_3/\
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M03Z[<?XT':3]X@>@!_\ U=>>E)<6YD[_ .S</K2]_P"PLMUU6FN!0N1=Y?\
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M7UU?F['5:%WJ]V]Y?A9[=C\</^'?'[;/_24G]I/_ ,%_@W_Y6T?\.^/VV?\
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M?;^S_!?]--)I/^'?'[;/_24G]I/_ ,%_@W_Y6U^R!'^V/P0_U:DQ_M?^._\
MV='^M>8_] _#O_ABR[],"@2BNK^;G_F?C>?^">O[;#<G_@J9^TJIP0 +#P:!
MTXX.G#)SGIT[]*_%[_@MY^QS^TK\/?V?_A!)\1?V\_C9\8M%UWXV:-HJ^'O%
MD'ARUL-.NI[21H=9A;3;*&6:\M$,K0B9I53=]SE:_LS! X)R._&.QP,9/0\Y
MSU/MQ_/5_P '%1!_9O\ @ 1T'[17AS@],BPEQTST&>GKCN:^]\+N+LUAX@\+
M2I4<AIU%F$I0J4\ER^G*,HX;'N,HU(8.-2#B]5.,HSBTDFD88B$)4JEW*S7\
MTK=.COIUV???0H^!O^"//QXU'P+X)OHO^"DG[1UC!>>$_#MU;V=M!X;^S6<-
MQHUK/':1,UB)#% K)#&S?,41<@#('2_\.:?CV/\ G)9^TH?^V'AD?I]A&?S'
M]#^W?PHY^%WPTSEB? OA#KT(_L'3N.?3YN@/?G&:]$"L0>%'ID#^6,^WZ\UY
M^/\ %SCZ&.Q<8YUAHI8K%I)91@7I'%8J*U6'UT2U=Y2WDW)MN%A,/9?NI/1:
M\\E?1=.;_(_ #_AS3\>_^DE?[2@_[8>&1_[9-_+\?5?^'-/Q[_Z25_M*'ZP^
M&OZ:>*_?[8_JG_?-(0PZLG_?%<W_ !%WQ Z9YAK^>48)K[OJX_JM#I1E\JDE
M_P"W'X!?\.:?CU_TDK_:3_[\^&O_ ) H_P"'-/QZ_P"DE?[2?_?GPU_\@5^_
MG/\ >3_O@_X4<_WD_P"^#_A1_P 1=\0O^AYA?_#+@O\ YG&\)1>]&3_[BR_^
M2/P$/_!&KX] $_\ #RK]I(8[^5X<X]_^/&F-_P $:_CV0<?\%*OVDFX!VM!X
M9<-Z JUD !SW]N#CG]_\\Y^7'IC],[:0J&^A R?3 R?Y?CCGM2_XB]X@)MRS
MC#M*,5>.4X&-FZU+_J'O?JFM>E[-ID<'0N_W;C9=6Y?/6]OO\]]3^"3_ (*C
M_L.?&'X$?MA?L4^&[[]L7XO_ !$UOQAKGA_3M#\7>)(M(&L^#&?79+4W.FFS
MM5B5;>9#(HN%>-E(5@RX4?;%U^QY^U3',P?_ (*"?'1VSG)'A_(R20,BTQC&
M,'"X'! P,^C?\%VR#^WQ_P $Z^!_R-GAT=ONGQ?=@@\XVD ;N<$#!R !7V?<
MDM.YW9.['J<!F/OTP,8P,=??^T>$>)<US7P]\/L9CWEF)Q%3*<?S5*N58%S?
M+F>,@M'AVH^ZM;64VG*7OI-^-7@J>(J0@_=5N_6/6WW:^BT/SD_X8_\ VJ/^
MD@?QR/OGP\/T^RC^0]N*3_AD#]JC_I(%\<_S\/\ _P B5^BI!_O >V2/R'U_
M/K28/]Y/T_PKUEF>*LK8;)K6T_X2L#M\\/K]R(7);63OU]Z1^=?_  R!^U1_
MTD"^.?Y^'_\ Y$H_X9 _:H_Z2!?'/\_#_P#\B5^BF#ZI^G^%&#ZI^G^%/^T\
M5_T#9-_X:\!_\SA^[_F?_@4C\Z_^&0/VJ/\ I(%\<_S\/_\ R)1_PR!^U1_T
MD"^.?_E _P#D7_/O7Z*8/JGZ?X4<C'*GZ;?UZ=:/[4Q2_P"8;)O_  U8!_\
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M_?/_ 'T*7]A</)_\DOPK_P"(K@/_ )G)]K6_Y^U?_ ZG^9\H?\()_P %!/\
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MO\0M?C\!ZS\1])^)^D:(QOI;O1O$>D:Q-KT#R:BUZSZA =3F:7R94151C&.
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M?W7_ "'^-'/'N_\ P&?_ ,@.S?0EHJ+S1_=?\A_C1YH_NO\ D/\ &CGCW?\
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M3A)*[>FG+/O'^X@L^S$;AI >K>61[@$ GVQ[U_-SXKY_X.*/#?\ V:AX?_\
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M9]F7_09BG_)V-5JE;LNC_EB2T5%YH_NO^0_QH\T?W7_(?XUS\\>[_P# 9_\
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ME_K?PZ]'X<\/IK:I'$9C%RTM[T(XBSW>C=M;]!.G-IKV\_\ P"/]?B?SI?\
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M\%._^D<WC?\ \)O5/_EO7]%NU_[WZFC:_P#>_4T?ZWY!_P!&[R;_ ,+\P_\
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M_!.3QSGW\.:IC_T[?RIO_#S?_@IY_P!(Y/''_A-ZK_\ +:OZ+^3P'.>V0?\
M&C;)_?'_ (]_C7G+C#A__HW>2_\ A?F*_*H7R5?^?[_\ 7^9_.C_ ,/-O^"G
M??\ X)R^.?\ PF]4_P#EN*/^'FW_  4[_P"D<OCG_P )K5/_ );U_1?M?NP_
M,C_&C:_][]30^,.'_P#HW63/_NH9A^M0ETZC=_;S^4(V_P#2C^<\_P#!3?\
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M4_AJ"]R.^C;W[W/YU/\ AYM_P4[_ .D<OCG_ ,)K5/\ Y;T'_@IM_P %//\
MI')XX_\ ";U3_P"6QK^B_:_][]32;9/[P_\ 'O\ &O+7&/#]_P#DW63+UQ^8
MK\JA:IU%JJ\GZP7^9_.A_P /-_\ @IY_TCD\<?\ A-ZK_P#+:C_AYO\ \%//
M^D<GCC_PF]5_^6U?T7[9/[X_\>_QHVR?WQ_X]_C3?&/#RW\/,D7_ '4,R_\
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M-ZG_ /+BD_X>;?\ !3S/_*.3QQC_ +%O5/\ Y;?UK^B_:_\ >_4TFV3^\/\
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MC.K:=/8K,/"EVIADFC>-) 1>@DC>1LQ\P))(V -_9+O!_P"6G_H8_D*3</\
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M_1#\.KRYL>OP^L$2RZFWI.:7:R?_ +<OR/XY?^%[?\%0/^D??B?_ ,)6\_\
MDRC_ (7M_P %0/\ I'UXG_\ "5N_ZWE?V-;E_P">A_.3_"C<O_/0_G)_A1_Q
M,'CO^B(X=_\  \?_ /- O[-A_P _)_<O_DS^&S]J"\_X*?\ [2/P-\8?!,?L
M'>*-%3QU$UC)K*^%KFW.G6]TZ*]T9/M+KNB5?O%3L4[]K;<'^N/]A;X?^)OA
M9^RG\#_ 'C*PFTOQ/X7\!Z#I6LZ?/&T4MM?6FDV-O<Q21M]QHYXW3&3TZ\D#
MZS !/^L<Y[989_$'(_ C\J>L84Y!;\6)]>3GDGYCR3Z>E?&\;^*V8\=9/@<B
MKY+E.58+ 9C6S*+P,:CJU:U1<L>:4[62WUNTTGRIG30PL:$G*,G)R5FW;;?3
M^OPT'T445^7G4%%%%  0#U /UJ-B5.!P,9Z#WHHKCK-J,FFU[_33JP&[V]?T
M'^%&]O7]!_A117)S2_FE][_S <K$D G]!Z5)@'J,T45TT6W%W;?O=7?IY@1O
MQC '?L/;VIF3[?D/\***RJRDIR2;2TV;[+S 7<WK^@_PHWMZ_H/\***SYI?S
M2^]_Y@&]O7]!_A1O;U_0?X444<TOYI?>_P#,!-Q/7!_ ?X5*H! ) _(>M%%7
M"4KOWI;=WW7F N!Z#\A4.3[?D/\ "BBG4E+3WI=>K\O,!R\GD#IZ#V]JDP/0
M?D***Z\,VZ>K;]Z6[OV ,#T'Y"C ]!^0HHKH C+,">>Y[#_"A6)(!Y![8'I]
M***\I2ES+WI?%W??U 28[8V*_*1CD<'[PIS'A?IW /IZT45I.4K/WI;=WW7F
M'7Y?J,R?;\A_A4PZ#Z"BBM,*VY2NV_=6[;^UYL / /T-1;V]?T'^%%%&*;4X
MV;7N]&U]KR -[>OZ#_"C>WK^@_PHHKEYI?S2^]_Y@&]O7]!_A2;C[?D/\***
M.:7\TOO?^8"[V]?T'^%.5B3R>WM[445492YE[TM^[\_,"2HV8@D _H/2BBKG
M*5E[TM^[[/S ;O;U_0?X5-115T&WS7;>V[;[]P$/]1^I%+1152;4FDVE9;-K
MOY@1NQ!X/;V]Z;O;U_0?X445SRE+F?O2W[OR\P)1R!]!2T45LI2LO>ELNK[+
MS ****.:7\TOO?\ F 4@Y ^@HHJH-N6K;T>[;ZKNP \ _0U%O;U_0?X445%=
MM.-FUH]FUU\@'*Q)Y/;V]J?@'J ?PHHI0E+E^*6[ZO\ S C9B"0. .V!Z?2F
MY/M^0_PHHK)RE=^]+=]7W]0%WMZ_H/\ "G*Q)Y/;V]J**<92YE[TM^[_ ,P)
M*C=B#P>WM[T45I.4N7XI;KJ_\P&[V]?T'^%2CD#Z"BBG1;;E=MZ+=M]?,!:,
M ]1FBBN@!.AX &0>WIC_ !-&!Z#\J**Q<I)R2D]^[[+S 6D/ /T-%%)RE9^]
M+9]7V?F!%O;U_0?X4]"3G)]/ZT45C&4N9>]+[WV]0'T445MS2_FE][_S *AW
M,>_]/Y445G4E+3WI=>K\O,!R,2<$]O\ "I***J$I<OQ2W?5_Y@1NQ!X/;V]Z
M;O;U_0?X445G*4N9^]+?N_\ ,":BBBMN:7\TOO?^8!4;G![=/0'N?4445,Y2
MY?BENNK_ ,P&9/M^0_PHS]/R'^%%%8\TOYI?>_\ ,!=[>OZ#_"C>WK^@_P *
M**.:7\TOO?\ F ]"3G)]/ZT^BBMH2ERKWI=>K[^H!2'H?H:**IRE9^]+9]7V
M?F!#D^WY#_"GH<D].GH!W'H***QC*7,O>EOW?GY@25&S$$@']!Z445<Y2LO>
MEOW?9^8#=[>OZ#_"IJ**N@V^:[;VW;??N A_J/U(I:**J3:DTFTK+9M=_,"-
MV(/![>WO3=S=<_Y^G2BBN>4I<S]Z6_=^7F!*.0,]P,TC8 )  ([X'K116KE+
ME?O2^'N^WJ!'O;U_0?X4]"3G)]/ZT45E"4N9>]+KU?;U ?419@3SW/8?X445
M=24K+WI;]WV]0$WMZ_H/\*-[>OZ#_"BBLN:7\TOO?^8#T).<GT_K3L ]0#^%
M%%;0E+E7O2Z]7W]0(V."0 /R'I]*;D^WY#_"BBLG*5W[TMWU??U ,GV_(?X4
M9/M^0_PHHI<TOYI?>_\ , R?;\A_A1D^WY#_  HHHYI?S2^]_P"8!D^WY#_"
MC)]OR'^%%%'-+^:7WO\ S ,GV_(?X49/M^0_PHHHYI?S2^]_Y@&3[?D/\*,G
MV_(?X444<TOYI?>_\P%)^G0=AW ]J ?IT/8=@?:BBGS2O\4M^[_S 3)]OR'^
M%&3[?D/\***7-+^:7WO_ # ,GV_(?X5*H! ) _(>M%%7"4KOWI;=WW7F N!Z
M#\A1@>@_(445KS2_FE][_P P&O@#@#KZ#W]JCR?;\A_A1164Y2YOBELNK_S
H,GV_(?X49/M^0_PHHJ.:7\TOO?\ F!/1117I4]WZ+\V 4445J!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>forms-1_013.jpg
<TEXT>
begin 644 forms-1_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $[ G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#YF_;=_:4\1?L_P"@^';7PQ:V9U/7_M:_
MVA=J9/LBQ)&,I'T+[IE8%LJ/+(*-NX^*/^&[/CC_ -#O_P"4FQ_^,5],_P#!
M23X?^*/'7_"N_P#A&_#>K^(?LO\ :/VC^RK&6Y\G=]EV[]BG;G:V,]=I]*^*
M/^&?_BA_T3?Q=_X(KK_XW7S^+G659J+=O(_,<ZQ&/CCIPHRDHJUK72V7;S.^
M_P"&[/CC_P!#O_Y2;'_XQ1_PW9\<?^AW_P#*38__ !BN!_X9_P#BA_T3?Q=_
MX(KK_P"-T?\ #/\ \4/^B;^+O_!%=?\ QNN3VF([O\3P_K&9_P ]3[Y'??\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKC:" =O)![/3YO$?P$^,OPJT[3/B3XB^)NG^-[:Y_M'3]<OUO/N0B1+JU/\
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MYDOG30+BWN+RX>-E$+W+SL+@"0AE,:,H\L8V X/O?]LP_P!V3\A_C1_;,/\
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M48AHEU%X3DUV,7VGV%F[_:+=;,?O#%&-\JM<,N\@-N"<@@&O&?\ AZS\)?\
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M@MDKOX(JA\0/#]_JVM2V9TB:>\M7L;*RO3I%Q=2B',6^ZCN]WEP$%WR$4/\
MN\G(QM\N_P"'K/PE_P"A>\:?^ 5I_P#)5;/A'_@I=\,?&>JSZ?9:%XMBFAL+
MW46:XL[4+Y=K:RW,@&+D_,4A8+V+$9(&2-(UL="2J3@W;S]/\G]_DC"I@<LJ
MTW1IU%%/31>NG3NK>:ZW=_1?&_AFWU+XF7NI:EX>NKK3HY;2"[EMM-EF:>U$
M$S'#(I,BF9XE=%R=L8W+MZV9M$:/P+J5I+H>IV?AK5-7WPV-E;EIM.M B;6^
MRA'+1O+'EH=O"S-E>HKQC_AZS\)?^A>\:?\ @%:?_)5'_#UGX2_]"]XT_P#
M*T_^2JGFQG+"/LW[MNO:VOD[K?Y;7OHZ. <YS]LKRN]M=;JS?6-GM\[[6]G\
M+Z/?Z9;6$]CX;=5L5U#48+6."2PBN) BPP[8G+"V:17D^0!><MM&XBKGP?\
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M@@]EEW/[3VJYKWO97O>+OMWB_P#P)GN?P?\ #-II.O7<NGZ7>0V:VBK]OO\
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MUK3+34+*43V=W"EQ!*H(#QNH96P>>00>:+,+K8M4444@"BBB@ HHHH ****
M"BBB@#G/B1XO_P"%>_#OQ3XI^R?;_P"P]*NM3^R>9Y?G>3"TFS?@[=VW&<'&
M<X-?B=XB_:O^,GB?6+C4[SXF^)X;F?;O33M2ELH!M4*-L,!2-> ,[5&3DG))
M-?L=^TA_R;O\4O\ L5=4_P#226OP:KVLOA%QDVCPLRG*,HI/0]%_X:0^+?\
MT5'QI_X4-W_\<H_X:0^+?_14?&G_ (4-W_\ '*\ZHKU>2/8\7VD^[/1?^&D/
MBW_T5'QI_P"%#=__ !RC_AI#XM_]%1\:?^%#=_\ QRNR\!_L[^%?&/AOP5J]
MQ\24TV+7-0?2KY1I!D&GW>S=##O:9%8OQS(8E^\5,FTU+\-?V6X/'U_<6=QX
MP32KBV\60^&+F+^RY7>!72Y;[0RNT>/^/5AY?7DY*D8.<G2BW%K;R\TOS:^^
M^QM&-::3B]_/R;_1_=;<XC_AI#XM_P#14?&G_A0W?_QRC_AI#XM_]%1\:?\
MA0W?_P <KK_C;^RU=?!/P%:>(+[7TOKJYUNXTM+&.U"J;=&E$5T)/,/$@B+!
M=HP"#DYKPNB#I5+\JV\OF*?M:;M)_CYV_0]%_P"&D/BW_P!%1\:?^%#=_P#Q
MRN]^!W[:7Q)^&/Q+T?6M<\9>(/$_A\2K#JFF:I?2WZRVK,OFF))9 %F &Y&#
M+\P )*LRGY]HJY4X25FB(U:D6FI']%=%%%?(GVH4444 %%%% !1110 4444
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M5M$C[UC18X5A*[N6#QMOZ-N  %/6?A)/<>'K#1['6KL&364U74]7N#%]LD=
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M+%,RJ[! %W;0 VT ;@< =*ZNKZ)]_P!2>K7;3[@HHHH **** .%\7_\ )4/
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M1>YN7BF)+*75=J9CV,N&/S;AQ1S*]OZ_I?\ #!TN>]44450@HHHH */V;_\
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M:;++)+'=>>RL[S%V)D<D/EGRQ\QCGDYS/^%X>"?^@U_Y*S__ !%'_"\/!/\
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M'[_RC7W_ ,CUR7_#Q#P+_P +,^R_\)OIW_"$?8?/^V?V!?\ VG[1G;Y&<?\
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M86<]Y"<J&&V:&)XVX(SM8X.0<$$5G"E.II"+?H:U*U.DKU))>KL?1U%?,/\
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M%_\ _&*_(.BC_5["_P TOO7^0?ZSXS^2/W/_ .2/U\_X;T^!7_0\_P#E(O\
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MN:9I1IRJU(044[?:?Y/;S/T*_P"&]/@5_P!#S_Y2+_\ ^,4?\-Z? K_H>?\
MRD7_ /\ &*^&I/@/X!U7XN:#X(TR'Q%9'4-"&M27M]K5JZ@OIS721 ?98U0*
M^T%V;!4'A<Y&;#^S/ID.K>!+6_U66.'4/#U]X@UN?3[RVOD2.V><E+9XB8V+
M+$JYW/AF)/3;5/*\!'XI26E^FWO/M_=?X=S-9OF<O@A!_?NW!):M;\\?Q[,^
M]_\ AO3X%?\ 0\_^4B__ /C%'_#>GP*_Z'G_ ,I%_P#_ !BOA'X?? GP-\2X
M/#_B#3SXAT_P_<7.IV.H:;<7T$MTDUM9-=1M'<"W52KJ #F+*D'KD&J.E_ /
MPSXLO?!FLZ9>ZMI?A'6=)U+5+Z"[DBN;VU%@',\:2*D:2;\)M8H,;^0<<MY7
M@(MQE*2MOMII)]NT6_\ AT"SC,Y14H0@[NRWUUBN_>26MON1]^?\-Z? K_H>
M?_*1?_\ QBC_ (;T^!7_ $//_E(O_P#XQ7PG\-O@%X*^+%UX/U/2I=>TK0M4
MU*_TB_L;N\@GN89H+-KF-XYUA165Q@$&/(P1DY!'F7PG\ Z5XJM?%NM^()KQ
M="\,Z;]ON+?3G1+BY=Y4ABB5W5EC!:3)<JV I^4YJUE&!O).4DXI-K3JVETZ
MV_(S>=YC[EH0:F[+?I;S\S].?^&]/@5_T//_ )2+_P#^,4?\-Z? K_H>?_*1
M?_\ QBO@>/X!^%+KPS;_ ! BN]9C\"G09=6FTUYHFU 7"70M/LRS^6$VF1E;
MS3%PN?D)K'B^%WA"'XD>'M&\0Z=XU\":1KUH8XI/$4,<36=TWRQ2^88U%Q;;
MMNY@D1 8\_+DI93@I-I.=U?MNKW6V^G3R[HJ6=9A%<THP2T[[.VN^WO+?]&?
MHA_PWI\"O^AY_P#*1?\ _P 8H_X;T^!7_0\_^4B__P#C%?F=\;OAKI'PBU+2
MO"ZWTNH>+K:V\SQ T<Z/:6]PYREO%A =R)MWL68%FP,8(KS2MZ>1X.M%3A*5
MGZ??ML^GD<M;B+'T)NG4A&ZWT>GE\6_<_7S_ (;T^!7_ $//_E(O_P#XQ1_P
MWI\"O^AY_P#*1?\ _P 8K\@Z*U_U>PO\TOO7^1C_ *SXS^2/W/\ ^2/U\_X;
MT^!7_0\_^4B__P#C%'_#>GP*_P"AY_\ *1?_ /QBOR#HH_U>PO\ -+[U_D'^
ML^,_DC]S_P#DC]?/^&]/@5_T//\ Y2+_ /\ C%'_  WI\"O^AY_\I%__ /&*
M_(.BC_5["_S2^]?Y!_K/C/Y(_<__ )(_7S_AO3X%?]#S_P"4B_\ _C%'_#>G
MP*_Z'G_RD7__ ,8K\@Z*/]7L+_-+[U_D'^L^,_DC]S_^2/U\_P"&]/@5_P!#
MS_Y2+_\ ^,5Z?\+_ (N>$_C-H-QK7@[5?[8TRWN6LY)_LTT&V541RNV5%)^6
M1#D#'/7K7X:5^GG_  3!_P"2"^(/^QEG_P#26UKR\RRFA@\.ZM-MNZWM_D>Q
ME.=XC'8E4:L8I6>R?^;/J;6O^/I?]P?S->$1?M4>$)]#L+V'4--O;Z6:Y-WI
M=CJ<<]U9VT,<\C3/&HW?<A'RD##2*N<XS[QKVES:DDD4;21B2(Q^;$P#IG(R
MN>XSZ5P%Y\"=)OO#^BZ)*ET=-TG2Y=)MX?.3F*2)8BS''+A%P#P/F;(.>/E.
M_P#7]?\ !Z'VC.,;X[ZE_P ("GBB/0-'N8&G:,?9?$D4T3@!=L,<BQDO=,[&
M,0!<;T(\S!4G6L_BMK-Q?37DGARS3PFFL'15U&/5&:\\W[0+8.;8P!0GG':<
M3$@#.#TJ\_[/JS6AMY_$7B"X6ZE:75=]Q; :MG8-LZ"$(H"Q(@,*Q-M!&>35
MCP[\"VT&ZC,WB#7-8TV&]EU&#2;Y[1;:*X>5I=^8H4D?#NS 2.X!P<952-+Q
MNG_73_@V]=3/WN6W7_A_^!_6@>+OC-X1\#:L^F:QJ-Q!>I$)FB@T^YN,*4E<
M9,4;#)6"9@N<D1L<<5I77Q$\/65S]GEU#]]MLW"I#(^1=2-';XPIR79&&.HQ
MDX'-9OBSX!:=XRU#4KR\N-1AFO@ZR?9YXE"AK22U^7*'&$E<CT8YZ9%.U;X$
M6NK^,(-?;4=6MC$;=_[/MYH5MG>!9%A=@8RYVB5B%W[<X.W(S6?]?Y_\ O7I
MY_?T_P""5O!WQET/Q>^G0+!JFGW>HI+-:1WNDWD$<T:%L%)9(51F*+OV [L'
M(R.:Q] _:-\+:M9/>74EQ8P^8R"/[!>O/&HVL99H_LX,47ER0/YC?(!,,L."
M9_!7[+FD>!O$D.MVE]J5W?0VOV6.2Y2R#A?)6'<9(X$D8[47 9BJ_P ( .*-
M(_9?TS1;*.UM]7UPQ/']GOPTUM_Q,K?9&@AFQ$,($A1?W7EL1G).36GN\VNW
M]?\  _K0GWK7_JW]?UU.CM_BEX:NO&DGA2*^F?6XY#"T8LI_)$@A6;R_/V>5
MO\M@^W?G&>.#75USEC\(;73_ !!'K"-=/=)>W-_AY(]IDGC6-LX4'"HBJHSP
M.N:ZW^S+G_GG_P"/#_&HTLN]E?UZE:W=RK15K^S+G_GG_P"/#_&C^S+G_GG_
M ./#_&D,JU^ -?T$?V9<_P#//_QX?XU\W_$S_@GA\,_B9K]SK<MKK&@ZG>74
M]Y?3Z3J(/VN:5][,ZSB55PVX@1A1\YX/&/8R[&4\*Y*IUM^%SPLTP-7&*#I[
MQO\ C8_(>BOU)_X=6?#7_H-^,/\ P.L__D:C_AU9\-?^@WXP_P# ZS_^1J]S
M^U<-W?W'SO\ 8N+[+[S\MJ*_4G_AU9\-?^@WXP_\#K/_ .1J/^'5GPU_Z#?C
M#_P.L_\ Y&H_M7#=W]P?V+B^R^\_+:BOU)_X=6?#7_H-^,/_  .L_P#Y&H_X
M=6?#7_H-^,/_  .L_P#Y&H_M7#=W]P?V+B^R^\_+:BOU)_X=6?#7_H-^,/\
MP.L__D:NG^&W_!.?X;_#7Q?8>(X3KVMWVGRQW%G'JE_'Y<$\<BR1S 0I&692
MG1B5()RIXQ,LVPZ5U=E1R7%-I.R^9Z=^T)_R0+XE_P#8LZG_ .DLE?B#7]!'
M]F7/_//_ ,>'^-?+'BC_ ()D?"CQ!J$=Q8P:]X:A6(1FTTO4E>-V!)WDW"2O
MN(('# 84<9R3Y&78VGAE*-3J>YFF7U<7*,Z5M#\GJ*_4G_AU9\-?^@WXP_\
M ZS_ /D:C_AU9\-?^@WXP_\  ZS_ /D:O9_M7#=W]QX/]BXOLOO/RVHK]2?^
M'5GPU_Z#?C#_ ,#K/_Y&K!L_^"9?P[N/'6KZ(VL>+!;V>FV5XC"]M=Y::6Z1
M@3]GQC%NN.,\MUXP?VKAN[^X/[&Q?9?>?FI17ZD_\.K/AK_T&_&'_@=9_P#R
M-1_PZL^&O_0;\8?^!UG_ /(U']JX;N_N#^Q<7V7WGY;5H>'M!O\ Q5K^F:)I
M<'VK4]2NHK.U@WJGF32.$1=S$*,LP&20!GDU^G/_  ZL^&O_ $&_&'_@=9__
M "-7;_"7_@G]\-_A%XFA\06MEJ7B'5K65)[*;7;J.5;210V'1(T1"V6!!<,5
M**R[2,U$\VPZBW&[9I#)<2Y)3LEZD_[<VGW6J?LJ^/(;.VFNYEBM9VC@C+L(
MX[N"21R /NJBLQ/0!23P*_'BOZ -0\-C5]/N;&^L8;VQNHF@GMKA5DCEC8%6
M1U/#*02"#P0:^6->_P""7_PLUC5I[RTD\2:';R;=MA8:C$T,6% .TS122<D%
MCN<\DXP, >9E^.IX>#IU.]SU\TRZKBJD:E+M8_*:BOU)_P"'5GPU_P"@WXP_
M\#K/_P"1J/\ AU9\-?\ H-^,/_ ZS_\ D:O6_M7#=W]QXG]BXOLOO/RVHK]2
M?^'5GPU_Z#?C#_P.L_\ Y&K!\._\$R_AWK&L>*;276/%BII6I)9Q%+VU!*FS
MMI\MFWY.Z=AQC@#ODD_M7#=W]P?V-B^R^\_-2BOU)_X=6?#7_H-^,/\ P.L_
M_D:C_AU9\-?^@WXP_P# ZS_^1J/[5PW=_<']BXOLOO/RVKTC]FW3[K5/V@OA
MO#9VTUW,OB&QG:.",NPCCG221R /NJBLQ/0!23P*_0'_ (=6?#7_ *#?C#_P
M.L__ )&KT_X(_L3> ?@/JQUG1-.O-4UY?,6'5M9N$FF@1U562-45(UX!^8)O
MP[KNVG%8ULTH.FU&[9O0R;$JI%SLDGW/:[7_ (^H?]]?YUT=8EOIUQ'<1LT>
M K GYAZ_6MNOD&?<H*_ 2OW+^,6O7_A7X1^.-:TN?[+J>FZ'?7EK/L5_+FCM
MW=&VL"IPR@X((..17F'_  P9\"O^A&_\J]__ /'Z^BRG'4\!&<JJ;YK6MY?-
M=SY;.LNJYE*$*+2Y+WO?KMLGV9^0=%?KY_PP7\"O^A&_\J]__P#'Z/\ A@OX
M%?\ 0C?^5>__ /C]>]_K#A?Y9?<O\SYO_5C&?SQ^]_\ R)^0=%?KY_PP7\"O
M^A&_\J]__P#'Z/\ A@OX%?\ 0C?^5>__ /C]'^L.%_EE]R_S#_5C&?SQ^]__
M ")^0=%?KY_PP7\"O^A&_P#*O?\ _P ?H_X8+^!7_0C?^5>__P#C]'^L.%_E
ME]R_S#_5C&?SQ^]__(GY!T5^OG_#!?P*_P"A&_\ *O?_ /Q^C_A@OX%?]"-_
MY5[_ /\ C]'^L.%_EE]R_P P_P!6,9_/'[W_ /(GY!UL^"_%5WX%\7:-XBL(
MX9KW2KN*]@CN5+1L\;!E# $$C(YP1]:_6/\ X8+^!7_0C?\ E7O_ /X_1_PP
M7\"O^A&_\J]__P#'Z/\ 6#"_RR^Y?YA_JQC?YX_>_P#Y$_/73?VQ/'6FVOA^
MV$&E7$&AOJ+VT<T4I#?;%=7#XE&0@D<)C&,\[JX?XI?%0?%;6+O6+OPKH>C:
MS>7+75W?Z6UYON&;J&6:XD11GGY%7\N*_4+_ (8+^!7_ $(W_E7O_P#X_1_P
MP7\"O^A&_P#*O?\ _P ?KECF^7PDIQIR3^7>_?N=D\DS2I!TYU8M/6S;[6_E
M['YFQ_'SQ!%X]L?%HL]-_M*ST==$CB,4GDF$6AM0Q'F9W[#G.<;N<8XJ/2?C
MQXDT6[\&7%G%I\;^%K&;3;9'@,B7-O,\K2I.K,0X83.IP%X([C-?IM_PP7\"
MO^A&_P#*O?\ _P ?H_X8+^!7_0C?^5>__P#C]6\ZP#WIO[EY^?\ >E][,UD&
M9+:K'[W_ '?[O]V/W(_.'2?VE=9\/7VAMH_AOP]I6CZ3]L:+0[>*Y-K+)=1&
M*:25FG,SL4.T'S/E  &!Q6>O[07B"S\1^&]3TJPTG1;/P_;36=CHMK!))9"&
M;?YZ.LTCO()?,?<6<GG@C Q^EW_#!?P*_P"A&_\ *O?_ /Q^C_A@OX%?]"-_
MY5[_ /\ C]3_ &QE][NG+[EY[ZZ[O[V7_8>9VY?:QMZOR>GNZ:I/3JDS\XM%
M_:8USPOK/AJZT/P]X?T?3= ENKBVT6VAN#:R37$1BEEE9YVF=BAP,R84*  !
MQ6/I/QH/AS4KJ?1?!OAW2["_L9-.U+24-[/:ZA"[*V)/.N7=2K(I5HG0@C.:
M_37_ (8+^!7_ $(W_E7O_P#X_1_PP7\"O^A&_P#*O?\ _P ?H_MC ?R2UTZ:
M[[^]KN]Q?V%F3M^\CIJM]/3W=-NA^:S?M$^(/[0M_+TO18?#\.E-H@\,I;R?
MV>UFS^8T; R&4L9,2>9YGF;@#NK$\<?%F_\ &S^&X_[)TK1-.\.P?9].TW2X
MY1#&ID,C$F61Y&+,226<U^HG_#!?P*_Z$;_RKW__ ,?H_P"&"_@5_P!"-_Y5
M[_\ ^/U4<ZP,9*482NM>F^NN^^KUWU?<F609C.#IRJ1L]-WMII\.VBT\EV/R
MF^(WCN_^)WCC6/%.J0VT&H:I.;B:.S5EB5B ,*&9B!QW)KG*_7S_ (8+^!7_
M $(W_E7O_P#X_1_PP7\"O^A&_P#*O?\ _P ?K2&?8.G%0C"22TV7^9E4X;Q]
M6;J3G%MZO5[O_MT_(.BOU\_X8+^!7_0C?^5>_P#_ (_1_P ,%_ K_H1O_*O?
M_P#Q^K_UAPO\LON7^9'^K&,_GC][_P#D3\@Z*_7S_A@OX%?]"-_Y5[__ ./T
M?\,%_ K_ *$;_P J]_\ _'Z/]8<+_++[E_F'^K&,_GC][_\ D3\@Z*_7S_A@
MOX%?]"-_Y5[_ /\ C]'_  P7\"O^A&_\J]__ /'Z/]8<+_++[E_F'^K&,_GC
M][_^1/R#HK]?/^&"_@5_T(W_ )5[_P#^/T?\,%_ K_H1O_*O?_\ Q^C_ %AP
MO\LON7^8?ZL8S^>/WO\ ^1/R#K]//^"8/_)!?$'_ &,L_P#Z2VM>@?\ #!?P
M*_Z$;_RKW_\ \?K?_9X\ Z%\,;GXD^&O#-C_ &;HEEXE3[/:^=)+LWZ5I\C?
M-(S,<L['DGKZ5YN89I1QV&E3IIIJSUMW]7W/5RO)L1E^*C5JR33NM+]O1=CV
M"BBBOD#[D**** "BBB@ HHHH **** "BBB@ HHHH **** ,[7/$6E>%[$WNL
MZG9Z39!@GVB^N$ACW'H-S$#)]*H)\0O"TEXEHOB71VNG>*-8%OXB[-*NZ)0N
M[)+KRH_B'(S5GQ9H+>)]!N-+%T;2.X:-9G";M\0=3)'C(^^@9,]MV>>E>=ZM
M\ (-5UC4[XZM]G\R1IM/^SP/')9N\BO(S,LH6;E1L5EVK@95\4X[Z["E>WN[
MGJ5CJ5IJD3RV=U#=Q)(\3/!(' =6*LI(/4$$$=B,59KD/ASX!D^'UKJ%FNJS
M7]A+.7L[>7>1:1<XC!=VSZ97:IP#MR6+=?0[= 5^H4444AA1110 4444 4#K
MVF#6AHYU&T&K&'[0+#SU\\Q9QO\ +SNVYXSC%<O:>+/ \?B#4_$$7B[27FN(
M[72)_P#B90&*-XWN'BCZ\2,9I?E)Y"# X.67GPWNI/B _B>TU6"#*AQ;361D
M/G"(P[BXD7*;"?DQG=SN[5G>(_@]<ZXUM<V_B*;3]4CU>;4WOH8Y%=E=2BQC
M9*O*1;4!8LIVG*$-BJC:ZO\ UK_D2[V=OZT_S_KJ=M;^*]$O) EOK&GSN;IK
M$+'=(Q-PH+-#P?\ 6  DKU !XK5KRG4?@/$WB ZMI&N76BR"[6XBCB:9A&I'
M[Y0?.!RY"8'^K41JOED;@WJU+2R[CUN^P4444AA1110 4444 5[C4+6UN+:"
M>YAAGN6*01R.%:5@I8A0?O$*"<#L":YBWUKPGX3UCQ.\WB/3[:\N+J*^U&&[
MOH4-JQ@@MX\J2"BLL4>-W4L<'D 7O$'A&/6M<T/5XWAM[[2Y9)$E>W#LZM#)
M'L)R"%!D#8SSMQQG(X]O@FU[J'BB?4M;DO+76@)A9*+B**&Y"H/-PMQT&S&$
MV$JQ5V?@AK?7^OZ_KN#\OZ_K^NQZ1:ZE:7TUS#;W4-Q-:N(YXXI S1,5#!6
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MC:_)I#7%Q#%I,;RW-RM_# WVE'@'DQ^4Q*N$B#,_'\*'=F\1?%G3XK^6ZO\
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MHXF8R!0Q7:.NW<Z#)SQ1U;XYW"6,E[IVD2>5Y3((;U/+ECF6XF@<L-W* Q9
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MI??:,YW^?)<IMV]MOV;.<G._H,<G]J?W/Q_X O[(_O\ X?\ !.$HKU3^Q/\
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M":DYWMY?\$H6O_'U#_OK_.NCK-BT?RY4?SL[6!QM_P#KUI5XK/>1P'[0?_)
M_B5_V+.I?^DLE=-XB\(Z5XL@$6J6[3J(I(08YI(F"N!NPR,"#\HY!R,<8KF?
MV@_^2!_$K_L6=2_])9*[ZMG_  H^K_)&$?XTO1?G(PM>\"Z'XGAGAU2R^V1S
MPQV\H>:0;XTD\Q0<-V89SU/?(K)D^#OA6;39]/>SO'LKB7SIH6U2[*RGRTCP
MW[WYEV1H-A^4;>E=I16*;6QOOO\ UT_(YS4_A[H&L:M>:E>63S7=Y:-8SM]I
ME"M"RE2NP-M!(8C< &Z<\"B'X?:%;WVHW4=I*LFH1RQW"?:IO*82;?,(CW[%
M+;02R@')8YRS9Z.BD4<KK'PQ\.:]#+#>V<SPS!1+%'>SQ)*%0(%<(X##:H&&
MR.,]:EM_AQX=L].O[&WT\P6M\(Q.D4\J[F3[D@(;*R#Y?WBD/\B<_(N.EHIW
M;W)24=CGM-\ Z%I,,D5O9-B6*:&5IKB65Y%E<O)O9V)8LQ)W$D]LXXJE8_"G
MPSI]E<6J6=S-%<)+'*;K4+FX=EDB2%QODD9L&.-%Z\8XP<FNNHH3:T7]=?S'
MUO\ U_6AQR_"/PLD<J+8W 5S%M_XF%SF$1-(T:Q'S/W2CS9!M3:-K%<;>*G_
M .%8>'5TZULDM;F&&V9VC:&_N(Y3O #AI%D#NK8&58D$J"1D UU5%(#@[SX'
M^#[XR&6QO<R1F#,>K7D>V$AP84VRC9%^\;]VN$Z<?*,:.L?"WPSKT:I>Z>[A
M9))08[N:([I'1WY1P<%HTXZ8&.A(/5T4#\SD=6^&.C7VDW%I:PFRG:*9(;@2
M2,8FD>-RP^<'.^*-L@JPV_*RGFL:R^"6EQZ/I6G7M[>W<%I)>S3A+NXC-R]T
MY>4,_FF0IEF^5W?(QDDC->CT4[LFRV1QTOPC\+3:PNJ?8;B.\69KA6AU"YC1
M9&D21F"+(%!+QH3@<XP>"13M.^$WA;2?/%KI\L4<W+P_;9VBR71R0A?:I+1J
M20 2=W]YL]?11=K3^OZT06.3D^%WAV1M1(MKN'^T'\RY^SZC<Q"1M\CDX208
MRTKYQC(.#P  W6?A/X3\06.FV6H:/'<6NFVILK2,RR*(H3L^4889_P!6G)Y&
M#SR<]=11=K8>^K.:M?AUX?L]8N-3ALG2\N)UNI&^TRE#*N_#["^T']X_0<Y]
MAA\?P_T.&32GBMIX#ID,=O;B&\FC7RXR#&LBJX$H4C(\S=C+>IST5%+;8/Z_
M7\SCH?A%X4AN+F8:=*[W%K)8MYM[.X2W?=NBC#.1&GSMA4P!GC&!5J;X:^')
MHHHWT[<D:&-1Y\G"DN2/O>LK_P#?7L*Z>B@#F+[X:^'-1CGCN-.WK,27(GE4
MY,<4>Y2&RK!8(L$8(* C!R:9IOPQ\.Z3J5K?VMM=)<V\IG0OJ%RZF4JZ%V1I
M"KMMD9=S D#:.BKCJJ*=V*R2LMCD=2^%/AC6)K^2\T^6<7R2QSPM>SB$K*T;
MR;8P^Q"S1(Q*@$D$_P 39P/%'P'T76]$ETS3[BZTJ*Y>3[5)]LNI9)(Y(5A=
M%?SE91L2,!<F/Y!F-L#'IM%"=MA];G+'X9^'?LL4"V<T(ACABBDM[R:*6-8F
MD*;9$<,I'FR D$$AR#D<52L?@SX1TVXMY[?3KA9;:+R8&?4+E_)3 !";I#MS
M@$XQD\]>:[:BEUN+I8R/#7A/3/"-K<6^F0RQ)<3&XF:>XDGDDD*JI9GD9F)P
MJCD]JUZ** VV"O/_ (:_\CI\5_\ L98/_3/IM>@5Y_\ #7_D=/BO_P!C+!_Z
M9]-K>G\,_3]485/BI^OZ,] HHHK Z HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH IZMK%AH.GS7^IWMOIUC" 9+F[E6*),D ;F8@#D@<^M9K>/?#*Z@+
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MH)*J6I)9/B#"UQ)!:Z]*5(DM8I)M+*F(9+12\@F4D$#:0H'EY?/F9K>)M?\
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M#=W.EWDLB2DS[8'\LNQ.(XR6P,9(X+H!N^(O%WQ(L9+Z?3]+M;B.(7+PV/\
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ME%Q:N>B1ZM#)(J!7RQP,@?XU=KG+7_CZA_WU_G71UY)[1P'[0?\ R0/XE?\
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M_) _B5_V+.I?^DLE=!XH\&V7BZ+9>2W$8^R7-G^X91\DZ!'/(/( X_7-<_\
MM!_\D#^)7_8LZE_Z2R5F?&[X8ZK\1'\.RZ:FE7BZ=-([V>M231P!G50ERIA&
M\RPD%D *'+'#H<&MG_#BO-_H8*ZK2:[+_P!N+;_"?PSHGBRV\0SZA+;7#7[3
M6\,[6ZI]HF(RJL8_,)9E)V[SR<#@*!2C_9WT*V2[%GJFJ6+7%I+IYD@6UWI:
MR;]T(8P$E<L#ELL"B_-R^[A;/]GOQ<OQNUGQA<7>BIIE[J=M=A()Y/.DCAF#
MH74PY+A"R_-*ZC "[%.T9_\ PSGXWTW2YTTY?"SWWVBYW7$MY=QOJ(FM;J![
MNX81LHG_ -(0[50Y$6#*1MV8ZJDI=>WW:?IZ+M<WU]JX]--?FW^&_KYV/5[K
MX5Z)XDOY[BT\0ZA&T,\Z7,-E/ \9D=P[1RJT;9VG'R-QR,@\$8GAGP#X7U3P
M[HOASPWK4>JZ;X>U4O>N]PAN$,7F1-"R1HJ[69&0@A00K8S7"6_[-?C*W^)7
MA371>:&=.TC4OMSL)Y1<A6")(B;H&&&13G:T9. &++@*[0_V7=9\/:%XSTZ&
MU\-W%EJ?B&+5H-)9WCM-0MDNI9OL]V! 0@*R(N LH_=+D$<5HK0BK/\ JZ_#
M5NWEU,FW)N\?ZM+\=E?SZ'N.M?#C2O$%W=3WCW#BYE\V6)7 5LVTEL5Z9 *2
M,>N<X.>U8V@_!'1/#[2R1WE]/-+):2O*ZV\98V\D<D8(CB0'F)0>,X) (XQY
MII'[,.J6>J:3J=U=Z7/JEC'9PPW^Z4S6T*+>B:&)L!O+ N844;EW+$,[2%KM
M_P!FGX4:M\&?AJ/#FKW%G/,MY-/&M@Y>*.-]OR@F./JP9L;!C=@ECEVF.\G>
MS6WG_5_S*DVU%6W_  Z_FE^!J-\$=%D5()+[4I--SYDFGM)$(II/(>#S&81B
M0-Y;XPKA?E4XSG,]]\(K/5]/O+;5-<U?4WNHH87N)V@5U2*19%"A(E4?,O/R
M]SWYKO**@UN]/Z\_SU]3@=:^#>EZ[>6\DVI:G%;13P79LHFA$4D\,7E)*Q,9
M?.P*" P7Y0<9SF2^^$.F7JN%U'4K8O))(WDR1D-OGEG965HRKKOF;Y6!&%7.
M2,UW5%-ZN[)225EVM\D>96/P%TO3?#J:-:Z[K,%NL,EJ)%-KO\B2&.*2+F#;
MM81(V0-P(^4@';1:? '0[.WN8$U'4&MYHVB6W=+4P1!CDE8?(\LDX&696+8&
MXG KTVBGS-_UV"RT_K??[SSO5/A&;[3=%TJ/7M2CT^SAO+>XF9XGN9XYQ@QY
M:(J%&2!M"[0%"X Q576_@#HVN:L^H2ZQK$,I61$6-K=O+1Y(W**SPL^P>4JA
M2Q"@G !P1Z=12Z\W4>RLCSNU^!N@6=_=723WA\XLPC98/W;-)%([*_E;_F:(
M9!8CYB, !=L&H? ?2;_4;J\76-6M9)YWN?W'V;=%(\DCLT4C0F2,YE(RC X
MYZD^ET4^9D\JM:QQ7CSX5Z?\0KFWEO\ 4=0@2'RBMO#Y+Q$QRB16V2QN Q(
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MF6W_ #S_ /'C_C730Q,\.VX=3DQ&%AB4E/H>8_V!?_\ /#_Q]?\ &C^P+_\
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M+HM2_F?W+_,.:M_*OO?_ ,B>@45Y_P#\*/\ #O\ T$?&'_A:ZS_\ET?\*/\
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@:@9P HP*=Z<8R46VWY>:?<FU64HN222?>_1KLNY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>forms-1_014.jpg
<TEXT>
begin 644 forms-1_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $[ G # 2(  A$! Q$!_\0
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MX(KK_P"-T?\ #/\ \4/^B;^+O_!%=?\ QNN3VF([O\3P_K&9_P ]3[Y'??\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F+CXE>'+
M7XB6O@674=OBJYL&U.*P\B0[K<,4+^9MV#Y@1@MGVHC^)7AN3XBR>!%U'/BN
M/3_[5;3_ ").+8N$\SS-NS[Q V[L^U?,'QK_ .$Y_P"&Z/#/_"O/^$>_X2'_
M (0I_P#D9O/^R>5]IEW_ .I^?=TQVZUPFK>,/B9\/_VCOB+XD\7Q^')/&>F?
M#&XN;3_A&$G>T"K<)Y;,L_S%@VXMVP![U4;<JD^TG_X#S;?^ K\29-\SBN\5
M_P"!<N_WO\#] :*_/S]G?Q9\8[/X@>"-1U>_U6?0_%EA//=KXA\;Z??K>KY)
MD%Q86:[)8 C<E$#D [3C;7*>#]8^)@^$?PH\<6WQ;\72:UXA\6'PY]ENKP7%
MI%!+++'N,<@/FR J2&D) !  &T&M?9/FY;]E\V^7\_ZNK&7MER\R6GZ6O?[D
M?I=17P-J'Q:\>? _P[^TAHMAXLU?Q,_A2YTL:3JGB&47EU:_:\+*Y9@ 0H(V
MKC:" =O)![/3YO$?P$^,OPJT[3/B3XB^)NG^-[:Y_M'3]<OUO/N0B1+JU/\
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MYDOG30+BWN+RX>-E$+W+SL+@"0AE,:,H\L8V X/O?]LP_P!V3\A_C1_;,/\
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M48AHEU%X3DUV,7VGV%F[_:+=;,?O#%&-\JM<,N\@-N"<@@&O&?\ AZS\)?\
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M@MDKOX(JA\0/#]_JVM2V9TB:>\M7L;*RO3I%Q=2B',6^ZCN]WEP$%WR$4/\
MN\G(QM\N_P"'K/PE_P"A>\:?^ 5I_P#)5;/A'_@I=\,?&>JSZ?9:%XMBFAL+
MW46:XL[4+Y=K:RW,@&+D_,4A8+V+$9(&2-(UL="2J3@W;S]/\G]_DC"I@<LJ
MTW1IU%%/31>NG3NK>:ZW=_1?&_AFWU+XF7NI:EX>NKK3HY;2"[EMM-EF:>U$
M$S'#(I,BF9XE=%R=L8W+MZV9M$:/P+J5I+H>IV?AK5-7WPV-E;EIM.M B;6^
MRA'+1O+'EH=O"S-E>HKQC_AZS\)?^A>\:?\ @%:?_)5'_#UGX2_]"]XT_P#
M*T_^2JGFQG+"/LW[MNO:VOD[K?Y;7OHZ. <YS]LKRN]M=;JS?6-GM\[[6]G\
M+Z/?Z9;6$]CX;=5L5U#48+6."2PBN) BPP[8G+"V:17D^0!><MM&XBKGP?\
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M@@]EEW/[3VJYKWO97O>+OMWB_P#P)GN?P?\ #-II.O7<NGZ7>0V:VBK]OO\
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MUK3+34+*43V=W"EQ!*H(#QNH96P>>00>:+,+K8M4444@"BBB@ HHHH ****
M"BBB@#G/B1XO_P"%>_#OQ3XI^R?;_P"P]*NM3^R>9Y?G>3"TFS?@[=VW&<'&
M<X-?B=XB_:O^,GB?6+C4[SXF^)X;F?;O33M2ELH!M4*-L,!2-> ,[5&3DG))
M-?L=^TA_R;O\4O\ L5=4_P#226OP:KVLOA%QDVCPLRG*,HI/0]%_X:0^+?\
MT5'QI_X4-W_\<H_X:0^+?_14?&G_ (4-W_\ '*\ZHKU>2/8\7VD^[/1?^&D/
MBW_T5'QI_P"%#=__ !RC_AI#XM_]%1\:?^%#=_\ QRNR\!_L[^%?&/AOP5J]
MQ\24TV+7-0?2KY1I!D&GW>S=##O:9%8OQS(8E^\5,FTU+\-?V6X/'U_<6=QX
MP32KBV\60^&+F+^RY7>!72Y;[0RNT>/^/5AY?7DY*D8.<G2BW%K;R\TOS:^^
M^QM&-::3B]_/R;_1_=;<XC_AI#XM_P#14?&G_A0W?_QRC_AI#XM_]%1\:?\
MA0W?_P <KK_C;^RU=?!/P%:>(+[7TOKJYUNXTM+&.U"J;=&E$5T)/,/$@B+!
M=HP"#DYKPNB#I5+\JV\OF*?M:;M)_CYV_0]%_P"&D/BW_P!%1\:?^%#=_P#Q
MRN]^!W[:7Q)^&/Q+T?6M<\9>(/$_A\2K#JFF:I?2WZRVK,OFF))9 %F &Y&#
M+\P )*LRGY]HJY4X25FB(U:D6FI']%=%%%?(GVH4444 %%%% !1110 4444
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M5M$C[UC18X5A*[N6#QMOZ-N  %/6?A)/<>'K#1['6KL&364U74]7N#%]LD=
M761%6'R=XE2#Y?+";5/!/!]*HHOK?^M[_FD_-BY5:W];6_+1=CSRZ^"NEW%K
M8VRZKJT,4=O);7RI+$?[5CDD\V5;DF,GYY"[$Q>63O89V\# T/\ 9]#:'9_V
MSXBU-=<C=;M);!X##87#3BYF^S!X/F5Y@&)E#M\JXVX 'L5%)::]OPZZ?U^H
M674\:U+]E?PKJFBPZ;+J&JND?E#SI_LUR[!(Y$Y\Z!UW'S9&+@!PSDJRY-;6
MN? 70M?U*WN[G4-446UA%8V]O%)$L<)BCE2.9?W>[S%$\F,DID\K7I=%'?S"
MRT\O^'.#7X/Z:\,1N]4U2_O@UU+-?W#P^=<33P"!I7"QA RQ *H554#^$UV&
MCZ7#HFDV6G6^[[/9P);Q[SEMJ*%&3ZX%7**/^!^&WW7"R_/\=_R"BBB@8444
M4 %%%% !1110 4444 ><_M(?\F[_ !2_[%75/_226OP:K^@#XI6_A[5? .N:
M'XHUB'0]'URSGTF:[ENH[=@LT3HPC>3Y=^TL1D'IG! K\BO%'["7Q,MO&1TG
MP;9Q_$/2)M[VGB#1SY5E(H9\*\TNV)9-J#<%=U#-L#LP('L8&I""DI.QXF8T
MISE&45<^=**^B_\ AWK^T!_T(/\ Y6=/_P#DBC_AWK^T!_T(/_E9T_\ ^2*]
M3V]+^9?>>/\ 5ZW\C^YG!Z#^TQ\2/#>EZ-IVG^(Q'8Z3$T%M;R6%M*IC*LH2
M4/&?/"AF""7=L_AVX%9'A[XV>-?"M[>7FFZX\-U>:HFM7$TD$4S27B+,JRDN
MAYQ<3<=#OR02!CU/_AWK^T!_T(/_ )6=/_\ DBJ<?[!7QVFU:YTQ/ V;ZW@B
MN98O[7L/ECD:14;/GX.3%)P#D;>>HS#GAY-MM:[[=[_GKZFBAB8I)*6GKVM^
M6GH>;^-OC9XV^(VBVND^)-=EU6PM3 T,<L,0*&& 01_,JAN(QCD\G).6)-<1
M7T7_ ,.]?V@/^A!_\K.G_P#R11_P[U_: _Z$'_RLZ?\ _)%4JM%7:DM?-$NC
M7=DXO3R9\Z45]%_\.]?V@/\ H0?_ "LZ?_\ )%=3^SY^Q;XA3QUX=U_XEMIO
M@?PYINJQ3W=AXJM94-]'$5D\I?,C%NXE(,91I=VT2-L8+AE+$4HJ_,@CAJTF
MERO[C]=Z*IZ3K%AKVGQ7^F7MOJ-C+GR[FTE66-\$J<,I(.""/J#5ROE3[$**
M** "BBB@ HHHH **** );7_CZA_WU_G71USEK_Q]0_[Z_P ZZ.I92"OQ$_9N
MDM9],^*NE3:GI>FWFK>%);.R_M;48+&.>8W-NPC$D[HF["L<%NQK]NZ_)S_A
MU_\ $K_H;_ ?_@SN?_D:O<RVI3C"K"I*W,K?F?.YM3JRJ49THWY6W^1!K6L>
M!/$OB77;#7M:\/W]YIOPZT[2)-9NY([F)]3CEMUD>WD!S*Z1EEW1'<RQMM..
M:]/OO!WPKU[Q!H%KI-KX,UK7[2YUN*TCTS^SY;694LM]E-<PV@(%L'4G-RTA
M49\V0\@>;_\ #K_XE_\ 0W^ _P#P9W/_ ,C5=T3_ ()M_%SPUJMMJ>D>/_!N
ME:E;-O@O+'6;R&:)L8RKK;@J<$]#WKU*CH26E6SL_O;;O^.GD>33CB(/WJ%U
M=;]DDK/O>VOF;7B*Q\)>$?!6F:KK^D?#^#Q/<?#N^O(F@LM.:UNM2%^HB>)4
M7R99-@8#RP5(#!<IQ4UU)\*[K5/"M[H"?#&..\N;*X\;1ZI]A54M&L;<R+9H
M_$9#FYW):@2B3:, 5D>)O^"=GQG\;:H=2\1?$GPGKVHE!&;S4]=O;F;:.B[W
MMR<#)XS63_PZ_P#B7_T-_@/_ ,&=S_\ (U*,J.\JBOKZ:R;M;MJE\D-QQ":4
M:3M:W2]^6,;W[Z-_-FCX#7X*:I\&=4M]03PSI-NBZDT=[)+9W&H.HG9H!)%*
M([Y)_+V+&;:26(\F1>JUT6O:K\&[3QEI$%KX:^'=WX?_ +64:1=7'B&R4O;?
M9'P9H[>P+(NXQY&HNY\Q1DE=[#C/^'7_ ,2_^AO\!_\ @SN?_D:C_AU_\2_^
MAO\  ?\ X,[G_P"1J/\ 9VV_:NWS^^_?MV6EA+ZTE;V"^Y?=;MU[WUN>6_M:
MVG@V'QQHTW@ZZTR6*?2HFO;;3([,>1.&88E:R=K5Y" "3 $7&,J#G/AU?8?_
M  Z_^)?_ $-_@/\ \&=S_P#(U'_#K_XE_P#0W^ __!G<_P#R-771Q%"E!0Y[
MG#6PN*K3<_9VV_*WX[GQY7HOP%_Y'C4O^Q7\1_\ IDO:]^_X=?\ Q+_Z&_P'
M_P"#.Y_^1JZSX8_\$Y_B#X0\27E_=^*?!4\4NBZOIX6VU&X9@]SIUS;(Q!MQ
M\H>92QZA0Q )X-5,70<))2Z$TL#B8U(MP>Z/ _@AXC\.^%?A7XROKVS\+WOB
M0:QI$=A'K]E:W<@MV:87)CCF5LKMVAB 0,J>"%(^@+S5/AAK6F_&&#1[;X7V
MNO:1K/V?P.;V+388)8F3YV+N!'<+@.5:<NBNRC(X%<?_ ,.O_B7_ -#?X#_\
M&=S_ /(U'_#K_P")?_0W^ __  9W/_R-7/6GAZTG+VEF_P#[3_Y%_P#@4NYU
M4*6*HJ,?972_^W_^27_@,2SKGB#X9>'-)\9WVEVG@&Y\3QGPVLD8M+.ZLVNS
MO&HFRCD#(8>0&\L;!U&,*:]4N/B5X)TOX@>!UT37? ]IX3T*^\46Q2WFTZ$0
M!XIOL@7!$ABD4D;E^1V*[B6VUY%_PZ_^)?\ T-_@/_P9W/\ \C4?\.O_ (E_
M]#?X#_\ !G<__(U8U%AJB:=3>_XQ4?PU:[-F]-XNGM1_E]?=DY;_ -ZZYN]C
MJ?ACK?PIUW2?#>IZ[IO@%==U#1+8ZFT3:39202)>W"MBTN8A9Y:/R?,&Z*;9
M@QY)R/CSXI6FCV/Q(\3V_A^\M;_1(]1G6SN;&)XH'BWG:8U9F8)CIEFX Y-?
M37_#K_XE_P#0W^ __!G<_P#R-1_PZ_\ B7_T-_@/_P &=S_\C5O"IAZ=5U%4
MWOITU=_PV7S.:I1Q52DJ3I;6U]%:_J]W\CX\HK[#_P"'7_Q+_P"AO\!_^#.Y
M_P#D:C_AU_\ $O\ Z&_P'_X,[G_Y&KK^N4/YCB^H8G^1GQY17V'_ ,.O_B7_
M -#?X#_\&=S_ /(U'_#K_P")?_0W^ __  9W/_R-1]<H?S!]0Q/\C/G3PE_R
M3/Q[_P!N'_HXU33XM>.8_"__  C2>,_$*^'/*-O_ &.NJ3BT\L]4\G?LV^V,
M5]/0_L'^./"EK<>#KKQ'X2FU'Q9M^QW%O?3M;P_93YLGG,8 5RK +A6R>N.M
M0?\ #K_XE_\ 0W^ _P#P9W/_ ,C4I8G#M>])69Y> P>*6(Q7)%W4TO\ RG39
M\KZ[XX\1^*'L'UG7]4U=]/C$5FU]>R3FV0<A8]S'8!@<# XJ_I_Q6\;:3JVJ
M:I9>,-?L]3U08O[VWU.=)KL?]-7#;I/^!$U],_\ #K_XE_\ 0W^ _P#P9W/_
M ,C4?\.O_B7_ -#?X#_\&=S_ /(U+ZUAK6YE_P .>O\ 4\8G=1?_  VWW'RU
MX3\?>)_ -U/<^&/$>K>'+BX01S3:3?2VKR*#D*QC8$C/.#5FX^*'C*\BUF*?
MQ;KLT6M$-J:2:E,POB  #."W[P@ #YL]*^G/^'7_ ,2_^AO\!_\ @SN?_D:C
M_AU_\2_^AO\  ?\ X,[G_P"1J3Q6&D[N2!8/&15E%GSHWQT^)+VEI:M\0O%3
M6UFT;VT)UJYV0,GW"B[\*5[8Z=JQ_%WQ!\4^/YK>;Q/XEUCQ)+;*4@DU>_EN
MFB4G)"F1CM!('3TKZC_X=?\ Q+_Z&_P'_P"#.Y_^1J/^'7_Q+_Z&_P !_P#@
MSN?_ )&H^LX6]TU<?U3&-6<78^/**^P_^'7_ ,2_^AO\!_\ @SN?_D:C_AU_
M\2_^AO\  ?\ X,[G_P"1JOZY0_F,_J&)_D9\>5^QW_!/?_DWFS_Z^$_])+>O
MC3_AU_\ $O\ Z&_P'_X,[G_Y&K[D_8J\+W7@?X4ZAX<O9K>XO-'U:33YYK5B
MT+O%!!&S(2 2I*D@D XQP*\O,J].KAVH.^J*P6'JT,UPSJ1M=3_(]\>&.0Y>
M-6/3+ &F_98?^>,?_?(J6BODC],(OLL/_/&/_OD4?98?^>,?_?(J6B@"+[+#
M_P \8_\ OD4?98?^>,?_ 'R*EHH B^RP_P#/&/\ [Y%'V6'_ )XQ_P#?(J6B
M@"+[+#_SQC_[Y%'V6'_GC'_WR*EHH B^RP_\\8_^^11]EA_YXQ_]\BI:* (O
MLL/_ #QC_P"^11]EA_YXQ_\ ?(J6B@"+[+#_ ,\8_P#OD4?98?\ GC'_ -\B
MI:B6YB;?B5#L;8V&'RMQP?0\C\Z #[+#_P \8_\ OD5!>O8:;9SW=V;>UM+>
M-I9IYBJ1QHHRS,QX  !))Z8JQY\?_/1>_P#$.W7\JHZOI^DZHMN=4MK*[%C.
MMY";R-'^SS)]V5=P^5EW<,,$9Z\T <S_ ,+6\%3_ /(.U&/Q#C_6?\([:2ZK
MY/IYGV5)/+SSC?C=M;&=IP?\)%XCU#]WI_P_FLIA\QD\0:A:V\!7T5K9KER^
M2, H%P&^8$ -VOG1[L;USG&,CKC./RH$T9SAU.#@\C@YQC\^*9)Q7]B^-M4^
M:?4O#^@0R_*]K9:=)>SP+T)CN9)(T9R/F!:WVJ2 5<#+'_"I[*\^?5]=\1:O
M<CA9_P"U9+#:O9?+LO(C/.3N*%N<%B H'<447'9'.Z'\.?"GA>[>ZT;PQHVD
MW3H8FFL=/BA=D)!*EE4$C(!Q["MW[+#_ ,\8_P#OD5+12&1?98?^>,?_ 'R*
M/LL/_/&/_OD5+2,P522< =2>U $?V6'_ )XQ_P#?(KC=+MH?^%Q>)QY28_L'
M23C:/^?C4:[-[B*/)>1%  )W,!P>AK(L_#ZV_C+5==%R'-Y8VE@;<)_J_(DN
M9-V[/.[[3C&!C9U.>'<1K?98?^>,?_?(H^RP_P#/&/\ [Y%*9XU4$R* 06!W
M#H.IIZL'4,I#*1D$=#2&1_98?^>,?_?(H^RP_P#/&/\ [Y%2T4 <MK'PO\*:
MY?37]SH5I'JLN-VJV:?9;X8 4;;F(K*ORC;PPRN5/!(JA_PJ[['\FD>*_$6D
M6QY:#[1#?[F[MYE[%/(.,#:'"\9"@EB>XHIW8K(X?^S_ !WIO[WS/"OB'/R_
M9?LD^E;>^_S?,NMV,8V>6,[L[AMPQ_PFEYI__(8\"ZQ90Q_+/?6207\ ;IF-
M(9#<R(6P ?(#8(+*@#;>XJ*.YBFP8Y4D!R!M8'.#@_D:+A8XS_A;'@6'Y=0U
MJRT";J+;Q C:7.R_WUBN5C=D)R X&TE6&<@@=9;O874MS% UO-);2"*=(RK&
M)RJN%8#[IVNC8/9@>A%6%GC<J%D5BPR,,.1Z_H?RKF_ W@?3/ [:\FCQVEKI
M^HWZWL=E8VZPQ6W^C01%0J\')A+YP/\ 6=.Y .C^RP_\\8_^^11]EA_YXQ_]
M\BE,\:J"9% (+ [AT'4T]6#J&4AE(R".AI#(_LL/_/&/_OD4?98?^>,?_?(J
M6B@");:%2"(D!'((45+110 5XCJ.N0:9J&E6<J2-+J4SP1% "JLL3R$MSP,(
M>F>2*]NKY\\:> -*\>R:,FLV=GJ5AI]TUR]C?6J7$4Q,,D8!5N!@ONS@_=_&
MO1PE_>MY'GXK[/S'1_$3P_Y\-O=ZI:Z7=7%[-I]K;W]Q'#)=31/L81*6R_)'
M YY' S2_\+&\)_;(;3_A*-%^U37+644']H0[Y+A=NZ%5W9+C>F5'(W#CD5YY
MJ7[.5LTUJND:C!I6GQR3B338H;J&V:"2?SA$L=K=0*-I+#YPZGCY1CFSKWP$
M;5&TPV^MB%+<31W4,BW:17,<EPT^-MO=P\@NP._S >#M'.>^-_=O\_Z_K?RU
MX)6O*WR_K^OQT['6/B=X?T?7FT0W]O=:O'$TT]E!=0"6W4*&!E#NOEA@PP6P
M#ZTEK\6?!EUY 'BG2(GGO);"&.:]CC>:>-]CQHK,"S!B.!UW*>A&>=UKX/WN
MLZM?.==MXM+F-U)!;?V>6GCDN GF%IO-PZ@KPH1< X). :IZ]\%-7UHQP)XL
M%KIR7]Q>_9H[6="?,N3<!6,=RBR89BI\Q74KC"H<L1<UXW^8W:SM_7]?U<]"
MTWQEH&LW5W;:?KFFWUS9[OM,-M=QR/!MQNW@$E<9&<],UIVMU#?6L-S;31W%
MO,@DCFB8,CJ1D,I'!!'.17EGB+X:7DB^&]%L;>6:#S[Q=1U93'%$MC<.TD]N
M4+[RTA\L JI *[B5Z'U>.-8T5$4(BC 51@ >E5&]M?Z_K_,3WT%HHHIB"KFE
M_P#'T_\ UPF_]%-5.KFE_P#'T_\ UPF_]%-4R^%E1^)%.BO/OB\-9CL;#^PO
M$^I:%JU[<)I]E;V=O:RQ2S.2?,D$T$C%8T61R%9<JA[\US7PH\;:]KFO:?-J
M^HZR+/4X;G[-#J%E9K:3F-P!Y#Q$3JZJ"6\U2KY8I@ 4*5W835E?^OZ_R/9J
M*\CU#QIK]IXWN;T:D[:1!KG]B?V&((MKI]A\_P [?M\SS/,/][9L'W<_-6!I
M_COQ;'I-K!/XA:ZNM>LM(O(KW[) /[-:\N?*E6,!-I55(\OS YW [BXXI1ES
M6MUM^*NOPU')<M[]/\[/[G_P#WNBN4^&NK7^IZ#=1:G=G4+NPU"ZL#>M&J-<
M+%,RJ[! %W;0 VT ;@< =*ZNKZ)]_P!2>K7;3[@HHHH **** .%\7_\ )4/
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M1>YN7BF)+*75=J9CV,N&/S;AQ1S*]OZ_I?\ #!TN>]44450@HHHH */V;_\
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M:;++)+'=>>RL[S%V)D<D/EGRQ\QCGDYS/^%X>"?^@U_Y*S__ !%'_"\/!/\
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M'[_RC7W_ ,CUR7_#Q#P+_P +,^R_\)OIW_"$?8?/^V?V!?\ VG[1G;Y&<?\
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M86<]Y"<J&&V:&)XVX(SM8X.0<$$5G"E.II"+?H:U*U.DKU))>KL?1U%?,/\
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M%_\ _&*_(.BC_5["_P TOO7^0?ZSXS^2/W/_ .2/U\_X;T^!7_0\_P#E(O\
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MN:9I1IRJU(044[?:?Y/;S/T*_P"&]/@5_P!#S_Y2+_\ ^,4?\-Z? K_H>?\
MRD7_ /\ &*^&I/@/X!U7XN:#X(TR'Q%9'4-"&M27M]K5JZ@OIS721 ?98U0*
M^T%V;!4'A<Y&;#^S/ID.K>!+6_U66.'4/#U]X@UN?3[RVOD2.V><E+9XB8V+
M+$JYW/AF)/3;5/*\!'XI26E^FWO/M_=?X=S-9OF<O@A!_?NW!):M;\\?Q[,^
M]_\ AO3X%?\ 0\_^4B__ /C%'_#>GP*_Z'G_ ,I%_P#_ !BOA'X?? GP-\2X
M/#_B#3SXAT_P_<7.IV.H:;<7T$MTDUM9-=1M'<"W52KJ #F+*D'KD&J.E_ /
MPSXLO?!FLZ9>ZMI?A'6=)U+5+Z"[DBN;VU%@',\:2*D:2;\)M8H,;^0<<MY7
M@(MQE*2MOMII)]NT6_\ AT"SC,Y14H0@[NRWUUBN_>26MON1]^?\-Z? K_H>
M?_*1?_\ QBC_ (;T^!7_ $//_E(O_P#XQ7PG\-O@%X*^+%UX/U/2I=>TK0M4
MU*_TB_L;N\@GN89H+-KF-XYUA165Q@$&/(P1DY!'F7PG\ Z5XJM?%NM^()KQ
M="\,Z;]ON+?3G1+BY=Y4ABB5W5EC!:3)<JV I^4YJUE&!O).4DXI-K3JVETZ
MV_(S>=YC[EH0:F[+?I;S\S].?^&]/@5_T//_ )2+_P#^,4?\-Z? K_H>?_*1
M?_\ QBO@>/X!^%+KPS;_ ! BN]9C\"G09=6FTUYHFU 7"70M/LRS^6$VF1E;
MS3%PN?D)K'B^%WA"'XD>'M&\0Z=XU\":1KUH8XI/$4,<36=TWRQ2^88U%Q;;
MMNY@D1 8\_+DI93@I-I.=U?MNKW6V^G3R[HJ6=9A%<THP2T[[.VN^WO+?]&?
MHA_PWI\"O^AY_P#*1?\ _P 8H_X;T^!7_0\_^4B__P#C%?F=\;OAKI'PBU+2
MO"ZWTNH>+K:V\SQ T<Z/:6]PYREO%A =R)MWL68%FP,8(KS2MZ>1X.M%3A*5
MGZ??ML^GD<M;B+'T)NG4A&ZWT>GE\6_<_7S_ (;T^!7_ $//_E(O_P#XQ1_P
MWI\"O^AY_P#*1?\ _P 8K\@Z*U_U>PO\TOO7^1C_ *SXS^2/W/\ ^2/U\_X;
MT^!7_0\_^4B__P#C%'_#>GP*_P"AY_\ *1?_ /QBOR#HH_U>PO\ -+[U_D'^
ML^,_DC]S_P#DC]?/^&]/@5_T//\ Y2+_ /\ C%'_  WI\"O^AY_\I%__ /&*
M_(.BC_5["_S2^]?Y!_K/C/Y(_<__ )(_7S_AO3X%?]#S_P"4B_\ _C%'_#>G
MP*_Z'G_RD7__ ,8K\@Z*/]7L+_-+[U_D'^L^,_DC]S_^2/U\_P"&]/@5_P!#
MS_Y2+_\ ^,5Z?\+_ (N>$_C-H-QK7@[5?[8TRWN6LY)_LTT&V541RNV5%)^6
M1#D#'/7K7X:5^GG_  3!_P"2"^(/^QEG_P#26UKR\RRFA@\.ZM-MNZWM_D>Q
ME.=XC'8E4:L8I6>R?^;/J;6O^/I?]P?S->$1?M4>$)]#L+V'4--O;Z6:Y-WI
M=CJ<<]U9VT,<\C3/&HW?<A'RD##2*N<XS[QKVES:DDD4;21B2(Q^;$P#IG(R
MN>XSZ5P%Y\"=)OO#^BZ)*ET=-TG2Y=)MX?.3F*2)8BS''+A%P#P/F;(.>/E.
M_P#7]?\ !Z'VC.,;X[ZE_P ("GBB/0-'N8&G:,?9?$D4T3@!=L,<BQDO=,[&
M,0!<;T(\S!4G6L_BMK-Q?37DGARS3PFFL'15U&/5&:\\W[0+8.;8P!0GG':<
M3$@#.#TJ\_[/JS6AMY_$7B"X6ZE:75=]Q; :MG8-LZ"$(H"Q(@,*Q-M!&>35
MCP[\"VT&ZC,WB#7-8TV&]EU&#2;Y[1;:*X>5I=^8H4D?#NS 2.X!P<952-+Q
MNG_73_@V]=3/WN6W7_A_^!_6@>+OC-X1\#:L^F:QJ-Q!>I$)FB@T^YN,*4E<
M9,4;#)6"9@N<D1L<<5I77Q$\/65S]GEU#]]MLW"I#(^1=2-';XPIR79&&.HQ
MDX'-9OBSX!:=XRU#4KR\N-1AFO@ZR?9YXE"AK22U^7*'&$E<CT8YZ9%.U;X$
M6NK^,(-?;4=6MC$;=_[/MYH5MG>!9%A=@8RYVB5B%W[<X.W(S6?]?Y_\ O7I
MY_?T_P""5O!WQET/Q>^G0+!JFGW>HI+-:1WNDWD$<T:%L%)9(51F*+OV [L'
M(R.:Q] _:-\+:M9/>74EQ8P^8R"/[!>O/&HVL99H_LX,47ER0/YC?(!,,L."
M9_!7[+FD>!O$D.MVE]J5W?0VOV6.2Y2R#A?)6'<9(X$D8[47 9BJ_P ( .*-
M(_9?TS1;*.UM]7UPQ/']GOPTUM_Q,K?9&@AFQ$,($A1?W7EL1G).36GN\VNW
M]?\  _K0GWK7_JW]?UU.CM_BEX:NO&DGA2*^F?6XY#"T8LI_)$@A6;R_/V>5
MO\M@^W?G&>.#75USEC\(;73_ !!'K"-=/=)>W-_AY(]IDGC6-LX4'"HBJHSP
M.N:ZW^S+G_GG_P"/#_&HTLN]E?UZE:W=RK15K^S+G_GG_P"/#_&C^S+G_GG_
M ./#_&D,JU^ -?T$?V9<_P#//_QX?XU\W_$S_@GA\,_B9K]SK<MKK&@ZG>74
M]Y?3Z3J(/VN:5][,ZSB55PVX@1A1\YX/&/8R[&4\*Y*IUM^%SPLTP-7&*#I[
MQO\ C8_(>BOU)_X=6?#7_H-^,/\ P.L__D:C_AU9\-?^@WXP_P# ZS_^1J]S
M^U<-W?W'SO\ 8N+[+[S\MJ*_4G_AU9\-?^@WXP_\#K/_ .1J/^'5GPU_Z#?C
M#_P.L_\ Y&H_M7#=W]P?V+B^R^\_+:BOU)_X=6?#7_H-^,/_  .L_P#Y&H_X
M=6?#7_H-^,/_  .L_P#Y&H_M7#=W]P?V+B^R^\_+:BOU)_X=6?#7_H-^,/\
MP.L__D:NG^&W_!.?X;_#7Q?8>(X3KVMWVGRQW%G'JE_'Y<$\<BR1S 0I&692
MG1B5()RIXQ,LVPZ5U=E1R7%-I.R^9Z=^T)_R0+XE_P#8LZG_ .DLE?B#7]!'
M]F7/_//_ ,>'^-?+'BC_ ()D?"CQ!J$=Q8P:]X:A6(1FTTO4E>-V!)WDW"2O
MN(('# 84<9R3Y&78VGAE*-3J>YFF7U<7*,Z5M#\GJ*_4G_AU9\-?^@WXP_\
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MV$JQ5V?@AK?7^OZ_KN#\OZ_K^NQZ1:ZE:7TUS#;W4-Q-:N(YXXI S1,5#!6
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MC:_)I#7%Q#%I,;RW-RM_# WVE'@'DQ^4Q*N$B#,_'\*'=F\1?%G3XK^6ZO\
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MHXF8R!0Q7:.NW<Z#)SQ1U;XYW"6,E[IVD2>5Y3((;U/+ECF6XF@<L-W* Q9
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MI??:,YW^?)<IMV]MOV;.<G._H,<G]J?W/Q_X O[(_O\ X?\ !.$HKU3^Q/\
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M":DYWMY?\$H6O_'U#_OK_.NCK-BT?RY4?SL[6!QM_P#KUI5XK/>1P'[0?_)
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M@ HHHH IZMK%AH.GS7^IWMOIUC" 9+F[E6*),D ;F8@#D@<^M9K>/?#*Z@+
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MH)*J6I)9/B#"UQ)!:Z]*5(DM8I)M+*F(9+12\@F4D$#:0H'EY?/F9K>)M?\
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M#=W.EWDLB2DS[8'\LNQ.(XR6P,9(X+H!N^(O%WQ(L9+Z?3]+M;B.(7+PV/\
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ME%Q:N>B1ZM#)(J!7RQP,@?XU=KG+7_CZA_WU_G71UY)[1P'[0?\ R0/XE?\
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M_) _B5_V+.I?^DLE=!XH\&V7BZ+9>2W$8^R7-G^X91\DZ!'/(/( X_7-<_\
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M9!8CYB, !=L&H? ?2;_4;J\76-6M9)YWN?W'V;=%(\DCLT4C0F2,YE(RC X
MYZD^ET4^9D\JM:QQ7CSX5Z?\0KFWEO\ 4=0@2'RBMO#Y+Q$QRB16V2QN Q(
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MF6W_ #S_ /'C_C730Q,\.VX=3DQ&%AB4E/H>8_V!?_\ /#_Q]?\ &C^P+_\
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M+HM2_F?W+_,.:M_*OO?_ ,B>@45Y_P#\*/\ #O\ T$?&'_A:ZS_\ET?\*/\
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@:@9P HP*=Z<8R46VWY>:?<FU64HN222?>_1KLNY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>forms-1_015.jpg
<TEXT>
begin 644 forms-1_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 G # 2(  A$! Q$!_\0
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M (W1_P ,_P#Q0_Z)OXN_\$5U_P#&ZX?:8CN_Q/G/K&9_SU/OD=]_PW9\<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!G^(-!L?%&@ZCHVJ0?:M-U"WDM+J'
M>R>9$ZE77<I!&02,@@UAQ_"OPM%\-3X 72\>$?L)TW^SOM$O_'N1@IYF[S.A
MZ[L^]=967X9\00>*=#MM5M8IHK:X#-&LP4,5#$!N"1@XR.>A'3I5<K<6[::7
M_&WZ_B1SQ4U&^NK7X7_3\#S[QE^RW\+?B!X?\/Z+K_A*WO[#0;9+/31]IGCE
M@A50JQ^:D@D90 .&8\\]>:W5^"?@F/4O!]]#H$-M<>$4DCT3[/))$EFLBA7
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MF%L]\UZ!<3/#Y>R"2?<X4^65&P'^([B.![9/M4M'-*RU\_G>]_6[#EC=Z?\
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M,&FVUUXSTNWU+2+P^*9]?GN)M3FM75?LL1ED@59B-KQ[4A&Q3@-R0&Z^<_\
M#>?_ %(W_E7_ /M%8.B_M=:+X?U*2^L?A[)%.X< /X@EDCB#MN<11M$4B#,
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MI7S)J/[:UGJUU8W%UX#DE>RD\V%?[<=8]_9F00[7(ZC<#M/(P>:O_P##>?\
MU(W_ )5__M%16R7-JL5%T.MW>4>B22OS>5WMJS7#\4</T*CDL5;2RM"?5MMV
MY++>RWT6MSL=(\$P-I^JZ?I6CZF+*_@M["34+C3);"[Q-.HG6?[@N"L>YO/*
M9'S#>Q8UNZA\-;$3:W+9^'S;N=9L8++9 3Y2@P&:\0$8#G=)F7&X^7RQKS'_
M (;S_P"I&_\ *O\ _:*/^&\_^I&_\J__ -HKHEEN=N7,J/\ Y/'R\_+\6<4<
MZX74.5XA?^"Y]I+2\7_-??=+IH=W>:;?ZI\1+/47T.6"_CUMGGN(]&N/-AMH
MEDV8OF8JR2K&O[N(!?WFTC))9VH>'-?F\*RFTM+ZPO4TNU\V18'>0&ZNS/?*
MJJ49V55&51@QS@'.*X+_ (;S_P"I&_\ *O\ _:*/^&\_^I&_\J__ -HH_LS.
M%RVP_P -K>]'I\]K::WT'_;G#C=1RQC]^][0FM^OP[IKFNK:]+:'HVD^#[IO
M!NOVEM;O#I^N7-I8"SL=%ETN..(R!+BX6%Y7=28V.68)_JP<'.3W7CC0VTSP
M!=V'A^TDM(C)&98M,4I-Y+3*;AH]OS&0H9#Q\Q)XY->*^+OVU/\ A%?%FM:+
M_P (;]J_LV]FL_/_ +4V>9Y<C)NV^2<9QG&3C/6LG_AO/_J1O_*O_P#:*Y'E
M6<5W&K[&ZNI?%'716OJNB[=6=\.(.',)&=!XFSLX_#/363=FXM[R[O9'I%]X
M?TF2&*?3O!U[I7A*2_CCU&WM;*>-[^!89"'>R50^T3-&I)0NX4Y!0#+M#\$I
MK&I6\5[H-S;>%H[F\U2STF>W*PQQ^5%!'$T710^Z>3R2!C=@J#D5YK_PWG_U
M(W_E7_\ M%'_  WG_P!2-_Y5_P#[171_9><V:5%]OC3^?Q?%Y_))(XUG_#3D
MI3Q*=FGI3DMG>WP_#O[O?5ML[Z+PV?!.@:9JUOH\MIJ$/AV\GN)1&1)Y\@B$
M-H7;H%+L%CR NP8 Q5_PSI)T%M1U#PIX9O+2VL?#_P!E>&ZMY;2;4KQ<&-2&
M 9RBJR^9W\W"L<<>4:G^V_:ZQ9FUO/ /G0%TD*?VR5RR.'7I"/XE''?H>*M?
M\-Y_]2-_Y5__ +152RO-Y1?-0NW>_O1M:]]?>UM=I=O4B&?\.TYKEQ5HQM:U
M.5T[)-KW-+\L6^^J>AU6C^$+BXN-7M;/2KB#3]0L;33IIK71+C3/M'G7.)Y'
M$K,[M'&K$R2'=\YY.[)[:\\*M%8^+[&PTM[6SU+4+2Q6*.!@LD9$0GG( YR'
MDW2'KLY/%>/_ /#>?_4C?^5?_P"T4?\ #>?_ %(W_E7_ /M%*IEF<U)7]A_Y
M-'HXONOY?Q8Z.><,T8N*Q6_]R?:2TO%O[7?H=[I7A;6K[Q\]Q>*ZZM'K$ET;
MQM"G\R.U20F.);YIQ%Y3QA4*(A/SG*9!:K_@'04F\?0ZH- OK2\F-Q=:A)?V
M4D,UG.W_ "R%X @NXB2P52)  JG*X KS/_AO/_J1O_*O_P#:*/\ AO/_ *D;
M_P J_P#]HHEEF<RBX^PW5OBC_GMV7EOO<CGO#49J?UJ]I<VL*CN[W3U6^]WL
MT]M(M?6=%?,7A?\ ;4_X234IK3_A#?L_EV5Y>;_[4W9\BVDGVX\D?>\O;GMG
M.#C%9/\ PWG_ -2-_P"5?_[17B_ZN9HY./LM5_>CU^?D?3/C3(5!5'B-&VOA
MGTM?[/FCZSHKY,_X;S_ZD;_RK_\ VBC_ (;S_P"I&_\ *O\ _:*O_5K-?^?/
M_DT?\R/]=^'_ /H)_P#))_\ R)]9T5\F?\-Y_P#4C?\ E7_^T4?\-Y_]2-_Y
M5_\ [11_JUFO_/G_ ,FC_F'^N_#_ /T$_P#DD_\ Y$^LZ*^3/^&\_P#J1O\
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M*]:_X93^*?\ T*__ )4+7_X[1_PRG\4_^A7_ /*A:_\ QVN_^U,!_P!!$/\
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MNT7$4C9/,B]I#\_ ^;@55D^&/Q^FFO99-*5Y+R^34Y&:73B5NDQMFC^;]VV
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M"U_^.T?\,I_%/_H5_P#RH6O_ ,=KV_[4P'_01#_P*/\ F?*?V#F__0)4_P#
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M<LZ>>P+OL D;* ;BHW =NU/1_@_X0U^RT*2SDUJVNM:TF\U&W\^XAD2W>W+
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M!STKKE^$WQZC\1Z?KL>D+#J.GHT=F89]/2*W5@P8)"&$:@[FSA>ISUK+TO\
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MK_\ E0M?_CM?2+-,#;7$0_\  H_YGQ,\BS5R;A@ZENGN2_R.1^$?_)5O!?\
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MDTNUO+C4'<S[3@ G%<_X;^*6FZIH,%]J$]C;R21O-G3+S^T+62-9A%YD4Z*
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MPQ2?>,IL._#;AR,=:/;1[![%]SE],TVVT>QCL[2,Q6T>=D>XL%!).!DG &<
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M_%4?V?8_\^4?_?<G_P 51[:/8/8R[G*T5U7]GV/_ #Y1_P#?<G_Q5']GV/\
MSY1_]]R?_%4>VCV#V,NYRM7(O^01<_\ 7>+_ -!DK>_L^Q_Y\H_^^Y/_ (JI
MEL;/['*OV./:9$)7>_)PV#][W/YU,JRML-47W./HJ=O''@-?$C^'3KF@CQ F
M=VE'5%^U+A-YS%YFX87YNG3GI6_;V^F7EO%/!;P3P2J'CECE=E=2,@@AL$$=
MZKVRM>PO8N]KG,T5U7]GV/\ SY1_]]R?_%5#>1Z3I]I-=74%O;6T*-)+--,Z
M)&H&2S,6P !R2:/;1[![&7<YNBNDMTTB[DGC@AMII+=Q',L<SL8V*A@K -P=
MK*V#V8'O4W]GV/\ SY1_]]R?_%4>V78/8ON<K175?V?8_P#/E'_WW)_\54-U
M'I-DL;7$-M LDBQ(99G4,['"J,MR2> .]'MH]@]C+N<W174M8Z>N,V<0R<#,
MC\_^/4V:UTVVADFFM88HHU+O(\KA54#)));@ 4O;Q[!["7<YBBNGAM=-N(4E
MBM898I%#(Z2.58$9!!W<BG_V?8_\^4?_ 'W)_P#%4_;+LQ>Q?='GOQ6L]7OE
MGCT5IENQJ2NYAF$1\L2?/SD<8[=Z\/U+0?&'A^QM/#>F:QJ?]L7MJ;B.*]UB
M2[N)66S"W!#/.& \T@ [T17=2K)G=7U;XENM#T&&_P!3U=K+3[&!FDGO+RX,
M,48W?>9BX51D^W6J^BW>@>)-+@U+26L=4TZX&Z&\LKEIH9 "02KJY!&01P>U
M91J1Y''77?[K?\'Y&DJ<N92NM/\ .Y\T:7X7\=Q:/I8U"W\37LL3S"VAMM52
MQDLY2Z%'N&:^N?/A #??><@$CRB,"I]+\#^+='TWQ1;+::V^GS:S]I6TM=:V
MW%U;M<SR2?9I3.#"2KPDY:(G:PR"<GZ7M(])U" 3VL-M<PDLHDAF=U)!*D9#
M=000?<&IO[/L?^?*/_ON3_XJK]K'16?X=T]>^W7_ "(]C+O_ %9KY;]#YS\-
M^"_&$.M:5JFH7.K^9;FUC%O)K+O$EO\ O_,66(2>7+(J-"K2,K$LNY2>M>Q5
MU*V.GNH9;.)E/0B1\?\ H5+_ &?8_P#/E'_WW)_\535:*35GO?\ K^MVP]C+
M1WZ6.5HKJO[/L?\ GRC_ .^Y/_BJ/[/L?^?*/_ON3_XJG[:/8/8R[G*T5TAC
MTE;Q;0PVPNFC,H@\Y]Y0$ MMW9P"0,^XHCCTF:ZFMDAMGN(0K2PK,Y= V=I8
M;L@'!QGK@T>VCV#V,NYCZ7_Q]/\ ]<)O_1353KL+.QLUE8K9QJ?+<9WOT*'(
M^]Z5@>)/$GA#P:MJVOZAI&AK=/Y5N=2OQ;B9_P"ZF^0;CR.!ZU/ME?8?L7;<
MR[B%+J"2&1=T<BE&7.,@C!%1Z?8P:78VUG;)Y5M;QK#$F2=JJ  ,GD\#O78_
MV?8_\^4?_?<G_P 54%XND:;;O/=Q6MK BEFDFF=%4#J22_ JO;1["]C+N<Y1
M75?V?8_\^4?_ 'W)_P#%5 %T@W@M1%:FZ*&00^<V\J" 6V[\X!(&?4BCVT>P
M>Q?<YRBNDFCTFWG@AEAMHYK@E88WF<-(0"Q"C=R0 3QV%3?V?8_\^4?_ 'W)
M_P#%4>VCV#V,NYRM%=5_9]C_ ,^4?_?<G_Q54WN-!CAN9G-DD5M)Y4\C7+!8
MGX^5CO\ E/S+P?4>M'MH]@]C+N8-%=):1Z3J$ FM8;:YA)91)#,[J2"01D-U
M!!!]P:F_L^Q_Y\H_^^Y/_BJ/;1[![&7<Y6BNJ_L^Q_Y\H_\ ON3_ .*H_L^Q
M_P"?*/\ [[D_^*H]M'L'L9=S!T?_ )"]C_UW3_T(5ZE7(V-C9I>6[+9QJPD4
MA@[\'/7[U==7!B9J;5CMP\'!.X4445QG6>:_&33+W6/!_B.RTZU>^OIK4K#;
M1NB-*V 0H+LJ@G_:('N*XSQ1JWBCQCIMGID?@+5M-M[R[MS+<7E[8[K,1W,3
ML\J1W#Y0H&V^6SL2I!51ACZUJS1_VA+NFA0\?*\RJ>@[$U4W1?\ /S;?^!"?
MXUW0V3.*6[/%(O@GJ]]X-U&._P!;O[R^9=0^PZ+?-:K8P--+)@;X81*5>-BA
MWN^!(W&0,=5I\WBKQ'<W5]9>&;3P+?>3#;_;-?MX;ZXF56=C&%M;D#RQO.TM
M*"&9_P!WSD^@[HO^?FV_\"$_QHW1?\_-M_X$)_C5+072W]?UH>"V_P +_&/A
M?QQXA\13F#Q=%<7-CJ'DV-JEI<W31S7/[K,UR4S#')%M)\M6")@@AB>FLOAO
M<GPWX#:ZTF#^UM(U/[84W(QL(Y&D9T1LXRJLJ'9U ..*]4W1?\_-M_X$)_C1
MNB_Y^;;_ ,"$_P :(^[RVZ--?*W^2%)*3;[IK[[_ .;"BC=%_P _-M_X$)_C
M1NB_Y^;;_P "$_QH&%%&Z+_GYMO_  (3_&C=%_S\VW_@0G^- !11NB_Y^;;_
M ,"$_P :-T7_ #\VW_@0G^- $T/^KN/]P?\ H2UXM\2OAWXA\4?$"6\LGU2U
MTIM-BC:;2]6DL'DFCCOBB,8I4<J'FA.#\I)&<@&O:86C\NX_TBW/R#I.AQ\R
M]>>*AW1?\_-M_P"!"?XU+7,FBD[6_KJ>/:OX+\:WGB*+6K6^U*WU".VLH(E.
MJ.+)6\J<7+O:K)Y3G>T>2R,>!MZ5GZ+H/Q TGPG?W>FV6M1:E:7%M/9Z1KVN
M+=RW4HC:.Z+3><ZB%A('2,L &BR$3(%>X[HO^?FV_P# A/\ &C=%_P _-M_X
M$)_C5O7F\W?T\EY>1FDER^2MZ^OF>)ZMX/\ B'I?AU[72+W4-4O3=2:=YESJ
MFQC9RV\*FZ#ECMD22(LO&X;W('/-SX)Z3XV\-Z#XG?7K'46FD=9]-LM1OVGD
MR(\&/?)?797+J.?-"_,#M4[@/8-T7_/S;?\ @0G^-&Z+_GYMO_ A/\:6MFO)
M+[OZOZCZKU;^\\VU[2=8\+P>!Y[#1+_Q3)I4DGVV/3YK9)F9[=U:7_2)HE.7
M;)PV>>E8GB72_'&K?&#PSJMAIFJ6&A0"!KS.HGR3&RMYD;Q+?"/>K.,C[-+D
M+E9<@*/9-T7_ #\VW_@0G^-&Z+_GYMO_  (3_&G]I2[._P#P/0+>ZX]U;^O,
M\E\=67C+Q1KUVNGZ#=:4-,LKR*VU.*_@"WPE:#"0$/YD4A1)1N=%"-@AF'S5
MS$?@'QE/<Z=?+I.H^1;3%[2SUC5DGO+>$74$BQS7!DD+-\DC!@\FU2HR2,5]
M [HO^?FV_P# A/\ &C=%_P _-M_X$)_C4I6DI=5_5_Z_5CE[T7%[,\H^ .A^
M+M$L]=7Q3!J%M'/<1RV4.I7KW,D:[,.N7O;LCYAGB4*<@A5)('J]&Z+_ )^;
M;_P(3_&C=%_S\VW_ ($)_C5-W$M KG/BIIM_J6CNVFV;:A>6>I6M^MFDB1O.
ML-RDC(C.0H<JK;=Q"YP"5'(Z/=%_S\VW_@0G^-37C1_:Y\W%NIWMPTZ CGTS
M4]4^VOW.Y71GA6L>"O%/C:YOM2>PUSPS%>WLEQ]AM]9%I= 1Z?Y4)E>UGP09
MP"$61A@*6QR!G2> /B)YGB>26>_9-6AD6SBTV^6S>RN#;Q*\[NDP\TR$,JG&
M8C&I4?.SCZ W1?\ /S;?^!"?XT;HO^?FV_\  A/\:<?=;?=6_KUZ_(F7O)*^
MSO\ U_7?N>#ZMX'\<6%U%9Z?_P )#=V<%Q.NDW">(6/V-C.K)/>&6?S+F'9D
M!&\T@*PV<@C3\.>%_B!;^)KE-1N+QM(BBN!;2_VD6WF)7AM]P+[B95E\QB<X
M:$$\X->R[HO^?FV_\"$_QHW1?\_-M_X$)_C4N-X\C[6_X/KYE+23DN]_QO;T
M_KN>??"'PIK/@_3[FSU2XU*ZC:&TD635-3DOY?/\A1<8>21V WC[H(7.2HYK
MT&C=%_S\VW_@0G^-&Z+_ )^;;_P(3_&M)2<FV1%**40HHW1?\_-M_P"!"?XT
M;HO^?FV_\"$_QJ2@HHW1?\_-M_X$)_C1NB_Y^;;_ ,"$_P : "IE_P"/23_?
M7^35#NB_Y^;;_P "$_QJ96C^R2?Z1;XWKSYZ8Z-WS28SR/\ X53J6I:OXFOK
M_6=46RFU1[ZST-#:?9)F$$:QR%O*\X'>N<>:!E1D8)!X'7/AO\0='\!Q:%H<
M6N7,C+:NEQ_;TQDMIA:A)/NWUNPB\P?=60HN,K"X/'TINB_Y^;;_ ,"$_P :
M-T7_ #\VW_@0G^-+E]SD6GP_^2[?\'T78/M<[\_QU_X;U9\[_$SPO\3]5U:Q
MF\/)K*3_ -CQPS2/>>7;1R^4_FA?*U*$&1L[07MW^8J5FC #Q]3X<\+^++CX
M$^)=$U9+Z?6[NUO8+2VU%E$RAXB$0R&]NRP+$X9YR><': !7K^Z+_GYMO_ A
M/\:-T7_/S;?^!"?XUI?5OO\ YW(2MRZ[6_!6//;GPWKT>D_$1;%7MKW4[I9;
M"2*<(\BBRMHFVN#^[8M'(H8XP0#TP:X&?PMXXD6S&GZ9XNLK17?^S(;WQ/'+
M-ITQDC/G7Q$Y-Q#P^(C)<D#(P-P5/H#=%_S\VW_@0G^-&Z+_ )^;;_P(3_&D
MM&GV27W:?U^ VDX\IX5_PK/QA',;\:EXBDO6\VZ,3>()?)%PM]F$",2A-GV=
MG!CQL8 ;U9@#6'H/A_QKXHM[F[T]-83_ (F+/]LUK5%N;>:6._?R9;>(RMY2
M11JRLNR,M\O#XW5]([HO^?FV_P# A/\ &C=%_P _-M_X$)_C4<NB7;_._P"'
M3T79#WYO/_*W]>K/FGPK\//B))I>COJR:VVH:?JZW,"WE[CR&:SN(C.6.IW3
M2QB5XBT991M#;8CN8&GIW@7XER>"[FQUFS\4ZE'(S+_9UOJJVMQYS0,JS?:'
MU6=I( _WHFD5>5(A/(KZBW1?\_-M_P"!"?XT;HO^?FV_\"$_QJIKG4D_M6_#
MM_7Z!'W7%KI_P=_O_K4SO#=I+8>'=+M9T\N>&UBCD7(.&" $9''45HT;HO\
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M5[>:Y5M8FN[QIC:A9&$CZC;-L$H.8_/V98$1L,X^E=T7_/S;?^!"?XT;HO\
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MY^;;_P "$_QJ%HK?UT_X?U;+ZW_KK_G^044;HO\ GYMO_ A/\:-T7_/S;?\
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MMI]L]G;,9'8K$Y0N"23N),:$LV6R#SR<ZU7T^_\ -_H 4444 %%%% !1110
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MD95 :0+N;G).369!\%_"]KILEC;KK%O;R.K2>3K^H)(^U-BJSB<,4"\!"=H
M&!3=^GE_P?\ @?TQ1MU\_P#@?U_PQ)XL^)$?A6_LHUL+S5C>0(T%G811>;*[
MS1QKAY)D0#,G(/&.=W&#<\&^-H?&4UPT$<T$26UO.(+B%5DB,F_*LRR,&(*$
M' P,<%@<B]=>#-&O+JPN)+%?,L$2.VV.R+$J.KJ H(& R+V[8Z5G^&O ,'AW
M5K^[2<^1(\?V6V@\R-88T1QM<F1O-):60\X7[N%RH:FMK>;^[I\^Y.M_DOOM
MJ=MI?_'T_P#UPF_]%-7">,O'A\&ZI#Y]NUQIZZ7>7\RVZ;IV:%[=55,L%Y$S
M<'N!R._=Z7_Q]/\ ]<)O_135SNM>%=+\12!]0M?M#?9Y+7/F.O[J1D9U^4CJ
M8DYZC;QU-3]K^NS_ %-.B./O?C;8Z;#=S7?A[7+>*WCEPY2W837$:;Y;5-LQ
MS*HW#)Q&2C8<XK=L_B!:S>$K_7;G3K[3_L+R13Z?<")KA9$;;Y8\N1HRS'&,
M.1\PR1SA+OX7^&K[5;[4+BPDEN+Q6653=S>3E@H9UBW[$=@H!=5#$=2<FM9_
M"^F2:=J-@UJ&M-0>22YC+L=[/]XYSD?AC';%'O6^7X_Y;_AYDZ?C^'^>WXG#
MWGQBN-/URQ@N_"^L6=K+"YNHIX81-9L)HHQ(["8QO%B4']TTC'/ RK 4K']H
M;1/$FI2:=H16:[@OH8'62>"8RPM.(G=5BF9HSDC F"-\P^4\XZZQ^%OAK3X9
M8X[*:4S*5FFNKV>>:7+HV7ED=G<YCCP6)("!1P,4Q?A3X;472-;7DUM<R>:]
MG/J=U+;*VXO^[A:0QQC)/"*!CC&.*/>]WRW^^_Y:!I[WGM]W^9RNF_M#:7K0
MMI++2;I[<:DUA?2_;+*9;55MI)S*6@GD5@%C.5#;A@_+G ;:T_XO6^H7UA8?
M\(YKEMJ5Y/'&EG.EN'2)T:1;AB)BHCVHYQN+Y0C9G -ZP^$GAC3XT2.TO)MD
MZ7.^[U.ZN'9T1HUW/)(S,NQV0J25*G!!  JSX?\ AKX>\,2PRV%G,)H9#)'-
M<7D]Q(I\LQA=TCL=@0D*F=JY. *:OK?R_P"#_7_ LGTM_7]?UY]/1115 %%%
M% !1110!<T?_ )"]C_UW3_T(5ZE7ENC_ /(7L?\ KNG_ *$*]2KR\7\2/2PO
MPL****X#N..\9ZUI_ANUU/5M26*.QLH3<3S?9?.945,DX52S' Z $^E87A7Q
MQH?C)KJ/3X)(KBV"M+:ZEHTMA.JMG:_E7$2.4)5@& VDJP!RIQ;^*^A7?BCP
MKXCTBP,*WM]9200FX<I'O:/"[F"L0,]2 ?H:\E^(GPK\8_%+2[V?5(=$TN^V
MV\$.E6M]]KMKF))O,D\^6XLF7D[-JFVD"F/.3O\ D[8O1?+^O/T^9QR6_?\
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M?Y_UU/H&XO+*SEMHYULXI+F3RH%>&,&1]K-M48Y.U6./12>U3[8O^?:V_P#
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M6/\ S^Q_]\2?_$URM%'L8]P]M+L=5_:%C_S^Q_\ ?$G_ ,31_:%C_P _L?\
MWQ)_\37*T4>QCW#VTNQV%O?6;17)%Y&0L8).Q^!O7G[OKC\ZA_M"Q_Y_8_\
MOB3_ .)K!L?^/74/^N _]&I7AWC[Q9XFTKX@7?V*YUU-&T\:<\HL8M.>Q19)
MF$IG$H^TME1P(?3UJ/91O:[W*=9VO8^C_P"T+'_G]C_[XD_^)H_M"Q_Y_8_^
M^)/_ (FOGV3XT:M)Y26GAJSFFU"2/^REDU8J)8VN1 S7!$#&!@6#;5$F?F&0
M5(IL'Q8UG7M0\/)9Z9;6%E+>6UOJ$S7N^599$=FBCC,(#QX4?O-R-_L<&B-.
M$N5IO5V^?]/^F)UI1NFME?Y'T)_:%C_S^Q_]\2?_ !-']H6/_/['_P!\2?\
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MQ(K-)MR7*A22$/%9RI1B]_R*C5DUL>D_VA8_\_L?_?$G_P 31_:%C_S^Q_\
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MTHDWB#+2;8V'E[<9V_/AMPI48OJ^GX["=:2MIO\ H>[_ -H6/_/['_WQ)_\
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M\_O#V*6E_(QZ*[;[9/\ \]Y/^^S1]LG_ .>\G_?9I>V?8/8KN<317;?;)_\
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M>H^'M*O],29KA;*ZLHI(1*Q8M($92-Q+L2V,_,?4UZE]LG_Y[R?]]FC[9/\
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M ,R_12_\+FTS_A)--T/??B\OKNZLU; V1- Q4M(=WRJ[#:AQ\QXP*[7[9/\
M\]Y/^^S25=M)I:,?L5=J^J.)HKMOMD__ #WD_P"^S1]LG_Y[R?\ ?9H]L^P>
MQ7<XFBNV^V3_ //>3_OLT?;)_P#GO)_WV:/;/L'L5W.5T?\ Y"]C_P!=T_\
M0A7J5<Y:W4[74(,TA!=006/K71UQ8B?.UH=M"'(GJ%%%%<ATG'>--/N-6M=2
ML[6];3KF>+9'=+$DOEL5&"4<%6'J#U&>G6O'="^!>L^%?(NM"UKPWHNH17IN
MEMK#PR\.EJI@:$A;5+L%9&W9:3S.=JC;Q7L^N:K:6VJ31RF82+MSLC!'W1WW
M"J/]N6']ZY_[]+_\77H0C+ENEND<,Y1YM7L<)XT^#Y\<6.M_;-7^RZKJ%A;0
M07]G:[39W$2SJ9D5G;*L+AU,9/*%E+'=FM:W^&MKI^EZ38VM_?%+'4(M09[Z
M[GO6D95(*J9I&,:GLJG:O8<UTO\ ;EA_>N?^_2__ !=']N6']ZY_[]+_ /%U
M?+*]TNJ?W:HARBU9OHU\GN<)>_"W4_$7B;Q!-XCUJRUGPYJMN]DNFK83VUS:
MVS 9ACN4N@ &8;G81AW^4%MJ(%Z'X>>!;?X=^'WTFVN[J]B:\NKL27EQ+/(/
M-F>0*7E=V.T,!DGYB"QY8UM?VY8?WKG_ +]+_P#%T?VY8?WKG_OTO_Q="C)*
MR0W*+=VRY15/^W+#^]<_]^E_^+H_MRP_O7/_ 'Z7_P"+HY9=@YX]RY15/^W+
M#^]<_P#?I?\ XNC^W+#^]<_]^E_^+HY9=@YX]RY15/\ MRP_O7/_ 'Z7_P"+
MH_MRP_O7/_?I?_BZ.678.>/<TH?]7<?[@_\ 0EKS#XB?".X\?>(["_?4-+2V
MMC&T;7FB)<7]DRN&9[*[$B- SX7)99,%00!T/HEOK%DT-T0;C"Q@MF)>F]1Q
M\WJ14']N6']ZY_[]+_\ %U*C*][; Y1:LWN>.:]^S;/J3">S\3M9WBR,0WEW
M<49C=IBZ-]ENX)#GS@/]9CY3E3NXZK0?@W;Z*T"B_'D(TY:*"%D.V2UBM\!F
MD9OE$0(+%CR 3QD]S_;EA_>N?^_2_P#Q=']N6']ZY_[]+_\ %T>S=I*WQ:,.
M:-XN^VQXIJ?[-VKZUJUG?WOBNQD\FTBTR2WM].O+.*>SB8&-9!;W\9DD^]EI
M"T?(VQ)@[O7]<\/?VUJ7A^[^T>3_ &3>M>;-F[S<V\T.W.1M_P!=NSS]W&.<
MBY_;EA_>N?\ OTO_ ,71_;EA_>N?^_2__%U=I[6_IDIP6QYUXL^!L7BB+5U&
MK-9/J%S<W?F0PLC+))##&F6216.TPJ20RD@X!7&:IZ#\"]0T/3+[RO$D::S<
MVEQ;G4(X+N0[Y7A;S"UQ>33=(54[9E/=2A ->H_VY8?WKG_OTO\ \71_;EA_
M>N?^_2__ !=2J;6RZ6^5K6^XKFB]WUO\[W_,\0L?V?\ Q!I]_;V(U^WN=/N+
M2[BU'4;FTFGF=9YX7>&)I;IY4?\ =G;([2@  $,0#6KH?[/,VCP>)K<^(?M,
M6HV<UG8R3+>S26:O)Y@#++>/$P!"Y$4<.<=LUZU_;EA_>N?^_2__ !=']N6'
M]ZY_[]+_ /%T^65HJVR:^3_K^M2;PNW?>S^X\LN/@3J.K7.EW6J>)K>:YAO+
MJZO6M=-:%9Q-+!(4B!G8Q;3 H!)?@GOS5?5O@7X@U;2XH3XJTNWO[<0P6]]9
MZ1<V4L5O%&Z(OF6U]%*SD.=VZ0Q' Q$O)/K?]N6']ZY_[]+_ /%T?VY8?WKG
M_OTO_P 724)*/(EII^&P^:/-S7UU_'5DNGVIL;"VMC*]P88EC,TF-SX &XX
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M(IT%W%/Y9^TSS2%<0[,222?>)Z (-;2O@7H^BK'IMG'8P>%HK^XO8]$CL%1
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M_P"">3>._&WB/2/%U[I^@RZ;;.(DE>;4H)[I=BV]Q*56-9XPI)C4;AC@G.[
MK D^(7B.V77KF66VFTJ[>=K>V8SBX@=(+>3B995PGSL-BJ#GYMW)6O>**F*:
M;=]U]W]6_4<M4EV9X-X/^)FIWEXFERZMI^N*FJA)%M6E6YT[-\T:Q7+"8[BZ
M'<@*H-L9!5QS5?0?C3XBA\1ZGI=YJ^@ZA<6NKW-HFEBU=+Z>(2R@2)B8@)"J
MJ6^0Y4')4D%OH&BIY7RJ-]=?T_R]1W7->W;]?\S#\#7^I:MX1TF_U>2UEU"[
MMTN)#90M%$N\;@H5G<\ @9SR03@9P-RBBMI--MI6(BFE9ES1_P#D+V/_ %W3
M_P!"%>I5Y;H__(7L?^NZ?^A"O4J\K%_$CT\+\+"BBBN [C!U.YFCOI%65U48
MX#$#H*J_;)_^>\G_ 'V:YKXV:O?Z#X'\3ZAI<LT&HV]FSP26ZQM(K[1@J) 4
M+>F\;<]>*\INOB5XQ^&?A74-1U?3=4U<F;?:VGB:6W74/*2(M,X&D6UPAC!V
M8+(,%F+NHV9[%RJ-WT.5W<K(][^V3_\ />3_ +[-'VR?_GO)_P!]FO++CXM:
MK_PE-G86OAZUDTJ:&S+7TVI,DRS7,<K1H(1"P*@Q ,Q<$!LA6Q@X?PQ^.VM>
M*M'T>ZUK0+"UCOK>55GL=2:5VNHH!,X:%HE,<97.&WL<[01A@QMI1YK_ &=_
MZ_K=$1ES<MNMK?/;\G]Q[?\ ;)_^>\G_ 'V:/MD__/>3_OLUXSH_QRUC4CI,
M4_AG3K*XOUAO&+ZV3!!8R6[S^:\OD#]X%B<&,#;G:?,P211T?X^>(M>5K>R\
M(:?)JZZE'8_8)M3O+9I$>-9/-C\[3T9@JEF8E%3: 5=BP%4X6DXM:K_AB5-.
M*DGHSW3[9/\ \]Y/^^S1]LG_ .>\G_?9KQGQI\9-4T_^V[>STZ&SM8WN;*RU
M);L27!NH$#R;[8QX2/&[#;V)^7*@,#6Q\,?B[<_$76M3M7\.7NF6,(=[2_D@
MNQ',BR%,.TMM%&'/#!8GF&-WS<<RDG:W57^13E:]^CM\ST[[9/\ \]Y/^^S1
M]LG_ .>\G_?9J&BBR'=DWVR?_GO)_P!]FC[9/_SWD_[[-0T46079;ANIS'.3
M-(2$R/F/]X5YCXM^.4GA+6O%>G3:?/.VC:/%J=JRW6#?R.SIY &WY"&\D;B3
MGS>GRG/I,/\ J[C_ '!_Z$M>:>+? GA'Q%XBU*_U+63;7]G;QSWL27<2>1;B
M.95:0$96,G+Y;@M IZ*P.<D[/E_K3]-RHO57_K7]=C>7XM:=!=:-9WLNI6MY
MJD$<L16QNI;96="PC:Y6/RE;"GY68$\<<C-%?COX=:U:47&O>8MP+8V7]@ZC
M]LW%-^1;>1YI3;SY@3;[YK$U3X"^'O$GB31_$;:IJ#36%M%%9-#]F.Q50J'C
MG,)F3<K'*QR*A)W;=WS5S(_9J\$QZ7=>%QX@;?>7B75Q;/8:,[RS+$P#>2UD
M8U?RR3N5 Y SNY8G:25Y65M=/2_^1E%NT;OIKZV_S.TOOVA-$M=;UO11-J*:
MIIA.1<65VMNZB*.5I/.2)U5 )47<?XB  =RY=KG[06@Z3YRPW5]=RV]Y%:RQ
M_8[I"ZM.(6>WS%_I05R%Q#O^8JN06&4;X)Z*VHZW=?;M3VZM:+9R0&6-DB4)
M"FY"4+EBMO'DLS=#QS4$/@'0=-MY-9G\77[^'K"<WL$$U[ FGV CF\V3!6-<
MJ'4@F5G* $*R@G*M&\+[=?O_ ,O^'0)S:EWZ>MO\_P#AC>T+XNZ=XFU:YL-,
M?49S#I<.K"XEM9H87BE:157<ZC:X,9RC88<C&58+2N/C1!I>A>']8U0366G:
MEI$FKSRK)),;5$CB<J%1"TA_>XX&?EZ<U%\.= \,R*-<\,>(5U[3)K(::6M;
MJ"YM91'-+(&WHOWU,TB\-C!Y&0#5.V^".GP63VEYXBUS4M/AL7TZQM[R2W":
M?;L4RL92%6<XBC7=,9& 7KEF).5:W7]:_GI_P!W>Z_K;];FY8?&#2M2CENH;
MVX2Q@LKB\G^TV]U!=1"!PL@:W>(.,9Z'#'C"D'-+)\:/#L7B*XT0ZM=F]MRJ
MS2)9W+6T;-&)$1K@)Y0=E((4ODY  ).*ETOX?Z9I>O7>K1R7$TUVLZR1RLK1
MD3.CN,;<]4&.>A/6N TO]E7PAH^M6.J6\]W)=6J[6DO+6QNI92"Y5C/+;-,A
M4,%'E.G"+WR3%O=6FMOQU_#8=]7KI?3TT_X)VFF?&_0=<:W33KO5;AKFW-U'
M(^DWT<"IABIEE,.V+<$)7>06!4J&#+EGA7XV:5XGU+^SA/>VMX9X[:-I;>X6
MWN)6M5NL13/&JM^[8D9VL0I.W&,Y-]\!=#U+Q%H6KW%[=O)HUE'8VL?V6RWA
M$1D'^D?9_M ^\2564(3D%<$@T_$GP;N5T)]*\/7K*EY>6,LMU?7(233U@BCA
M,UL(X<O*T42J59U7DD$#*MI:-Y6^7W]?D3>6E^VOK;_,].T/Q1#XDTN#4M.O
M9+FRGW&*;YU#@,5W#<!E20<'H1@C((-:=U=3K=3 32 !V  8^M9MC8P:98V]
MG:Q+!;6\:PQ1(,*B* %4#T  K'^)>M7.@VEM<6LXMC)K-C;2.RJ1Y<MW'&Z\
MCC(<C/7GCFILN9)=7;[W8I-\MV=+]LG_ .>\G_?9H^V3_P#/>3_OLUX_XH^*
MFO>'?$6N6>F:99Z^8K[R8X;N^^QQVT::>MU)ETAE9F/92/XQR!65:_'O4%N/
M&"0:-)J/]E1/?P?;I#9I+&882D$+B)A*59QYC?\ +,2Q_>)V@BE)M+HK_P!?
MUT82ERI-]7;^OZZGNOVR?_GO)_WV:/MD_P#SWD_[[->-S_''5K)9H[GPU8K=
M:9YLFLI'J[%(84F$>ZV9H%-PYSG:RQ8X&[)7-O0?CD->UN;2DT81W5NCM<+]
MKSL,4<GG@?NP3Y<JQQ$\9\T'CA2GRJ/.]K7^7<:NY.*W6GS/6?MD_P#SWD_[
M[-'VR?\ Y[R?]]FN#^%WC[4O'6GW$FKZ-;:)>QQV\X@M+]KQ#%-"LB$NT46'
M&2"H4@8X8YX[:KE#E=FM28RYE=/0F^V3_P#/>3_OLT?;)_\ GO)_WV:AHJ;(
MJ[)OMD__ #WD_P"^S1]LG_Y[R?\ ?9J&BBR"[)OMD_\ SWD_[[-2K=3_ &60
M^=)G>HSN/HU5*F7_ (])/]]?Y-2:078?;)_^>\G_ 'V:/MD__/>3_OLUX8OB
M+QQ-\1-<FM'\07&B:;JC1.D@TI=(%NMNCNI./MOF98X(RNXKGY<U9\._'G5]
M7\3Z+I-SX-FC6]AMI;J>P:\O%M?M"EXLR+9B':$*%R\L94E@H<*"SBE))KK;
M\5=?K]Q,I<K:?2_X.S_KS1[5]LG_ .>\G_?9H^V3_P#/>3_OLUX)XH^-6OP7
MEBXT^'2])NOMTEK)::E%+=7,<"R*?,BD@_<L'"-\OFKSAB#@'9A^,6JWVD>(
MYKS1(])2UMIKJQFL=2$\LT<=S) 2X>W"Q,2@8#]X,-R01R))V\_T_P"&#FM?
MR_6W^:/8OMD__/>3_OLT?;)_^>\G_?9KPSQ1^T!K?AW3I=07PII]S9R_:);$
M+JUQ)<300.R2O);P6<LD9!"'A7C4,=\D9VAN_P#"7B:ZU_Q+JZ.Y6Q6QL+F"
M JN8S*LC-R!D_=7KZ<4)*2NOZ_JP.5GR_P!=/\SM/MD__/>3_OLT?;)_^>\G
M_?9J&BBR*NR;[9/_ ,]Y/^^S1]LG_P">\G_?9J&BBR"[)OMD_P#SWD_[[-'V
MR?\ Y[R?]]FH:*+(+LMW5U.MU,!-( '8 !CZU%]LG_Y[R?\ ?9KE/BIK%YI.
MGQ1V-\NE2ZAJ<&GG4617-LLLFW>H?Y=YR%7<"NYERK?=/#P?$#6_"/B:?PQ+
M=P^+5ANXU?5]5N8K)[:(V[W$HF,,/ELZ*FY0$CRLD>XCES,;<K?;_@?YH&W>
MW]=?\CV/[9/_ ,]Y/^^S1]LG_P">\G_?9KQ;P3\9=6\<>*-.L)]-71#%J$EM
M<PQ_:&6=#:-,C W-K;R#D Y";2,89@:ZCXB_$B]\":MHD":(UYIEXY%WJ4GV
MGRK50Z+R8+:90<,3F9H4X^_][;?+JE;<E2NF^QZ#]LG_ .>\G_?9H^V3_P#/
M>3_OLUY1X=^.46O:])I3:9':2VZLUU))>X2$11R?:#DH.(Y52,DX'[P'CH>)
MU#X^>(=9TVY-O9+X=O;*XFAE6-9Y5E7[(TT;#[5:P..<'A"I&,,P-))/8'+E
MW/HW[9/_ ,]Y/^^S1]LG_P">\G_?9KQB3X_SV:_:KWP_!#IDZ/<6=Q%J7F2-
M")&A!F3RAY3M*85"!G'[QLME"ICU;]H2ZMO#NF:CIWA:;4;C4+EX(;:)KJ?B
M.%7F)^S6LS[ED9HL;-I*$EEZ4E9KF6W_  ;?FQW:=OZ[GM?VR?\ Y[R?]]FC
M[9/_ ,]Y/^^S7DNA_$_6?%'CS1;>+3%TKP]<_:H\7,V+V22*.,LLMNT0\G:S
MD#$C$XY"Y KU2JY?(2E?8MV]U.TA!FD(V.?O'^Z:XGQ=\8=&\!^)--TWQ%KM
MCH5M?6D]Q'?:IJ26R%XWB7RQO(#$B4G@\;>GIV-K_K&_W'_]!-<]JEKI5AXB
MT[6[Z^2SN?*?2[=9ID2.5IGC8( >6<F)0 #Z\'M*7O+M_P !V_&Q3;Y?Z\OT
M,WPO\7[+Q%X?AU1IIK96TM=7?:S21+ =W*R@!6X4]*I> _C%-X^:..TM?+EM
ME=M7C^VES8-N=8X\!,O(^S=MPNU2"3RH:AI^M_#PV<7@"W\9Z1<7UK_HTFGK
MJENUZPA;?)$\8.>B,'&T87=TZTSX<V?@'5+Z&Z\$>*+#5)]-,_VO^QK^WN!,
MEQ+)+LN!&#D>8SNAX8$-@X9PS23U_KK_ %\ODY;:Z_UI_P '[SHM0^+VG:?9
M^&[MVU1[?7K@VUN\=K,_ED122%I  2BXC/)^O0$BO9_'+P[??V88[S6%AU)/
M,M;J;1K^*!QAB,RM"$4L$)4,06!4C(92=3Q1X/MO%4>F++=7-B=/N?M,36FP
M;LQ21,C!T8;2DK@X /(((-<-KGP%\+OK.E>(=1U:\@&B6L4$#7 M-L*QH4W>
M<\)D0,I.Y5D5"26V[N:FSL].J^[6_P"EBKZK7I^/0WK/]H#POJ.DQ:C:W^LW
M$4TJQ1P1:)J#74FZ,2*ZVXA\TQE"#Y@79S]ZKEQ\;O#-IJ6HV,VLW,4VGH[7
M#M:7(A!5%<QK+LV/+M=6\M6+D'(4UR_C3X$^&M:\-M9ZEJT]EID2VYE>ZM]/
MN(\00F%&/VJVE5#M)^90#DG! XJD?A!I$6L:E!KGBBXCM[NY,VEZ6+R)?L[F
M**!+E"T?FF8%=HR[)EA\I8U=H\TDMM;>>UOU_P"!N1>7+%O?KY;G2:M^T-X:
MTO1Y;\7>L73QVMU=FRATJ\^T(MN,RB6,Q@PD94?O=F=Z_P!X9E_X7QH-KJ$-
ME?7U[!<W$NR%(K&]EV+^Y&ZX/D@6^&GC!\PA1N&6SD"G:_"G0S'K-C<Z[?ZG
MJFH65Q9ZC=7$T'VF07( \QE2-55ML2JN$"X3[IY-6O\ A3NE/)>RSZAJ5S<7
MB;)YI'B#,2T+%L+& "3;IT&.6XZ8(I77-M9W]>EOZ_X!)RM[N]_PT_X)N>'?
MBEH_BS6+W2],U*ZFO;0%Y$EMIX59 Y3S(W=%61"RL Z%E.TX)Q72_;)_^>\G
M_?9KR;X6_#?Q'X1\6ZQ?:SJ$%QI8A-GI5M#.)!%!YSR !?(C,8 *@*SS-U_>
M$ "O4Z22Y8M[]?O?Z6*N^9KI_P !?K<F^V3_ //>3_OLT?;)_P#GO)_WV:AH
MHLAW9;M;J=KJ$&:0@NH(+'UKHZY>S_X^X/\ ?7^==17/5W1O3V"BBBL#4Y?Q
M%9V^H37-M=01W-O( KPS('1A@<$'@UA^(O".A>+H;:+7=%T_6HK:43P)J-K'
M<+%(!@.H<':PR>1SS7S;^T3^WY%\$_C%X@\%MX!?6FTS[/\ Z<-:%N)?,MXI
M?]7]G?;CS-OWCG&>,XKSC_AZA!_T2V3_ ,*,?_(E=L?A6AQRDN9ZGV_'X=TJ
M)HRFF6:&/R]A6W0;?+!$>..-H)"^F3BLO3_AKX4T6:ZGTKPWI.D7ES;M:27>
MGV,4$QB/)3>J@XSS@\9%?&G_  ]0@_Z);)_X48_^1*/^'J$'_1+9/_"C'_R)
M5-<R::W)4E&S3/LGPI\-?#'@O1[;3=)T/3[2"'YMT=I$C22&,1O*Y51F1U&&
M;&3WXK/D^!_PXFM8;63X?^%WMH23%"VBVQ1">25&S S[5\C?\/4(/^B6R?\
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MD_\ "C'_ ,B4?\/4(/\ HELG_A1C_P"1*2NERVZ-?>U_E;TT'S*_-?M^%_\
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M/^@EX-_\+C1?_DNC_A1/B3_H)>#?_"XT7_Y+IKW>6SV?W[;_ -=25>\FUO\
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MKY[C5HVN+@/)(#O,>H$P1A2A/F6D.T+S,?X_.O\ A1/B3_H)>#?_  N-%_\
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M/P)_Y'?4O^Q8\1?^F6]KG/"OC[7?!+(VCWBVVR\@U +);Q3*9X1(L;$2*P(
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M/XA7?AN+QA/Y/VY;_P 4R6<PVPHL>Z$7"!?W8CQ\HR,'G.:XW_A0/[&'_/\
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M,B[_ #P02#QG<(]IS/\ 9.'YW#VSNOZ_X;N5_;>*Y%4]A&S\_P"OGT1]N?\
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MV^K6JV5ZG_"9NWFPK/%.%R;HE?WD$397!^7&<$@YW_"@?V,/^?[P?_X6TO\
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MM;_/[]-Q+/,5:3]A'W;7UVO?_+[M=C[0_P"% _L8?\_W@_\ \+:7_P"2Z/\
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M>>(O#=AJUMJ^E:8;FUC>&UOKB=Y;V9_M+!(A';E4.VV?B1MH./G^;"T?A/\
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M?=:IJ=U+>W<__"9NGF32.7=MJW0499B<  #/ K._X4#^QA_S_>#_ /PMI?\
MY+KXF\7?L_W.AV&IZC;:[H[16L;RPZ>9[B6YNHHXK>265&^S(@7%PC!7*-C(
M 8KDX?B+X+ZMX?L-.F&HZ7J=W=WL>FOI]E)+]HM;IXU<0RAXU7(#*"R,RYR
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MT6F_LTZF^I:)::IXBT?3KB]OH+2\L5%Q+=6"R74EL)' B\MOWD3+M20GE20
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M]A]7H_R+[D'_  SW\+/^B:>#_P#P0VO_ ,;H_P"&>_A9_P!$T\'_ /@AM?\
MXW111[>K_._O8?5Z/\B^Y!_PSW\+/^B:>#__  0VO_QNC_AGOX6?]$T\'_\
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G1;:.2*12&5U8)E6! ((Y!%=Q116<IRG\3N:QIPIZ05@HHHJ"S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>forms-1_016.jpg
<TEXT>
begin 644 forms-1_016.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %L IX# 2(  A$! Q$!_\0
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MOX@?#GXL_";2_$WQQT2]\>Z;\5/ _P 9?B!\0_$/C+Q5\3XO@REWXXN/BGX
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M10PQ1GK&AXQRB].>.G3D_F?6D\F+_GE'_P!\+_A4E%%D^B^Y?Y!R0_DA_P"
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M!5%S0G"FXJ[E*=2KB,-"-*+M*MS8G"8N@G3NE/"XER<8T*LX_KZS!1D^N/\
M/T&2?84H(8 CH:_F\_:D_;^_;AE_;[_X)?\ @+X(? KQGH?PO^._@#XF_%2Y
M^ 'Q-^(?A[X%^//B]XDLOA?J;^(?!WQC&N_#[Q)XA^$\O[.,6IS^)5\,#4?$
M/AGXQ>(#9Q6T<,WA_0=6'O.@_P#!7;XL?%/XO_&;PG^S5^PEXJ_:"^%'[/\
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M_P""DO[9'[2_B;X/>+_AG-^T=\'?VI_B+;?$;X%?%SPIXW\8^'O!&O:7\./
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M'VN'FJU-3=-S@FX\S3@OH.BBBLC<**** "BBB@ HHHH **** "BBB@ HHHH
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M9=7M/#>B6-OK5GXBFMG>[D\3:G)>>(KKQ5;1>%NU\ ?L3_MV:Y^RI_P41?\
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MA_2O%?A+7;-)TN5M=:\.:]::AHVIVZ7$,-P(;VSG3SH89 N^*,KP?P<_9O\
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MI3G.I&I.4Y3G._\ /C_P2>_X).?&+]D/XA_M"^,/VH?&&D_$F"V^'%M^Q_\
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M)RE4IRE*A*O+ZQ&A2K+G%HHHK$Z@HHHH **** "BBB@ HHHH **** "BBB@
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MCCP_XSN?AO\  9/@AX:.B>$K_P .0O;W?C=_$_B3Q3=IJ?B;Q+(^J>++'1?
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M:F-E7PF4Y7E^"A2Q-?&X[AR& Q];-\54SRG]>Q5?*L;5R^IE=:O1HX?G+/\
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M<#2QF=X[#UE"GF&94<FE)8NG#,Z&&HFE?M@07W@VQNY/AMXFF^+&M?%KQO\
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MKNBO/3 \M2%QC SVSG);/WS-^RO\![7]J/\ :<M+'P1I=WX;^&O[.W@KXO>
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M7>*R]3YB%4#!BH/)++E68(0"*#^W9^V2H*C]I;XN$;LJY\573$@.4()V[?F
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M*GD[B3S@G&0=J@+_ ,-V_ME9S_PTK\6AP  /%%T!@?AGGODX] *^3Z*_1_\
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M5/V@_C7I*WD3W%I]NUK5-/AN+==NZ6TEO;=?M*%FC'F1B9%:50[J74U[?^T
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M^.M0M6@:VOO&]O/XQEC\87EK]EMC9W/B(:C-:/;PR0N'0$?M1Y$7_/*/\O\
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MTNUN9$EN+73+OQ1XLU2ZL+:XFC26X@M9XH9I561X_,W._P"V/D1?\\H_R_\
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M?M+ZY\!O$?A'0[#PK\&K32O$'A[4]?G\??M$_'>;]G'X;:CJEGJ]GI-C\*_
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MN6'AK58-0\97,.I>';#6KV^UFRT._2ZTJUU>^O-4@LTO[F:XDIZM_P $X_\
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MP?\ M"VOA?3O$GF0RVSKX@L=!\7Z=:ZVKVTTL$JZG%="2&:>$!8)FB$6E?\
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M &<)?&/P.\<7UI/K>M_ WP'\%?A]IUYXM^&W[-_C_6O%>E? &UM+7X=:E?\
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M)**LT?K!_P (!I__ $%;_N?^/2UZ#U_TGC@@_C1_P@&G?]!6_P"__+G;=O\
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M/]/ )_M6_P"/^G.U_P#DFN]I&Z'Z'^5/Z]C?^@NO_P"!K_Y6/^S\#_T"TO\
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MYNUK--IIL_L_ J]\+25N6_NRTYFXQUYK:R3BK-ZIK1IVQO\ A7^G_P#05O\
M_P  [7_Y)H_X5_I__05O_P#P#M?_ ))KO:*/KV-_Z"Z__@:_^5A_9^"_Z!:7
M_@+_ /DS@O\ A7^G_P#05O\ _P  [7_Y)H_X5_I__05O_P#P#M?_ ))KO:*/
MKV-_Z"Z__@:_^5A_9^"_Z!:7_@+_ /DS@O\ A7^G_P#05O\ _P  [7_Y)H_X
M5_I__05O_P#P#M?_ ))KO:*/KV-_Z"Z__@:_^5A_9^"_Z!:7_@+_ /DS@C\/
MM//!U2__ / .U_\ DFK5KX TZ.'4E_M._(FL8XR?LMJ-H&IZ9,"!YYY+PHI.
MY<([D9*J#V=6(3B*])[6B'\K^QJ*F.QC@T\56:;@FG)/[</^G?>S]4AQP&#B
MTXX:DFGI9/5M-?SZ[V^9YU_PK[3_ /H*7_\ X!VO_P DT?\ "O\ 3_\ H*W_
M /X!VO\ \DUU9UK1QK">'?[7TK_A(9-*EUY/#_\ :5E_;KZ%#?0:9-KB:/Y_
M]I/HT6IW-OILNJK:FPCU":&Q>X6[FAADMFYMQ.+7[1!]J,#72VIGB%RUK'*D
M$ETMOO\ /:VBED2.298RB2.D;$221HU_7\9O];K]/MQZMQ7_ "[ZR32[O0GZ
MA@;*V&I6=[>Z^B3=O?ULFF[7LFO*_$_\*_T__H*W_P#X!VO_ ,DT?\*_T_\
MZ"M__P" =K_\DUW>X>AZ YXQSZ<Y..^,XHW>@)X)XQV]LYS[&E]?QFO^V5M-
MW[2-EON^2R^&6[5K.]K.S>7X%;X:BM]T^EKN_/:RNM;VLT[V:;X3_A7^G_\
M05O_ /P#M?\ Y)H_X5_I_P#T%;__ , [7_Y)KN]P[<]?3J.W)')[?TH# ^W?
MDCIV/7OV_P#U4_KV-LW];KV5V_>6B3<6_P"'LI1DKVM=-7NG8_L_!*_^RTM-
M_=E=-QC*S7-=/EE&7*[2M)-Q29PG_"O]/_Z"M_\ ^ =K_P#)-'_"O]/_ .@K
M?_\ @':__)-=WN'_ -;C/\\'\"?T.,RQUW0]4O=<TW3-9TC4M2\+ZC:Z/XFT
M[3M4L+[4/#>KWNAZ3XGLM*\0V-K<376AZG>>&=?T'Q)::?JL5I>W7A_7-&UJ
MW@DTS5;&ZG/KV-U_VNOIS7]Y?9Y5+_EWK9RBFU=*4HQOS-18\OP25WA:26NK
MB[+E4I._OZ6C"3UMI&35U&37+_\ "O\ 3_\ H*W_ /X!VO\ \DT?\*_T_P#Z
M"M__ . =K_\ )-=3::YHE_J.L:-8:SI%]K'AU]/C\0Z19:G8WFJZ!+J]BNIZ
M1#KFG6UQ+>:/+JNF,NI:9'J4-J^H:>1?68FM664Z@Y_S_G_/6DL?C'MBZ_7[
M:Z.S_P"7?=-=O-@\OP2;3PM)-.S3B[I]G[^YP)^'VG'.=5O^H!Q:6OX=;@C@
MG/0@]^,U:N? .G/!IRG4[X+#8R1KBT@8LC:IJ<Y+YG49#3LH !!55/+%P.R/
M?_>7_P!EJQ*2J:>1C(M6/(#=+^^QE6RI!/4,"IX##'52QV-<Z36)JMJ4K7FD
MKN,*>K5-M)J7O:.Z5K6;M<<!@N2=\-34;)RM%NT8>TJ^ZG-)RO%\MWHW?HCS
ML_#S3P,MJ6H 9!W&RMQUY/)N.,]N2-W7)--_X5_IO+?VK?@X/_+G;$[<DD9%
MR>O0CH2< #)K\P/$W@X_ #XG?M1^._A)XL^*.H^-_ASK?['/AOX7:)\>/VK?
MVTOC5\&/#FK?M4?$"R^&?C?6/$WPC\4?M*KH7BVRA@\5MK/AW1;]K,>']0TO
M3&\*WGATQ!JX&7_@I7\=/!_QX^/_ ,+?'G@[X8:EI?P*\%_M W&L6.@:7\-O
M#/C6TG^ /PH\5>-;3XY7G@QOV[OB-^T7=_"GXP:]X2LK?PSX$O\ ]D'P1H_A
MGP[\0M OU_:>\>66BQ^)/%^;S7&*$:CQ6*M*A/$2A[MXPI0Q-1\J4&V^3#RC
M)-PE3FZ/LU+VJE&5EF#YJL7A*#Y*WL4HMOVE1U,+22OSQC%2GC*=I3YN:<*L
M9248-O\ 7X?#[3LDC5;_ #QTL[8]L8XN>0!D >^!CI2#X?Z?@$:I?CN/]#MP
M>@ZYN,@9Z],8 /<5^%D/_!0'X[?%+X46/C;4/C!^S;H^G>!/C_\ 'CX2>+-5
M\":9+8>!OCOHS_\ !/W6?C_\-_">D^)/@[^W5\7])\ >-9/$FL7_ (-L[GX<
M?M'_ !;O]1\>Z/X=\4^$;_P[K7AC4/"=Y]3:?^V1^TGX?7QCXKO/#7P:^(7P
M\L?#'[7FE_##X6>"O"OQ9LOC'?\ C3]E7X8Z1\0?#P\1?$?4_B9\2K7QC8_$
M,'5O#.H^']$^$L/C'3KM=(\1V/B#QGJ.IW'A2 _M7&\TE+$UH2IV=KTY>].E
M.O&$$X1C-RY)K1\L^63<Z<7"9/U#+VJ7+AZ4HU7*FI.,X/W:KPTIS5Y.'*Y4
MYZIN*KTVE5G3G"7Z7#X?:=U&JZASP/\ 0[;I@<?\?/<Y&/P[XH_X5]IP/_(5
MO^.?^/2WZ@Y)_P"/GG&%.<9R #CBOSV^$/[47C/XT?!W]N<7?QY_9I^.-O\
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M=4O^<\FTMNHSD9^TG_:!Y[G'4U^6W[2_[<W[1WP;TWXJ^+=&TOX.Z#X*T/\
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MN1B_:D35/B!=^'/#/P"^.OC3X9Z7\2I_@AX@_:"\*Z'X U/X::7\0],\1Q^
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MSW?BO6->GU*"!?"][X/\(W\NGZOIGV^W>:ZLKJ9X-+DN+^#\]=._X)=QZ?\
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M %+4;?1K_0WL[/\ 9C<!GYCGJ,$GG.1@X''^R,+@L,89@4&T<C'0 8P"%Q@
M?0$@Y(XR#P>7[.5I_O)3G5?/.<W=U)RJ*<IRYNKC*O&4')0?M9/24N:GCHN5
M))4Z;?+35XJ,/83H<E.4$N6+M3::C*44KQ;4(0E^-?CSX:_\%#_"_P =_P!G
MG2O#WCWXI>-/!OA[P9^S]8ZSXWT.\U76?!FI>.;;QCJ5_P#M3:Q\7-&O?VDO
MA3X?N].\4:9=BU\.VGQ"^%OQEL?#7@I=+TSX(VFA>.=&DTQOV9;;N8IG86)7
M)R=I)VY/&>,<X'T%1?+D$GD>_08P2,#&3@#C#%0JDA0%#@RXZ_H?Z5<5:/+9
M7=2I5E*VK=5Q:3;U?+",8M:13IQ<80;FI2H*,W+6[ITH.U^5RII\\U%-PC[2
MHW-1@HQC!\D4H1BAU%-WKZ_H?\*-Z^OZ'_"G9]B[_P!6?^0ZBF[U]?T/^%&]
M?7]#_A19]@O_ %9_Y#J*;O7U_0_X4;U]?T/^%%GV"_\ 5G_D.HIN]?7]#_A1
MN4]_T/\ A2LQW_JS_P BQ(<+:<9_T=R1DC(^V7>1^.<9/3K7XFVG[%G[1FI_
ML@^!;?XA>.+'7OB3X _9@T[X9_"GX4> ?@GX3^'/B_X;ZSXS'PQM?%L'C#X@
MZQ\0OB5%\3M>\(:)X+CMK*W_ +.\'^"-1US3KCQ5KWA3Q#J-EX:M=#_;"4CR
MK0Y'S6S%3G(/^F79SG_]7/'7I#N''(R#GTR<KSGCH5!SR<C=R<YQC3O:HI2C
M+D5/:$HVAB5B+\LDU[S@Z4GUIRE"VJE%3491Y))M?O=FX2_>T)4I:I=(RYH:
M>[4C"2NXJ+_$;]J#X<?MV:'\,=8^&OP+U;]K/Q'%H/Q;_:.NOAIX^T#XI7WB
MCXES:.?!WPZUOX Z9XV\3ZI\?_@=XS\3>![CQMK7Q/T_3O%/Q ^(WC+PGX7L
M/#5OX?\ B+\*_B+87?A)](D^-WAS_@I'<?&[Q_J_P/;XX7D?C'X+):Z5+XB\
M2Z#X1^$_PVU)_P!GG3HM0_X0329OCQ>_#7Q7XUN_C!IEU'HVF>(/@;\'OC!H
M?Q,\4W&O7WQZ7]G_ ,-IIFN?MGQT!7'..@QGTP>G&0. "<@ DT?+G(QGU)P<
MCHQSU(R2#G/S-W)RXT[4U3?[SEY_>FE>;GA(X3]XXQC%N<(6JI1BE'WJ?LIS
MJSK$E>ISJ4D[TFE'W4E#$SQ,G&[2CR.HU2AS<TY^_5G54:=*E\-?L(Z1^T'I
M/PA\:67Q]?XAO=3^/=7D^&NF_%5=<G\>Z7X(E\*>'89[/5-3\9?'W]I'XA:O
M97'C4>*KW2KGX@_$F?7K2"[ETO3M,LO!UMX55LO]@CX4_$3X5^$)=/\ B'X2
MU'PE>M\ _P!A_P *BVU"33Y'/B+X9_LP>$_!/CS2<V%Y>(;CPOXLL;[0M0?=
MY#7ENYLIKJWQ,?OGC&.,$8*[NV, #G&.A[<C.<XI00.2>I)XQU/7@<@'T'!/
M)R<,=)+FJ*HDE>*BX1227[N5.^F_*I244DK1Y-^57B$%"DJ/-*24X33;N_W5
M2I."O>5U>K)M.3NW+962?13=Z^OZ'_"C>OK^A_PJK/L7?^K/_(=13=Z^OZ'_
M  HWKZ_H?\*+/L%_ZL_\AU%-WKZ_H?\ "C>OK^A_PHL^P7_JS_R'5/$,PWP]
M;11_Y/6-5MZ^OZ'_  JQ"P\J]Y_Y=4_]+[$G\AU[]NN!43NHW[2@]=M*D'KK
MY#3U5M6G?9O;7MMIJ?GO^TS\*_B]XX^-W@C4_A[<?$?PWX<U'P=\+? GC7Q]
M\,/%K^"?$FF>%KK]JSX=>)OB7I-EXCL-0L]<TQ;KX7V'B.YU:ZTE4O$TE;M=
M.NHM4-F5^5=;_9]_:>E\2_#*_P#[1_:LD\3S^$_^&?\ 4?BEH/QNUNR\0:#\
M'_#O_!4'P)JMQJ/C;5+?QM9SW/CCQ-^Q9<:MJME\2Y=#UGQ9XBTS1M:?6-4B
M\8P6T%[^U.4SUZ9'T!Z@<=#D]/7Z8,IWQD C@=B,$< =N >J@ +M 4!>RC:G
M&S:A&<&G;FG"I"K3GS3:OS<E:I"^B<).+BTVR6DXM1;C=0LXW7*Z4Z52#2ZN
M-6C2JIOX:D.=:NS_ !^E^'?[96N_MKZ[H46M_M.^"/V>-:T[XI_":7Q:GQ!U
M+Q!X T;X>W7[/,FE?"?XG>&O$MS\?;B;_A947Q1TVV\2/JNG_L\Z1\5]"\43
MWD?Q$^-WBK3KVV_MOS3XW>&O^"F7BSP+\-_&^FK\7_#&O^*]=^*C_$'X8_"W
MQ)?7>M_#GQ=X2\*_!GX9? >]TZ#PM^T?^SW;W/P]\6ZUX&^.7QPU&VOO%VO>
M K[5?BWX8TOXV?#WQ%INC::VA?N9D#H0.,=2/3'I@;@2<=RS=78E"0"#GIG!
MR&(SP2<\^ISR=V&/(%2J3O"3DYR@])3C"\YQKSK1E*,80C[\*DXU)SC./M%'
MW8\O*QJ+E4;BU&?.E&+;4*;I>RC32W<4U3;6C2C-M^\[_F#I/PS_ &S;7XBW
M7Q%B\?\ Q3N/&NL^/?B7X/?P_P"(_&YF_9STOP?)^P]97/@OQ9;?"&/6=9\+
M:%I/_#86CV-Q!J^DPZGXELY=2U[18]0G\$ZG=1GS[X31_M;^!]5\'>-(/AW^
MW-K_ ,-?"GCO]G^_^)OPO^-OQ>^&OQ$^,_CKQC<?#?\ :;\%_M!ZGX#>^^+]
MYX>O_@M%XP\8?LS>)I/"DOC'PM\-?[4\'^(O%GPF\!Z%9^'+V/6/U_X Z@<
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M[\_N5IP2O%24*/->2J5)_!'[(?Q)^)&O>)?'_A?XGZCXE\6>-/#_ (>_9?\
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M !AH?AZQTS7;V[\51LR^(YKN^M9;EM:PCZF9?M<T-K-));Q^V[AZ$?7'^/\
MGGT..^6$PBE)1HX:<4[1FJ%-*2T=[..C]Z-XO57C?XE?!8K$M)NOB(MJ[BZU
M2\=W9OF5]%>Z25GM=,WO^$H\3?\ 0>U+_O\ M1_PE'B;_H/:E_W_ &K!W#L"
M>GZG&/\ /'O1N QD$9&1[COTSTR,YYY'J*7U3#?] V'VO_ I;7BK_!M>44^S
MDD[-V']8Q7_01B/_  ;4[V_F[Z>IO?\ "4>)O^@]J7_?]J/^$H\3?]![4O\
MO^U8(<'H">0O SR1D# ).6!!'J"&''- 8'D=#T/'^/\ ^L@@9(-#PN%2;>'P
MZ25VW1I))6E*[?+:W+"3O?:,GLFP6)Q+T6(KMWM95:F^FGQ;ZK3S7<WO^$H\
M3?\ 0>U+_O\ M1_PE'B8?\QW4C[?:&Y_^OZ>]86?8_I_CWR""."#G.,TFX$
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M8U?:@!=C)*%3=RF]BN$W $C=CC& 0RY;_P )1XF_Z#VI?]_VK\;_ !M^R/\
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M7GUH'1+W6K[PWI=S]C[X.>/O@_X:;3/'FF66F7?_  IK]D3P8L=EJ^FZLO\
M;_PC_9S\+?#GQW;%]-N+B-8]-\6:3>6-M>[C:ZO:QP7VG2SVK"0[?5J"JPA]
M5P[@Z4I2G]7I*TU"<DMI15Y1C:*E)\LXJ_.VHX/%8CDE)5ZZDJM."C[>I+W9
M5)QG).\7)1BHOFY8I-3NG'D<ON3_ (2CQ-_T'M2_[_M1_P )1XF_Z#VI?]_V
MK#HK3ZIA?^@;#_\ @BE_\B'UG$_]!-?_ ,&U/_DC<_X2CQ-_T'M2_P"_[4?\
M)1XF_P"@]J7_ '_:L.BCZIA?^@;#_P#@BE_\B'UG$_\ 037_ /!M3_Y(W/\
MA*/$W_0>U+_O^U'_  E'B;_H/:E_W_:L.BCZIA?^@;#_ /@BE_\ (A]9Q/\
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M9M/4 )<C/]H:4W)M9T7(2^+8RP7@$Y93PJN5H#P?XDQC^SAQQ_R$=''\[_\
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M3%?] V(_\%?_ '0YVBNB_P"$0\2?] [_ ,J&C_\ R=1_PB'B3_H'?^5#1_\
MY.H^MX7_ *"<-_X-E_\ *@^J8K_H&Q'_ (*_^Z'.T5T7_"(>)/\ H'?^5#1_
M_DZC_A$/$G_0._\ *AH__P G4?6\+_T$X;_P;+_Y4'U3%?\ 0-B/_!7_ -T.
M=J]:$&VUC'_0-@_]/VA]_P#.3D=JU/\ A$/$G_0._P#*CH__ ,G5>M/"/B%+
M?5@=/ ,NFQ*A_M'22=ZZUH\Y!/V[:O[N%R"Y124V;R[QJ<:^+PWLI?[3A[^X
MU:I)[5:3?_+M=$^NR;\C2EA,3[2%\/B%J_\ EU_=E;[;ZO\ (X^BNC_X0_Q)
M_P! X?\ @QT?_P"3_P _3O1_PB'B3_H'#_P9:-_\G_EZ]JV^N87_ *"<-V_C
M/LG_ ,^^THNW:2>S3>?U3%67^S8C;_GUVTO_ !.Z:]4UNFESE%='_P (?XE_
MZ!WO_P A'1__ )/H_P"$/\2?] [_ ,J.C^W_ $_^XH^MX7_H)PW_ (.?7;_E
MUUZ=^EP^J8IVMAL0[NRM2O=[67[S5WZ+7R.<HKH_^$/\2_\ 0.'_ (,M&_\
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MXLU"]\60:_:3^*-3_9WU7X>Z=>WEU]Y^,/V8OAY\0_"&H_#[Q_\ !+X8>./
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M]\+?B5XAU+3/AS\3O%T=]X+\!>*/$7B_2M3T.TD^$W[;W[/WQ6UCX;^!=/\
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M>_\  #]G;PM^SSI#:+X7U[Q)KUN?A_\  WX=F;Q&=):?^S/@-\+='^%'AO4
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M>$M,U71_V7KGQE<ZY=^%]0\?W+^'Y_'.L_'[08/&^A>%)K+] ?VF_!WQ$!^
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M?7L'_P!!-'_P)'?45P/_  L+3/\ H':E_P!_K'_XJC_A86F?] [4O^_UC_\
M%4?4L9_T"XC_ ,%O_,/K^#_Z":7_ (&COJ*X'_A86F?] [4O^_UC_P#%4?\
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MJU;>/-,>'4B-.U!1%81RONFLQN4ZKI<"A2#M!+S*2254(C9.XH&F>"QG(_\
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MC6?C3\.GL[C3K/\ 1-[6UDE:=[6V>=[F.\>9[>%IGO(H/LL5XTK(7:[BM?\
M18[DL9TM@+=9!" E--E8M?6^J-963:I:6\MI::FUI;MJ5I:3EC/:VM^T9N[>
MVG+N9H(9DBE+N9$8LV>B=&M*FH+$<K4\0W-4H1<HUJ5:G%2IP?LG[*555XPM
M[%U:=-N#C2II<].I&#;G353W:%DYSNI4:M.I)JH[U%[6,'1G--5O93J)5.:K
M5<ORC7_@H;?^+](\*/X$^(W[)_ABP\1^%?V<;CQ%\9?B-J.N:S\%/A7XX^)_
MPB^/'Q0\=^$_')T7XH^#E74FU;X1Z#X \&^'K[Q[X3U7PQKGB74!XGO/%6O6
M6G^$-2[OQA^UG\6=.U'Q?>6?B_\ 96\"_#F'XS?!/X&:!\4?B!I?Q UCP-X*
MU#XE?LD_#G]J+5OBW\0?%G_"TOAII6M^ ]2U#QE_PJ[X7^'HX_A5>:UKWB?P
M7JWB'QWIDBW'AS7OT7;1-$>UN+%]$T9[&[*&[L6TK3VLKLQWDNHQFZM#;FWN
M#'J$\]_&9HW*7T\UVI%Q+)(UFYL;&]AO[>]L;*\M]5;=JEO=VEO<V^IL([>$
M-J4$\<D5^PAL[2$-=I,1%:VT0.RWB5)=#$>\_K4FY2<G&47RN\VU'GC-58*,
M)3A3<))TURM*HG.+%-*/)R*W*ES6@YJ48/\ >N+C[&4YU53J5(2A[&RJ1I*@
MZLIGY/:%_P %!?B#=_%?]F+PQK=O\#(/ OQENO"WAK5]1\*W3>*O$OC;Q#XF
M^.GCSX)Z7XU^%VBW?QM\-?$GP[\)_%D?AGPQX]^&^OV7P+_:#T#7M$\4W=GX
MU\??#;P]X:O/B/)WG[!W[;7Q _:NUWQ5IWC3P9X.\.06W@+P]\1+&V\-:AX#
M&N?#RZUS69],G^%/Q#TW0?VB/C1XJU7Q1I<9$C>+_%/@+]G>]NK_ $CQ#I-_
M\(="O;)/-_21[#3WN+&\>PL'O-+AEM]+O&LK9KO3+>>$6\\&FW)B,]A!/;@0
M30VDD,<L($3JT8"TZ"RLK22\FM+*SM)M1NC?:C-:6MO;2ZC>L"K7M_+!'&][
M=LI*M<W32SLI(+D'%:PI2C4YG5E."^L<L'[KO5=.5.3Y&H7A*DI/EA!)N7)=
MOVB4Y0E#EA3]F_W.SC)+V?M(5$FX*I+VE&4*2=2=5ODYI\J?(3+SG(&>#Z]>
MW/M@XR>O;I3L#T'Y"EQC^=%;?UVULKNRT5W=V6BO9:)$?\'JWU=M7J[*RN]7
M:[U;$P/0?D*,#T'Y"EHH 3 ]!^0J\,C2;C' _M6R/ Z'[#J6#C\_Y=ZI5> _
MXE,YX_Y"MD.>G_'CJ))/MCC\SVK*K:T+MI>UIW:=G:\[V=G;3F;TV36E[K2G
M)1<Y.UE2J-WV^&-KKJKI:=[=C\O_ (A?'"'3-;^/'P;C^,TFD_&_4/VV/V9M
M,^&?PR_X6+/IOQ/O/A9XFNOV3-=UN#P%X5.K0>)9?AAJOAE?BM>^)9/#EBW@
MTV3_ !#C\03Q>9XEMVQ]?_:I^-+:3\1Y_&%C\)G\%ZUX3_:SU[X;1?#^;XN^
M!?'7A^+]E7]L7X;_ +.D\'C3QGI7Q2M[O5)?'6@?$6P\0_:/ /\ PKV7PSK/
MA^^TFZE\0Z-XA^P:)]-^-OVJOA)X%N(M6\2>%O&/]N:;^T+%^S!=/;^&/#-W
MXA\-ZQ?:!8^,KGQW?7LOB*)M.^#%KX"UW3/'NL>(+?4)-9M_#.L6LDO@Z35[
MB725VX/VC_@C'=_' >,M6\*_"SP?\ -=M?#7C3XE_%GQ=\'?!7P\N;GQ#XBU
MC0]6N[&[O_'\VO\ A_PW'\1/"6K>$;SQ#\2O#'@'0O&WC_0-7TOP%>>.-3\*
M^(VT3E6].V+ARW4&N7E4U##T*32G*:5.JZ-G5FT^:I6G.C"I.,H0U?-%MJFX
MRC4A.[:<HSCB)RM'36,:E*M3IQ?PP4(R<ES*7RQ\1_VV?BUX+\!?&[7X? O@
M6\\0?L_>(?"'P>^)MRNG7-GX:T;XU>-?C=?>"QKL,'B?XL> ]$MOAIX:^"P\
M&_&VYT?Q/\2?"AU6P^+'@?2[SXK>#;6SU?5;KEO#7[;WQ^\:?#R3QGX=T7]G
M72O^$5^!GQU^*7BBZ\7ZC8Q>&O'>J_#7XBWGPR\&77A3Q5X)_:2\;_#/X7>#
M]<U:ZTOQ+XO'B;XL_%&T\/-H&N^ )O&EL=:B^)OA3]$K#XM?!+7/$NC^ M*^
M*WP>USQG\1/!H^(/A_P)IWQ!\!:IXM^('P\O;,0#QYH?A*TUJXUOQGX&NK"#
MR3XMTW3M4\.7%E;^6-2DMHE*\A;_ +2G[*$?@K4O'MI^T9^S)'\-O#.KW/PZ
MU;QS9_&KX/CP!X>UZRTJ\UR_^'^I>*K?Q0/#6CZU9Z'INI:U>>#+J^MM3M]&
MTW4=6GTD:;93W"/V=2*;GC8\[4;V4%#GA&M";4(RE&*]MB8SA:3FJ?)1J3JP
MP]'VDQ<8*'+1LHSYG'7F=*U"I3@KJ]XPPDW=W<DKVO=O\Q+W]M_XI?$;P/\
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MOA[H/AWQ-\*?VLOB7!X \82:WJMYH%M+X(^._CO7#XUT7P[KVAW'AW7]$O\
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M]_R-\?\ ]?O_ ''2/TC(O^13@O\ KT__ $Y4"BBBO(/6/@+Q:1_PEWBSD?\
M(R>(1^/]LW_'UK#R/4?F*]X\?:YX/\&0>*/%7C"7PUH7A[2;^XGU?7M8T[3(
M[2S2[U=;&&>]O)+1Y ;F_NX(1+*7:6XN1O9BY:M!K&P1BC:1HP9258'1=(!#
M*=K C[%\N&^4DG:#]YER,_H^'SF,:5&#PTKT\/AXR_?T;K_9L-&+MRW7.J<I
M+R5MS\^KY1.=:I+ZQ!<]2K-1]C5O:5:O*6O-9\CJP@VMY.ZT/G?(]1^8HR/4
M?F*]NU35/">B:MX7T'6%\-Z;K7C;4M0T;PCIEWI&F17GB/5M)\.ZMXMU+3M*
MA.G;KJZLO#.@ZSK=Q$O*:?IMU/RL9JU>3^'+"\TG3[Z/PK8ZAK]Q=66@Z?>6
M6@6U[KEY8Z?>:Q?VFBV<\$=SJEW8:1IU]JUY!91S2VNF65Y?3*EK;7$D6O\
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M_P#T"-'_ /!+H_\ \AT?8M/_ .@1H_\ X)='_P#D.G_;,?\ H&G_ .#J7_R
M?V-+_H*I_P#@JI_\L/GC(]1^8HR/4?F*^A_L6G_] C1__!+H_P#\AT?8M/\
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MD 9P,D8.3CY@ >G&?K7T5]CT_P#Z!&C?^"31_P#Y#H^Q:?C']DZ-]?[$T?\
M^0\UM#-J5**C3P<XQBH*WUBFVU3IQIQ;;B[RY()2D]9/5MO4B643E)S>*I7D
MYN7[FI:]27/.R]IHKI<J2]U722O9^"Z61_:$/(_U=UW_ .G*[J@I&!R.@[CT
MKZ1M;.P%P@&E:.I*S8*:-I2MCRGR-RV:LN00N%(!4LK9#8KD?&'B/P+\/?"'
MBOQ_XXN_"/A/P3X%\-ZWXP\8^*=<T_1;#1/#?A;PUIMSK&O:[JUY+:!;;3M)
MTNSNKZ[F()2""0JCL IEYU&,YR>%FE&C24FZ]%)*#K-R;Y+)>_:S[/6PUDTY
M0C&.)@W[2HU^YK;.-**^UWAY[^1X[D>H_,49'J/S%?0-C%I&I6UM?:;I^@:A
M97MM;7ME=V6D:-=6U[9WL,=Q9W=K/!:/%-:W<$L<UM<1L8I8I$D1_+>-VP-)
M\2^ ]>O8+#0;WP;KMQ=Z'-XDM6T6RT35;2YT&WUI_#L^JVVHV-M<Z;<6\.N0
MS:7*(+N2>.[AFB>%6C>M'G*3<7A*BDFU9UZ*LXRY91E>/N2C).+C)73Z$1R:
M4DI1Q5.49*,E*-*JTXR7,FG[1+6G*%3K[LUUN>.Y'J/S%&1ZC\Q7T2=.M1N)
MT72 $V[_ /B1:7\GF?<#'[$0NXX"Y/S$@)N) +?L6GG_ )A.C?AHND8_#_0^
MG\^M"SJ#VPTGWM7I.W_E-?F_U#^Q9_\ 052_\%5?_DU^;_4^>,CU'YBC(]1^
M8KZ'^Q:?_P! C1__  2Z/_\ (='V+3_^@1H__@ET?_Y#I_VS'_H&G_X.I?\
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M^)*;7E3EY,/[&E_T%4__  36_P#DD>)Y'J/S%&1ZC\Q7T/\ 8M/_ .@1H_\
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M1@>@_(48'H/R%+105\W][_S$P/0?D*,#T'Y"EHH#YO[W_F)@>@_(5-@"SEP
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M&@>--#L_V>O&.D_$KQK\;[AK+PQK&FZY\,YM9_9P\!>"/&MAXKC@U"[T;3O
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M!X+^ .AR_$$>+KA(?#/BSPIXNU/6OVCO%7Q \/ZI^TW\+5U0_&RVOI7E^R_
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M!^0HP/0?D*6B@/F_O?\ F)@>@_(48'H/R%+10'S?WO\ S$P/0?D*GB4>3?8
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MPQ#XC\,^'-0\5: O[-;1P.@'8$COGL>3GG)YS]31@<^XP?4C  ^F% 5<8VH
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M6KB37K'7_!EKID/Q2BO-!\30WVL7^D>(M!U/PG=_1?P._:TUWXK_ +0GQ0^
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M'7M=TEM#T9-6UB^LK.32N?VMO@A8VB^([_QQI4'@:[\)>#?$6C:K!I/Q*O\
MQWJ^J>-/'7COP!8>%;3X0V?PX?QI/KZZ]X"UK3H_#>GIJ?Q$36=*\4:9KOP\
M\.6_AEM5U9+*J,HJ:S!\KC3FW[&E>,*D/:0E**JN:O3:J.')[11YKP3A.(_[
M7K7:^IQNJCI6<YQ<JD9QIRC'FC%22G+E=1-4].;FY)TJD_T;_M+2O^@YX?\
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M+J>F:QI4NM^'[.VU;2-2L-7TJ2_TR[@N'^:/AC^UYXLU30_A;XR^/GP>\)?
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MCUW1I&QY#G(1+YF)4!B3MPH!9L**JC4M*P/^)YX?Z?\ 0PZ/_34,?EQ7AFE
M&_@4@8,=SD$?+DV5UR1T_3BO)?B]\0KCX6_#G7_&>F^&[GQOXCMY-"\/^!O
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M;4_^@:G_ .#)?_(GT!_:6E?]!SP__P"%#H__ ,L*/[2TK_H.>'__  H='_\
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M_P#Y8']M3_Z!J?\ X,E_\B?0']I:5_T'/#__ (4.C_\ RPH_M+2O^@YX?_\
M"AT?_P"6%?/]%']BK_H,J?\ A/3_ /E@?VU/_H&I_P#@R7_R)] ?VEI7_0<\
M/_\ A0Z/_P#+"C^TM*_Z#GA__P *'1__ )85\_T4?V*O^@RI_P"$]/\ ^6!_
M;4_^@:G_ .#)?_(GT"-3TK/_ "'/#_\ X4.C_P!=0Q5J'4=,:&_*:SH15;12
MS+KVCL$'VZQPSE;TB-2P"!F(4NR1@F22-6^=*NVGRVVL$8XTR' Z '^W=#YS
M@[3_ +0&1UYP,9U<G48-_6I2LX;T(+>I32M^\MHW?6VVZW*CG,G)7PT%H_\
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MXS,J:IJUK;:IJ(NK^"*X3X0\1?MU? ?3M*\+:GX<UG6_$R^+?$_Q*\$0M>^
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M@1X^3XH^+KR3X!Z)^S_I7AG2=8\%_"[7;J63]G[PG:^"='BTOQIJWA2Y\>>
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MU>%_V:?!7B;PCX>U=-<N?&7B:Z\5^(=8A\%> O %O-J$N@Z1X;MHK+P[\/\
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M_-%1_P *#F_Z&]/_  FS_P#-%7TI@>_YG_&C ]_S/^-5_K!G/_09+_P3A/\
MYG(_L#*O^@7_ ,K8O_YH/FO_ (4'-_T-Z?\ A-G_ .:*C_A0<W_0WI_X39_^
M:*OI3 ]_S/\ C1@>_P"9_P :/]8,Y_Z#)?\ @G"?_,X?V!E7_0+_ .5L7_\
M-!\U_P#"@YO^AO3_ ,)L_P#S14?\*#F_Z&]/_";/_P T5?2F![_F?\:,#W_,
M_P"-'^L&<_\ 09+_ ,$X3_YG#^P,J_Z!?_*V+_\ F@^:_P#A0<W_ $-Z?^$V
M?_FBH_X4'-_T-Z?^$V?_ )HJ^E,#W_,_XT8'O^9_QH_U@SG_ *#)?^"<)_\
M,X?V!E7_ $"_^5L7_P#-!\U_\*#F_P"AO3_PFS_\T5'_  H.;_H;T_\ ";/_
M ,T5?2F![_F?\:,#W_,_XT?ZP9S_ -!DO_!.$_\ F</[ RK_ *!?_*V+_P#F
M@^:_^%!S?]#>G_A-G_YHJG'P*F%G):_\)8GSW<-T)!X=.5,,%Q!LV?V^00PN
M&.XNNUE4$,"<?1N![_F?\::4SCDC&>Y/IZGVI//\XDK/&-I--7HX3=7L_P"
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MRMH+Y\K?N^?:M?\ X4'-_P!#>G_A-G_YHJ^DP@&>3SZ9'\C2X'O^9_QI+/\
M.(JRQC2NW94<)O)N3_Y<=7)OYC>0Y6W=X773>MBNB26V(MLDCYK_ .%!S?\
M0WI_X39_^:*C_A0<W_0WI_X39_\ FBKZ4P/?\S_C1@>_YG_&G_K!G/\ T&2_
M\$X3_P"9Q?V!E7_0+_Y6Q?\ \T'S7_PH.;_H;T_\)L__ #14?\*#F_Z&]/\
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M_P#-%1_PH.;_ *&]/_";/_S15]*8'O\ F?\ &C ]_P S_C3_ -8,Y_Z#)?\
M@G"?_,XO]7\J_P"@5?\ @[%__-!\U_\ "@YO^AO3_P )L_\ S14?\*#F_P"A
MO3_PFS_\T5?2F![_ )G_ !HP/?\ ,_XT?ZP9S_T&2_\ !.$_^9P_L#*O^@7_
M ,K8O_YH/FO_ (4'-_T-Z?\ A-G_ .:*C_A0<W_0WI_X39_^:*OI3 ]_S/\
MC1@>_P"9_P :/]8,Y_Z#)?\ @G"?_,X?V!E7_0+_ .5L7_\ -!\U_P#"@YO^
MAO3_ ,)L_P#S14?\*#F_Z&]/_";/_P T5?2F![_F?\:,#W_,_P"-'^L&<_\
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MDWY7TM9)#R#*GOA4[W_Y?8OK:_\ S$=;*_\ P]_FK_A0,O\ T-Z#Z>&S]/\
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M7B3I_P R/,^NJ_YA>J:MWNNZ'_KUP3_T5_#'_A_RC_YN^X_8RBOQT_X?[?\
M!)W!;_AJ:\P._P#PSU^U+Z9Z?\*2.?PZ4G_#_C_@DT/O?M37HST(_9Z_:DY]
M?O?!,9[=,^^,BA<&\7N]N%.)'9V?_"'F>_\ X2KU7=:B_P!>^"?^BOX8^6?Y
M2_EICGKY6/V,HK\<_P#A_P!?\$F/^CI[[_Q'K]J+_P"<K1_P_P"O^"3'_1T]
M]_XCU^U%_P#.5I_ZF<8?]$IQ)_X8\R_^9@_UZX)_Z*_AG_P^Y7_\V'[&45^.
M?_#_ )_X),=OVIKXG_LWK]J+^GP4.*/^'_/_  2:/3]J>\R 6/\ QCU^U*>
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M,/\ HE.)/_#'F7_S,'^O?!/_ $5_#/\ X?<K_P#FP_8RBOQS/_!?;_@DZ/\
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M?!0@=.,D9'H>*?\ J9Q@O^:4XEMW_L/,[:Z*[^K65WHK[L/]>N"?^BOX8_\
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M_P"BOX8^6?92^E[Z8UZ:^1^QE%?CG_P_Z_X),?\ 1T]]_P"(]_M1?_.4IO\
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MZX/[/7[4O\Q\$B#^'3IUH_U,XP_Z)3B2W?\ L/,[??\ 5F'^O7!/_17\,?\
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MF/\ HZ>^_']GK]J/^GP4/ZX'N.Y_J9QATX4XD?33(\RZ?]RU_P !+CO@E_\
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M/@H2>!T )],]*0?\%^?^"3A*@?M27V6 (!_9Z_:D7(;A2-WP2!.6XP 64<L
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M$HO-X99"C17[W%3G&@L?'ZS*<&\/4<JE"5#ZJZ?L.Z_:<_X)X^._@9H/QO\
MB[H6NZ5J/P)^'?[1?QO^#'@IO$,OBNX^(>LZ'\*OC]XO^ ]IJ_B#6]*^&^E_
M!A/$UQK'A99KSP3;^/-(^)-[I)D\<Z;\+;;P \&O5D_#G]@/Q]\9?"WPFU_P
M=XP^%?@:3XEZ3\+=&\.V?Q4^)>J6]Y\1OBM\:OB;^TSX#^&/@GP+IV@?",Q>
M'-5\4W?[.6OZ!%H'B36-<TO2M5%AXLUSXD:;X9\3WFG?#[@/%/[<OQZ\6^$/
MC3X/OY_A[81_M">)_&GB;XM^*- ^%?P^T'QYXQ3X@?$\_&;Q/X9U7QOIOAZ'
MQ)=^%KGXD;-<TZRGU%]1T6PMK'PGIVJQ>#K"VT!>9\,?M=_&[P?I?P?T?0]:
MT2"Q^!7CGX,?$3X=)<>%]$NGT[Q/\ ?&_P :OB%\,[C4I)K9I-9M=-\3?M!_
M%"YU*SOY)(=6M=5TVQO/-M]$T](L\)A^.(Y8L/BL=@)9AAZ[AA\5#DK1EA(Y
M-2A&5>%2E1HUZ\LU@U.I.FI^RJUJT:<'"A"%8C%>'DLUC7IX+-7E=?"3EB,'
M&=2$Z>.GFU:<%AZKK5YT*4<LE3]M&E.4%6I4Z-&M6A/$59<M\#?@1JOQTB\?
M:G:_$+X7?"WPK\,/!^D>.O''C;XP>(-?\/\ AC1O#^M>,_"_@*S*'PKX1\;>
M(=5U=_$?C'0[>/0=(\/7VK7D4MPVG6UY<0"VD][\6_\ !//XU^"-.U^+Q!XR
M^!\'Q"T?1?$'CC2O@S;?$H7/Q+\;_"+PQXTO_ ^K_&WP9(N@+\.-0^&2WVC>
M(/$>G7>I?$72?%FL_#WPSXD^(FD^$;OPCI%QJA\L_9T_:('[/>C?'&VL_!7A
M7QKJ'Q6^'?A;P'I^G>/_  GX1\?>!+>+1?B]\.?B-J3^*?!GC/1]7TG6[>\T
MOP/-IVG2PVT.I:3K=QI^M65W;2V98]?XF_;U_:3\9^&O$.A>+/$'@?7M7\36
M_B/1;_XBWOP@^%)^)]EX$\7^,KWQ]XF^%'A_QLOA :KH'PCU3Q1JFKW)^'&E
M26GABST/7O$?@:PL;7P+KNH^'9NS'/BZ69S67O+X993E@$OK-+#>TJN5.$L9
M*ES.5;V,:_M(8B-2I3JSPOLX99.AC%6Q"Y, N!(933EF2S&KFE1YL[8:6)C&
ME"-?DRU8A0E&C&M.@E4H^R52E&OSU,R57".&&/9_'G_!,KXE_"&\^./AGXE_
M$CP)8_$+X7_!WP]\2_"'@[P[HGQCO=5^)?B#6_CEX+^# \ ^']&\0_!_PUXJ
MO]0OM4\3C3_!^OZ9H$_@?Q]XHUKP7'X-\8:UX6NO%'BGPMX7X?\ V.OB+'X?
MU;Q/\6=8\(_ =M)^(%Q\.K+X;_&>_P!<^''QD^(/B3PUI?P\\6?$3P[\/O!N
MK>$KJ"#Q!X1\$?%+X?:T+7XAZAX*M_%%QXX\-Z!X!/C/Q+<S:';ZOC+]O;X_
M^.-%NO"NI_\ "L=)\%77PZ\6_#B+P'X3^$?PZ\)>"='MO&WBKP3XZU[Q9X:\
M.^'O#NG6WAOQP/&GPU^'WB;1?$FCR6EYX9U'PCHX\.MI=M'/!<>>>#/VI_BO
MX*\$:UX!MQX$\5:/J?B+6?%NEZI\2_AIX!^)_B_P-XG\4:)X4\->,/$/PY\8
M>.O#NN:[X)UKQCX<\#^#]#\0:AHMU!=&V\*^&M0TB72=;T/3M2@Y\%2XVCAI
M/&XG*ZF,GB,&VZ4*<%&A"I*&*6'E.C'"493HQC.:KT,1-NK)8.M&O"#AKC*O
MAZZZ>!PV:PHQPV/E"56>(<5BIT(2P,,3%5?K]6%&NJD(5,+/#P;Y)8ZE+#Z/
MZG\7_P#!,7XJR_'S4?A/\'_&/P[^)/A2Z\2_M'6^E>,= U[Q;X[E\!Z)^S?X
MMTS0O'F@_%;3_ 'PMO?%-_\ $;PQ9>,/APFJZ1\(? 'C^Q\2ZWXSTRQ\!#7&
M74+;2^7_ .'9WQ_MM;\7>&-?\7?!+P1XF\,^)_&7A73/#GQ \=:[X)UGQU>^
M!_@IX _:0U?4?"MKX@\#V4>F:%)\"/B1H/Q*74?B/<?#Z31;&"^\,^,[/PIX
M\GT'PIKGDWA_]MGX^^'/$O\ PE%GJ_A2]GNO%_QX\9Z_H>M>!/"VM>$_%E]^
MTMJ'@S5/B_I/B?PWJ>G7>EZMX<UR_P#A]X2O=(TJXMV'A/4M(MM6\+3:/JUO
M:WUO3U']LGXXZGK0UQ]1\'V$T6N_%CQ!8Z?HGP\\%Z!HVEW'QF^"?A3]G;QE
M8Z;HVA:-IFE6FF_\*C\$>&M T>&*R673]1LI_$LTU]XCU+4M5N^94/$*G&C1
MAC\EJQA@J49XC$8>,L14Q<9>TG.:C'V<>=N.&E:3IK#^UJJ,<=%3?>\3X7U:
MU:O6P.>TH5,=6E'"X:M4<:.$G[D(4I3J/F4(N6(BG)S^M<E+FE@7*DO5K'_@
MG5\4M1\16V@6WQ@_9N2#Q;J7PV\._!#Q)>_$/Q1IWA[]I'QC\6_!6D^// W@
M[X-R7WPYM]8BUB^TC7] L=6O_B[HWPF\+^%O$6OZ#H/BCQ#HU_K.GI/X5\,/
MV9?'?Q9\ ^(/'GAW7/!>FR:7\2OAS\&O#O@3Q%J>N67Q"^(_Q7^*;:J?"/@/
MP+HNG>%]6TU]7DMM#UJ^U>\\6:WX3\/Z%;:7<+JFM6UY-8VEWZ#X'_;P_:$\
M 0:)%HUY\.]2D\(:?\.(_A]=^,/A)\-O'%[\,O$_PE\,1^#_ (??$CX<7?BW
MPUK$W@_XDZ#H5O902>*]),5UJ]UI6AZCJ\=[J7A_0+O2?!?"GQB^(7@?PU;>
M%O"NORZ'9:?\5/!OQLTS4;&WMUU[2_B5\/M(U[1O"WB.PUB2.2^@DTZS\1:G
M+]F$PM9;\V]_.DDMK$1Z>'I\6_[7#$8G+G)5,(L#7AAZ%ITHXJJ\1.OAZ=.+
MA4K8&G0C5HQG45/&8FK]1E"EAZ4)^3BJG K>"GA,+FOO0Q[QN'=2NN6M4P=-
M8&G1K5:TISA1S&I5=.<81E5PF'IQQRJ5:ZM]L>._^"6?[0'PMOXYOBCXX^#'
MPP\ &QO$F^,OQ+U/XK_#SX7V_C#3_$VA^$KKX<)<^-?@WH/C?4O$ZZMXDT:Y
MC\0Z-X%U+X4W'AB>^\<V_P 29?!'A_Q/XAT3R?PA^PU\2?&'A3PQXAB^)7P(
MT#7?%6C:1XVM?AGXA\?ZO#\1-,^$>J_$F'X6/\;-8M=*\&:MX0@^&^D>(9)M
M8U=;'QGJ/CZ+P!97OQ&L/ 6H^"X#K1U]1_X*%?'G5=;GUK4=$^ 5[IMUI-S9
MZ_X%O/V</@C?_#?Q#K$FNZ=XND\;>)? =WX';P_K7C&SU_1=-U/1]:O[2:+0
M(8M3T71;33?#7B7Q1H6N<WXN_:*_:-\-?"'2/@_XQT_P?HNA>/?AA':^'_&M
MW\(_AMI?Q4UKX!^)OB%JWC2V\"Z5\4+#PS%XUL_A1JOQ!L-;U*U\-VFJ64%N
MD5WX7M&@\)N-!3SL-+CI4J4,;B<DCBJM2ARRH0POLI45"K6Q#C1JQC5J58TU
M*K4]A447@X826"=*K_:6*J^GB(>'4JE:K@<'GU7"T:%>4XS^LN<*U2&'IX1R
MK4JLX4:56M-K#NM%SABUB8XU8S ULMI8?L_AA_P3B_:,^*6M_P!@:?!X?\.W
MUEX'\1?$#Q1%K.G?%'Q!J'@G0?#_ ,</%W[.D,7B3PK\+?A?\1O'4FK^)/BM
MX"\8:5X?TSPYX4\030:%X>U/QEXO;PCX3@36)<'XB?L%?&;X5&;1O&WB+X7:
M=\3;/P'\7_B3J/P2MO$7B?4_BGIWA'X'^,/%7@WQUJ%U96'@:;P>9H[CP#\0
M=?T73[;QI/?:MX1\"^(O$BP06*:;_:5K2_VT/VGY_&WQ*_:'U&_\*^-_^$PT
M?X7_  O^*5GXX\#> _$W@;78--TB9_AK'?\ @;6-.ETV/Q"9?ACJWB:'Q7HF
MFVNIMXC'BC4M3U7SO&VMV_B'3^%O[67CS2/C/X!_:Z^*%C>>+KOX 0W_ (<\
M"?\ "&V_@'X?Z#-X]\6:K\7?B?X.\,^.-#T_PO)I]W\,-<U_Q5\28O&^@^&?
M#>GW$_@62;PEH-]H2QZ*8:E/C>E4JU9U\GJT*&"3>&PV%E.O5S94,1*EE[G7
M5!T(XK%U\JA.KS/$1P.(E6PV'CB*3>,4*7A_6I4*=#!9W#%5L;)*KBL54]C2
MRI5<&ZF835"G+VE3#86GFTE02I0EB<)1C6J2HXI1P]/X/?L?_P#"2_'GXZ_
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MPY\)>)_AYH7CCQ=XG\7>)_%DD7PQM_ _@'P?-\0]3\<6'C#0-'\1-K'A;5_
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M&7P6\=>(8M:\9^-8];T30O#_ (,T[QGK%A;>$_$GBWQG9^$_ \6E>)]6\Z\
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M[<RR:=$U=-H/[97QX\,?#+0/ACH&K^$-(C\+Z/H?A70?B+9_#?P#_P +HL/
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M]0?+-1JQ4DFTFGJS^%; ]1^O^%&!ZC]?\*_NI_XA>?V#/^BV?ME?^%Y\"_\
MZ'2C_B%Y_8,_Z+9^V5_X7GP+_P#H=*ZO^([< ?\ /_.O_#'B/_FXY/\ B7+Q
M*_Y\Y!_X?J'_ ,[S^%; ]1^O^%&!ZC]?\*_NI_XA>?V#/^BV?ME?^%Y\"_\
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M?\0O/[!G_1;/VRO_  O/@7_]#I1_Q"\_L&?]%L_;)/U\>? L_C_R;I37COP
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MNCR>#+-/#7PW\0:QX*FU^S\=Z-X3U3Q-X:43_P!8!_X->_V#""I^-?[9.,
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M(7G]@S_HMG[97_A>? O_ .ATH_XCMP!_S_SK_P ,>(_^;@_XER\2O^?.0?\
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A]_F&,Q%/DK0ITXS_ '-6GSV@E&:E%72NRBBBOC3[T__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>forms-1_017.jpg
<TEXT>
begin 644 forms-1_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 .$# 2(  A$! Q$!_\0
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M,TN10 44F1ZTN: "BC(I,CUH"XM%&:* "BBB@ HHS29'J*!7%HHS10,****
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M*** "BBB@!#7DVJ_\E8B_P"N\7_H(KUFO,]0T;49?B5%>1V4K6HGC8RA?EP
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M7![!@<?IBL'2/!6JZSJ(U#7V=4R"4D.6?V_V17H>HP;M%NK>),DP.B*/]T@
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+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
